Lista_Unique_identifiers,Summary_EN,Summary_ES
114537,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo.",""
115477,Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may decrease flunisolide concentrations. Monitor steroid effect and adjust dosage if needed.&nbsp;,""
115478,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4.,""
115938,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is primarily metabolised by UGT1A9 and UGT2B4. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
71179,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely.,""
115939,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is primarily metabolised by UGT1A9. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115972,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Astemizole is metabolized by CYP2D6, CYP2J2 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115973,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. No interaction is expected with dolutegravir. Lamivudine is eliminated by OCT2 and in vitro data indicate that cetirizine inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown and given the good tolerability of lamivudine, no a priori dose adjustment of lamivudine is needed.",""
115432,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Rilpivirine, emtricitabine and tenofovir alafenamide do not interact with ciclesonide metabolism.",""
75461,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Efavirenz is unlikely to have clinically significant effect on ciclesonide metabolism.,""
116023,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116024,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
71672,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,""
116025,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116202,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vincristine is metabolized by CYP3A5/4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116232,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. ,""
75462,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Etravirine is unlikely to have clinically significant effect on ciclesonide metabolism.,""
116233,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. ,""
116234,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. ,""
116235,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
75463,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Nevirapine is unlikely to have clinically significant effect on ciclesonide metabolism.,""
115454,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Dolutegravir/rilpivirine does not interact with flunisolide metabolism.,""
115455,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Doravirine does not interact with flunisolide metabolism.,""
115456,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Maraviroc does not interact with flunisolide metabolism.,""
67533,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sumatriptan is eliminated primarily by metabolism mediated by monoamine oxidase A.,""
67046,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as azithromycin is mainly eliminated via biliary excretion.,""
67048,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine.,""
67069,Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely as ofloxacin is primarily eliminated by the kidney.,""
115459,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Rilpivirine, emtricitabine and tenofovir alafenamide do not interact with flunisolide metabolism.",""
115460,"No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Flunisolide undergoes CYP3A4-mediated metabolism. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
115461,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with atazanavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
116456,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
68596,Coadministration has not been studied but may increase testosterone concentrations. A dose adjustment of testosterone may be required.,""
67140,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%).,""
67172,Coadministration has not been studied. Clindamycin is metabolized by CYP3A4 and coadministration may increase clindamycin concentrations due to inhibition of CYP3A. A decrease in clindamycin dose may be needed.,""
116476,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116480,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
70627,No interactions due to cytochrome P450 metabolism or renal secretion expected.,""
67198,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine.",""
67346,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cidofovir is mainly eliminated unchanged renally.,""
67564,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The exact metabolic pathway of pentamidine has not been clearly established. Data from animal studies suggest the involvement of CYPs 1A1, 2D6 and 2C19 in the oxidative metabolism of pentamidine. ",""
67518,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion.,""
116481,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116484,Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. When prednisone (more than 80% of which is converted to prednisolone by first pass hepatic metabolism) was coadministered with dolutegravir there was no clinically significant effect on the pharmacokinetics of dolutegravir. No interaction is expected with lamivudine.,""
67827,Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely as lorazepam is mainly glucuronidated.,""
67857,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2.,""
116487,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
67926,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug-drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, P-gp, UGT and OATP.",""
67942,Coadministration has not been studied. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4. No a priori clinically relevant drug-drug interaction is anticipated. ,""
114546,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with atazanavir is unlikely.",""
67961,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Non-pegylated interferon alpha appears to be metabolized principally in the kidney.,""
75022,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2.",""
67985,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gemfibrozil is metabolised mainly by UGT2B7.,""
68026,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as megestrol acetate is mainly eliminated in the urine.,""
116488,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
68046,Coadministration has not been studied but may decrease testosterone concentrations. A dose adjustment of testosterone may be required. ,""
116556,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-glycoprotein and MRP2. In vitro data indicate that dolutegravir does not inhibit P-glycoprotein and MRP2 at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116555,"Coadministration has not been studied. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion; it is reduced by probenecid. About 20 to 40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60 to 80% is excreted in the urine within 6 hours. No interaction is expected with dolutegravir or abacavir. As lamivudine is eliminated by renal tubular secretion, there is potential for competition with ampicillin for renal transporters, which could lead to increased levels of either drug when ampicillin is administered intravenously. When administered orally, there is little potential for significant interaction. ",""
116552,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116553,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely as amikacin is eliminated by glomerular filtration. ,""
116554,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3, but dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by OCT2. No interaction is expected with abacavir.",""
116557,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. Concentrations are unlikely to be affected by dolutegravir, abacavir or lamivudine. There are no clinical data on the safety and efficacy of bedaquiline when co-administered with antiretroviral agents.",""
116558,"Coadministration has not been studied. Capreomycin is predominantly excreted via the kidneys as unchanged drug, partly by glomerular filtration and possibly partly by tubular secretion (renal transporter not identified). There is some potential for exposure of capreomycin to be increased since dolutegravir inhibits the renal transporter OCT2. No interaction is expected with abacavir. As capreomycin may potentially compete with lamivudine for renal elimination transport mechanisms, levels of capreomycin or lamivudine may hypothetically be raised. Renal function should be monitored as clinically appropriate.",""
116559,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged via the kidneys (by glomerular filtration and tubular secretion via OAT1 and MATE1). Dolutegravir is not expected to inhibit these renal transporters and lamivudine is eliminated by different renal transporters. No interaction is expected with abacavir.,""
116602,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telithromycin is metabolized by CYP3A4. Dolutegravir does not affect CYP enzymes. No interaction is expected with abacavir or lamivudine.,""
116831,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116832,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Drug-drug interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116605,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via renal glomerular filtration. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
68162,"Coadministration has not been studied. Apomorphine is metabolized by several pathways that include mainly glucuronidation and sulfation and to a lesser extent N-demethylation. Although protease inhibitors have the potential to induce glucuronidation, the clinical relevance of such an interaction is unknown considering the numerous pathways contributing to apomorphine metabolism. No a priori dosage adjustment is required.&nbsp;However, use with caution due to the risk of QT interval prolongation reported for both drugs.",""
116833,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116606,Coadministration has not been studied but based on metabolism and clearance a significant interaction is unlikely. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116607,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Dolutegravir is mainly metabolized by UGT1A1 and is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116834,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116835,"Coadministration has not been studied. Clobazam is metabolised by CYP3A4 (major) and CYP2B6 and CYP2C19 (minor) to the active metabolite N-desmethylclobazam, which is metabolised by CYP2C19. Clobazam is a weak inducer and could potentially decrease dolutegravir exposure although to a limited extent. No interaction is expected with abacavir or lamivudine.",""
116836,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
68339,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halothane undergoes both oxidative and reductive metabolism by cytochromes. In vitro data have shown that oxidation occurs mainly via CYP2E1 and to a lesser extent CYP2A6 and reduction via CYP2A6 and CYP3A4. Furthermore, in vivo studies have shown a minimal effect of CYP3A4 inhibitors on halothane elimination. ",""
117222,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
68736,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Saquinavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
68734,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nevirapine is metabolised by CYP3A4 which is not affected by peginterferon alfa-2a.The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
69159,"Based on the results of in vitro experiments and the known elimination pathways of emtricitabine, the potential for CYP450 mediated interactions involving emtricitabine with other medicinal products is low.",""
68691,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Lopinavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
68729,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Indinavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
68735,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Ritonavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
68771,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized by CYP1A2 (major) and glucuronidation (UGT1A4).,""
68779,In vitro and in vivo studies suggest that enfuvirtide is unlikely to have significant drug interactions with drugs metabolised by CYP450 enzymes. No drug interactions with other antiretroviral medications have been identified that would warrant dose alteration of either drug. ,""
69165,"Halofantrine is extensively metabolized by CYP3A4. Inhibition of halofantrine metabolism could potentially prolong the QT interval. Given the narrow therapeutic index of this drug, combination with PIs is contraindicated. ",""
69176,"Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA). MPA undergoes glucuronidation; coadministration of inducers or inhibitors of glucuronidation, such as some PIs and NNRTIs, could alter mycophenolate levels. Concentration monitoring of mycophenolate is recommended. ",""
69179,"Lumefantrine is metabolised predominantly by CYP3A4. Caution is recommended when combining lumefantrine with drugs exhibiting variable patterns of inhibition, induction or competition for CYP3A4 as the therapeutic effects could be altered. ",""
69225,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1.,""
69201,"Results from in vitro and in vivo studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Drug interactions resulting from cytochrome P450-mediated metabolism are not expected. ",""
69285,"Coadministration may increase plasma levels of artemisinins. Close monitoring for artemisinin toxicity required. Artemisinin and derivatives are rapidly metabolized via CYP3A4 to an active metabolite, dihydroartemisinin which has greater potency than the parent drugs. Inhibition of CYP3A4 would reduce dihydroartemisinin, but increase concentrations of the parent drug. The effects of PIs and NNRTIs are unclear. ",""
117223,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
69309,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases.,""
69510,Coadministration has not been studied but based on metabolism and clearance a clinically significant&nbsp;interaction is unlikely. Tetracyclines are eliminated unchanged primarily by glomerular filtration.,""
69655,No significant interaction observed. ,""
114547,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with atazanavir/cobicistat is unlikely.",""
103776,Coadministration is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis. Simvastatin is metabolised by CYP3A4 and coadministration may increase concentrations.,""
69595,Coadministration with didanosine gastro-resistant capsules has not been studied.&nbsp;Coadministration of trimethoprim and didanosine buffered tablets had no effect on didanosine AUC but increased Cmax by 17%; trimethoprim AUC increased by 10% and Cmax decreased by 22%. Coadministration of sulfamethoxazole and didanosine buffered tablets had no effect on didanosine AUC or Cmax; sulfamethoxazole AUC and Cmax decreased by 11% and 12%. No dose adjustment is necessary.,""
69600,No interaction with didanosine gastro-resistant capsules (Videx EC). Other formulations may require dose separation. ,""
69612,Coadministration of indinavir (800 mg single dose) and didanosine gastro-resistant capsules (400 mg single dose) had no effect on indinavir AUC or Cmax. Enteric-coated didanosine can be administered without any restrictions with respect to time of administration or food. Other formulations of didanosine should be administered at least one hour apart on an empty stomach.,""
103365,Coadministration is contraindicated as it may increase astemizole concentrations which may increase potential serious and/or life-threatening adverse reactions such as cardiac arrhythmias.,""
102915,Coadministration is contraindicated as it may increase cisapride concentrations which may increase potential serious and/or life-threatening adverse reactions such as cardiac arrhythmias.,""
69698,No clinically significant drug interactions were observed when tenofovir-DF was coadminstered with oral contraceptives (ethinylestradiol/norgestimate).,""
102791,Coadministration of triazolam and atazanavir is contraindicated due to potential for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression.,""
70401,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as bupropion is primarily metabolized by CYP2B6.",""
102665,Coadministration of ergotamine and atazanavir is contraindicated due to potential for serious and/or life threatening events such as acute ergot toxicity.,""
103375,Coadministration of dihydroergotamine and atazanavir is contraindicated due to potential for serious and/or life threatening events such as acute ergot toxicity.,""
69744,"Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive drugs (e.g. vincristine) may also increase the risk of adverse reactions to zidovudine. Monitor renal function and haematological parameters and consider dose reduction if required.",""
69739,"Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive drugs (e.g. flucytosine) may also increase the risk of adverse reactions to zidovudine. Monitor renal function and haematological parameters and consider dose reduction if required.",""
69743,"Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive drugs (e.g. vinblastine) may also increase the risk of adverse reactions to zidovudine.Monitor renal function and haematological parameters and consider dose reduction if required.",""
69747,Coadministration of nevirapine (200 mg twice daily) with zidovudine (100-200 mg three times daily) decreased zidovudine AUC (28%) and Cmax (30%). There was no significant effect on nevirapine pharmacokinetics. No dosage adjustments are recommended. Granulocytopenia is commonly associated with zidovudine. Haematological parameters should be carefully monitored in patients receiving nevirapine and zidovudine and who have an increased risk of granulocytopenia.,""
69750,Coadministration with didanosine gastro-resistant capsules has not been studied. Coadministration with didanosine buffered tablets had no effect on didanosine AUC and Cmax; zidovudine AUC and Cmax decreased by 10% and 17%. No dose adjustment is necessary.,""
69755,No significant interaction was observed&nbsp;when zidovudine (500 mg/day) and aciclovir were coadministered to 20 HIV-infected subjects.,""
103438,"Coadministration of nevirapine with atazanavir/ritonavir is contraindicated as it increases nevirapine exposure and decreases atazanavir exposure. There is potential risk for nevirapine-associated toxicity due to increased nevirapine exposures, whereas the decreased atazanavir exposure may result in loss of therapeutic effect and development of resistance.",""
70103,Coadministration is contraindicated as it may increase astemizole concentrations which may increase potential serious and/or life-threatening adverse reactions such as cardiac arrhythmias. ,""
70127,Coadministration is contraindicated as it may increase cisapride concentrations which may increase potential serious and/or life-threatening adverse reactions such as cardiac arrhythmias. ,""
70148,Coadministration is contraindicated as it may increase dihydroergotamine concentrations which may increase potential serious and/or life-threatening adverse reactions such as acute ergot toxicity. ,""
70153,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxorubicin is mainly eliminated in the bile and does not undergo CYP-mediated metabolism. Doxorubicin is a substrate of P-glycoprotein, however, coadministration with protease inhibitors did not modify significantly doxorubicin exposure.",""
70162,Coadministration is contraindicated as it may increase ergometrine concentrations which may increase potential serious and/or life-threatening adverse reactions such as acute ergot toxicity. ,""
70163,Coadministration is contraindicated as it may increase ergotamine concentrations which may increase potential serious and/or life-threatening adverse reactions such as acute ergot toxicity. ,""
70179,"Coadministration has not been studied. Fluconazole is a moderate inhibitor of CYP3A4, however, drug interactions studies with other protease inhibitors showed no clinically significant interactions with fluconazole.",""
70207,"Coadministration is contraindicated as it is expected to markedly increase lovastatin concentrations which may cause myopathy, including rhabdomyolysis. ",""
70243,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Fosamprenavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
70249,Coadministration is contraindicated as it may increase pimozide concentrations which may increase potential serious and/or life-threatening adverse reactions such as cardiac arrhythmias. ,""
70295,Coadministration is not recommended as it may increase triazolam concentrations which may increase potential serious and/or life-threatening adverse reactions such as prolonged sedation or respiratory depression. ,""
70275,"Coadministration is contraindicated as it is expected to markedly increase simvastatin concentrations which may cause myopathy, including rhabdomyolysis. ",""
70288,Coadministration is contraindicated as it may increase terfenadine concentrations which may increase potential serious and/or life-threatening adverse reactions such as cardiac arrhythmias. ,""
114548,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with atazanavir/ritonavir is unlikely.",""
114549,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with darunavir/cobicistat is unlikely.",""
115816,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115817,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116026,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
70611,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Varenicline is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion by OCT2. There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms as cimetidine (an inhibitor of renal transporters) was shown to increase varenicline exposure to a limited extent (29%).,""
116027,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sulpiride is mainly excreted in the urine and faeces as unchanged drug.,""
116028,"Coadministration has not been studied. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. No effect on thioridazine is expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Thioridazine is a moderate inducer of CYP3A4 and could potentially decrease dolutegravir concentrations, but this is unlikely to be of clinical significance as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
70893,,""
71104,"Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19.",""
70953,No significant interactions are expected with either formulation of didanosine (chewable tablets or gastro-resistant capsules). No dose separation or dosage adjustments are necessary.,""
71077,No clinically significant interaction observed. ,""
71156,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atovaquone is mainly eliminated unchanged in the faeces.,""
71469,"No data in humans, but inhibited CYP3A-mediated metabolism of saquinavir in rat liver microsomes. Simultaneous coadministration with saquinavir in rats increased saquinavir exposure by ~3-fold. Separating the doses by 2 h overcame the interaction. ",""
71520,"Coadministration has not been studied. Quetiapine is primarily metabolised by CYP3A4 and coadministration with ketoconazole (a CYP3A4 inhibitor) increased quetiapine AUC by 5- 8 fold. The European SPC for quetiapine contraindicates quetiapine with CYP3A4 inhibitors (such as HIV protease inhibitors). However, the US Prescribing Information recommends that quetiapine should be reduced to one sixth of the original dose if coadministered with a potent CYP3A4 inhibitor. These interaction charts reflect the more cautious option.",""
71690,Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Levetiracetam undergoes enzymatic hydrolysis (non CYP) and is eliminated unchanged in the urine by glomerular filtration. ,""
71722,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation.",""
71873,Coadministration of valerian with probe substrates for CYP3A4 (alprazolam) and CYP2D6 (dextromethorphan) modestly increased alprazolam Cmax and AUC (~20%) and had no effect on dextromethorphan. A clinically significant interaction is unlikely with drugs metabolised by CYP3A4 or CYP2D6. ,""
81936,Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely.,""
114550,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with darunavir/ritonavir is unlikely.",""
114551,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with darunavir/cobicistat is unlikely. No interaction is expected with emtricitabine or tenofovir alafenamide.",""
72412,"Coadministration has not been studied.Caffeine is mainly metabolized by CYP1A2. In vivo data indicate that ritonavir induces CYP1A2 and therefore boosted protease inhibitors could potentially decrease caffeine concentrations. However, no a priori dose adjustment is required.",""
72362,"Coadministration not recommended due to increased risk of hepatotoxicity, peripheral neuropathy and pancreatitis.",""
124243,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is eliminated unchanged in the kidneys by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
124244,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124245,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan, which is eliminated in the faeces and urine.",""
72803,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally.,""
124246,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olodaterol is metabolized by CYP2C8, CYP2C9, is glucuronidated via several UGTs, and is a substrate of P-gp. Cabotegravir does not inhibit or induce CYP or UGT enzymes, or P-glycoprotein at clinically relevant concentrations.",""
124247,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interaction is expected with ombitasvir. Paritaprevir/ritonavir inhibit intestinal P-glycoprotein and BCRP. Cabotegravir is a substrate of P-glycoprotein and BCRP but inhibition of these transporters is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.,""
73015,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Emtricitabine does not affect the zolmitriptan metabolic pathway.,""
73016,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Lamivudine does not affect the zolmitriptan metabolic pathway.,""
124248,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interaction is expected with ombitasvir or dasabuvir. Paritaprevir/ritonavir and dasabuvir inhibit intestinal P-glycoprotein and BCRP. Cabotegravir is a substrate of P-glycoprotein and BCRP but inhibition of these transporters is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.,""
124249,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Omeprazole is mainly metabolized by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.,""
124250,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124251,"Coadministration has not been studied. Orlistat should only be used with cabotegravir if separated by 4-5 hours. Orlistat reduces dietary fat absorption and may affect the absorption of antiretrovirals (especially if lipophilic). [Note: this interaction is not specific for cabotegravir, but for any medication taken with orlistat.]",""
73001,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with fosamprenavir/ritonavir. However, fosamprenavir/ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
73002,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with indinavir/ritonavir. However, indinavir/ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
73006,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with saquinavir/ritonavir. However, saquinavir/ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
124252,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases. The latter is excreted in the urine by glomerular filtration and tubular secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.,""
124253,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
73056,Coadministration has not been studied. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4. Coadministration could potentially increase prednisolone concentrations thus increasing the risk of steroid related toxicity. Careful monitoring for adverse effects is recommended.,""
73093,Ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid.,""
114552,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with elvitegravir/cobicistat is unlikely. No interaction is expected with emtricitabine or tenofovir alafenamide.",""
73358,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected.",""
103355,Coadministration of atazanavir/ritonavir (300/100 mg once daily) and fluconazole (200 mg once daily) resulted in no clinically significant interaction. No dosage adjustments are needed for atazanavir/ritonavir and fluconazole.,""
73413,"In vitro data indicate that extracts of hops activate PXR and induce expression of CYP3A4, CYP2B6 and MDR1 genes to a degree similar to that of St John's wort. ",""
114553,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with elvitegravir/cobicistat is unlikely. No interaction is expected with emtricitabine or tenofovir-DF.",""
124254,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Oxamniquine is thought to be predominantly metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124256,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated (by UGTs 2B15, 1A9 and 2B7). Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
73607,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as benserazide is hydrolysed to trihydroxybenzylhydrazine. ,""
73726,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. In vivo data indicate that ritonavir is a modest inducer of CYP2C9, but a dose adjustment is unlikely to be required for nimesulide when coadministered with a boosted protease inhibitor.",""
73908,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ropinirole is metabolised predominantly by CYP1A2.,""
73756,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion.,""
124257,Coadministration has not been studied but is contraindicated. Cabotegravir exposure is expected to decrease due to induction of UGT by oxcarbazepine and thereby result in loss of therapeutic effect and development of resistance.,""
73834,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT).,""
73924,"Coadministration has not been studied but may potentially reduce the efficacy of tamoxifen as inhibition of CYPs 3A4 and 2D6 may reduce the amount of drug converted to endoxifen (a pharmacologically active metabolite). Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4. ",""
73983,"Coadministration has not been studied. Darifenacin is metabolized by CYP3A4 and CYP2D6 and coadministration is likely to increase concentrations. A 5-fold increase in darifenacin exposure was seen with ketoconazole (a strong inhibitor of CYP3A4) and the magnitude of the interaction could be even more pronounced in poor metabolizer individuals. The European Summary of Product Characteristics for darifenacin contraindicates its use with potent CYP3A4 inhibitors (such as ritonavir), but the US Prescribing Information recommends that the dose of darifenacin should not exceed 7.5mg when coadministered with potent CYP3A4 inhibitors.",""
74002,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amikacin is eliminated renally by glomerular filtration.,""
74156,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. ",""
74307,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that Serenoa repens inhibits CYP2C9, CYP2D6 and CYP3A4 activity. However, clinical studies found that administration of Serenoa repens did not alter CYP3A4 or CYP2D6 activity in healthy volunteers. Thus, a clinically relevant interaction is unlikely with substrates of CYP3A4 and CYP2D6.",""
114554,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with fosamprenavir is unlikely.",""
114555,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with indinavir is unlikely.",""
74530,"Coadministration has not been studied. Duloxetine is metabolized by CYP2D6 and CYP1A2. In vitro data indicate that ritonavir induces CYP1A2 but inhibits CYP2D6. The net clinical effect of this interaction is difficult to predict, but is expected to be of weak intensity. No a priori dosage adjustment is required.",""
74588,Coadministration has not been studied. Nebivolol metabolism involves CYP2D6. Coadministration could potentially increase nebivolol concentrations although to a moderate extent and no a priori dosage adjustment is recommended.,""
74751,Coadministration has not been studied. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers. The European SPC for tolterodine advises that coadministration with potent CYP3A4 inhibitors should be avoided due to increased tolterodine concentrations in CYP2D6 poor metabolisers whereas the US Prescribing Information recommends a maximum tolterodine dose of 1 mg twice daily.,""
114556,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with lopinavir is unlikely.",""
74773,Coadministration has not been studied. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. Coadministration could potentially increase zonisamide concentrations. This interaction may not be clinically relevant as coadministration of zonisamide and ketoconazole (a strong inhibitor of CYP3A4) had no effect on the single-dose pharmacokinetics of zonisamide given to healthy subjects.,""
124258,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised by glucuronidation. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
124259,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects,""
124260,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Oxycodone is metabolised principally by CYP3A and CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
75470,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism.,""
75268,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is metabolized to 6-mercaptopurine which is further inactivated by xanthine oxidase and thiopurine methyltransferase. ,""
75336,"Coadministration has not been studied. Finasteride is metabolised by CYP3A4 and coadministration may increase finasteride concentrations. However, any increase is unlikely to be of clinical significance due to finasterideâ€™s wide margin of safety and no a priori dose alteration is recommended.",""
75473,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Maraviroc does not interact with ciclesonide metabolism.,""
75519,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases which is then excreted in the urine by glomerular filtration and tubular secretion by OAT1.,""
75457,"Coadministration has not been studied. Ciclesonide can be administered with ritonavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with ritonavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
75499,Coadministration has not been studied. Reboxetine is metabolized by CYP3A4 and coadministration could potentially increase reboxetine concentrations. Monitor side effects.,""
75546,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated renally by glomerular filtration and active secretion. A bicarbonate dependent organic cation transporter has been identified as  the major uptake transporter of amantadine in the renal proximal tubule.,""
75621,"Coadministration with ritonavir may increase concentrations of docetaxel and increase the risk of severe toxicities. There have been several case reports of severe haematological and cutaneous toxicity when coadministered with ritonavir, a potent CYP3A inhibitor. Ideally avoid coadministration with boosted protease inhibitors or consider using an alternative taxane. ",""
124262,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. In vitro data suggest that paclitaxel activates PXR and therefore has potential inducing properties. No significant effect is expected on cabotegravir based on the drug interaction study with rifabutin (a moderate inducer).,""
75776,Coadministration has not been studied significant drug interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role.,""
75738,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism, although the exact pathway is not known. It is unlikely that CYP enzymes are involved in this process and no transporter interactions have been described. There is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes.",""
75853,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase.,""
75960,"Coadministration has not been studied. As ulipristal is mainly metabolized by CYP3A4, there is the potential for coadministration to increase ulipristal exposure. However, since ulipristal is used as a single dose for emergency contraception, this interaction is unlikely to be clinically significant.",""
114557,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with saquinavir is unlikely.",""
114558,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with tipranavir is unlikely.",""
76009,The use of rivaroxaban is not recommended with HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree which may lead to an increased bleeding risk. ,""
76120,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desipramine is metabolized by CYP2D6.,""
76225,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway.,""
76385,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amiodarone is metabolized by CYP3A4.,""
114559,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and an interaction with ritonavir is unlikely.",""
76471,Coadministration has not been studied. Erythromycin is considered to be a moderate inhibitor of CYP3A4 but a clinically significant interaction is not expected as raltegravir is metabolised by UGT1A1.,""
114561,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of rilpivirine.",""
114562,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of rilpivirine, emtricitabine or tenofovir alafenamide.",""
124263,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly OCT), with minimal metabolism occurring via CYP2D6 and 3A4. Cabotegravir does not cause clinically relevant inhibition of renal transporters and was shown to have no inhibitory or inducing effects on CYP enzymes at clinically relevant concentrations.",""
124264,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.,""
76577,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely is unlikely as vigabatrin is cleared mainly by glomerular filtration.,""
124265,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
114563,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of doravirine.",""
124266,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (via UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15) and sulfation and, to a lesser extent, by oxidation. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124267,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as paromomycin is not metabolized, but is eliminated unchanged by renal glomerular filtration.",""
124268,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYPs 2D6 and 3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
76754,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as perphenazine is metabolized by CYP2D6. ,""
124269,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Pazopanib is metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C8. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. In vitro data indicate that pazopanib inhibits UGT1A1. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, but it is unlikely to be affected by pazopanib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. ",""
76817,Coadministration has not been studied but based on  metabolism and clearance a clinically significant interaction is unlikely as alprazolam is metabolized mainly by CYP3A4. ,""
114564,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of doravirine, lamivudine or tenofovir-DF.",""
124270,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is primarily metabolised by UGT1A1, and to a lesser extent by UGT1A9. These pathways are not affected by peginterferon alfa-2a.The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
77067,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolized by CYP3A4 and CYP2C8. ,""
124271,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is primarily metabolised by UGT1A1, and to a lesser extent UGT1A9. These pathways are not affected by peginterferon alfa-2b.",""
124272,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although metabolism of penicillamine is not fully elucidated, multiple mechanisms and sites of metabolism are thought to be involved. There is, therefore, low potential for clinically significant interactions with cabotegravir.",""
124273,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3.,""
77159,"Based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alfa and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
77220,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is&nbsp;unlikely with vitamin E when given alone or in multivitamins.,""
124274,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The exact metabolic pathway of pentamidine has not been clearly established. Data from animal studies suggest the involvement of CYPs 1A1, 2D6 and 2C19 in the oxidative metabolism of pentamidine. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124275,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124276,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124277,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
114565,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of bictegravir, emtricitabine or tenofovir alafenamide.",""
114566,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of dolutegravir.",""
114567,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of dolutegravir or rilpivirine.",""
114568,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of raltegravir.",""
114569,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of maraviroc.",""
114570,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and it is unlikely that efavirenz will significantly reduce argatroban exposure due to induction of CYP3A4.",""
124279,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124280,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
77766,"This interaction has not been studied. Based on the metabolism/elimination profiles of both drugs, there is little potential for pharmacokinetic interaction, however caution is advised due to possible cardiac toxicities (ECG abnormalities and sometimes arrhythmias). Use with caution. ECG monitoring is recommended.",""
124281,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4). Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
124283,"Coadministration has not been studied. The interaction between phenobarbital (an inducer of UGT1A1) and oral cabotegravir (30 mg once daily) was evaluated using a PBPK model, which predicted a 28% decrease in cabotegravir exposure. The US product information contraindicates the coadministration due to potential for loss of therapeutic effect and development of resistance.",""
124284,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
77889,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic biostranformation through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly 2A6).",""
77923,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as isoflurane is almost exclusively eliminated unchanged by the lungs.",""
77958,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally.,""
80338,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with pyridoxine when given alone or in multivitamins. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid.,""
77975,Coadministration has not been studied but based on metabolism and clearance a clinically significant&nbsp;interaction is unlikely as sevoflurane is almost exclusively eliminated unchanged by the lungs.,""
78038,Coadministration of valerian with probe substrates for CYP3A4 (alprazolam) and CYP2D6 (dextromethorphan) modestly increased alprazolam Cmax and AUC (~20%) and had no effect on dextromethorphan. A clinically significant interaction is unlikely with drugs metabolised by CYP3A4 or CYP2D6.,""
114467,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of&nbsp;atazanavir.",""
114468,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of&nbsp;atazanavir/ritonavir.",""
114470,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of&nbsp;indinavir.",""
124285,Coadministration has not been studied. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir AUC by 59%. A similar effect is expected with phenytoin. Therefore coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.,""
124286,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal. No effect is expected on cabotegravir.,""
78116,"Coadministration is expected to increase colchicine concentrations. Ritonavir (100 mg twice daily) significantly increased colchicine Cmax (2.7-fold) and AUC (3.5-fold) when given with a single dose of colchicine (0.6 mg). Patients with renal or hepatic impairment should not be coadministered colchicine. A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function. When coadministered for treatment of gout flares, the recommended dosage is 0.6 mg (1 tablet) for 1 dose, followed by 0.3 mg (half tablet) 1 hour later. The dose is to be repeated no earlier than 3 days. When coadministered for prophylaxis of gout flares, if the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day; if the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day. When coadministered for treatment of familial Mediterranean fever (FMF) do not exceed a maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).",""
80800,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4/5 but does not inhibit or induce this enzyme.,""
114479,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil exposure by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of elvitegravir/cobicistat. Emtricitabine and tenofovir alafenamide do not interact with this pathway.",""
114480,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil exposure by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of elvitegravir/cobicistat. Emtricitabine and tenofovir-DF do not interact with this pathway.",""
114481,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Dolutegravir is mainly metabolized by UGT1A1 and is not expected to inhibit or induce CYP enzymes at clinically relevant concentrations.,""
114482,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Dolutegravir and rilpivirine are not expected to inhibit or induce CYP enzymes at clinically relevant concentrations.,""
114483,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce UGTs.,""
114484,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs. Doravirine does not inhibit or induce CYP enzymes.,""
114485,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs. Doravirine does not inhibit or induce CYP enzymes. Lamivudine and tenofovir-DF do not interact with avanafilâ€™s metabolic pathway.,""
114486,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Bictegravir does not inhibit or induce CYP450 enzymes; emtricitabine and tenofovir alafenamide do not interact with avanafilâ€™s metabolic pathway.,""
114487,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.,""
114488,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway.,""
114489,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs. Maraviroc does not inhibit or induce CYPs.,""
114490,Coadministration has not been studied but is not recommended. Avanafil is primarily metabolized by CYP3A4 and concentrations (and efficacy) may decrease due to induction of CYP3A4 by&nbsp;efavirenz.,""
114491,Coadministration has not been studied but is not recommended. Avanafil is primarily metabolized by CYP3A4 and concentrations (and efficacy) may decrease due to induction of CYP3A4 by&nbsp;etravirine.,""
114492,Coadministration has not been studied but is not recommended. Avanafil is primarily metabolized by CYP3A4 and concentrations (and efficacy) may decrease due to induction of CYP3A4 by&nbsp;nevirapine.,""
114493,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4.&nbsp;,""
103321,Coadministration of tricyclic antidepressants has the potential to produce serious and/or life-threatening adverse events and has not been studied. Concentration monitoring of these drugs is recommended. Nortriptyline is metabolized mainly by CYP2D6. Atazanavir/ritonavir could potentially increase nortriptyline exposure although to a moderate extent. Caution should also be exercised when administering both drugs due to the risk of QT prolongation. ECG monitoring is recommended.,""
124287,"Coadministration has not been studied. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal. A pharmacokinetic interaction is unlikely with phytomenadione itself. However, phytomenadione can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124288,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
114469,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of fosamprenavir.",""
114471,Coadministration is contraindicated. Avanafil is primarily metabolized by CYP3A4. Coadministration of avanafil (50 mg single dose) and ritonavir (600 mg twice daily) increased avanafil AUC and Cmax by 13-fold and 2.4-fold.,""
124289,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is metabolized mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124291,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124292,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperacillin is eliminated renally via glomerular filtration and active secretion by OAT1/3. Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3.,""
124293,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperaquine is a modest inhibitor of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124294,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
78238,"This interaction has not been studied. 8 days co-administration of ritonavir and mebendazole significantly decreased mebendazole exposure (AUC 57%, Cmax 59%). Administration of mebendazole with cimetidine, a CYP3A4 inhibitor, resulted in increased serum levels of mebendazole. The effect of administering a ritonavir-boosted protease inhibitor on mebendazole pharmacokinetics is not known. ",""
124295,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124296,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
78590,"This interaction has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, there is little potential for interaction, although due to the lack of data, vigilance is required if administering nifurtimox with antiretrovirals. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase.",""
85767,Coadministration is contraindicated as it may increase alfuzosin concentrations which may lead to severe hypotension.,""
78508,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elimination of sodium stibogluconate is predominantly via renal glomerular filtration.,""
78666,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion.",""
124298,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4). Posaconazole is a strong inhibitor of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124299,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely as potassium is eliminated renally.",""
124300,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
124301,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
78385,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Suramin appears to be eliminated predominantly unchanged via renal glomerular filtration. Suramin is not expected to affect metabolism mediated via CYP450 enzymes.",""
124303,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Praziquantel is predominantly metabolised via CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
78855,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefazolin is predominantly eliminated unchanged via the kidneys.",""
124304,"Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124305,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone is metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. ,""
80402,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with thiamine when given alone or in multivitamins.,""
78483,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Paromomycin is not metabolized, it is eliminated unchanged by renal glomerular filtration. ",""
78551,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Eflornithine is predominantly eliminated unchanged via the kidneys.",""
87672,"Coadministration has not been studied. Increased didanosine concentrations and toxicity were observed when combined with tenofovir-DF. A similar effect with tenofovir alafenamide cannot be excluded. If this combination is judged strictly necessary, patients should be carefully monitored for efficacy and didanosine related adverse events.",""
103396,"Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. The AUCs of single dose atovaquone/proguanil (250/100 mg) were 46% and 41% lower, respectively, in HIV-infected individuals on stable antiretroviral treatment containing atazanavir/ritonavir (300/100 mg once daily) than in healthy volunteers. The decrease in proguanil exposure has been attributed to possible induction of CYP2C19 by atazanavir/ritonavir. The clinical relevance of this interaction is unknown due to the lack of data on the minimal effective atovaquone plasma concentration in the setting of malaria prophylaxis. Consider taking atovaquone/proguanil with a high fat meal to increase its bioavailability and increase the dosage if required.",""
78715,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cycloserine is predominantly excreted renally via glomerular filtration.",""
78737,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ethionamide is extensively metabolized in the liver, animal studies suggest involvement of flavin-containing monooxygenases. Ethionamide does not affect metabolism mediated by CYP450 enzymes in vitro.",""
114571,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and it is unlikely that etravirine will significantly reduce argatroban exposure due to induction of CYP3A4.",""
114572,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Erythromycin (a strong CYP3A4 inhibitor) had no effect on argatroban pharmacokinetics and pharmacodynamics and it is unlikely that nevirapine will significantly reduce argatroban exposure due to induction of CYP3A4.",""
114574,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperaquine is mainly metabolized by CYP3A4.,""
114586,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Atazanavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
114587,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Atazanavir/cobicistat could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
124306,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
114588,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Atazanavir/ritonavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
114589,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Darunavir/cobicistat could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
114590,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Darunavir/ritonavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
114591,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Darunavir/cobicistat could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered. No interaction is expected with emtricitabine or tenofovir alafenamide.,""
114592,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Elvitegravir/cobicistat could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered. No interaction is expected with emtricitabine or tenofovir alafenamide.,""
78813,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ampicillin is predominantly eliminated unchanged via renal pathways.",""
78836,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefalexin is predominantly eliminated unchanged via the kidneys.",""
114593,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Elvitegravir/cobicistat could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered. No interaction is expected with emtricitabine or tenofovir-DF.,""
114594,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Fosamprenavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
79158,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;Vancomycin is predominantly eliminated unchanged via renal glomerular filtration.,""
80841,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vildagliptin is inactivated via non-CYP mediated hydrolysis.,""
114595,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Indinavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
124308,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
114596,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Lopinavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
124309,"Coadministration has not been studied. Primidone is metabolised by CYP3A4 to the active metabolite phenobarbital. The interaction between phenobarbital (inducer of UGT1A1) and oral cabotegravir (30 mg once daily) was evaluated using a PBPK model, which predicted a 28% decrease in cabotegravir exposure. The US product information contraindicates the coadministration due to potential for loss of therapeutic effect and development of resistance.",""
124310,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. In vitro data suggest that probenecid is a non-selective inhibitor of UGT however it is unlikely to significantly impact cabotegravir exposure. Coadministration with the strong UGT1A1 inhibitor atazanavir was indeed predicted to minimally increase cabotegravir exposure (11%).",""
124311,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and CYP1A) and monoamine oxidase. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
78883,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Approximately 50% of the absorbed dose is excreted unchanged in the urine; there is no evidence of metabolism of cefixime in vivo. In vitro studies have shown that cefixime does not inhibit/induce major cytochrome P450 metabolic enzymes, and would not be expected to cause clinically significant interactions with other drugs, which are metabolized by CYP450 enzymes.",""
124312,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124313,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
114597,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Tipranavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
79380,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. CYP2D6 is thought to have a role in clomifene metabolism.",""
114598,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4. Ritonavir could potentially increase piperaquine concentrations and thereby increase the risk of QT interval prolongation. Caution is advised and ECG monitoring should be considered.,""
114599,Coadministration has not been studied. Saquinavir is contraindicated in patients on concomitant therapy with other drugs that prolong the QT interval such as piperaquine.,""
114601,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4 and may increase rilpivirine concentrations. Rilpivirine should be used with caution when coadministered with a drug that has a potential risk to prolong the QT interval. In healthy subjects, supratherapeutic doses of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QT interval. No interaction is expected with emtricitabine and tenofovir alafenamide.",""
78913,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Cefotaxime is predominantly eliminated unchanged via the kidneys.",""
124314,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
80753,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is primarily eliminated by glomerular filtration. ,""
124315,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124316,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated via UGT1A9 and UGT1A8, and is oxidized mainly via CYP2B6. Cabotegravir was shown to have no inhibitory or inducing effects on CYP or UGT enzymes at clinically relevant concentrations.",""
80996,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cisplatin is eliminated renally.,""
78945,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Ceftriaxone is eliminated mainly as unchanged drug; approximately 60% of the dose being excreted in the urine, almost exclusively by glomerular filtration, and the remainder via the biliary and intestinal tracts.",""
124317,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124318,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Propylthiouracil is extensively metabolised, predominantly via glucuronidation, but the exact glucuronidation pathways are unknown. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124319,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of protamine has not been fully elucidated, however protamine complexed with heparin is thought to be partially metabolised by fibrinolysin.",""
124320,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
124321,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrantel is metabolized by CYP2D6 in vitro, however, absorption of an oral dose is minimal and over 50% of a dose is excreted unchanged in the faeces.",""
124323,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Pyridostigmine is mainly eliminated unchanged by the kidney (via glomerular filtration and active tubular secretion most likely by a cation transporter). Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
79263,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp; An in vitro study has shown that daunorubicin was able to inhibit metabolism mediated by CYP3A4, but was unlikely to cause clinically significant drug interactions via this mechanism. A clinical study showed that protease inhibitors indinavir, saquinavir or ritonavir did not significantly affect liposomal daunorubicin pharmacokinetics.",""
106853,"Coadministration of twice daily raltegravir and atazanavir alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of raltegravir (400 mg twice daily) and atazanavir/ritonavir increased raltegravir AUC (41%), Cmax (24%) and Cmin (77%). However, concomitant use of twice daily raltegravir and atazanavir/ritonavir did not result in a unique safety signal in clinical studies, therefore, no dose adjustment of raltegravir is required when given twice daily. Coadministration of raltegravir (1200 mg single dose) and atazanavir alone increased raltegravir AUC (67%), Cmax (16%) and Cmin (26%). The US product label for raltegravir states that no dose adjustment is required with atazanavir and once daily raltegravir, however, the European label does not recommend coadministration with once daily raltegravir.",""
79024,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal clearance of unchanged drug occurs via glomerular filtration and to a lesser extent, active tubular secretion for both imipenem (when administered with cliastatin), and cilastatin.",""
79078,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. No significant metabolism of doxycycline occurs, it is cleared intact by renal and biliary mechanisms.",""
106873,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with other antiretroviral agents is not recommended in Delstrigo product labels. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir would be possible from a pharmacokinetic standpoint. Coadministration with ritonavir increased doravirine AUC by 3.5 fold and Cmin by 2.9 fold. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure. In a combined analysis of several clinical studies with tenofovir-DF (300 mg) and atazanavir/ritonavir (300/100 mg), tenofovir AUC, Cmax and Cmin increased by 37%, 34% and 29%, respectively. Thus, patients should be closely monitored for tenofovir-associated adverse events, including renal disorders. Atazanavir/r should be dosed at 400/100 mg once daily in presence of tenofovir-DF and an H2-receptor antagonist due to the resulting decrease in atazanavir exposure.",""
102332,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Atazanavir is metabolised by CYP3A4. Cobicistat is primarily metabolised by CYP3A4 with minor contribution from CYP2D6. Peginterferon alfa-2a has no effect on CYP3A4 or CYP2D6. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
96133,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Darunavir is metabolised by CYP3A4. Cobicistat is primarily metabolised by CYP3A4 with minor contribution from CYP2D6. Peginterferon alfa-2a has no effect on CYP3A4 or CYP2D6. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
97593,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Darunavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
79034,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Renal clearance of unchanged drug occurs via glomerular filtration and to a lesser extent, active tubular secretion for both imipenem (when administered with cilastatin), and cilastatin.",""
124325,"Coadministration has not been studied. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. A pharmacokinetic interaction is unlikely with pyridoxine itself. However, pyridoxine can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
69329,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Tipranavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
114602,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4. No interaction is expected with dolutegravir as CYP3A4 plays a minor role in dolutegravir metabolism. However, piperaquine may increase rilpivirine concentrations. Rilpivirine should be used with caution when coadministered with a drug that has a potential risk to prolong the QT interval. In healthy subjects, supratherapeutic doses of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QT interval.&nbsp;",""
124327,Coadministration has not been studied. Quercetin has the ability to modulate CYP/P-gp activities although there are inconsistencies in the literature. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124328,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is metabolized mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124329,"Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat, which is eliminated primarily by renal excretion via OAT3. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
114603,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4 and concentrations and efficacy may be reduced due to induction of CYP3A4 by efavirenz. Concomitant administration is not recommended.,""
124330,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinidine is metabolized by CYP3A4, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
124331,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinine is extensively metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
114604,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4 and concentrations and efficacy may be reduced due to induction of CYP3A4 by etravirine. Concomitant administration is not recommended.,""
114605,Coadministration has not been studied. Piperaquine is metabolized predominantly by CYP3A4 and concentrations and efficacy may be reduced due to induction of CYP3A4 by nevirapine. Concomitant administration is not recommended.,""
114606,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4 and may increase doravirine concentrations, although to a limited extent. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure.",""
124332,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolized by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.,""
116099,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
79114,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. 30-40% of a nitrofurantoin dose is eliminated unchanged via the kidneys, with a small proportion metabolized to aminofurantoin.",""
114607,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4 and may increase doravirine concentrations, although to a limited extent. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure. No interaction is expected with lamivudine and tenofovir-DF.",""
70506,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etravirine is metabolised by CYPs 3A4, 2C9 and 2C19 which are not affected by peginterferon alfa-2a.The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.&nbsp;",""
77803,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rilpivirine is metabolised primarily by CYP3A which is not affected by peginterferon alfa-2a. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.&nbsp;",""
124333,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Raltegravir is mainly glucuronidated by UGT1A1. Cabotegravir does not inhibit or induce UGT enzymes.,""
124334,"Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
77157,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Abacavir is metabolised by alcohol dehydrogenase and UGT which are not affected by peginterferon alfa-2a. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
124335,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranitidine is excreted via the kidney, partially by the cationic system. Cabotegravir does not cause clinically relevant inhibition of renal transporters.Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.",""
87555,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia. Dose Descovy according to the concomitant antiretroviral.",""
124336,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124337,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as rasagiline is metabolised predominantly by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
93731,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. No effect of peginterferon alfa-2a on bictegravir, emtricitabine or tenofovir alafenamide is expected. The metabolism of peginterferon alfa-2a is not fully characterized, however studies in rats indicate that the kidney is a major organ for excretion. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
82108,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. These pathways are not affected by peginterferon alfa-2a. The metabolism of peginterferon alfa-2a is not fully characterized, however studies in rats indicate that the kidney is a major organ for excretion.",""
86396,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. No effect of peginterferon alfa-2a on elvitegravir, cobicistat, emtricitabine or tenofovir-DF is expected. The metabolism of peginterferon alfa-2a is not fully characterized, however studies in rats indicate that the kidney is a major organ for excretion. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Therefore, patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114143,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Atazanavir is metabolised by CYP3A4. Cobicistat is primarily metabolised by CYP3A4 with minor contribution from CYP2D6. Peginterferon alfa-2b may inhibit CYP2D6 to a limited extent, however, this is unlikely to be clinically relevant. Peginterferon alfa-2b has no effect on CYP3A4.",""
114152,"Coadministration has not been studied but, based on metabolism and clearance, a pharmacokinetic interaction is unlikely. Darunavir is metabolised by CYP3A4. Cobicistat is primarily metabolised by CYP3A4 with minor contribution from CYP2D6. Peginterferon alfa-2b may inhibit CYP2D6 to a limited extent, however, this is unlikely to be clinically relevant. Peginterferon alfa-2b has no effect on CYP3A4. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114144,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Darunavir is metabolised by CYP3A4. Cobicistat is primarily metabolised by CYP3A4 with minor contribution from CYP2D6. Peginterferon alfa-2b may inhibit CYP2D6 to a limited extent, however, this is unlikely to be clinically relevant. Peginterferon alfa-2b has no effect on CYP3A4.",""
114145,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Atazanavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114146,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Fosamprenavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114147,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Indinavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114148,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Lopinavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114149,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Saquinavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114150,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Tipranavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114151,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Ritonavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114153,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Doravirine is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114154,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Doravirine is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
79300,"This interaction has not been studied. Based on the metabolic/toxicity profiles of both drugs, there is little potential for interaction. Mesna is rapidly oxidised to its only metabolite, mesna disulphide via the physiological cysteine system. Approximately 32% and 33% of an administered dose is eliminated in the urine in 24 hours as mesna and mesna disulphide respectively.",""
124338,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124339,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K, a natural component with the same chemical structure as lovastatin. Monacolin K is metabolised by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.",""
114155,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Efavirenz is a substrate and inducer of CYP3A4. Peginterferon alfa-2b neither affects, nor is affected by, CYP3A4.",""
114156,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etravirine is metabolised by CYPs 3A4, 2C9 and 2C19. Peginterferon alfa-2b may inhibit CYP2C19 to a limited extent which could potentially lead to a small increase in etravirine concentrations, but this is unlikely to be clinically relevant. Peginterferon alfa-2b has no effect on CYP3A4 or CYP2C9.",""
114157,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Nevirapine is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114158,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Rilpivirine is metabolised primarily by CYP3A which is not affected by peginterferon alfa-2b.,""
114159,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. Rilpivirine is metabolised primarily by CYP3A. These pathways are not affected by peginterferon alfa-2b.&nbsp;",""
114161,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Abacavir is metabolised by alcohol dehydrogenase and UGT which are not affected by peginterferon alfa-2b. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114162,"Coadministration of peginterferon alfa-2b, ribavirin and didanosine is not recommended. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.",""
114164,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia. Dose Descovy according to the concomitant antiretroviral.",""
114172,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. No effect of peginterferon alfa-2b on elvitegravir, cobicistat, emtricitabine or tenofovir alafenamide is expected. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Therefore, patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114166,"Coadministration with peginterferon alfa-2b has not been studied. In a trial with another pegylated interferon alfa, no evidence of a pharmacokinetic or pharmacodynamic (e.g., loss of HIV/HCV virologic suppression) interaction was seen when lamivudine and ribavirin were co-administered to 18 HIV/HCV co-infected subjects as part of a multidrug regimen. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114167,"Coadministration with peginterferon alfa-2b has not been studied. In a trial with another pegylated interferon alfa, no pharmacokinetic or pharmacodynamic (e.g., loss of HIV/HCV virologic suppression) interaction was seen when stavudine and ribavirin were coadministered to 10 HIV/HCV co-infected subjects as part of a multidrug regimen. However, the incidence of pancreatitis and/or lactic acidosis in patients concurrently treated with stavudine and interferon therapy with or without ribavirin was 3% (12/398; study NR15961). If coadministration cannot be avoided, monitor for treatment-associated toxicities, especially hepatic decompensation.",""
114168,"Based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114169,"Coadministration is not recommended. Based on the metabolism and clearance a pharmacokinetic interaction is unlikely. However, patients treated with peginterferon and zidovudine (with or without ribavirin) are at increased risk of developing anaemia. Monitor blood cell count and suppressive effect on bone marrow function if zidovudine is coadministered with peginterferon alfa-2b. Discontinuation of zidovudine should be considered as medically appropriate. Dose reduction or discontinuation of peginterferon alfa-2b, ribavirin or both should also be considered if worsening clinical toxicities are observed.",""
79416,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Misoprostol is predominantly metabolised via fatty acid oxidising systems and has no effect on the CYP450 enzyme system.",""
114170,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. No effect of peginterferon alfa-2b on bictegravir, emtricitabine or tenofovir alafenamide is expected. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114175,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Raltegravir is metabolised by UGT1A1 which is not affected by peginterferon alfa-2b.,""
114174,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Maraviroc is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.,""
114584,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperaquine is a modest inhibitor of CYP3A4 but this is unlikely to cause a clinically significant interaction as CYP3A4 plays a minor role in dolutegravir metabolism.,""
114173,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. No effect of peginterferon alfa-2b on elvitegravir, cobicistat, emtricitabine or tenofovir-DF is expected. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Therefore, patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114177,"Coadministration of atazanavir alone and tenofovir alafenamide alone has not been studied. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and tenofovir alafenamide (10 mg once daily, with emtricitabine) increased tenofovir AUC and Cmax by 91% and 77%. Coadministration of atazanavir/cobicistat (300/150 mg once daily) and tenofovir alafenamide (10 mg, with emtricitabine) increased tenofovir alafenamide AUC and Cmax by 75% and 80%. No significant effects were observed on atazanavir pharmacokinetics.&nbsp;",""
114608,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperaquine is a modest inhibitor of CYP3A4 and may increase bictegravir concentrations but to a limited extent. This increase is unlikely to be clinically significant; available dose exposure data, as well as data from phase 2 and phase 3 studies (48 weeks treatment), have shown a good safety profile with up to a 2.4 fold increase in bictegravir AUC. No interaction is expected with emtricitabine and tenofovir alafenamide.",""
114609,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4 and may increase maraviroc concentrations, although to a limited extent. No dose adjustment of maraviroc is required.",""
79452,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. However, As few data are available, care should be taken when administering oxytocin with antiretrovirals. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes.",""
124340,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYPs 2C8 and 3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
79458,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes.&nbsp;However, as few data are available, care should be taken when administering oxytocin with antiretrovirals. In addition, use with caution due to the risk of QT interval prolongation reported for both drugs.",""
81729,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as&nbsp;sevoflurane is almost exclusively eliminated unchanged by the lungs.,""
76039,"Coadministration has not been studied but based on metabolism and clearance a clinically significant&nbsp;interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6.",""
114178,"Coadministration of atazanavir/cobicistat and tenofovir alafenamide 25 mg for treatment of HBV infection is not recommended. Coadministration of atazanavir/cobicistat (300/150 mg once daily) and tenofovir alafenamide (10 mg once daily) increased atazanavir AUC and Cmin by 6% and 18%, Cmax decreased by 2%. Coadministration is expected to increase tenofovir alafenamide and tenofovir concentrations.&nbsp;",""
114179,"Coadministration with tenofovir alafenamide alone has not been studied. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and tenofovir alafenamide (10 mg once daily, with emtricitabine) increased tenofovir alafenamide AUC and Cmax by 91% and 77%. Tenofovir AUC and Cmax by 162% and 112% (n=10). No significant effects were observed on atazanavir pharmacokinetics relative to historical controls. The European SmPC for tenofovir alafenamide states that coadministration is not recommended but atazanavir is not mentioned in the US PI. This checker reflects the more cautious option.",""
115819,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3, but dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by OCT2.",""
115852,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. Dolutegravir is not expected to inhibit these renal transporters and lamivudine is excreted by different renal transporters.,""
79546,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;Absorbed tetracaine is predominantly metabolised by pseudocholinesterases in the plasma.,""
114180,"Coadministration with tenofovir alafenamide alone has not been studied. Coadministration of darunavir/cobicistat (800/150 mg once daily) and tenofovir alafenamide alone (25 mg once daily, with emtricitabine) decreased tenofovir alafenamide Cmax and AUC by 7% and 2%. Tenofovir Cmax, AUC and Cmin increased by 216%, 224% and 221%, respectively. No significant effects were observed on darunavir or cobicistat pharmacokinetics. The European SmPC for tenofovir alafenamide states that coadministration is not recommended but darunavir is not mentioned in the US PI. This checker reflects the more cautious option.",""
114201,Emtricitabine/tenofovir-DF should not be administered with products containing tenofovir alafenamide.,""
114202,Tenofovir alafenamide can be coadministered with lamivudine. A clinically significant interaction is unlikely.,""
79564,"This interaction has not been studied. Erlotinib is mainly metabolized by CYP3A4 and coadministration could potentially increase erlotinib concentrations. Coadministration of a potent CYP3A4 inhibitor should be avoided, but if this is not possible, use with caution and close monitoring for erlotinib mediated toxicity is necessary.",""
115854,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. In vitro studies indicate that dolutegravir does not inhibit UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
114203,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Stavudine is primarily excreted as unchanged drug in the urine. Renal excretion of intact tenofovir alafenamide is a minor pathway as it is mainly eliminated following metabolism to tenofovir. This results in 90% lower systemic levels of tenofovir compared to tenofovir-DF so clinically significant interactions via this pathway are unlikely.,""
114204,Tenofovir alafenamide should not be administered with tenofovir-DF.,""
114206,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide contains tenofovir alafenamide and must not be administered with other products containing tenofovir alafenamide.",""
80781,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as linagliptin is mainly eliminated as parent compound in faeces.,""
85857,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway. (Note, caution is required if given with calcium supplements as elvitegravir may be subject to chelation by high concentrations of divalent cations which may result in reduced elvitegravir concentrations.)",""
85858,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Zoledronic acid is eliminated unchanged renally.,""
67601,Coadministration is contraindicated as it may increase concentrations of ergot alkaloids which may result in serious or life threatening side effects such as acute ergot toxicity characterised by peripheral vasospasm and ischemia of the extremities and other tissues.,""
114611,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Atazanavir does not interfere with this metabolic pathway.,""
79773,This interaction has not been studied. Gefitinib is metabolized by CYP3A4 and 2D6 and coadministration could potentially increase gefitinib concentrations. Close monitoring of gefitinib induced toxicity is recommended.,""
114208,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) contains tenofovir alafenamide and must not be administered with other products containing tenofovir alafenamide.",""
124342,"Coadministration has not been studied. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. A pharmacokinetic interaction is unlikely with retinol itself. However, retinol can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
114207,"Coadministration with tenofovir alafenamide alone has not been studied. Coadministration of tenofovir alafenamide (10 mg once daily, with emtricitabine) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Cmin by 15%, 2% and 5%, respectively. Tenofovir alafenamide Cmax and AUC increased by 24% and 19%; tenofovir Cmax and AUC increased by 10% and 25%. No dose adjustment of tenofovir alafenamide or dolutegravir is required.",""
124343,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ribavirin is partly metabolized (non CYP mediated) and partly excreted in the urine. Cabotegravir does not cause clinically significant inhibition of renal transporters.,""
114209,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) contains tenofovir-DF and must not be administered with products containing tenofovir alafenamide.",""
114210,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tenofovir alafenamide exposure is not expected to be affected by maraviroc nor is it expected to affect the metabolic and excretion pathways relevant to maraviroc.,""
114211,Coadministration had not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tenofovir alafenamide exposure is not expected to be affected by raltegravir nor is it expected to affect the metabolic and excretion pathways relevant to raltegravir. No dose adjustment of tenofovir alafenamide or raltegravir is expected.,""
114212,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Tenofovir alafenamide is eliminated renally whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
114171,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. These pathways are not affected by peginterferon alfa-2b.&nbsp;",""
114214,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Darunavir is metabolised by CYP3A4 which is not affected by peginterferon alfa-2b.",""
114160,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Rilpivirine is metabolised primarily by CYP3A which is not affected by peginterferon alfa-2b. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
114613,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Atazanavir/cobicistat does not interfere with this metabolic pathway.,""
124345,"Coadministration has not been studied. A pharmacokinetic interaction is unlikely with riboflavin itself. However, riboflavin can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
79861,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. it is unlikely to affect the disposition of antiretrovirals, or to be altered by co-administration with antiretrovirals.",""
124346,"Coadministration of rifabutin (300 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 17%, AUC by 23% and Ctrough by 26%. This reduction in cabotegravir exposure is not considered to be clinically relevant. No dose adjustment is needed. ",""
124347,"Concomitant administration with rifampicin is contraindicated due to the potential for loss of therapeutic effect and development of resistance. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 6%, AUC by 59% and oral clearance was increased by 2.4 fold. ",""
124348,"Coadministration has not been studied. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 6%, AUC by 59% and oral clearance was increased by 2.4 fold. A similar effect is expected with rifapentine. Thus concomitant administration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
124350,The coadministration of oral cabotegravir (30 mg) and oral rilpivirine (25 mg) did not significantly alter cabotegravir and rilpivirine pharmacokinetics.,""
124352,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
124353,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, CYP2J2 and is also eliminated unchanged in the bile and renally. Riociguat is a substrate of P-gp and BCRP. Cabotegravir does not inhibit or induce CYP enzymes, P-glycoprotein or BCRP at clinically relevant concentrations.",""
124354,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
79953,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.",""
124355,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. ",""
124357,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). Cabotegravir does not inhibit or induce CYPs or P-gp and BCRP at clinically relevant concentrations.",""
124359,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally. P-gp was shown to mediate biliary excretion of rocuronium in a rat model. However cabotegravir does not inhibit P-gp at clinically relevant concentrations.,""
79974,This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction. Alcuronium is predominantly eliminated unchanged via the kidneys.,""
124360,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Roflumilast is metabolized by CYP3A4 and CYP1A2 to form roflumilast N-oxide, with both roflumilast and roflumilast N-oxide having PDE4 inhibitory activity. Roflumilast N-oxide is subsequently dealkylated by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124361,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolised predominantly by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124362,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124363,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rosuvastatin is largely excreted unchanged via the faeces.,""
107201,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly glucuronidated by UGT2B7. Naloxone does not induce or inhibit CYP450 enzymes.,""
124365,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-O-sulphate. Cabotegravir does not interfere with this metabolic pathway.,""
124366,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124367,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost saquinavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. ",""
124368,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that Serenoa repens inhibits CYP2C9, CYP2D6 and CYP3A4 activity. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
124369,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
80050,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vecuronium is partly deacetylated and partly cleared in the bile as parent compound.,""
124370,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
114614,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Darunavir/cobicistat does not interfere with this metabolic pathway.,""
80128,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as liraglutide is degraded by endogenous endopeptidases.,""
85891,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination). ,""
85892,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desflurane is almost exclusively eliminated unchanged by the lungs. ,""
116100,"Coadministration has not been studied. Clobazam is metabolised by CYP3A4 (major) and CYP2B6 and CYP2C19 (minor) to the active metabolite N-desmethylclobazam, which is metabolised by CYP2C19. Clobazam is a weak inducer and could potentially decrease dolutegravir exposure although to a limited extent. No interaction is expected with lamivudine.",""
124372,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124374,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Seville orange juice inhibits intestinal CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
115886,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115920,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolized by CYPs 3A4, 2C19 and 1A2 to desipramine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
124376,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124377,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124378,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simeprevir is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124379,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124380,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
80370,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with riboflavin when given alone or in multivitamins.&nbsp;,""
124381,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp), with metabolism by CYP3A4 representing a minor elimination pathway. Cabotegravir does not inhibit these transporters at clinically relevant concentrations. ",""
124382,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little potential for sodium nitroprusside to affect the disposition of antiretrovirals, or to be affected by antiretrovirals.",""
124384,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir is a weak inhibitor of intestinal P-glycoprotein and BCRP. Cabotegravir is a substrate of P-glycoprotein and BCRP but inhibition of these transporters is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.,""
80516,"This interaction has not been studied. Dasatinib is metabolized by CYP3A4 and coadministration could potentially increase dasatinib concentrations. Coadministration of a potent CYP3A4 inhibitor is not recommended, but if unavoidable close monitoring for toxicity is required.",""
80487,"Coadministration has not been studied. Enhanced levodopa effects including severe diskinesias were described in a case report after initiation of an antiretroviral regimen containing indinavir to an individual who was previously stable on levodopa/carbidopa therapy. When reintroduced alone, indinavir monotherapy induced the abnormal movements, which resolved on discontinuation. Clinical monitoring for levodopa efficacy is warranted if co-administered with protease inhibitors.",""
80488,"Coadministration has not been studied. Enhanced levodopa effects including severe diskinesias were described in a case report after initiation of an antiretroviral regimen containing indinavir to an individual who was previously stable on levodopa/carbidopa therapy. When reintroduced alone, indinavir monotherapy induced the abnormal movements, which resolved on discontinuation. Clinical monitoring for levodopa/carbidopa efficacy is warranted if co-administered with protease inhibitors.",""
80617,"This interaction has not been studied. Lapatinib is metabolized by CYP3A4 and an effect on QT interval cannot be ruled out. Coadministration of lapatinib with strong inhibitors of CYP3A4 such as ritonavir should be avoided as it could potentially increase lapatinib concentrations, thus increasing the risk of QT prolongation.",""
80628,"Coadministration has not been studied. Nilotinib is metabolized by CYP3A4 and has been shown to prolong the QT interval. Coadministration could potentially increase nilotinib concentrations and thus increase the risk for QT interval prolongation. Avoid combination if possible or monitor both drugs closely, including for QT prolongation.",""
124385,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir and velpatasvir are inhibitors of intestinal P-glycoprotein and BCRP. Cabotegravir is a substrate of P-glycoprotein and BCRP but inhibition of these transporters is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.,""
124386,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir, velpatasvir and voxilaprevir are inhibitors of intestinal P-glycoprotein and BCRP. Cabotegravir is a substrate of P-glycoprotein and BCRP but inhibition of these transporters is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.",""
80688,"Coadministration has not been studied. Sunitinib is metabolized by CYP3A4. Coadministration with ketoconazole (a strong CYP3A4 inhibitor) increased sunitinib Cmax and AUC by 49% and 51%, respectively, due to inhibition of CYP3A4. Coadministration with potent CYP3A4 inhibitors should be avoided. If this is not possible, the doses of sunitinib may need to be reduced to a minimum of 37.5 mg once daily for gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (MRCC) or 25 mg once daily for pancreatic neuroendocrine tumors (pNET) based on careful monitoring of the tolerability. Sunitinib can cause dose-related QT prolongation. Consider monitoring of sunitinib plasma concentrations if available.",""
124387,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects,""
124388,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1. Sorafenib inhibits UGT1A1 and UGT1A9. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, but it is unlikely to be affected by sorafenib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. ",""
80894,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4.,""
124390,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases. Cabotegravir does not interfere with this metabolic pathway.,""
81032,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally.,""
124391,"Coadministration has not been studied. St Johnâ€™s Wort is an inducer and therefore can reduce cabotegravir exposure. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir AUC by 59% A similar effect is expected with St Johnâ€™s Wort. Therefore coadministration is contraindicated with oral cabotegravir due to potential for loss of therapeutic effect and development of resistance. However, a recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (<1 mg/day) of St Johnâ€™s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp). Coadministration may be considered with St Johnâ€™s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of 1 mg or less.",""
81023,Coadministration has not been studied. Saquinavir is contraindicated in patients on concomitant therapy with other drugs that prolong the QT interval. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K.,""
124392,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
81044,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is activated by sequential enzyme reactions to fluorouracil.,""
81056,Coadministration has not been studied. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as abacavir may compete for these metabolic pathways. The clinical relevance of this interaction is unknown.,""
124396,Coadministration has not been studied. Strontium is a divalent cation and can chelate with the integrase inhibitor cabotegravir thereby reducing its absorption. It is recommended to administer strontium ranelate at least 2 hours before or 4 hours after intake of oral cabotegravir. ,""
124397,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sufentanil undergoes extensive CYP3A4 metabolism, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
124398,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that sulfadiazine is metabolized in part by CYP2C9. Cabotegravir does not induce or inhibit CYPs at clinically relevant concentrations.,""
124400,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. There is, therefore, low potential for clinically significant interactions with cabotegravir.",""
115921,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys and is freely filtered at a rate that is dependent upon the glomerular filtration rate. No interactions is expected with dolutegravir or lamivudine.,""
124403,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sunitinib is metabolized by CYP3A4. However, cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.",""
124404,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as suramin appears to be eliminated predominantly unchanged via renal glomerular filtration.",""
115922,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
124406,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tacrolimus is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
115923,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
124407,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124408,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
98653,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
98655,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.&nbsp;",""
81719,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Desflurane is almost exclusively eliminated unchanged by the lungs. ",""
81724,"This interaction has not been studied. Based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction as isoflurane is almost exclusively eliminated unchanged by the lungs. ",""
124409,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. ",""
81790,Coadministration has not been studied but based on metabolism and clearance a clinically significant&nbsp;interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%).,""
81781,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolized (likely non CYP mediated pathway) and excreted in the urine by glomerular filtration.,""
81798,Coadministration has not been studied but based on metabolism and clearance a clinically significant&nbsp;interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug.,""
81802,Coadministration has not been studied but based on metabolism and clearance a clinically significant&nbsp;interaction is unlikely. Pyrazinamide is mainly metabolized by xanthine oxidase.,""
81825,Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely as pregabalin is cleared mainly by glomerular filtration.,""
81867,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amphotericin is not appreciably metabolized and is eliminated to a large extent in the bile.,""
81949,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ribavirin is partly metabolized (non CYP mediated) and partly excreted in the urine. ,""
81952,Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. A small amount of the orally inhaled zanamivir is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces.,""
124410,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124411,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol is mainly glucuronidated by UGT1A6, UGT1A9 and UGT2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124412,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is only minimally metabolised and is eliminated renally via glomerular filtration and active secretion by OAT1/3. Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3.,""
124414,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telithromycin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124415,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telmisartan is mainly glucuronidated by UGT1A3. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
116152,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
124416,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
124417,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4 and inhibits this same enzyme. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
82160,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. In the presence of a peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) levodopa is metabolised mainly to 3-O-methyldopa by catechol-O-methyltransferase.,""
82170,No clinically relevant drug interactions are expected with the topical use of hydrocortisone.,""
82175,"Coadministration has not been studied but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations.",""
82200,"No clinically significant pharmacokinetic interaction was observed between rilpivirine and dolutegravir. Coadministration of rilpivirine (25 mg once daily) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Ctrough by 13%, 12% and 22%, respectively. Rilpivirine Cmax, AUC and Ctrough increased by 10%, 6% and 21%, respectively. No dosage adjustment is necessary.&nbsp;[Dolutegravir is available coformulated with rilpivirine&nbsp;as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.]",""
124420,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terazosin is extensively metabolized in the liver possibly via CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124421,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYPs 2C8 and 2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
82241,Coadministration is contraindicated with strong cytochrome P450 3A4 inhibitors. Coadministration is likely to increase ivabradine concentrations which may be associated with the risk of excessive bradycardia.,""
82243,Coadministration is contraindicated with strong cytochrome P450 3A4 inhibitors. Coadministration is likely to increase ivabradine concentrations which may be associated with the risk of excessive bradycardia. ,""
124422,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124423,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124427,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
82359,"Coadministration has not been studied. In an interaction study of single-dose bedaquiline and multiple-dose lopinavir/ritonavir, bedaquiline AUC was increased by 22%. This increase is likely due to ritonavir and increases in bedaquiline exposure would be expected when coadministered with other ritonavir-boosted HIV protease inhibitors. The combination of bedaquiline and moderate or strong CYP3A4 inhibitors used systemically for more than 14 consecutive days should be avoided. If coadministration is necessary, clinical monitoring including frequent electrocardiogram assessment and monitoring of transaminases is recommended. There are no clinical data on the safety and efficacy of bedaquiline when co-administered with antiretroviral agents.",""
86098,Coadministration of dihydroergotamine and elvitegravir/cobicistat is contraindicated due to potential for serious and/or life threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.,""
116153,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bleomycin is inactivated by a cytosolic enzyme, bleomycin hydrolase. Furthermore, ~67% of the administered drug is excreted unchanged in urine probably by glomerular filtration. ",""
124429,"Coadministration has not been studied. A pharmacokinetic interaction is unlikely with thiamine itself. However, thiamine can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124430,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although pentobarbital (a potent inducer of hepatic microsomal drug metabolism) is formed during thiopental metabolism, levels do not reach the therapeutic range. Therefore, cabotegravir pharmacokinetics are unlikely to be affected significantly by coadministration with thiopental.",""
82975,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. ",""
82986,"Coadministration has not been studied. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Coadministration could potentially increase LSD concentrations. Ensure the patient is aware of signs/symptoms of LSD toxicity (i.e. hallucinations, agitation, psychosis, flashbacks).",""
124431,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is a moderate inducer. Based on the drug-drug interaction study rifabutin (also a moderate inducer), the decrease in cabotegravir exposure after intramuscular administration is expected to be not clinically relevant. No dose adjustment is required.",""
124432,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolised by CYP3A4/5. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
83009,"Coadministration has not been studied. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4) and coadministration may potentially increase phencyclidine concentrations. Ensure the patient is aware of signs/symptoms of PCP toxicity (i.e. seizure, hypertension, hyperthermia).",""
86099,Coadministration of ergotamine and elvitegravir/cobicistat is contraindicated due to potential for serious and/or life threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.,""
124434,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is only a mild inhibitor of CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124435,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124436,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinidazole is partly metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
116252,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
124437,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiotropium bromide is predominantly excreted unchanged in the urine. Metabolism by CYP2D6 and CYP3A4 is only a minor role in its elimination. ,""
124438,Coadministration has not been studied. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir AUC by 59%. Tipranavir has inducing properties is predicted to reduce cabotegravir exposure. Coadministration with oral cabotegravir is contraindicated due to the potential for loss of therapeutic effect and development of resistance.,""
124439,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Tizanidine is metabolised by CYP1A2, which is not inhibited or induced by cabotegravir.",""
83326,"Coadministration has not been studied but may increase fluocinolone concentrations. Careful monitoring of corticoid side effects is recommended. Note, the extent of percutaneous absorption is determined by many factors such as the degree of inflammation or alteration of the skin, the duration, frequency and surface of application and the use of occlusive dressings.",""
83353,Coadministration has not been studied. Methylprednisolone is metabolized by CYP3A4 and coadministration could potentially increase methylprednisolone concentrations thus increasing the risk of steroid related side effect. Use the lowest possible corticosteroid dose and monitor for corticosteroid side effects.,""
124441,"Coadministration has not been studied. A pharmacokinetic interaction is unlikely with vitamin E itself. However, vitamin E can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
83382,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora.",""
124442,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124443,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124444,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Weak induction of CYP isozymes has been observed with higher doses of topiramate. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124445,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration. Furthermore, topotecan is a substrate for P-gp and BCRP. Cabotegravir does not inhibit or induce CYP enzymes or drug transporters at clinically relevant concentrations. ",""
124446,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolized mainly by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124447,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124448,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
83537,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4.,""
83559,"Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely as captopril is largely excreted in the urine (40-50% as unchanged drug, the rest as disulfide and other metabolites).",""
83586,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole). Despite this potential hepatic metabolism very few data exist on carbimazole drug interactions and a marked interaction is not expected.",""
124453,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trastuzumab emtansine is a monoclonal antibody-drug conjugate. Trastuzumab does not undergo CYP mediated metabolism, whereas DM1 (an active component of emtansine) is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
124454,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124455,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
83683,Coadministration has not been studied. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Coadministration could potentially increase hydroxyzine exposure due to inhibition of CYP3A4. Monitor side effects.,""
83709,Coadministration has not been studied. Iloperidone is metabolised by CYP3A4 and CYP2D6 and coadministration may increase concentrations. The US Prescribing Information for iloperidone suggests a dose reduction of ~50% when coadministered with strong inhibitors of CYP3A4. ,""
83882,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as droloxifene is mainly glucuronidated.,""
124456,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
114615,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Darunavir, cobicistat, emtricitabine and tenofovir alafenamide do not interfere with this metabolic pathway.",""
114616,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases.,""
83760,"Coadministration has not been studied. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4. The magnitude of the interaction is predicted to be of moderate intensity as ritonavir has an opposite effect on CYP3A4 (inhibition) and UGT1A4 (induction), which might result in a counterbalancing effect. No a priori dosage adjustment is recommended.",""
124457,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
83839,"Coadministration has not been studied. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Coadministration could potentially increase dolasetron concentrations although this is unlikely to be clinically meaningful since CYP-mediated metabolism is minor and dolasetron has a wide therapeutic margin.",""
83867,Coadministration has not been studied. Droloxifene is mainly glucuronidated and coadministration could potentially decrease droloxifene exposure due to induction of glucuronidation. Monitor droloxifene therapeutic effect.,""
124458,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triclabendazole and its active sulfoxide metabolite were shown to inhibit CYP3A4 in vitro. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124459,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
84151,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as levofloxacin is metabolised to a very small extent.",""
83945,Coadministration has not been studied. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Coadministration could potentially decrease formestane exposure due to induction of glucuronidation. Monitor formestane therapeutic effect.,""
83955,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation.,""
84022,"Coadministration has not been studied. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration. Topotecan is a substrate for P-gp and BCRP and concomitant use of P-gp and BCRP inhibitors has been shown to increase topotecan exposure. Coadministration could potentially increase topotecan exposure due to inhibition of P-gp and BCRP and thus increase the risk and severity of topotecan-related side effects.",""
84055,Coadministration has not been studied. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene. Coadministration could potentially increase toremifene exposure. Use with caution due to the dose (concentration) dependent risk of QT interval prolongation associated with toremifene. ECG monitoring is recommended.,""
124460,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
84079,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated).,""
84100,Coadministration has not been studied. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7. Coadministration could potentially decrease labetalol exposure due to induction of UGT2B7 by ritonavir. Monitor effect and increase dosage if needed.,""
124462,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
84106,Coadministration has not been studied. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7. Coadministration could potentially decrease labetalol exposure due to induction of UGTs 2B7 and 1A1. Monitor effect and increase dosage if needed.,""
124464,Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Ulipristal is metabolized mainly by CY3A4 and to a lesser extent by CYPs 1A2 and 2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
84192,"Coadministration has not been studied. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase). Although coadministration may increase almotriptan concentrations due to inhibition of CYP3A4 this is unlikely to be of clinical significance.",""
84230,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8).",""
124465,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Umeclidinium bromide is mainly metabolized by CYP2D6 and is a substrate of P-gp. Cabotegravir does not inhibit or induce CYP enzymes or P-glycoprotein at clinically relevant concentrations.,""
84246,"Coadministration has not been studied. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. In vitro inhibition of P450 was shown to improve mitoxantrone cytotoxicity, however the impact on the antitumoral effect is unknown. Caution is advised due to mitoxantrone related cardiotoxicity. ECG monitoring is recommended.",""
84250,"Coadministration has not been studied. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. In vitro inhibition of P450 was shown to improve mitoxantrone cytotoxicity, however the impact on the antitumoral effect is unknown.",""
84273,Coadministration has not been studied. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Coadministration of flibanserin with moderate or strong inhibitors of CYP3A4 is contraindicated due to increased flibanserin concentrations which can cause severe hypotension and syncope. ,""
124466,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir, which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.",""
84379,Coadministration has not been studied. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Coadministration could potentially increase modafinil exposure. Monitor side effects and adjust modafinil dosage if needed.,""
124468,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19. Valproate has no inducing effects on metabolism. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124470,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via renal glomerular filtration.,""
84461,"Coadministration has not been studied. Nitrendipine is extensively metabolized, mainly by CYP3A4, and coadministration may increase nitrendipine concentrations. When coadministered, blood pressure should be monitored and, if necessary, a reduction of nitrendipine dose should be considered.",""
124471,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
84489,Coadministration has not been studied. Oxprenolol is largely metabolized by glucuronidation (UGT unknown). Coadministration could potentially reduce oxprenolol concentrations due to induction of glucuronidation. Monitor the therapeutic effect and adjust dosage if needed.,""
124472,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Varenicline is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion by OCT2. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
84511,"Coadministration has not been studied. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2, reduction by carbonyl reductase, and oxidation by carboxylase. Coadministration may decrease pentoxifylline concentrations due to induction of CYP1A2 but this is unlikely to be clinically relevant.",""
84519,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2, reduction by carbonyl reductase, and oxidation by carboxylase.",""
124474,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
84539,"Coadministration has not been studied. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3. Coadministration could potentially increase perazine concentrations. Monitor side effects and adjust dosage if needed.",""
124475,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Verapamil is metabolised mainly by CYP3A4 and is a moderate inhibitor of CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
84565,"Coadministration has not been studied. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Coadministration could potentially increase periciazine concentrations, although to a moderate extent and no a priori dosage adjustment is recommended.",""
124477,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Cabotegravir does not inhibit or induce CYP enzymes or P-glycoprotein at clinically relevant concentrations.,""
124479,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vinblastine is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. In vitro data suggest that vinblastine activates PXR and therefore has potential inducing properties. No significant effect is expected on cabotegravir based on the drug interaction study with rifabutin (a moderate inducer).,""
84620,"Coadministration has not been studied. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine. Coadministration could potentially increase pindolol concentrations although to a moderate extent, and no a priori dosage adjustment is recommended.",""
84680,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8.,""
124480,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vincristine is metabolized by CYP3A5/4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
84720,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. Systemic exposure to prucalopride may be increased due to inhibition of P-gp, but any increase is unlikely to be clinically relevant and no a priori dose adjustment is recommended.",""
84749,Coadministration has not been studied. Coadministration of ranolazine with potent CYP3A4 inhibitors is contraindicated due to increased ranolazine concentrations and potential for serious adverse effects.,""
124481,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vinorelbine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124482,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Voriconazole is a strong inhibitor of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124483,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated). Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
84965,Coadministration has not been studied. Tranylcypromine is hydroxylated and acetylated and coadministration could potentially increase tranylcypromine concentrations. Monitor side effects and adjust dosage if needed.,""
85017,"Coadministration has not been studied. The US Prescribing information for ziprasidone contraindicates its use in the presence of other drugs that prolong the QT interval. Coadministration is not recommended due to the potential of life threatening arrhythmias such as torsade de pointes and sudden death. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Coadministration could potentially increase ziprasidone concentrations due to inhibition of CYP3A4. ",""
85021,"Coadministration has not been studied. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Coadministration could potentially increase ziprasidone concentrations due to inhibition of CYP3A4. Monitor side effects and decrease dosage if needed. Of note, the effect of ziprasidone on QT interval was not increased in presence of a metabolic inhibitor. Thus, the risk of QT interval prolongation is not increased in presence of CYPs inhibitors that do not prolong the QT interval.",""
85050,"Coadministration has not been studied. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. Coadministration could potentially increase zuclopenthixol concentrations. Monitor side effects and reduce zuclopenthixol dosage if needed.",""
85095,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally partly by glomerular filtration and partly by active secretion via OAT1.,""
85160,"Coadministration has not been studied. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6, and can prolong the QT interval. Coadministration may increase zotepine concentrations and thereby increase the risk of QT interval. Caution should be exercised when administering both drugs due to the risk of QT prolongation. ECG monitoring is recommended. Monitor for side effects and reduce zotepine dosage as needed.",""
85163,"Coadministration has not been studied. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6, and coadministration may increase zotepine concentrations. Monitor for side effects and reduce zotepine dosage as needed.",""
85228,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After oral administration, absorption of niclosamide is considered minimal.",""
86977,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is eliminated predominantly renally.,""
85286,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. ,""
85314,Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Levetiracetam undergoes enzymatic hydrolysis (non CYP) and is eliminated unchanged in the urine by glomerular filtration. ,""
85450,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., raltegravir and elvitegravir) is unlikely to be of clinical benefit.",""
124484,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioxetine is mainly metabolized by CYP2D6 and to a lesser extent by CYP2C9 and CYP3A4/5. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
85456,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Genvoya should not be used in conjunction with non-nucleoside reverse transcriptase inhibitors due to potential drug-drug interactions including altered and/or suboptimal pharmacokinetics of cobicistat, elvitegravir and/or the coadministered antiretroviral products.",""
85464,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with abacavir would be possible from a pharmacokinetic standpoint.",""
85466,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, increased didanosine concentrations and toxicity were observed when combined with tenofovir-DF. A similar effect with tenofovir alafenamide cannot be excluded.",""
85470,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
124485,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYP1A2 and 3A4. S-warfarin (more potent) is metabolized by CYP2C9. Cabotegravir does not inhibit or induce CYPs at clinically relevant concentrations.,""
85535,"Coadministration of PARENTERAL midazolam should be done with caution and in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Coadministration of ORAL midazolam and cobicistat is contraindicated due to potential for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression.",""
72628,"Coadministration has not been studied. Tizanidine is metabolised by CYP1A2 and coadministration may decrease concentrations due to induction of CYP1A2 by ritonavir. Since both drugs can prolong the QT interval, caution should be exercised if increasing the dosage of tizanidine.",""
86018,Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (~30% of the dose) and is eliminated unchanged through the kidneys (~40% of the dose). ,""
86154,"Coadministration has not been studied. The use of Stribild should be avoided with concurrent or recent use of a nephrotoxic medicinal product, e.g., cidofovir. If concomitant use of Stribild and nephrotoxic agents is unavoidable, renal function must be monitored weekly. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1, OAT3. Elvitegravir/cobicistat is unlikely to inhibit OATs at clinically relevant concentrations. As emtricitabine and tenofovir, components of Stribild, are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion, coadministration of Stribild may increase concentrations of emtricitabine and tenofovir.",""
86156,Coadministration with Stribild has not been studied but based on the metabolism and clearance a clinically significant drug-drug interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anion and cation transporters. Elvitegravir/cobicistat is unlikely to inhibit OATs at clinically relevant concentrations.,""
86186,Coadministration of triazolam and elvitegravir/cobicistat is contraindicated due to potential for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression.,""
114638,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Significant interactions are not expected with emtricitabine and tenofovir alafenamide. Dose Descovy according to the concomitant antiretroviral.,""
86416,"Coadministration of rosuvastatin (10 mg single dose) and elvitegravir/cobicistat (150/150 mg once daily) decreased elvitegravir Cmax and Cmin by 6% and 2%, and increased AUC by 2% (n=10). Rosuvastatin AUC and Cmax increased by 38% and 89%, respectively. The increase in rosuvastatin exposure is transient and not considered clinically relevant. Dose modifications are not necessary when rosuvastatin is administered in combination with Stribild.",""
86428,"Coadministration is expected to increase colchicine concentrations. Patients with renal or hepatic impairment should not be coadministered colchicine. A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function. The US Prescribing Information gives the following dose modifications. For treatment of gout flares, the recommended dosage is 0.6 mg (1 tablet) for 1 dose, followed by 0.3 mg (half tablet) 1 hour later. The dose is to be repeated no earlier than 3 days. For prophylaxis of gout flares, if the original regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day; if the original regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day. For treatment of familial Mediterranean fever (FMF) do not exceed a maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day). ",""
86490,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with enfuvirtide would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
86498,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, coadministering two integrase inhibitors (i.e., raltegravir and elvitegravir) is unlikely to be of clinical benefit.",""
86510,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with abacavir would be possible from a pharmacokinetic standpoint. Based on metabolism and clearance a clinically significant interaction with elvitegravir/cobicistat or emtricitabine is unlikely. Coadministration of tenofovir-DF (300 mg once daily) and abacavir (300 mg single dose) had no effect on abacavir AUC but Cmax increased by 12%. A similar increase in abacavir Cmax may occur with elvitegravir/cobicistat/emtricitabine/tenofovir-DF.&nbsp;",""
86520,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
86526,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.",""
124487,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
86542,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF)&nbsp;is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Stribild should not be used in conjunction with protease inhibitors inhibitors due to potential drug-drug interactions including altered and/or suboptimal pharmacokinetics of cobicistat, elvitegravir, and/or the coadministered antiretroviral products. Stribild should not be administered concurrently with products containing ritonavir or regimens containing ritonavir due to similar effects of cobicistat and ritonavir on CYP3A.",""
86547,"Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Stribild should not be used in conjunction with protease inhibitors inhibitors due to potential drug-drug interactions including altered and/or suboptimal pharmacokinetics of cobicistat, elvitegravir, and/or the coadministered antiretroviral products. Stribild should not be administered concurrently with products containing ritonavir or regimens containing ritonavir due to similar effects of cobicistat and ritonavir on CYP3A. ",""
124491,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Zoledronic acid is eliminated unchanged renally. (Note, caution is required if given with calcium supplements as cabotegravir may be subject to chelation which may result in reduced cabotegravir concentrations.)",""
86548,"Stribild is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Stribild should not be used in conjunction with protease inhibitors inhibitors due to potential drug-drug interactions including altered and/or suboptimal pharmacokinetics of cobicistat, elvitegravir, and/or the coadministered antiretroviral products. Stribild should not be administered concurrently with products containing ritonavir or regimens containing ritonavir due to similar effects of cobicistat and ritonavir on CYP3A.",""
124492,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124493,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. Zonisamide is a weak inhibitor of P-gp but is unlikely to have a significant effect on cabotegravir exposure. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124494,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124495,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124496,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
76782,Coadministration has not been studied but based on metabolism/elimination and toxicity profiles of both drugs there is little potential for interaction as sulpiride is mainly excreted in the urine and faeces as unchanged drug. ,""
124498,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is mainly glucuronidated by UGT1A1. Cabotegravir does not inhibit or induce UGT enzymes.,""
124504,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9 whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Dose modifications of ibalizumab are not required when administered with any other antiretroviral.",""
124505,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maraviroc is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
83836,"Coadministration has not been studied. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Coadministration could potentially increase dolasetron concentrations although this is unlikely to be clinically meaningful since CYP-mediated metabolism is minor and dolasetron has a wide therapeutic margin. However, dolasetron may prolong the QT interval and the European SPC for lopinavir advises caution when coprescribing with drugs known to induce QT interval prolongation.",""
83837,"Coadministration has not been studied. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Coadministration could potentially increase dolasetron concentrations although this is unlikely to be clinically meaningful since CYP-mediated metabolism is minor and dolasetron has a wide therapeutic margin. However, dolasetron may prolong the QT interval and saquinavir is contraindicated in patients on concomitant therapy with other drugs that prolong the QT interval. ",""
85640,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Genvoya is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir alafenamide do not interact with esomeprazole.",""
85642,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Genvoya is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir alafenamide do not interact with lansoprazole.",""
85649,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Genvoya is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir alafenamide do not interact with rabeprazole.",""
85655,"Coadministration has not been studied. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Coadministration could potentially increase dolasetron concentrations although this is unlikely to be clinically meaningful since CYP-mediated metabolism is minor and dolasetron has a wide therapeutic margin. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway.",""
86290,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Stribild is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir-DF do not interact with esomeprazole.",""
86293,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Stribild is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir-DF do not interact with lansoprazole.",""
86296,"No dose adjustment is needed when Stribild is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, the AUC and Cmax of elvitegravir increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir-DF do not interact with omeprazole.",""
86297,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Stribild is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir-DF do not interact with pantoprazole.",""
86300,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Stribild is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (<10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir-DF do not interact with rabeprazole.",""
86304,"Coadministration has not been studied. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Coadministration could potentially increase dolasetron concentrations although this is unlikely to be clinically meaningful since CYP-mediated metabolism is minor and dolasetron has a wide therapeutic margin. Emtricitabine and tenofovir-DF do not interact with this metabolic pathway.",""
72630,Coadministration has not been studied. Tizanidine is metabolised by CYP1A2 and coadministration may decrease concentrations due to induction of CYP1A2 by ritonavir. Increase tizanidine dose if clinically indicated.,""
124507,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9 whereas albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.,""
124508,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124510,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Efavirenz is a moderate inducer. Based on drug-drug interaction studies with rifabutin (also a moderate inducer), the decrease in cabotegravir exposure is expected not to be clinically relevant. No dose adjustment is required.",""
124511,"Coadministration of etravirine 200 mg twice daily and oral cabotegravir 30 mg once daily did not significantly alter cabotegravir AUC, Cmax and Cmax. No dose adjustment is required.",""
124677,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sufentanil undergoes extensive CYP3A4 metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124512,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nevirapine is a weak inducer. Based on drug-drug interaction studies with rifabutin (also a moderate inducer), the decrease in cabotegravir exposure is expected not to be clinically relevant. No dose adjustment is required.",""
124679,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Absorbed tetracaine is predominantly metabolised by pseudocholinesterases in the plasma. ,""
86914,Coadministration has not been studied and is not recommended. Concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by ritonavir. Increased concentrations of apixaban increase the bleeding risk and the combination should be avoided if possible.,""
86941,"Coadministration has not been studied. Edoxaban is a substrate for P-gp and coadministration is expected to increase edoxaban concentrations due to P-gp inhibition. The European product label for edoxaban states to consider a dose reduction of edoxaban from 60 mg to 30 mg with strong P-gp inhibitors, however, the US product label recommends no dose modification.",""
86994,"Coadministration has not been studied. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Coadministration could potentially decrease dipyridamole exposure due to induction of glucuronidation, thereby reducing the antiplatelet effect.",""
124680,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although pentobarbital (a potent inducer of hepatic microsomal drug metabolism) is formed during thiopental metabolism, levels do not reach the therapeutic range. Therefore, pharmacokinetics of fostemsavir and its active metabolite temsavir are unlikely to be affected significantly by coadministration with thiopental. ",""
116315,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eplerenone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
124524,Coadministration has not been studied. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase cabotegravir (30 mg once daily) exposure by 11% which is considered not to be clinically relevant. A comparable effect is expected with atazanavir/ritonavir. No dosage adjustment is necessary.,""
124525,Coadministration has not been studied. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase cabotegravir (30 mg once daily) exposure by 11% which is considered not to be clinically relevant. No dosage adjustment is necessary.,""
124526,Coadministration has not been studied. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase cabotegravir (30 mg once daily) exposure by 11% which is considered not to be clinically relevant. A comparable effect is expected with atazanavir/cobicistat. No dosage adjustment is necessary.,""
124527,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Induction of UGTs by ritonavir used to boost darunavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer.&nbsp;",""
124528,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Darunavir/cobicistat do not inhibit UGT enzymes.,""
124530,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost fosamprenavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer.&nbsp;",""
124681,"Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. Tizanidine is metabolised by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Tizanidine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with tizanidine.",""
124531,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost indinavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer.&nbsp;",""
124532,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost lopinavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer.&nbsp;",""
124533,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer.&nbsp;",""
116337,"Coadministration has not been studied, based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation.",""
124534,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost saquinavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer.&nbsp;",""
87487,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with pyridoxine when given alone or in multivitamins. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. Dose Descovy according to the concomitant antiretroviral.,""
87490,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with riboflavin when given alone or in multivitamins.&nbsp;Dose Descovy according to the concomitant antiretroviral.,""
87493,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with thiamine when given alone or in multivitamins.&nbsp;Dose Descovy according to the concomitant antiretroviral.,""
87495,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with vitamin E when given alone or in multivitamins. Dose Descovy according to the concomitant antiretroviral.,""
87640,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxandrolone is metabolized in the kidney. Dose Descovy according to the concomitant antiretroviral.,""
124682,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vecuronium is partly deacetylated and partly cleared in the bile as parent compound. ,""
124683,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124800,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. ",""
124801,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124537,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, if a patient plans to miss a scheduled injection visit by more than 7 days, oral therapy (cabotegravir 30 mg and rilpivirine 25 mg once daily) may be used to replace up to 2 consecutive monthly injection visits. The first dose of oral therapy should be taken approximately 1 month after the last injection dose of Cabenuva. Injection dosing should be resumed on the day oral dosing completes.",""
124558,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, if a patient plans to miss a scheduled injection visit by more than 7 days, oral therapy (cabotegravir 30 mg and rilpivirine 25 mg once daily) may be used to replace up to 2 consecutive monthly injection visits. The first dose of oral therapy should be taken approximately 1 month after the last injection dose of Cabenuva. Injection dosing should be resumed on the day oral dosing completes.&nbsp;",""
124509,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with cabotegravir would be possible from a pharmacokinetic standpoint. Doravirine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. No interaction is expected with lamivudine and tenofovir-DF.",""
124554,"Cabenuva (cabotegravir LA, rilpivirine LA) and Delstrigo (doravirine, lamivudine, tenofovir-DF) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, doravirine should not be administered with another NNRTI (i.e., rilpivirine).",""
124497,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and bictegravir) is unlikely to be of clinical benefit.",""
124542,"Cabenuva (cabotegravir LA, rilpivirine LA) and Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and bictegravir) is unlikely to be of clinical benefit.",""
124553,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, doravirine should not be administered with another NNRTI (i.e., rilpivirine).",""
124555,"Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.&nbsp;Efavirenz is a moderate inducer of CYP3A. Based on the drug-drug interaction study with rifabutin (also a moderate inducer), the decrease in cabotegravir exposure after intramuscular administration is expected not to be clinically relevant. However, efavirenz has the potential to significantly reduce rilpivirine exposure.",""
124802,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and 3A4. S-warfarin (more potent) is metabolised by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
115487,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Bictegravir does not inhibit or induce CYP enzymes; emtricitabine and tenofovir alafenamide do not interact with monacolin K metabolism.,""
115925,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115488,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Doravirine does not inhibit or induce CYP enzymes; lamivudine and tenofovir-DF do not interact with monacolin K metabolism.,""
115489,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Dolutegravir does not inhibit or induce CYP enzymes.,""
124556,"Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.&nbsp;Etravirine is a moderate inducer of CYP3A. Coadministration of etravirine (200 mg twice daily) and oral cabotegravir (30 mg once daily) did not significantly alter cabotegravir AUC, Cmax and Cmax. Similarly, no significant effect is expected on cabotegravir when administered intramuscularly. However, etravirine has the potential to significantly reduce rilpivirine exposure.",""
124557,"Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.&nbsp;Nevirapine has enzyme inducing properties. Based on the drug-drug interaction study with rifabutin (a moderate inducer), the decrease in cabotegravir exposure after intramuscular administration is expected not to be clinically relevant. However, nevirapine has the potential to significantly reduce rilpivirine exposure.",""
115490,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Dolutegravir/rilpivirine does not inhibit or induce CYP enzymes.,""
115491,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Doravirine does not inhibit or induce CYP enzymes.,""
115492,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Maraviroc does not inhibit or induce CYP enzymes.,""
115493,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Rilpivirine does not inhibit or induce CYP enzymes.,""
124560,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with abacavir would be possible from a pharmacokinetic standpoint.",""
124543,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir) is unlikely to be of clinical benefit.",""
124804,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
88478,"Coadministration has not been studied. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest it could act as an inducer of phase I and phase II metabolic enzymes although the clinical relevance has not been evaluated. In the absence of data, caution is recommended and TDM should be considered if available.",""
115494,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Raltegravir does not interact with monacolin K metabolism.,""
116338,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Dolutegravir is not expected to inhibit OATs. Lamivudine is eliminated by other renal transporters.,""
124544,"Cabenuva (cabotegravir LA, rilpivirine LA) and Dovato (dolutegravir/lamivudine) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir) is unlikely to be of clinical benefit.",""
116374,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is metabolized to 6-mercaptopurine which is further inactivated by xanthine oxidase and thiopurine methyltransferase.,""
124546,"Cabenuva (cabotegravir LA, rilpivirine LA) and Juluca (dolutegravir, rilpivirine) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;In addition, both products contain rilpivirine and, furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir) is unlikely to be of clinical benefit.",""
124547,"Cabenuva (cabotegravir LA, rilpivirine LA) and Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and elvitegravir) is unlikely to be of clinical benefit.",""
116377,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclosporin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116378,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and 2B7. No interaction is expected with dolutegravir as it is primarily glucuronidated by UGT1A1 and is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116379,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
124805,Coadministration has not been studied and is not recommended. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Eslicarbazepine is an inducer and has the potential to substantially reduce temsavir which may result in a potential loss of therapeutic effect. ,""
116380,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tacrolimus is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
124548,"Cabenuva (cabotegravir LA, rilpivirine LA) and Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and elvitegravir) is unlikely to be of clinical benefit.",""
124862,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is eliminated unchanged in the urine via OCT2 and MATE1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2 or MATE1 to a clinically significant extent.,""
124551,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and raltegravir) is unlikely to be of clinical benefit.",""
124552,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with albuvirtide would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected. Cabotegravir and rilpivirine undergo hepatic metabolism whereas albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.",""
89043,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Rilpivirine at a dose of 25 mg once daily does not inhibit or induce CYPs or UGTs. Emtricitabine and tenofovir alafenamide do not interact with levonorgestrel metabolic pathway.&nbsp;,""
124549,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ibalizumab would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Cabotegravir and rilpivirine undergo hepatic metabolism whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Dose modifications of ibalizumab are not required when administered with any other antiretroviral.",""
124550,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with maraviroc (dosed at 300 mg twice daily)&nbsp;would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected. Maraviroc is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
124500,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. If intensification of HIV treatment is needed, alternatives to cabotegravir should be considered as coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir) is unlikely to be of clinical benefit.",""
89164,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with vitamin E when given alone or in multivitamins.&nbsp;,""
124499,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection.&nbsp;If intensification of HIV treatment is needed, alternatives to cabotegravir should be considered as coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir) is unlikely to be of clinical benefit.",""
124501,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to cabotegravir should be considered as coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir is unlikely to be of clinical benefit.",""
124502,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and elvitegravir) is unlikely to be of clinical benefit.",""
124503,"Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and elvitegravir) is unlikely to be of clinical benefit.",""
124580,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, tipranavir has inducing properties and therefore has the potential to reduce cabotegravir and rilpivirine exposures.&nbsp;",""
124863,Coadministration has not been studied. Nateglinide is mainly metabolized by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Nateglinide is a substrate of OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and therefore has the potential to increase nateglinide exposure. Monitor glucose.,""
88947,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. Furthermore, etravirine could potentially decrease rilpivirine exposure and thereby result in loss of efficacy.",""
88948,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. Furthermore, nevirapine could potentially decrease rilpivirine exposure and thereby result in loss of efficacy.",""
88951,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. Furthermore, increased didanosine concentrations and toxicity has been observed when didanosine and tenofovir-DF are coadministered and a similar effect with tenofovir alafenamide cannot be excluded.",""
116381,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atorvastatin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
89347,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
124864,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
89350,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint. Based on metabolism and clearance a clinically significant interaction with zidovudine and rilpivirine or tenofovir alafenamide is unlikely. No significant interactions were observed when emtricitabine (200 mg once daily for 7 days) and zidovudine (300 mg once daily for 7 days) was studied in 27 HIV-negative subjects.",""
90117,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goldenseal has been shown to inhibit CYP3A4 in vitro, however, no significant effect of golden seal root on indinavir pharmacokinetics was observed in a study in HIV-negative subjects. Interactions with other drugs metabolized by CYP3A4 are unlikely.",""
124865,"Coadministration has not been studied. Repaglinide is metabolized by CYP2C8 and CYP3A4, and is a substrate of OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and therefore has the potential to increase repaglinide exposure. Monitor glucose.",""
90153,Coadministration has not been studied. Cyproterone acetate is metabolized by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by cobicistat. A dose adjustment of cyproterone may be required.,""
124866,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
90354,Coadministration has not been studied. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4. Concentrations of the active metabolite of fesoterodine are likely to increase due to inhibition of CYP3A4. The maximum daily dose of fesoterodine should not exceed 4 mg when used concomitantly with potent CYP3A4 inhibitors such as ritonavir.,""
90383,"Coadministration has not been studied. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. It is also a substrate of P-gp. Coadministration may increase mirabegron concentrations, however, only a modest increase in mirabegron exposure was observed with ketoconazole (a strong inhibitor of CYP3A4/P-gp). No dose adjustment is recommended when mirabegron is combined with strong inhibitors of CYP3A4 and/or P-gp in patients with normal hepatic or renal function. However, a dose decrease of mirabegron to 25 mg once daily in patients is recommended for patients who have mildly impaired hepatic or renal function and who are taking a strong inhibitor of CYP3A4.",""
90411,Coadministration has not been studied. Solifenacin is metabolized by CYP3A4 and concentrations are likely to increase due to inhibition of CYP3A4. A 3-fold increase in solifenacin exposure was observed with ketoconazole (a strong inhibitor of CYP3A4). It is recommended that solifenacin dosage should be limited to 5 mg once daily if coadministered with a strong CYP3A4 inhibitor such as ritonavir.,""
90439,"Coadministration has not been studied. Darifenacin is metabolized by CYP3A4 and CYP2D6 and coadministration is likely to increase concentrations. A 5-fold increase in darifenacin exposure was seen with ketoconazole (a strong inhibitor of CYP3A4) and the magnitude of the interaction could be even more pronounced in poor metabolizer individuals The European Summary of Product Characteristics for darifenacin contraindicates its use with potent CYP3A4 inhibitors (such as cobicistat), but the US Prescribing Information recommends that the dose of darifenacin should not exceed 7.5mg when coadministered with potent CYP3A4 inhibitors.",""
116887,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
115495,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Rilpivirine, emtricitabine and tenofovir alafenamide do not interact with monacolin K metabolism.",""
115496,"No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
115497,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Atazanavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with atazanavir.&nbsp;",""
124867,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
69802,"Based on the results of in vitro experiments and the known elimination pathways of emtricitabine, the potential for CYP450 mediated interactions involving emtricitabine with other medicinal products is low. Nevirapine trough concentrations in 7 HIV+ subjects receiving nevirapine (200 mg twice daily) with tenofovir/emtricitabine were comparable to historical values.",""
69157,"Based on the results of in vitro experiments and the known elimination pathways of emtricitabine, the potential for CYP450 mediated interactions involving emtricitabine with other medicinal products is low.&nbsp;Nevirapine trough concentrations in 7 HIV+ subjects receiving nevirapine (200 mg twice daily) with tenofovir/emtricitabine were comparable to historical values.",""
69647,No data with indinavir/ritonavir. Coadministration with indinavir alone showed no clinically significant interactions.,""
69642,Coadministration of zidovudine (200 mg single dose) and lamivudine (300 mg twice daily) to&nbsp;12 asymptomatic HIV-infected adult patients increased zidovudine Cmax and AUC by 28% and 13%.&nbsp;Zidovudine had no effect on the pharmacokinetics of lamivudine. No dose adjustments are necessary.,""
79511,Coadministration has not been studied. Ephedrine is predominantly eliminated unchanged via the kidneys possibly via the renal transporter OCT2. There is potential for competition with lamivudine for active renal transport mechanisms which may lead to increased levels of either drug.,""
124868,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce OAT3 or P-gp.",""
124869,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124870,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vildagliptin is inactivated via non CYP mediated hydrolysis. ,""
124872,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperature. ,""
96590,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as oxprenolol is largely metabolised by glucuronidation.,""
116994,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
124873,Coadministration has not been studied. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. Caspofungin is a substrate of OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATP1B1 and therefore has the potential to increase caspofungin exposure. Monitor for side effects.,""
124874,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Fluconazole is a moderate inhibitor of CYP3A4 but is unlikely to cause a significant increase in temsavir. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.,""
92356,"Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4.&nbsp;<span class=""ng-binding"">Ethinylestradiol is mainly metabolized by hydroxylation.</span>",""
92398,"Coadministration with a drospirenone-containing combined oral contraceptive (COC) has not been studied. Drospirenone is metabolised in part by CYP3A4. Coadministration is predicted to increase drospirenone exposure. When used in a combined pill, the estrogen component is reduced. Given the lack of clinical data on the contraceptive efficacy, caution is recommended and additional contraceptives measures should be used.",""
92427,"Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Coadministration is predicted to increase gestodene exposure. When used in a combined pill, the estrogen component is reduced. Given the lack of clinical data on the contraceptive efficacy, caution is recommended and additional contraceptives measures should be used.",""
124875,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucytosine is metabolised to 5-flurouracil which is further metabolised by dihydropyrimidine dehydrogenase. ,""
92514,"Coadministration with a levonorgestrel-containing combined oral contraceptive (COC) has not been studied. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration is predicted to increase levonorgestrel exposure. When used in combined pill, the estrogen component is reduced. Given the lack of clinical data on the contraceptive efficacy, caution is recommended and additional contraceptives measures should be used.",""
92662,"Ritonavir, although known as a strong inhibitor, by contrast exhibits inducing properties when used concomitantly with steroid hormones and may increase the metabolism of norethisterone.",""
92687,"Administration of norethisterone (0.35 mg/day, as a progestogen only pill (POP)) was studied in a group of HIV+ women receiving protease inhibitors (atazanavir, atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir; n=16) or no protease inhibitors (n=17). Norethisterone exposure was increased by 50% in the presence of a protease inhibitor. In addition, the contraceptive efficacy of norethisterone was not impaired as no changes were noted in the cervical mucus of women receiving a regimen containing boosted protease inhibitor versus a regimen without a boosted protease inhibitor.",""
92803,"Coadministration with levonorgestrel as hormone replacement therapy (HRT) has not been studied. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration is predicted to increase levonorgestrel exposure. The clinical significance of this increase in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown. The use of an estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
92833,"Coadministration with drospirenone as hormone replacement therapy (HRT) has not been studied. CYP3A4 contributes to drospirenone metabolism. Coadministration is predicted to increase drospirenone exposure. The clinical significance of this increase in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown. The use of an estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
92862,"Coadministration with dydrogesterone as hormone replacement therapy (HRT) has not been studied. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Coadministration is predicted to increase dydrogesterone exposure due to inhibition of CYP3A4. The clinical significance of this increase in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown. The use of estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
93012,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6).",""
92893,"Coadministration with norethisterone as hormone replacement therapy (HRT) has not been studied. Norethisterone is metabolized by CYP3A4. Coadministration is predicted to increase norethisterone&nbsp;exposure. The clinical significance of this increase in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown. The use of an estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
92919,"Coadministration with norgestrel as hormone replacement therapy (HRT) has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration is predicted to increase norgestrel exposure. The clinical significance of this increase in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown. The use of an estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
73458,"Triple therapy with zidovudine, lamivudine and efavirenz is unlikely to interfere with the contraceptive effectiveness of medroxprogesterone when administered as an IM depot injection. Coadministration of medroxyprogesterone and zidovudine, lamivudine and efavirenz did not the affect the pharmacokinetics of medroxyprogesterone. Pharmacokinetics of zidovudine, lamivudine and efavirenz were not studied. Coadministration with a medroxyprogesterone sub-cutaneous depot injection has not been studied.",""
87355,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway. Dose Descovy according to the concomitant antiretroviral.,""
69304,Coadministration with tipranavir/ritonavir has not been studied. The effect of tipranavir/ritonavir on calcium channel blockers that are dual substrates of CYP 3A and P-gp can not be predicted due to the conflicting effect of tipranavir/ritonavir on CYP 3A and P-gp. Caution is warranted and clinical monitoring of patients is recommended.,""
70577,"Coadministration of raltegravir (400 mg twice daily) and tipranavir/ritonavir decreased raltegravir AUC, Cmax and Cmin by 24%, 18% and 55%, respectively. However, comparable efficacy was observed in clinical studies in subjects receiving raltegravir/tipranavir/ritonavir relative to subjects not receiving tipranavir/ritonavir.&nbsp;No dose adjustment is required with twice daily raltegravir. Coadministration with once daily raltegravir is&nbsp;not recommended.<span></span>",""
80510,"Coadministration has not been studied but should be avoided. Dasatinib is metabolized by CYP3A4 and coadministration may significantly increase exposure to dasatinib concentrations. In addition, both drugs have the potential to prolong the QT interval. If coadministration is unavoidable, close monitoring for toxicity and QT prolongation is required and a dose reduction of dasatinib to 20-40 mg daily should be considered.",""
124876,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Griseofulvin is a liver microsomal enzyme inducer however it is unlikely alter temsavir exposure significantly. The coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir exposure by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with griseofulvin.,""
124879,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Miconazole inhibits CYP2C9 and CYP3A4 but is unlikely to cause a clinically significant increase in temsavir exposure. ,""
124880,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected. ",""
124882,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYPs 2C8 and 2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124883,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Voriconazole is a strong inhibitor of CYP3A4 and coadministration may increase temsavir exposure, but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124885,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. ,""
124886,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized in the liver via CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125011,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.",""
125012,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small amount of the orally inhaled zanamivir is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces. ,""
95189,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely&nbsp;when folic acid is administered in a multivitamin preparation. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
68237,"Coadministration has not been studied. Apomorphine is metabolized by several pathways that include mainly glucuronidation and sulfation and to a lesser extent N-demethylation. Although protease inhibitors have the potential to induce glucuronidation, the clinical relevance of such an interaction is unknown considering the numerous pathways contributing to apomorphine metabolism. No a priori dosage adjustment is required.&nbsp;However, the European SPC for lopinavir advises caution when coprescribing with drugs known to induce QT interval prolongation.",""
125013,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125014,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Drug-drug interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may play a role. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125015,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
76031,"Coadministration has not been studied but could potentially result in increased risk of nephrotoxicity. The risk is increased if an NSAID is used for a long duration, if the patient has a pre-existing renal dysfunction, has a low body weight, or receives other drugs that may increase tenofovir exposure. Cases of acute renal failure after initiation of high dose or multiple NSAIDs have been reported in patients treated with tenofovir-DF and with risk factors for renal dysfunction. Alternatives to NSAIDs should be considered in patients at risk for renal dysfunction. If tenofovir-DF is co-administered with an NSAID, renal function should be monitored adequately.",""
125016,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125017,"Coadministration has not been studied. Clobazam is metabolised by CYP3A4 (major) and CYP2B6 and CYP2C19 (minor) to the active metabolite N-desmethylclobazam, which is metabolised by CYP2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Clobazam is a weak inducer but is unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce the exposure of the active metabolite temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with clobazam.",""
125018,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
93858,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.&nbsp;",""
125019,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125020,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
93882,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bictegravir does not inhibit or induce P450 or UGT enzymes. Significant interactions are not expected with emtricitabine and tenofovir alafenamide.,""
125021,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and CYP2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125022,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125023,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. ,""
93911,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, both products contain emtricitabine and tenofovir alafenamide and must not be administered with other products containing emtricitabine and tenofovir alafenamide.",""
93919,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.",""
125024,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is mainly glucuronidated (by UGTs 2B15, 2B4, 2B7, 1A7, 1A10). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125025,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated (possibly by UGTs 2B15, 1A9 and 2B7). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
93932,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lopinavir would be possible from a pharmacokinetic standpoint. Coadministration may increase bictegravir concentrations due to inhibition of CYP3A4 by lopinavir/ritonavir but this is unlikely to require dose modification. Coadministration of lopinavir/ritonavir and emtricitabine/tenofovir alafenamide had no significant effect on lopinavir and increased exposure of tenofovir alafenamide. The recommended dose of 10 mg tenofovir alafenamide with P-gp inhibitors is not possible with Biktarvy which is only available as a fixed dose combination containing 25 mg tenofovir alafenamide, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile.",""
93938,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, tipranavir is expected to decrease the absorption (and thereby plasma concentrations) of tenofovir alafenamide due to induction of P-gp which may result in loss of therapeutic effect and development of resistance.",""
125026,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Midazolam is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125028,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated (by UGTs 2B15, 1A9 and 2B7). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125029,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125030,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125031,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125032,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125033,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125034,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCTs or MATE1 transporters to a clinically significant extent. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125035,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
95957,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dactinomycin is minimally metabolized.,""
125036,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and metabolism via CYP2D6 and to a lesser extent by CYPs 2C9 and 1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125037,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125038,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125039,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolized via glucuronidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125040,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125041,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125042,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.",""
125044,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Theophylline is mainly metabolized by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
125045,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with formoterol. However, the product labels for fostemsavir indicate that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125046,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glycopyrronium bromide is mainly eliminated renally (active secretion via organic cation transporter) and is also partly hydroxylated via multiple CYPs. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes and does not inhibit OCT transporters.,""
125047,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is eliminated partly unchanged (33%) and partly metabolized by CYP3A4 and UGT1A1, and is a weak substrate of P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes and does not inhibit P-gp. ",""
125048,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. ,""
125078,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cytarabine is metabolized by cytidine deaminase. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.,""
125079,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine undergoes activation to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. In vitro data indicate that dacarbazine is a substrate of the renal transporter OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes and does not inhibit OAT1.",""
125080,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dactinomycin is minimally metabolized. ,""
125081,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dasatinib is metabolized by CYP3A4 and is a weak inhibitor of CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Dasatinib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with dasatinib.,""
125082,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Fostemsavir has been shown to increase tenofovir alafenamide exposure (likely due to intestinal inhibition of BCRP), but to a modest extent. The Daunorubicin is a BCRP substrate and concentrations may increase. Caution is needed since damage to the myocardium is one of the major risks of daunorubicin treatment and may include: dose-independent supraventricular arrhythmias (sinus tachycardia, premature ventricular contractions, AV-block) and/or non-specific ECG abnormalities. Note: fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses. ",""
125083,Coadministration has not been studied. Docetaxel is metabolized by CYP3A4 and is a substrate of OATP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and has the potential to increase docetaxel exposure and increase the risk of toxicities. Use with caution.,""
125084,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Doxorubicin is mainly eliminated in the bile and is a substrate of P-gp and BCRP. Fostemsavir has been shown to increase tenofovir alafenamide exposure (likely due to intestinal inhibition of BCRP), but to a modest extent. An increase in doxorubicin exposure cannot be excluded. Caution is advised due to possible cardiac toxicities (ECG abnormalities and sometimes arrhythmias).",""
125085,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Droloxifene is mainly glucuronidated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125086,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Epirubicin is glucuronidated by UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Epirubicin has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with epirubicin.,""
125087,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erlotinib is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125088,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine phosphate undergoes rapid dephosphorylation to estramustine which is then oxidized by 17beta-hydroxysteroid dehydrogenases to estromustine. Estramustine and estromustine are subsequently hydrolyzed to estradiol and estrone, respectively. Estradiol is then hydroxylated by CYP1A1, 1A2 and 3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125209,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest it could act as an inducer of phase I and phase II metabolic enzymes, however, it is expected to have a limited effect on temsavir. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with Malabar nut tree.",""
125210,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Menthol is a moderate inhibitor of CYP3A4 but is not expected to significantly affect temsavir exposure. Coadministration of fostemsavir with ritonavir (a strong CYP3A4 inhibitor) was shown to increase temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
125263,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
95499,"Coadministration has not been studied. Metabolism and elimination of levamisole has not been well characterized. Based on limited information, and single dose use of levamisole, clinically significant interactions are not considered likely.",""
95186,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with cyanocobalamin when given alone or in multivitamins. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
95205,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with pyridoxine when given alone or in multivitamins.&nbsp;No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
95208,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with riboflavin when given alone or in multivitamins.&nbsp;No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
95215,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with vitamin E when given alone or in multivitamins. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
95536,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No significant metabolism of doxycycline occurs - it is cleared intact by renal and biliary mechanisms.,""
96319,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alfentanil undergoes extensive CYP3A4 metabolism.,""
125264,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration. ,""
93936,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to saquinavir should be considered.",""
125265,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125266,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125267,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. ",""
125268,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as metolazone is largely excreted unchanged in the urine. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit renal transporters to a clinically significant extent.",""
95743,"Coadministration has not been studied. Betrixaban is largely eliminated unchanged through biliary secretion via P-gp. Coadministration with a P-gp inhibitor (such as cobicistat) is expected to increase betrixaban exposure. The US product label for betrixaban recommends for patients receiving or starting a strong P-gp inhibitor to reduce betrixaban dose and use an initial dose of 80 mg followed by 40 mg once daily.&nbsp; Furthermore, patients should be monitored closely and any signs or symptoms of blood loss should be evaluated promptly. Of note, coadministration of betrixaban might need to be reconsidered in patients with concomitant renal impairment (creatinine clearance &lt;60 ml/ml) as renal impairment per se does increase betrixaban exposure.",""
125269,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxonidine is only minimally metabolized and is eliminated renally by glomerular filtration and active secretion, mainly as unchanged moxonidine. The renal transporter involved in moxonidine excretion is unknown. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit renal transporters to a clinically significant extent.",""
125270,Coadministration has not been studied. Olmesartan is a substrate of OATP1B1/3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir inhibits OATP and has the potential to increase olmesartan exposure. Monitor blood pressure and adjust olmesartan dose if needed.,""
125271,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolized to other inactive metabolites. Elimination occurs predominantly via the urine. ,""
125272,"Coadministration has not been studied. Prazosin is extensively metabolized, primarily by demethylation and conjugation and is a substrate of BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. However, temsavir inhibits BCRP and has the potential to increase prazosin exposure. Monitor blood pressure and adjust prazosin dose if needed.",""
125273,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT3.,""
125274,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Fostemsavir does not interfere with these metabolic pathways. ",""
125276,"Coadministration has not been studied. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, CYP2J2 and is also eliminated unchanged in the bile and renally. Riociguat is a substrate of P-gp and BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit BCRP and has the potential to increase riociguat exposure. Monitor for signs and symptoms of hypotension and consider dose reduction if needed. ",""
125277,"Coadministration has not been studied. Sacubitril is rapidly converted to LBQ657 (active metabolite) by carboxylesterases and the active metabolite is not further metabolized to a significant extent. Sacubitril inhibits OATP1B1 and LBQ657 is a substrate of OATP1B1/3, OAT1 and OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is not a substrate of OATPs but does inhibit these transporters and has the potential to increase the exposure of sacubitrilâ€™s active metabolite. Start with the lowest recommended dose of sacubitril and titrate dosage as tolerated by the patient.",""
103694,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys.,""
125278,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
125279,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is primarily metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
95898,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is eliminated partly unchanged (33%) and partly metabolized by CYP3A4 and UGT1A1, and is a weak substrate of P-gp. Coadministration with ritonavir increased indacaterol exposure up to two-fold and a similar effect may occur with cobicistat. However, this increase does not raise any safety concerns given the safety experience of indacaterol at doses up to twice the maximum recommended therapeutic dose in clinical studies of up to one year and dose adjustment is not required.",""
95901,"Coadministration has not been studied. Olodaterol is metabolized by CYP2C8, CYP2C9, is glucuronidated via several UGTs, and is a substrate of P-gp. Coadministration with ketoconazole (an inhibitor of P-gp) increased olodaterol exposure by 70% and a similar magnitude of interaction may occur with cobicistat. No a priori dose adjustment is recommended.",""
95953,Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1 and in vitro data indicate that cobicistat is a moderate inhibitor of MATE1. Cobicistat could potentially slow down cisplatin renal elimination and thus increase the risk of nephrotoxicity. Close monitoring of renal function is recommended.,""
125280,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little potential for sodium nitroprusside to affect the disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals. ",""
125281,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases. Fostemsavir does not interfere with this metabolic pathway. ,""
95951,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carboplatin is excreted primarily by renal glomerular filtration. In vitro studies have shown that carboplatin does not significantly inhibit cytochrome P450 metabolic enzymes.,""
95964,"Coadministration has not been studied. Erlotinib is mainly metabolized by CYP3A4 and coadministration could potentially increase erlotinib concentrations. Coadministration of a potent CYP3A4 inhibitor should be avoided, but if this is not possible, use with caution and close monitoring for erlotinib mediated toxicity is necessary.",""
95968,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Exemestane is metabolised by CYP3A4 but coadministration with ketoconazole (a potent CYP3A4 inhibitor) showed no clinically significant effects and no effect is expected due to inhibition of CYP3A4 by cobicistat. No a priori dose adjustment is required.",""
125282,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tadalafil is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125283,Coadministration has not been studied Telmisartan is mainly glucuronidated by UGT1A3 and is a substrate of OATP1B3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes but inhibits OATPs and has the potential to increase telmisartan exposure. Monitor blood pressure and adjust telmisartan dose if needed.,""
125284,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as terazosin is extensively metabolized in the liver possibly via CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
96030,"Coadministration has not been studied. Catâ€™s claw is a strong inhibitor of CYP3A4 in vitro and increased concentrations of atazanavir, saquinavir and ritonavir were reported in a patient receiving Catâ€™s claw. Similar increases would be expected for other CYP3A4 substrates, such as darunavir. Coadministration should be avoided.",""
125285,Coadministration has not been studied. Torasemide is metabolized mainly by CYP2C9 and is a substrate of OATPs. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and has the potential to increase torasemide exposure. Monitor blood pressure and adjust torasemide dose if needed.,""
96023,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). In vitro data indicate that cobicistat is a weak inhibitor of CYP2D6 and thus is unlikely to significantly alter metoclopramide concentrations.,""
125286,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat. Fostemsavir does not interact with this metabolic pathway. ,""
96066,"Coadministration has not been studied. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Ambrisentan concentrations may increase due to inhibition of OATP1B1 by darunavir. Start ambrisentan at 5 mg and closely monitor the patient for tolerability.",""
125287,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125288,Coadministration has not been studied. Valsartan is a substrate of OATPs. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir inhibits OATPs and has the potential to increase valsartan exposure. Monitor blood pressure and adjust valsartan dose if needed.,""
96118,Coadministration has not been studied. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4. No a priori clinically relevant drug-drug interaction is anticipated.,""
125289,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). ",""
125290,"Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4, however, no clinically relevant effect is expected on temsavir exposure (active metabolite of fostemsavir). ",""
96173,Coadministration has not been studied. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Coadministration of flibanserin with moderate or strong inhibitors of CYP3A4 is contraindicated due to increased flibanserin concentrations which can cause severe hypotension and syncope.,""
125291,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
96215,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as benserazide is hydrolysed to trihydroxybenzylhydrazine.,""
125345,"Coadministration has not been studied but a clinically significant interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole). Despite this potential hepatic metabolism very few data exist on carbimazole drug interactions and a marked interaction is not expected. ",""
125346,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have suggested that transformation of clomifene to its active metabolite is likely to be mediated via CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
96178,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. There is no evidence that cobicistat inhibits or induces UGTs.",""
96250,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Inhibition of metabolism by darunavir is unlikely to affect ibalizumab, a monoclonal antibody binding to the CD4 receptor, which is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Dose modifications of ibalizumab are not required when administered with any other antiretroviral.",""
125347,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125348,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125349,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway. ,""
125350,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disulfiram is reduced to diethyldithiocarbamic acid, is conjugated with glucuronic acid, oxidised to sulphate, methylated and decomposed to diethylamine and carbon disulphide. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce drug metabolizing enzymes.",""
125351,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
117010,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goldenseal has been shown to inhibit CYP3A4 in vitro but not in vivo. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
96307,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as isoflurane is almost exclusively eliminated unchanged by the lungs.,""
95482,"Coadministration has not been studied. Fentanyl undergoes extensive CYP3A4 metabolism. Coadministration may increase fentanyl concentrations due to inhibition of CYP3A4, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Monitor patients closely at frequent intervals and consider dosage reduction of fentanyl until stable drug effects are achieved. Discontinuation of a CYP3A4 inhibitor could decrease fentanyl concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to fentanyl. When discontinuing CYP3A4 inhibitors in fentanyl-treated patients, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur. Note, the use of fentanyl in a non-therapeutic setting (i.e., as a recreational drug) should be avoided with darunavir as fentanyl exposure is expected to significantly increase and serious, life-threatening, or fatal respiratory depression may occur. Patients should be aware that recreational use could be potentially fatal.",""
125353,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolised by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
95922,"Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Contrary to ritonavir, cobicistat does not induce CYP1A2 and glucuronidation and therefore coadministration is predicted to increase estradiol exposure due to inhibition of CYP3A4. The clinical significance of this increase in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones in unknown. The use of estradiol alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
95998,"Coadministration has not been studied but is expected to substantially increase sildenafil concentrations and may result in an increase in associated adverse events including hypotension, syncope, visual changes and prolonged erection. Use sildenafil with caution at a reduced dose not exceeding 25 mg in 48 h with increased monitoring for adverse events.",""
96560,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4.,""
95999,"Coadministration has not been studied but may increase tadalafil concentrations and result in increased tadalafil-associated adverse events, including hypotension, visual changes, and priapism. For erectile dysfunction, use tadalafil with caution at a reduced dose not exceeding 10 mg in 72 hours with increased monitoring for adverse events.",""
96324,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dextropropoxyphene is mainly metabolized by CYP3A4.,""
122974,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Cabotegravir and rilpivirine were shown to have no inhibitory or inducing effects on CYP1A2, CYP2C9 and CYP2C19 at clinically relevant concentrations.",""
122975,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion and in vitro studies have shown it may competitively inhibit the renal transporters OAT1, OAT3 and OAT4. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters and are unlikely to be affected by inhibition of OATs.",""
122976,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1. Likewise, rilpivirine does not inhibit OAT1.",""
122977,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as acitretin undergoes isomerisation and glucuronidation. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
125354,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
122980,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1. Likewise, rilpivirine does not inhibit OAT1.",""
96452,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation.,""
96432,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYPs 1A2 and 3A4 whereas S-warfarin (more potent) is metabolized by CYP2C9.,""
122981,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Adrenaline is rapidly inactivated, mostly in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Cabotegravir and rilpivirine do not interfere with this metabolic pathway.",""
96451,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bupropion is primarily metabolized by CYP2B6.,""
122982,Coadministration has not been studied. African potato was shown to inhibit CYP3A4 and P-gp in vitro and to activate PXR suggesting that inhibition may occur initially followed by induction of CYP3A4 and P-gp when used for extended periods. African potato is unlikely to alter cabotegravir exposure based on the drug interaction study with rifabutin (a moderate inducer) but has the potential to decrease rilpivirine exposure. ,""
122983,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
125355,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Glyceryl trinitrate is metabolised by aldehyde dehydrogenase-2. Glyceryl trinitrate is not known to induce or inhibit CYP enzymes. ,""
125356,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Goserelin is mainly hydrolyzed. Note, androgen deprivation treatment may prolong the QT interval. Caution should be taken when using with antiretroviral drugs that can potentially prolong the QT interval such as fostemsavir (although at supra-therapeutic concentrations).",""
122984,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized by CYP3A4 and by the flavine-containing monooxygenase system. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
96548,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol undergoes glucuronidation (UGT2B7&gt;1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6).",""
96546,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is predominantly metabolised via CYP2D6.,""
125357,Coadministration has not been studied. Ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid. ,""
96566,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bromazepam undergoes oxidative biotransformation.,""
96569,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4.,""
125358,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
96603,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4â€™-O-sulphate.,""
96609,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amlodipine is metabolized by CYP3A4.,""
122986,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.No clinically relevant effect is expected on rilpivirine exposure. ,""
125359,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Leuprorelin acetate is a peptide that is primarily degraded by peptidases. Note, androgen deprivation treatment may prolong the QT interval. Caution should be taken when using with antiretroviral drugs that can potentially prolong the QT interval such as fostemsavir (although at supra-therapeutic concentrations).",""
96639,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly glucuronidated by UGT1A1 and partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase.,""
96664,"Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 &gt; 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4.",""
122987,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcuronium is predominantly excreted unchanged via the kidneys possibly via active tubular secretion. However, cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
125360,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125361,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mannitol is metabolised only very slightly, if at all, to glycogen in the liver; it is predominantly eliminated unchanged via glomerular filtration. There is little potential for mannitol to affect the disposition of antiretrovirals, or to be altered if co-administered with antiretrovirals. ",""
122988,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. However, this interaction is not relevant when cabotegravir and rilpivirine are administered intramuscularly.",""
122989,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes CYP3A4 metabolism, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
125362,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolized by cytochrome P450 to a clinically relevant extent and does not inhibit cytochrome P450s. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.,""
125364,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naftidrofuryl is metabolized to 3 major metabolites primarily by plasma pseudo-choline esterases. ,""
96721,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as granisetron is metabolized by CYP3A4.,""
96724,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19.,""
122990,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Alfuzosin is metabolised mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
96768,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bosentan is metabolized by CYP3A4 and CYP2C9.,""
125365,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly glucuronidated by UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
96791,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is mainly metabolized by CYP3A4.,""
125366,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that neither naltrexone nor its main metabolite 6-beta-naltrexol is metabolized by CYP enzymes. ,""
96817,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase.,""
96818,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolized by CYP2D6.,""
122991,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized by CYP450 but is a substrate of P-glycoprotein. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes or P-glycoprotein at clinically relevant concentrations.,""
122992,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Cabotegravir and rilpivirine do not interfere with this metabolic pathway.,""
96859,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase.,""
96863,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as caffeine is mainly metabolized by CYP1A2.,""
122993,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
122994,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and is unlikely to cause a clinically significant interaction with rilpivirine. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. ",""
125367,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Neostigmine is thought to undergo a degree of hepatic metabolism, although the mechanisms are unknown. However, as metabolism also occurs via hydrolysis by cholinesterase and up to 50% of a dose is excreted unchanged via the kidneys, there is little potential for clinically significant interaction with fostemsavir. ",""
96913,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion).,""
122995,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
122996,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
125368,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of nicorandil takes place mainly via denitration with the denitrated product then merging into the nicotinamide pathway. ,""
125369,"Coadministration has not been studied. Orlistat should only be used with fostemsavir if separated by 4-5 hours. Orlistat reduces dietary fat absorption and may affect the absorption of antiretrovirals (especially if lipophilic). [Note: this interaction is not specific for fostemsavir, but for any medication taken with orlistat.]",""
96926,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4.,""
122997,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated in the kidney by glomerular filtration and active secretion. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
125370,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although metabolism of penicillamine is not fully elucidated, multiple mechanisms and sites of metabolism are thought to be involved. There is therefore low potential for clinically significant interactions via modulation of, or competition for metabolic pathways. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.",""
125371,"Coadministration has not been studied but based on limited data available an interaction appears unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation via CYP1A2, reduction by carbonyl reductase, oxidation by carboxylase. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
96563,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6.,""
122998,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes, P-glycoprotein, or OATP1B1 at clinically relevant concentrations.",""
122999,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amikacin is eliminated by glomerular filtration. ,""
125372,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
73014,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Didanosine does not affect the zolmitriptan metabolic pathway.,""
123000,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged by the kidney with in vitro data indicating that it is a substrate of OCT2. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
115926,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nefazodone is metabolized mainly by CYP3A4 and is also an inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
123001,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Theophylline is mainly metabolized by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123002,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amiodarone inhibits intestinal P-gp but this is not relevant in the case of intramuscular administration of cabotegravir and rilpivirine. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with amiodarone. However, given the QT prolongation risk associated with amiodarone, caution is recommended.",""
123003,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally, possibly via OCT. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
73017,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Stavudine does not affect the zolmitriptan metabolic pathway.,""
97041,Coadministration has not been studied. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C9 in the range of concentrations used in anaesthesia. Darunavir/ritonavir could potentially increase ketamine exposure. A dose adjustment may be needed.,""
97046,Coadministration has not been studied. Sufentanil undergoes extensive CYP3A4 metabolism and darunavir/ritonavir could potentially increase sufentanil exposure. The extent of this drug-drug interaction is difficult to predict as sufentanil is a high hepatic extraction drug and therefore its rate of hepatic elimination is in theory more dependent on liver blood flow.,""
115927,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
73018,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Tenofovir-DF does not affect the zolmitriptan metabolic pathway.,""
115928,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123005,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123006,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is metabolized mainly by CYP2C8. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
73019,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Zidovudine does not affect the zolmitriptan metabolic pathway.,""
97055,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolized by CYP2C9 and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. A dose adjustment is unlikely to be required for celecoxib when coadministered with darunavir/ritonavir.,""
123007,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion via OAT3. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters,""
123008,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Amphetamine is metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
125822,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Emtricitabine/tenofovir alafenamide does not affect the zolmitriptan metabolic pathway.,""
125823,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Emtricitabine/tenofovir-DF does not affect the zolmitriptan metabolic pathway.,""
97058,"Coadministration has not been studied. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7&gt;UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7&gt;UGT1A1). As ritonavir induces glucuronidation, darunavir/ritonavir could potentially decrease the analgesic effect although to a moderate extent as induction of glucuronidation may increase the formation of the active metabolite. No a priori dosage adjustment is recommended but monitor the analgesic effect and signs of opiate withdrawal.",""
97060,"Coadministration has not been studied. Dihydrocodeine is converted to dihydromorphine (active metabolite) via CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine via CYP3A4. The analgesic effect appears to be primarily due to the parent compound. Darunavir/ritonavir could potentially increase dihydrocodeine exposure (inhibition of CYP3A4 and CYP2D6) and increase the conversion to dihydrocodeine-6-glucuronide (induction of UGT2B7). The net clinical effect of this interaction is difficult to predict. No a priori dose adjustment is required, but monitoring for analgesic effect and for signs of opiate toxicity may be required as clinically indicated.",""
97065,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and additionally glucuronidated by UGT2B7 and UGT1A9. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9, but a dose adjustment is unlikely to be required for mefenamic acid when coadministered with darunavir/ritonavir.",""
97067,"Coadministration has not been studied. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7&gt;UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7&gt;UGT1A1). As darunavir/ritonavir induces glucuronidation, coadministration could potentially decrease morphine concentration but facilitate the formation of the active metabolite morphine-6-glucuronide. Morphine and morphine-6-glucuronide are substrates of P-gp and coadministration may potentiate the effects of opiate in the CNS (via inhibition of P-gp at the blood-brain barrier). Monitor for sign of opiate toxicity.",""
125824,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.,""
125825,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125826,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. Cabotegravir does not inhibit or induce CYP enzymes.&nbsp;,""
97036,"Coadministration has not been studied. Dexmedetomidine undergoes extensive hepatic biotransformation through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly 2A6). Study data indicate that ritonavir decreases exposure of lamotrigine, a UGT1A4 probe substrate. Darunavir/ritonavir could potentially decrease dexmedetomidine concentrations. No a priori dosage adjustment is recommended but monitor clinical effect.",""
123010,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ampicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters,""
97062,"Coadministration has not been studied. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Inhibition of CYP3A4 and CYP2D6 by darunavir/ritonavir may increase hydrocodone concentrations but decrease concentrations of norhydrocodone and hydromorphone. The clinical significance of this is unclear. Monitor the analgesic effect and for signs of opiate toxicity.",""
97063,"Coadministration has not been studied. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Ritonavir induces glucuronidation and coadministration with darunavir/ritonavir could potentially decrease the analgesic effect. Monitor the analgesic effect.",""
97073,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9 and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. A dose adjustment is unlikely to be required for piroxicam when coadministered with darunavir/ritonavir.,""
97098,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-glycoprotein and MRP2. Darunavir/ritonavir could potentially increase azithromycin exposure (inhibition of P-glycoprotein and MRP2), however, no a priori dosage adjustment is recommended for azithromycin.",""
123011,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
125827,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes.&nbsp;,""
97142,"Coadministration has not been studied. In vitro studies suggest that sulfadiazine is partly metabolized by CYP2C9. Ritonavir has been found to induce metabolism mediated by CYP2C9 in clinical studies with probe substrates. Coadministration of darunavir/ritonavir may decrease levels of sulfadiazine to a moderate extent, but the clinical significance of this potential interaction is unknown.",""
97143,Coadministration has not been studied. Telithromycin is both an inhibitor and substrate of CYP3A4 and coadministration may increase darunavir and telithromycin concentrations.,""
123013,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations contained in antacids resulting in a reduced absorption of cabotegravir. However, there is no such interaction when cabotegravir is administered intramuscularly. Furthermore, rilpivirine absorption is not impacted by antacids when administered intramuscularly.",""
125828,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.&nbsp;,""
97156,"Coadministration has not been studied. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8). Coadministration of eltrombopag (100 mg single dose) with lopinavir/ritonavir decreased eltrombopag AUC by 17%. Similarly, darunavir/ritonavir could potentially decrease eltrombopag exposure. Caution should be used when coadministering these drugs and platelet count monitoring is recommended.",""
97160,Coadministration has not been studied. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. The net effect difficult to predict. Darunavir/ritonavir could potentially decrease or increase phenprocoumon concentrations. Monitor INR,""
97171,"Coadministration has not been studied but based on data with other boosted protease inhibitors, darunavir/ritonavir could potentially decrease lamotrigine exposure possibly due to induction of glucuronidation. Monitor the therapeutic response to lamotrigine and increase dose if needed.",""
97173,"Coadministration has not been studied. Oxcarbazepine is rapidly reduced by cytosolic arylketone reductases to its active metabolite, 10-hydroxycarbazepine. Oxcarbazepine is a moderate inducer of CYP3A4 and could potentially decrease darunavir/ritonavir exposure although to a moderate extent. Perform TDM for darunavir.",""
97181,Coadministration has not been studied. Agomelatine is metabolised predominantly by CYP1A2 which is induced by ritonavir. Coadministration with darunavir/ritonavir could potentially decrease agomelatine exposure. Monitor clinical effect and increase dosage if needed.,""
97183,Coadministration has not been studied. Bupropion is primarily metabolized by CYP2B6 and in vivo data indicate that ritonavir induces CYP2B6. Darunavir/ritonavir could potentially decrease bupropion concentrations. Titrate bupropion dose based on response.,""
125818,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Dolutegravir does not inhibit or induce CYP1A2 or P-glycoprotein. Zolmitriptan does not interact with abacavir or lamivudine.,""
125830,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Rilpivirine does not inhibit or induce CYP1A2 or P-glycoprotein.,""
97198,Coadministration has not been studied. Nefazodone is metabolized mainly by CYP3A4 and is also an inhibitor of CYP3A4. Darunavir/ritonavir may increase nefazodone exposure. Monitor side effects and reduce dosage if needed.,""
97259,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diloxanide furoate is largely hydrolysed under the combined action of bacterial and gut esterases and consequently glucuronidated. No clinically significant drug interactions are known, and significant interactions with antiretrovirals are unlikely.",""
97209,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is metabolised by UGTs and is a substrate of P-gp, BCRP, OAT3 and OATP1B1/1B3. Although darunavir/ritonavir inhibits P-gp and OATP, data with verapamil (a P-gp inhibitor) and rifampicin (an OATP1B1/1B3 inhibitor) suggest a clinically relevant effect on empagliflozin is unlikely.",""
97211,Coadministration has not been studied. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Darunavir/ritonavir could potentially increase glibenclamide concentrations. Monitor clinical effect and reduce glibenclamide dosage if needed.,""
97212,Coadministration has not been studied. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially decrease gliclazide concentrations. Monitor clinical effect and increase gliclazide dosage if needed.,""
97213,Coadministration has not been studied. Glimepiride is mainly metabolized by CYP2C9. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially decrease glimepiride concentrations. Monitor clinical effect and increase glimepiride dosage if needed.,""
97214,Coadministration has not been studied. Glipizide is mainly metabolized by CYP2C9. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially decrease glipizide concentrations. Monitor clinical effect and increase glipizide dosage if needed.,""
97219,Coadministration has not been studied. Nateglinide is metabolized mainly by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%) and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. The net clinical effect of this interaction is difficult to predict as darunavir/ritonavir could potentially decrease nateglinide concentrations (induction CYP2C9) or increase nateglinide concentrations (inhibition CYP3A4). Monitor clinical effect and adjust nateglinide dosage as needed.,""
97225,Coadministration has not been studied. Tolbutamide is mainly metabolized by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially decrease tolbutamide concentrations. Monitor clinical effect and increase tolbutamide dosage if needed.,""
97229,Coadministration has not been studied. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. In vitro data indicate that caspofungin is a substrate of the hepatic transporter OATP1B1 and that darunavir and ritonavir are inhibitors of OATP1B1. Darunavir/ritonavir could potentially increase caspofungin exposure. No a priori dosage adjustment is recommended for caspofungin but monitor side effects.,""
97260,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eflornithine is predominantly eliminated unchanged via the kidneys.,""
97244,"Coadministration has not been studied. Fexofenadine does not undergo CYP mediated metabolism but is a substrate of P-gp/OATP. Darunavir/ritonavir could potentially increase fexofenadine exposure by inhibition of P-gp. However, due to the large therapeutic index of fexofenadine, no dosage adjustment is recommended.",""
97246,"Coadministration has not been studied. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Darunavir/ritonavir could potentially increase loratadine concentrations. Due to the large therapeutic index of loratadine, no dosage adjustment is recommended.",""
97258,"Coadministration has not been studied. Chloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Darunavir/ritonavir could potentially increase chloroquine exposure by inhibition of CYPs 2C8, 3A4 and 2D6 although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for chloroquine but monitor toxicity.",""
97256,"Coadministration has not been studied. Atovaquone is mainly eliminated unchanged in the faeces. Administration of a single dose of atovaquone/proguanil with lopinavir/ritonavir or atazanavir/ritonavir decreased atovaquone AUC by 70% or 40-50%, respectively; proguanil AUC was also decreased. A possible mechanism was suggested to be induction of glucuronidation by ritonavir and so darunavir/ritonavir could potentially decrease atovaquone and proguanil. The clinical relevance of this interaction is unknown due to the lack of data on the minimal effective atovaquone plasma concentration in the setting of malaria prophylaxis. Consider taking atovaquone with a high fat meal to increase its bioavailability and increase the dosage if required.",""
123015,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123016,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with apomorphine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
97270,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450. The oxidative metabolites rather than the parent drug are primarily responsible for the haemolytic effects of primaquine. In theory, inhibition of CYP3A4 by darunavir/ritonavir could potentially reduce the conversion to haemotoxic metabolites.",""
97278,"Coadministration has not been studied. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6). As ritonavir induces CYP1A2 and UGT1A4, darunavir/ritonavir could potentially decrease asenapine exposure. Monitor the clinical effect and increase dosage if needed.",""
97280,"Coadministration has not been studied. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6. Darunavir/ritonavir could potentially increase clozapine exposure. Monitor patient closely for toxicity.",""
97285,"Coadministration has not been studied. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Ritonavir induces CYP1A2 and UGT1A4. Darunavir/ritonavir could potentially decrease olanzapine exposure. Monitor the clinical effect and increase dosage if needed.",""
97286,"Coadministration has not been studied. Paliperidone is primarily eliminated renally, with minimal metabolism occurring via CYP2D6 and CYP3A4. Darunavir/ritonavir could potentially increase paliperidone concentrations although to a limited extent and therefore no a priori dosage adjustment is needed.",""
123017,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Aprepitant is a moderate inhibitor of CYP3A4 and may increase rilpivirine exposure although to a limited extent. No dose adjustment is required. Aprepitant does not alter cabotegravir exposure as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123018,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
125831,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as atazanavir is a weak inhibitor of CYP2C8 and inhibits CYP3A4 (minor pathway). However, atazanavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease atazanavir exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, atazanavir has a conditional QT risk and androgen deprivation therapy may prolong the QT interval.",""
97332,Coadministration has not been studied. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Darunavir/ritonavir could potentially increase estazolam exposure. This could prolong sedation and a dosage reduction may be required.,""
97341,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as temazepam is mainly glucuronidated.,""
97345,Coadministration has not been studied. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Darunavir/ritonavir could potentially increase zopiclone exposure which could result in increased sedation. A dosage reduction may be needed.,""
97363,"Coadministration has not been studied. Roflumilast is metabolized by CYP3A4 and CYP1A2 to form roflumilast N-oxide, with both roflumilast and roflumilast N-oxide having PDE4 inhibitory activity. Roflumilast N-oxide is subsequently dealkylated by CYP3A4. Coadministration with ketoconazole (a strong inhibitor of CYP3A4) increased roflumilast exposure by 2 fold with no significant effect on roflumilast N-oxide exposure. These changes did not translate into significant changes in the inhibitory effect on PDE4 and did not affect the known safety and tolerability profile of roflumilast. A comparable effect may occur with darunavir/ritonavir, although the magnitude of the interaction may be less pronounced given that ritonavir inhibits CYP3A4 but also induces CYP1A2. No a priori dosage adjustment is recommended.",""
97334,Coadministration has not been studied. The metabolism of flurazepam is most likely CYP-mediated. Darunavir/ritonavir could potentially increase flurazepam exposure which could result in increased sedation or respiratory sedation. A dosage reduction may be required.,""
97356,Coadministration has not been studied. Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Theophylline is mainly metabolized by CYP1A2 and in vitro data indicate that ritonavir induces CYP1A2. Darunavir/ritonavir could potentially decrease theophylline concentrations. Monitor plasma concentrations and increase aminophylline dosage if needed.,""
97366,Coadministration has not been studied. Theophylline is mainly metabolized by CYP1A2 and in vitro data indicate that ritonavir induces CYP1A2. Darunavir/ritonavir could potentially decrease theophylline concentrations. Monitor plasma concentrations and increase theophylline dosage if needed.,""
97368,"Coadministration has not been studied. Umeclidinium bromide is mainly metabolized by CYP2D6 and is a substrate of P-gp. Darunavir could potentially increase umeclidinium bromide exposure, however, the interaction is predicted to be of weak to moderate intensity and dosage adjustment is not required.",""
125816,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Doravirine does not inhibit or induce CYP1A2 or P-glycoprotein. Zolmitriptan does not interact with lamivudine and tenofovir-DF.,""
123020,"Coadministration has not been studied. Artemisinins undergo rapid metabolism via several CYP450 (CYP3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolised via UGTs 1A9 and 2B7. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. However, artemisinins induce CYP3A4 and/or CYP2C19. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9 but rilpivirine concentrations could potentially decrease. Given the short duration treatment with artemisinin, coadministration might be possible after careful evaluation of the risks and benefits. ",""
125832,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as atazanavir is a weak inhibitor of CYP2C8 and atazanavir/cobicistat inhibits CYP3A4 (minor pathway). However, atazanavir/cobicistat is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease atazanavir/cobicistat exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, atazanavir has a conditional QT risk and androgen deprivation therapy may prolong the QT interval.",""
125833,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as darunavir/cobicistat inhibits CYP3A4 (minor pathway). However, darunavir/cobicistat is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease darunavir/cobicistat exposure leading to loss of therapeutic effect and possible development of resistance.",""
123021,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. Cabotegravir and rilpivirine do not interfere with this metabolic pathway. ,""
125834,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as atazanavir is a weak inhibitor of CYP2C8 and atazanavir/ritonavir inhibits CYP3A4 (minor pathway). However, atazanavir/ritonavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease atazanavir/ritonavir exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, atazanavir has a conditional QT risk and androgen deprivation therapy may prolong the QT interval.",""
97408,Coadministration has not been studied. Bexarotene is mainly metabolized by CYP3A4 and induces CYP3A4 (after repeated administration and especially at doses greater than 300 mg/m2/day). Coadministration could potentially increase bexarotene concentrations and thus increase the risk of side effects. Bexarotene could potentially decrease darunavir exposure. Consider TDM of darunavir if available.,""
123022,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. Cabotegravir and rilpivirine do not interfere with this metabolic pathway. Vitamin C can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
125835,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as darunavir/ritonavir inhibits CYP3A4 (minor pathway). However, darunavir/ritonavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease darunavir/ritonavir exposure leading to loss of therapeutic effect and possible development of resistance.",""
97415,"Coadministration has not been studied. Cyclophosphamide is metabolized by two pathways. Activation (major pathway) to 4-hydroxycyclophosphamide is catalyzed by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. In vivo data indicate that ritonavir induces CYP2B6. In theory, darunavir/ritonavir could potentially reduce the risk of neurotoxicity and increase the amount of drug available for the activation pathway which may increase the efficacy and the toxicity of cyclophosphamide. Careful monitoring of cyclophosphamide related side effects is recommended.",""
97417,"Coadministration has not been studied. Dacarbazine undergoes activation to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. In vitro data indicate that ritonavir induces CYP1A2. Darunavir/ritonavir may increase the conversion to MTIC and thereby increase the efficacy and toxicity of dacarbazine. Monitor side effects.",""
97423,Coadministration has not been studied. Droloxifene is mainly glucuronidated and coadministration with darunavir/ritonavir could potentially decrease droloxifene exposure due to induction of glucuronidation. Monitor droloxifene therapeutic effect.,""
97424,Coadministration has not been studied. Epirubicin is glucuronidated by UGT2B7. Darunavir/ritonavir could potentially reduce epirubicin concentrations (induction of UGT2B7 by ritonavir) and thus decrease the efficacy.,""
97427,"Coadministration has not been studied. Etoposide is partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. Furthermore, etoposide is partly glucuronidated by UGT1A1. Darunavir/ritonavir could potentially increase etoposide exposure. Close monitoring of etoposide induced toxicity is recommended.",""
97429,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Exemestane is metabolised by CYP3A4 but coadministration with ketoconazole (a potent CYP3A4 inhibitor) showed no clinically significant effects and no effect is expected due to inhibition of CYP3A4 by darunavir/ritonavir. No a priori dose adjustment is required.",""
97432,Coadministration has not been studied. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Coadministration with darunavir/ritonavir could potentially decrease formestane exposure due to induction of glucuronidation. Monitor formestane therapeutic effect.,""
125770,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although fosamprenavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on fosamprenavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125771,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although indinavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on indinavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
97448,Coadministration has not been studied. Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and 1A) and monoamine oxidase. Darunavir/ritonavir could potentially decrease procarbazine concentrations due to induction of CYPs 2B and 1A by ritonavir. No a priori dosage adjustment is recommended but monitor the therapeutic effect.,""
97573,Coadministration has not been studied. Torasemide is metabolized mainly by CYP2C9. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially decrease torasemide exposure. No a priori dosage adjustment is recommended.,""
97462,"Coadministration has not been studied. In vitro data indicate that alosetron is metabolized by CYPs 2C9 (30%), 3A4 (18%) and 1A2 (10%); however, in vivo data suggest that CYP1A2 plays a more prominent role. In vitro data indicate that ritonavir induces CYP1A2, therefore coadministration with darunavir/ritonavir could potentially decrease alosetron exposure.",""
97481,"Coadministration has not been studied and is contraindicated with potent CYP3A4 inhibitors, such as ritonavir. Domperidone is mainly metabolized by CYP3A4. Darunavir/ritonavir could potentially increase domperidone exposure and increase the risk of cardiac adverse effects (QT interval prolongation).",""
97495,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies using a cocktail of probe drugs showed Echinacea inhibited CYP1A2 and intestinal CYP3A activity, and induced hepatic CYP3A activity. However, coadministration of Echinacea and lopinavir/ritonavir showed no clinically significant effect of Echinacea on lopinavir or ritonavir concentrations (most likely due to the potent CYP3A inhibition by ritonavir). Based on these data, Echinacea is unlikely to alter darunavir/ritonavir exposure.",""
97525,"Coadministration has not been studied and is not recommended. Aliskiren is minimally metabolized by CYP450, however, P-gp is a major determinant of aliskiren bioavailability. A 5-6 fold increase in exposure was observed with itraconazole 100 mg twice daily (a CYP3A4 and P-gp inhibitor) and a similar interaction is possible with darunavir/ritonavir (due to inhibition of P-gp by ritonavir). The product labels for aliskiren recommend avoiding concomitant use with CYP3A4 and P-gp inhibitors.",""
125772,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although lopinavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on lopinavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
97547,Coadministration has not been studied. Irbesartan is metabolized by via glucuronidation and oxidation (mainly CYP2C9). In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially decrease irbesartan exposure although to a moderate extent. No a priori dosage adjustment is recommended.,""
97551,Coadministration has not been studied. Lacidipine is metabolized by CYP3A4. Darunavir/ritonavir is predicted to increase lacidipine exposure. Use with caution and consider dose titration of lacidipine.,""
97554,Coadministration has not been studied. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Darunavir/ritonavir could potentially increase the conversion to the more pharmacologically active metabolite. No a priori dose adjustment is recommended.,""
97555,"Coadministration has not been studied. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Darunavir/ritonavir could potentially increase macitentan exposure. Of note, since macitentan is not a substrate of OATPs, the magnitude of interaction is expected to be lower than that observed with bosentan. No a priori dosage adjustment is recommended, but caution should be exercised when macitentan is administered concomitantly with strong inhibitors of CYP3A4.",""
97566,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Coadministration of lopinavir/ritonavir (a strong inhibitor of CYP3A4) increased selexipag exposure by two-fold but there was no change in the exposure of the active metabolite. A similar result is expected with darunavir/ritonavir, but this is unlikely to be clinically relevant as the majority of the pharmacological effect is driven by the active metabolite.",""
125773,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although ritonavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on ritonavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125774,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although saquinavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on saquinavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
97581,"Coadministration has not been studied. Cocaine is metabolized by several pathways, with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Darunavir/ritonavir could potentially increase concentrations of the parent compound. The clinical relevance is unknown as cocaine is metabolized by other non-CYP mediated pathways. Ensure the patient is aware of signs/symptoms of cocaine toxicity.",""
97582,Coadministration has not been studied. MDMA is metabolized mainly by CYP2D6. Darunavir/ritonavir could potentially increase MDMA concentrations. Ensure the patient is aware of signs/symptoms of MDMA toxicity.,""
97583,Coadministration has not been studied. A case was reported of a patient experiencing a near fatal reaction from a small dose of GHB while on saquinavir and ritonavir (400 mg twice daily). Darunavir/ritonavir may increase gamma-hydroxybutyrate concentrations. Ensure the patient is aware of signs/symptoms of GHB toxicity.,""
97584,"Coadministration has not been studied. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorphine (6-MAM) and subsequently to morphine by plasma and liver esterases, respectively. 6-MAM (the first metabolite to appear in vivo) has been shown to enter the brain at a much faster rate (35 times faster) than morphine where it binds to mu opioid receptors. 6-MAM was shown to correlate with the acute effects of heroin. Darunavir/ritonavir is unlikely to alter 6-MAM concentrations but may alter morphine concentrations. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7&gt;UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7&gt;UGT1A1). As ritonavir induces glucuronidation, coadministration could potentially decrease morphine concentration but facilitate the formation of the active metabolite morphine-6-glucuronide. Morphine and morphine-6-glucuronide are substrates of P-gp and coadministration may potentiate the effects of opiate in the CNS (via inhibition of P-gp at the blood-brain barrier). Monitor for sign of opiate toxicity.",""
123025,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetylsalicylic acid is deacetylated to form salicylic acid which is further glucuronidated. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
97611,Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Data from pharmacokinetic studies suggest no clinically significant interaction between darunavir/ritonavir and pravastatin. Coadministration of darunavir/ritonavir (800/100 mg once daily) and pitavastatin (2 or 4 mg once daily) was investigated in two studies in HIV-negative subjects. Coadministration with 2 mg pitavastatin decreased pitavastatin AUC and Cmax by 9% and 7% (n=10) and increased darunavir AUC and Cmax by 8% and 3% (n=14). Coadministration with 4 mg pitavastatin decreased pitavastatin AUC and Cmax by 26% and 4% (n=27) and increased darunavir and ritonavir exposure (darunavir AUC and Cmax increased by 3% and 6%; ritonavir AUC and Cmax increased by 8% and 2%).,""
97631,Coadministration has not been studied. Dutasteride is mainly metabolized by CYP3A4. Darunavir/ritonavir could potentially increase dutasteride concentrations. A reduction of dutasteride dosing frequency can be considered if side effects are noted.,""
97688,Coadministration has not been studied but may increase hydrocortisone concentrations. Careful monitoring of adverse effects is recommended when hydrocortisone is coadministered with darunavir/ritonavir.,""
97636,Coadministration has not been studied. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. Ritonavir dosed as a pharmacokinetic booster is a weak inhibitor of CYP2C8 but a strong inhibitor of CYP3A4. Darunavir/ritonavir could potentially increase isotretinoin concentrations by inhibition of CYP2C8 and CYP3A4. Monitoring of side effects is recommended.,""
123027,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Astemizole is metabolized by CYP2D6, CYP2J2 and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with astemizole. However, given the QT prolongation risk associated with astemizole, caution is recommended.",""
125775,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although tipranavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on tipranavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
97679,Coadministration has not been studied. Rasagiline is metabolised predominantly by CYP1A2 and coadministration with darunavir/ritonavir could potentially decrease rasagiline exposure due to induction of CYP1A2 by ritonavir. Monitor clinical effect and increase dosage if needed.,""
97680,Coadministration has not been studied. Ropinirole is metabolised predominantly by CYP1A2 and coadministration with darunavir/ritonavir could potentially decrease ropinirole exposure due to induction of CYP1A2 by ritonavir. Monitor clinical effect and increase dosage if needed.,""
97685,Coadministration has not been studied. Concomitant administration of darunavir/ritonavir and corticosteroids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Fludrocortisone is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Use alternative treatments.,""
97613,"Based on published data, coadministration of rosuvastatin (10 mg once daily) and darunavir/ritonavir increased rosuvastatin AUC and Cmax by 48% and 144%. Coadministration of rosuvastatin (10 mg/day) and darunavir/ritonavir (600/100 mg twice daily) to 12 HIV-negative subjects increased rosuvastatin levels, whereas the lipid-lowering benefits were blunted. The geometric mean AUC of rosuvastatin increased from 109 to 161 ng.h/mL and Cmax increased 6.7 to 16.3 ng/mL. Total cholesterol and triglyceride levels increased by 10% and 56%, whereas HDL cholesterol decreased by 13% relative to rosuvastatin alone. Use the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety.",""
125776,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although elvitegravir/cobicistat inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on elvitegravir, cobicistat, emtricitabine or tenofovir alafenamide is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
125777,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although elvitegravir/cobicistat inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on elvitegravir, cobicistat, emtricitabine or tenofovir-DF is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
97684,"Coadministration has not been studied but may increase dexamethasone concentrations and a dose reduction of the glucocorticoid may be necessary with monitoring for symptoms of Cushing's syndrome. Chronic or high doses of dexamethasone, a CYP3A inducer, may significantly decrease darunavir and ritonavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance. Use with caution.",""
123031,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. Cabotegravir and rilpivirine do not cause clinically significant inhibition of renal transporters.",""
97466,Coadministration is contraindicated as it may increase cisapride concentrations which may result in serious and/or life threatening reactions such as cardiac arrhythmias.,""
97695,Coadministration has not been studied but may increase prednisolone concentrations. Careful monitoring of adverse effects is recommended when prednisolone is coadministered with darunavir/ritonavir.,""
97619,Coadministration is contraindicated as darunavir/ritonavir may increase alfuzosin concentrations which may lead to severe hypotension.,""
123032,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral rilpivirine (150 mg once daily) and atorvastatin (40 mg once daily) decreased rilpivirine Cmax, AUC and Cmin by 9%, 10% and 10%, respectively. Atorvastatin Cmax and AUC increased by 35% and 4%; Cmin decreased by 15%. Cmax, AUC and Cmin of 2-hydroxy atorvastatin increased by 58%, 39% and 32%, whilst Cmax and AUC of 4-hydroxy atorvastatin increased by 28% and 23%. [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug]. These effects are not considered to be clinically relevant. No effect is expected on cabotegravir.",""
97240,Coadministration is contraindicated as it may increase astemizole concentrations which may result in serious and/or life threatening reactions such as cardiac arrhythmias.,""
97250,Coadministration is contraindicated as it may increase dihydroergotamine concentrations which may result in serious and/or life threatening reactions such as acute ergot toxicity.,""
97251,Coadministration is contraindicated as it may increase ergotamine concentrations which may result in serious and/or life threatening reactions such as acute ergot toxicity.,""
97222,Coadministration has not been studied. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Darunavir/ritonavir is predicted to have a weak effect on rosiglitazone exposure. No a priori dosage adjustment is needed.,""
97221,Coadministration has not been studied. Repaglinide is metabolized by CYP2C8 and CYP3A4 and is a substrate of the hepatic transporter OATP1B1. Darunavir/ritonavir could potentially increase repaglinide concentrations. Monitor clinical effect and decrease repaglinide dosage if needed.,""
123034,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. There is, therefore, little potential for clinically significant interactions with cabotegravir or rilpivirine.",""
97166,"Coadministration with twice daily darunavir/ritonavir had no significant effect on darunavir exposure, but increased carbamazepine AUC by 45%. No a priori dose modification of darunavir/ritonavir or carbamazepine is recommended when initiating therapy, but patients should be monitored for potential carbamazepine related adverse events. Carbamazepine concentrations should be monitored; the carbamazepine dose may need to be reduced by 25% to 50% to achieve the desired clinical response.",""
123035,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123036,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolized analogously to natural purines. Cabotegravir and rilpivirine do not interfere with this metabolic pathway.,""
97138,Coadministration has not been studied and is not recommended as it may significantly decrease darunavir/ritonavir concentrations which may reduce the therapeutic effect. The magnitude of rifapentine-mediated CYP3A4 induction is predicted to be lower than with rifampicin but higher than with rifabutin. Consider using rifabutin.,""
97419,"Coadministration has not been studied but should be avoided. Dasatinib is metabolized by CYP3A4 and darunavir may significantly increase dasatinib concentrations. If coadministration is unavoidable, close monitoring for toxicity is required and dasatinib dose reduction to 20-40 mg daily should be considered.",""
123037,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-glycoprotein and MRP2. Cabotegravir and rilpivirine do not inhibit these transporters. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with azithromycin. However, given the QT prolongation risk associated with azithromycin, caution is recommended.",""
97348,"Coadministration has not been studied. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Darunavir/ritonavir could potentially increase carvedilol concentrations via CYP2D6 inhibition or decrease carvedilol concentrations via induction of glucuronidation. The net effect on carvedilol concentrations is difficult to predict but likely to be moderate in magnitude. No a priori dosage adjustment is required.",""
97370,"Coadministration has not been studied. Amlodipine is metabolized by CYP3A4 and darunavir/ritonavir is predicted to increase amlodipine exposure by ~2-fold based on drug-drug interactions studies with amlodipine and indinavir/ritonavir or paritaprevir/ritonavir. If coadministration is indicated, consider a dose reduction for amlodipine of 50%. Close monitoring is recommended.",""
115930,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
97318,"Coadministration is not recommended as it resulted in increased plasma concentrations of simeprevir due to CYP3A inhibition by darunavir/ritonavir. Coadministration of darunavir/ritonavir (800/100 mg once daily for 7 days) and simeprevir (150 mg once daily alone, 50 mg once daily in combination) was studied in 25 subjects. In combination, simeprevir Cmax, AUC and Cmin increased by 1.79-, 2.59- and 4.58-fold when compared to 150 mg alone (note, higher concentrations would be expected if the licensed dose of simeprevir were given in combination). Darunavir Cmax, AUC and Cmin increased by 4%, 18% and 31%, respectively. Ritonavir Cmax, AUC and Cmin increased by 23%, 32% and 44%, respectively.",""
115942,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is cleared mainly by glomerular filtration.,""
97074,"Coadministration has not been studied. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Metabolism by CYP2D6 is to a metabolite more potent than the parent compound. Darunavir/ritonavir may increase tramadol exposure but also reduce the conversion to the more potent active metabolite. Monitoring for tramadol related side effects and for the analgesic effect may be required as clinically indicated. Adjust tramadol dosage if needed.",""
123040,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone -17-monopropionate. ",""
125778,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although darunavir/cobicistat inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on darunavir, cobicistat, emtricitabine or tenofovir alafenamide is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
97378,"Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied. Desogestrel is a prodrug that requires activation to etonogestrel. Activation to etonogestrel is by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Coadministration is predicted to increase etonogestrel due to induction of CYP2C9 and inhibition of CYP3A4. When used in a combined pill, the estrogen component is reduced. Given the lack of clinical data on the contraceptive efficacy, caution is recommended and additional contraceptives measures should be used.",""
123041,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with bedaquiline. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
97344,Coadministration has not been studied. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Darunavir/ritonavir could potentially increase zolpidem exposure which could result in increased sedation. A dosage reduction may be required.,""
97328,Coadministration has not been studied. Buspirone is metabolized by CYP3A4 but does not inhibit CYP3A4. Darunavir/ritonavir could potentially increase buspirone concentrations. A low dose of buspirone used cautiously is recommended and adjust dosage based on the clinical response.,""
97331,Coadministration has not been studied. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). Darunavir/ritonavir could potentially increase diazepam exposure by inhibition of CYP3A4. This could prolong sedation and a dosage reduction may be required.,""
97342,Coadministration is contraindicated as it may increase triazolam concentrations which may result in serious and/or life threatening reactions such as prolonged or increased sedation or respiratory depression.,""
125779,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) and does not inhibit or induce drug metabolizing enzymes.&nbsp;,""
125782,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) and is a substrate of P-gp. In vitro data indicate that nevirapine does not induce or inhibit P-gp in the range of clinical concentrations. No effect on nevirapine is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.,""
97747,Darunavir/cobicistat coformulations (Rezolsta; Prezcobix) should not be administered with other products containing darunavir.,""
123044,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%, exact pathway not known) and excreted unchanged in the urine (30%). There is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes or renal drug transporters at clinically relevant concentrations.",""
125783,Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) and is a substrate of P-gp. Etravirine is a weak inhibitor of P-gp but no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on etravirine is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;,""
97741,"Note: this interaction was studied using a darunavir/ritonavir dose lower than that licensed. Coadministration of tenofovir-DF (300 mg once daily) and darunavir/ritonavir (300/100 mg twice daily) increased darunavir Cmax (16%), AUC (21%) and Cmin (24%). Tenofovir Cmax, AUC and Cmin increased by 24%, 22% and 37%, respectively. No adjustments to the licensed doses are required. A higher risk of renal impairment has been reported in patients receiving tenofovir-DF and a ritonavir or cobicistat boosted protease inhibitor. Close monitoring of renal function and for tenofovir-associated adverse reactions is required in these patients.",""
123047,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bepridil is metabolized by CYP2D6 (major) and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with bepridil. However, given the QT prolongation risk associated with bepridil, caution is recommended.",""
125784,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) and does not inhibit or induce drug metabolizing enzymes.,""
123048,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betahistine is metabolized by monoamine oxidase. ,""
97436,"Coadministration has not been studied. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9 and 2C19. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9 and 2C19. The effect of darunavir/ritonavir on imatinib exposure is difficult to predict as clinical studies with CYP3A4 inhibitors have yielded differing results. Ketoconazole increased imatinib exposure; however, ritonavir (600 mg once daily for 3 days) had no significant effect on imatinib exposure. Use with caution and monitor for imatinib related side effects. Imatinib may increase exposure of CYP3A4 substrates, such as darunavir.",""
123060,"Coadministration has not been studied. Bosentan is a substrate and inducer of CYP3A4 and CYP2C9. Bosentan is unlikely to affect cabotegravir as it is metabolized mainly by UGT1A1 and to a lesser extent by UGT1A9. However, bosentan could decrease rilpivirine exposure. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. ",""
123061,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Drug-drug interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123049,"Coadministration has not been studied. Betamethasone is metabolized by CYP3A4 and is a moderate inducer of CYP3A4 and therefore could decrease rilpivirine concentrations particularly if betamethasone is administered orally or intravenously at high doses or for a long duration, in which case coadministration is contraindicated. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
97401,"Coadministration with a combined oral contraceptive (COC) containing norgestimate/ethinylestradiol has not been studied. Norgestimate is metabolized to norelgestromin and norgestrel (possibly via CYP3A4). Atazanavir/ritonavir was shown to increase norgestimate exposure. Similarly, darunavir/ritonavir could potentially increase norgestimate exposure. When used in combined pill, the estrogen component is reduced. Given the lack of clinical data on the contraceptive efficacy, caution is recommended and additional contraceptives measures should be used in addition to oral contraception.",""
97511,"Coadministration of milk thistle (150 mg every 8 hours for 14 days) to HIV-infected subjects who had been receiving darunavir/ritonavir (600/100 mg twice daily) for at least 4 weeks, decreased darunavir AUC, Cmax and Ctrough by 14%, 17% and 6%, respectively. However, all subjects had darunavir concentrations well above the median protein-binding-adjusted IC50 of 550 ng/ml and no dose adjustment for darunavir/ritonavir appears to be necessary.",""
123052,"Coadministration has not been studied. Bexarotene is mainly metabolized by CYP3A4 and induces CYP3A4 (after repeated administration and especially at doses greater than 300 mg/m2/day). No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. However, bexarotene is expected to significantly decrease the exposure of intramuscular rilpivirine leading to potential loss of therapeutic effect and development of resistance. Thus, coadministration is contraindicated.",""
123055,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited human data suggest biperiden undergoes hydroxylation in the liver. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
79486,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with retinol when given alone or in multivitamins.&nbsp;A clinical study demonstrated that ritonavir, indinavir, nelfinavir and saquinavir increased activity of retinal dehydrogenase, an enzyme involved in retinoic acid synthesis. Enhanced retinal dehydrogenase activity by some protease inhibitors could increase retinoic acid concentrations. This is unlikely to be of clinical importance, unless high doses of retinol supplementation are given long term.",""
123057,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
97165,Coadministration may alter warfarin concentrations. Monitor INR. Data from 12 HIV- subjects showed that darunavir/ritonavir (600/100 mg twice daily) decreased exposure of S-warfarin by 21% following a single dose of warfarin (10 mg).,""
97216,"Coadministration with darunavir/ritonavir has not been studied. Linagliptin is mainly eliminated as parent compound in faeces and metabolism by CYP3A4 represents a minor elimination pathway. Coadministration of linagliptin (5 mg single dose) and ritonavir (200 mg twice daily for 3 days) increased linagliptin AUC and Cmax by 2-fold and 3-fold respectively, but these changes were not considered to be clinically relevant. Darunavir/ritonavir could potentially increase linagliptin concentrations, however, this increase is unlikely to be clinically significant as the drug is mainly eliminated unchanged and has a large safety window.",""
117011,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inhibition of intestinal CYP3A4 by grapefruit juice is unlikely to alter significantly dolutegravir concentrations as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
123059,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bortezomib is mainly metabolized by CYPs 3A4 and 2C19 and to a lesser extent CYPs 1A2, 2D6 and 2C9. Bortezomib is a weak inhibitor of CYP enzymes. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. A clinically relevant effect on rilpivirine concentrations is unlikely. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with bortezomib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. ",""
123062,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123063,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupivacaine is predominantly metabolized via CYP3A4, however cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123064,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine is mainly metabolized by CYP3A4 to form the active metabolite norbuprenorphine. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123065,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolized by CYP2B6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123066,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123067,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caffeine is mainly metabolized by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123068,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with cabotegravir and potentially decrease the amount of cabotegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. No interaction is predicted with rilpivirine.",""
123069,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Calcium is eliminated through faeces, urine and sweat. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as calcium resulting in a reduced absorption of cabotegravir. However, there is no such interaction when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
123070,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is primarily metabolised by UGT1A9 and UGT2B4. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123072,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19 and is unlikely to significantly inhibit CYP3A4, UGT1A1 or intestinal transporters in the range of doses in clinical use. Cabotegravir and rilpivirine do not inhibit or induce CYP or intestinal transporters at clinically relevant concentrations.",""
115931,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
123073,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Tetrahydrocannabinol (THC, the psychoactive component of cannabis), is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123074,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Cabotegravir does not interfere with this metabolic pathway.,""
123075,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug, partly by glomerular filtration and possibly partly by tubular secretion (renal transporter not identified). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123076,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as captopril is largely excreted in the urine (40-50% as unchanged drug, the rest as disulfide and other metabolites).",""
123077,"Coadministration has not been studied with intramuscular cabotegravir and rilpivirine. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 6%, AUC by 59% whereas oral clearance was increased by 2.4 fold. A similar effect is expected with carbamazepine, therefore coadministration is not recommended with intramuscular cabotegravir. In addition, carbamazepine is expected to substantially decrease rilpivirine exposure. Thus coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
98372,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoflurane is almost exclusively eliminated unchanged by the lungs.,""
123081,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123082,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. In vitro data indicate that caspofungin is a substrate of the hepatic transporter OATP1B1, however cabotegravir and rilpivirine do not inhibit OATP1B1.",""
123083,Coadministration has not been studied. Catâ€™s claw was demonstrated to inhibit CYP3A4 in vitro. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.Catâ€™s claw may increase rilpivirine exposure although to a limited extent. No dose adjustment is needed. ,""
123084,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged via the kidneys (by glomerular filtration and tubular secretion via OAT1 and MATE1). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
123085,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123087,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine (about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite). In vitro studies indicate that OATs participate to the renal elimination of cefotaxime, but cabotegravir does not cause clinically relevant inhibition of OATs. Likewise, rilpivirine does not inhibit OATs.",""
123090,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is metabolised mainly by CYP2C9, however, cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123094,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly metabolized by glucuronidation via UGT2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
125795,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism).,""
123095,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlordiazepoxide is extensively metabolized by hepatic microsomal enzymes but does not inhibit cytochromes. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123097,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized in the liver by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123098,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with chlorpromazine. However, given the QT prolongation risk associated with chlorpromazine, caution is recommended",""
123100,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Cabotegravir and rilpivirine do not interact with ciclesonide metabolism.,""
98788,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;Doxorubicin is mainly eliminated in the bile and&nbsp;does not undergo CYP-mediated metabolism. Doxorubicin is a substrate of P-glycoprotein, however, coadministration with protease inhibitors did not modify significantly doxorubicin exposure.",""
123101,Coadministration has not been studied. Ciclosporin inhibits CYP3A4 and OATP1B1. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Rilpivirine is metabolised mainly by CYP3A4 and is transported by OATP1B1 and concentrations could potentially increase although to a limited extent. No dose adjustment is needed. ,""
123102,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1 and OAT3. Cabotegravir does not cause clinically relevant inhibition of OAT1 or OAT3. Likewise, rilpivirine does not inhibit OATs.",""
125804,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism). Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.,""
123104,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Rilpivirine absorption is not impaired by H2-receptor antagonists when administered intramuscularly. Cimetidine is primarily eliminated by the kidneys. ,""
123106,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cisapride is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with cisapride. However, given the QT prolongation risk associated with cisapride, caution is recommended",""
123107,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature. ,""
123108,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Cisplatin is eliminated renally via OCT2 and MATE1. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123109,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Citalopram is metabolized by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with citalopram. However, given the QT prolongation risk associated with citalopram, caution is recommended",""
125805,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
123110,"Coadministration has not been studied. Clarithromycin is a strong inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with clarithromycin. However, given the QT prolongation risk associated with clarithromycin, caution is recommended. Consider alternatives such as azithromycin.",""
123112,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123113,"Coadministration has not been studied. Clobazam is metabolised by CYP3A4 (major) and CYP2B6 and CYP2C19 (minor) to the active metabolite N-desmethylclobazam, which is metabolised by CYP2C19. Cabotegravir and rilpivirine not inhibit or induce CYP enzymes at clinically relevant concentrations. However, clobazam is a weak inducer and therefore could potentially decrease intramuscular rilpivirine exposure although to limited extent. Weak inducers are not expected to significantly affect intramuscular cabotegravir.",""
125806,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes or P-gp. No effect on fostemsavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
80966,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4.&nbsp;There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in paliperidoneâ€™s elimination.,""
123115,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. However, rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with clofazimine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123116,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123117,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. CYP2D6 is thought to have a role in clomifene metabolism. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123119,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4 and does not induce metabolizing enzymes. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Similarly, rilpivirine has no inhibitory or inducing effects on CYP3A4.",""
123121,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123122,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam, which is then metabolized to oxazepam by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123123,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted via glomerular filtration and tubular secretion. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123124,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with clozapine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123125,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cocaine is metabolized by several non CYP mediated pathways, with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with cocaine. However, given the QT prolongation risk associated with cocaine, caution is recommended",""
123126,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism. Cabotegravir and rilpivirine do not inhibit or induce UGT or CYP enzymes at clinically relevant concentrations. ",""
123127,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is a substrate of CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123128,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for an interaction with cabotegravir or rilpivirine via modulation of, or competition for, metabolic pathways. ",""
123129,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for an interaction with cabotegravir or rilpivirine via modulation of, or competition for, metabolic pathways. Vitamin D can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
123130,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Several constituents of Piper cubeba were shown to inhibit CYP3A4 in vitro. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Cubeb pepper could potentially increase the exposure of rilpivirine although to a limited extent. No dose adjustment is needed. ",""
123132,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine. Vitamin B12 can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
123133,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123135,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123136,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Cytarabine is metabolized by cytidine deaminase. Cabotegravir and rilpivirine do not interfere with this metabolic pathway.",""
123137,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. The prodrug of dabigatran is a substrate of P-gp. Cabotegravir does not inhibit P-gp at clinically relevant concentrations. Although oral administration of rilpivirine may increase dabigatran absorption due to intestinal P-gp inhibition, there is no such interaction when rilpivirine is administered intramuscularly. ",""
123138,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine is activated to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123139,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Daclatasvir is partly metabolized by CYP3A4 and is eliminated for a large part unchanged in the bile. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Likewise, rilpivirine does not inhibit or induce CYP3A4.",""
123141,Coadministration has not been studied but a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged by the kidneys.,""
123142,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is primarily metabolised by UGT1A9. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123143,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapsone is mainly metabolized by N-acetylation with a component of N-hydroxylation, and is via multiple CYP P450 enzymes. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123144,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darifenacin is metabolized by CYP3A4 and CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123148,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dasatinib is metabolized by CYP3A4 and is a weak inhibitor of this enzyme. No effect is expected on cabotegravir as it mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Dasatinib could increase rilpivirine exposure but not to an extent that is considered to be clinically relevant. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with dasatinib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. ",""
123149,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic is unlikely. An in vitro study has shown that daunorubicin was able to inhibit metabolism mediated by CYP3A4, but was unlikely to cause clinically significant drug interactions via this mechanism. However, damage to the myocardium is one of the major risks of daunorubicin treatment and may include: dose-independent supraventricular arrhythmias (sinus tachycardia, premature ventricular contractions, AV-block) and/or non-specific ECG abnormalities. Use with caution.",""
123150,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. However, QTc prolongation has been reported with delamanid (and is very closely correlated with the metabolite DM-6705). Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with delamanid. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123153,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Desipramine is metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with desipramine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123154,"Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and desogestrel exposures. Similarly, no interaction is expected with intramuscular rilpivirine.",""
123155,Coadministration with a desogestrel-containing progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123156,Coadministration is contraindicated with systemic dexamethasone (except as a single dose) as significant decreases in rilpivirine plasma concentrations may occur. No significant effect is expected on cabotegravir as indicated by a drug-drug interaction study with rifabutin (a moderate inducer).,""
123157,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGTs 1A4 and 2B10) and cytochrome P450 (mainly CYP2A6). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123158,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolized by CYP3A, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123159,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123160,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYPs 3A4 and 2C19) and to temazepam (mainly by CYP3A4). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123161,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9 (catalyzes the major route of diclofenac oxidative metabolism). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123162,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to didanosine should be considered.",""
123164,Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The elimination of digoxin is dependent on P-glycoprotein which is not inhibited by cabotegravir or rilpivirine. Coadministration of digoxin (0.5 mg single dose) and oral rilpivirine (25 mg once daily) did not significantly alter digoxin pharmacokinetics.,""
123165,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) via CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine via CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123166,"Coadministration has not been studied. Dihydroergotamine is a substrate and inhibitor of CYP3A4. No effect is expected on dihydroergotamine as Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase although to a limited extent. No dose adjustment is needed. ",""
99442,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to raltegravir should be considered as coadministering two integrase inhibitors (i.e., raltegravir and dolutegravir is unlikely to be of clinical benefit.",""
99457,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
99455,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to stavudine should be considered.&nbsp;",""
99467,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, tipranavir decreases dolutegravir concentrations and could potentially decrease rilpivirine exposure and thereby result in loss of efficacy.",""
123168,Coadministration has not been studied. Diltiazem is metabolized by CYP3A4 and is a moderate inhibitor of CYP3A4. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Diltiazem could increase rilpivirine concentrations although to a limited extent. No dose adjustment is needed. ,""
76918,"Coadministration has not been studied.&nbsp;Atenolol is mainly eliminated unchanged by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. There is potential for competition with lamivudine for elimination via renal transport proteins, which may lead to increased concentrations of either drug.",""
123169,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123170,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123171,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) whereas 50% of the drug is eliminated unchanged in the urine (possibly via OCT2). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters and do not inhibit or induce CYP3A4. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with disopyramide. However, given the QT prolongation risk associated with disopyramide, caution is recommended.",""
123173,"Some European product labels for docetaxel warn in vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which are metabolised by cytochrome P450 3A (and thus may inhibit the enzyme competitively). As a result, caution should be exercised when treating patients with rilpivirine since there is a potential for a significant interaction. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
123174,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with dofetilide. However, given the QT prolongation risk associated with dofetilide, caution is recommended.",""
123175,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with dolasetron. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
99694,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile.,""
99696,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces.,""
99738,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat.,""
123180,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Domperidone is mainly metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with domperidone. However, given the QT prolongation risk associated with domperidone, caution is recommended",""
123181,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect the disposition of antiretrovirals, or to be affected by antiretrovirals.",""
123184,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolized mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123185,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123186,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However caution is advised due to possible cardiac toxicities (ECG abnormalities and sometimes arrhythmias). Use with caution. ECG monitoring is recommended.",""
99830,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. However, as few data are available, care should be taken when administering oxytocin with antiretrovirals. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes.&nbsp;Renal excretion of unchanged oxytocin is thought to be minimal. No interaction is expected with dolutegravir and rilpivirine. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with oxytocin. However, the product labels for dolutegravir/rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. As few data are available, care should be taken when administering oxytocin with antiretrovirals.",""
115934,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
99848,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine.,""
123188,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Droloxifene is mainly glucuronidated. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
99855,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir and rilpivirine are not expected to inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123189,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYPs.,""
123190,"Coadministration with a drospirenone-containing combined oral contraceptive (COC) has not been studied. Drospirenone is metabolized to a minor extent via CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and drospirenone exposures. Likewise, no interaction is expected with intramuscular rilpivirine.",""
115933,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123191,Coadministration with drospirenone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123192,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dulaglutide is presumed to be degraded by general protein catabolism pathways. Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. However, this effect is not relevant when cabotegravir and rilpivirine are administered intramuscularly.",""
123193,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123194,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123195,Coadministration with dydrogesterone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123196,"Coadministration has not been studied. Echinacea has a selective effect on CYP3A4 activity (inhibition of intestinal CYP3A4 and induction of hepatic CYP3A4). No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. However, echinacea could reduce rilpivirine exposure although to a modest extent.",""
123197,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. MDMA is metabolized mainly by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123198,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is a substrate for P-gp. Cabotegravir and rilpivirine do not inhibit or induce P-gp.,""
123200,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eflornithine is predominantly eliminated unchanged via the kidneys. Cabotegravir and rilpivirine do not inhibit eflornithine renal elimination.,""
123201,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elbasvir/grazoprevir are substrates of CYP3A4 and P-glycoprotein. Cabotegravir does not inhibit or induce CYP3A4 and P-glycoprotein. Coadministration of oral rilpivirine (25 mg daily) and elbasvir + grazoprevir (50 + 200 mg once daily) had no clinically meaningful effect on exposures of grazoprevir, elbasvir, or rilpivirine. No dose adjustments are required. Coadministration of rilpivirine (25 mg once daily) and elbasvir + grazoprevir (50 + 200 mg once daily) to 19 subjects increased elbasvir AUC, Cmax and C24 by 7%, 7% and 4%, respectively; grazoprevir AUC and Cmax decreased by 2% and 3%, with no change in C24. Rilpivirine AUC, Cmax and Ctrough increased by 13%, 7% and 16%, respectively.",""
123202,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eletriptan is metabolised by CYP3A4 and does not induce or inhibit CYPs. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123203,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8) and in vitro data indicate it is an inhibitor of UGTs 1A1 and 1A3. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Inhibition of UGT1A1 by eltrombopag is unlikely to significantly alter cabotegravir exposure as coadministration of atazanavir (a strong inhibitor of UGT1A1) was predicted to increase cabotegravir exposure by 11%. No interaction is expected with rilpivirine at it is metabolized by CYP3A4.,""
99865,"Juluca (dolutegravir/rilpivirine) and Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. Furthermore, coadministering two integrase inhibitors (i.e., elvitegravir and dolutegravir) is unlikely to be of clinical benefit.",""
99874,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lamivudine would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
123206,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3. Cabotegravir and rilpivirine do not inhibit or induce UGTs or P-gp or BCRP at clinically relevant concentrations.",""
99900,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to didanosine should be considered.&nbsp;",""
99953,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrantel is metabolized by CYP2D6 in vitro, however, absorption of an oral dose is minimal and over 50% of a dose is excreted unchanged in the faeces.",""
123210,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat, which is eliminated renally (possibly via OATs). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123211,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enflurane is predominantly metabolized by CYP2E1, however, cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
117112,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclosporin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123214,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anions and cations transporters. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
123215,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ephedrine is predominantly excreted unchanged via renal pathways. There are no available data to determine whether excretion is via active tubular secretion or glomerular filtration. However, cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123216,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Epirubicin is glucuronidated by UGT2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Epirubicin may lead to cardiotoxicity consisting of tachycardia and/or ECG abnormalities. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with epirubicin. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. ",""
123217,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eplerenone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
100206,"Coadministration has not been studied. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). There is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. Tenofovir and doravirine are not eliminated by organic cation transporters and therefore do not interfere with dofetilideâ€™s elimination.",""
123220,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123221,"Coadministration has not been studied. Ergotamine is a substrate and inhibitor of CYP3A4. No effect is expected on ergotamine as Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase although to a limited extent. No dose adjustment is needed.",""
123222,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erlotinib is mainly metabolized by CYP3A4, but cabotegravir and rilpivirine do not inhibit or induce CYP450 enzymes at clinically relevant concentrations. Erlotinib is a strong inhibitor of UGT1A1. However, based on the drug interaction study with atazanavir (another strong inhibitor of UGT1A1), this is unlikely to alter intramuscular cabotegravir exposure to a clinically significant extent. Erlotinib does not affect rilpivirine as it is metabolized by CYP3A4.",""
123224,"Coadministration has not been studied. Erythromycin is a moderate inhibitor of CYP3A. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with erythromycin. However, given the QT prolongation risk associated with erythromycin, caution is recommended. Consider alternatives such as azithromycin.",""
123225,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Escitalopram is metabolized by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with escitalopram. However, given the QT prolongation risk associated with escitalopram, caution is recommended",""
123226,Coadministration has not been studied. Eslicarbazepine is partly eliminated unchanged renally and partly glucuronidated by UGT2B4. Eslicarbazepine is an inducer and therefore is expected to decrease the exposure of cabotegravir and rilpivirine. Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. ,""
123227,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Esomeprazole is mainly metabolized by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Furthermore, rilpivirine absorption is not impacted by esomeprazole when administered intramuscularly.",""
123228,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123229,"Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123230,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine phosphate undergoes rapid dephosphorylation to estramustine which is then oxidized by 17beta-hydroxysteroid dehydrogenases to estromustine. Estramustine and estromustine are subsequently hydrolyzed to estradiol and estrone, respectively. Estradiol is then hydroxylated by CYPs 1A1, 1A2 and 3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123232,Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. A similar effect is expected with intramuscular cabotegravir. No interaction is expected with intramuscular rilpivirine.,""
123233,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolized in the liver with animal studies suggesting involvement of flavin-containing monooxygenases.,""
123234,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is mainly metabolized by CYP3A4 and does not induce metabolizing enzymes. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Similarly, rilpivirine does not inhibit or induce CYP3A4.",""
123235,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etidocaine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123236,Coadministration with an etonogestrel-containing progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123237,"Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and etonogestrel exposures. No interaction is expected with intramuscular rilpivirine. ",""
123238,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Etoposide is partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. Furthermore, etoposide is partly glucuronidated by UGT1A1. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123240,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eucalyptus is only a weak inhibitor of CYP3A4 and is unlikely to impact the exposure of rilpivirine. No effect is expected on cabotegravir as there is no evidence to suggest that eucalyptus impacts UGTs.,""
123241,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Everolimus is metabolized by CYP3A4 and is a modest inhibitor of CYP3A4 in vivo. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Cabotegravir is unlikely to be impacted by everolimus as it mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Everolimus is unlikely to increase rilpivirine exposure to a clinically significant extent. ",""
123243,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
100439,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) and Delstrigo (doravirine, lamivudine, tenofovir-DF) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, Delstrigo contains lamivudine and tenofovir-DF and should not be administered products containing emtricitabine or tenofovir alafenamide.ts.",""
100926,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged by the kidney both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1.&nbsp;,""
123245,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123246,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase, which is then eliminated in the urine, possibly by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1. Likewise, rilpivirine does not inhibit OAT1.",""
123247,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%). Cabotegravir and rilpivirine do not inhibit renal transporters to a clinically significant extent. Furthermore, rilpivirine absorption is not impacted by famotidine when administered intramuscularly.",""
123248,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolized by CYP3A4. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123250,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123251,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as iron resulting in a reduced absorption of cabotegravir. However, there is no such interaction when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
123252,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123253,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine does not undergo CYP-mediated metabolism but is a substrate of P-glycoprotein. Cabotegravir and rilpivirine do not inhibit or induce P-gp at clinically relevant concentrations.",""
123255,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
101054,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, coadministration is expected to decrease doravirine exposure.",""
123257,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion of the parent drug also eliminated unchanged renally. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with flecainide. However, given the QT prolongation risk associated with flecainide, caution is recommended.",""
123258,"Coadministration has not been studied. Flibanserin is primarily metabolized by CYP3A4 and has been shown to moderately increase the exposure of simvastatin, a CYP3A4 substrate. No effect is expected on cabotegravir as it is metabolized mainly by UGT1A1 and to a lesser extent by UGT1A9. However, flibanserin could potentially increase rilpivirine exposure although to a limited extent. No dose adjustment is needed. ",""
123259,"Coadministration has not been studied. Flucloxacillin is mainly eliminated renally partly by glomerular filtration and partly by active secretion via OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1. Likewise, rilpivirine does not inhibit OAT1. Flucloxacillin was shown to induce CYP3A4 in vitro however, it is unclear whether it impacts intramuscular rilpivirine to a clinically significant extent. Weak or moderate inducers do not significantly impact intramuscular cabotegravir.",""
123263,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123264,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123265,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYPs 3A4 and 2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123267,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluorouracil is metabolised via the same mechanisms as endogenous uracil, including via dihydropyrimidine dehydrogenase. There is therefore little potential for an interaction with cabotegravir or rilpivirine via modulation of, or competition for, metabolic pathways.",""
123268,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by CYPs 2C19 and 3A4 to form norfluoxetine. Cabotegravir and rilpivirine do not inhibit or induce CYP enyzmes at clinically relevant concentrations.,""
123269,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with fluphenazine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123270,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123271,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123272,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolized by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123273,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123275,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Cabotegravir and rilpivirine do not interfere with this metabolic pathway. Folic acid can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation with cabotegravir when cabotegravir is administered intramuscularly.,""
123277,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Cabotegravir and rilpivirine do not interfere with formestaneâ€™s metabolic pathway. ,""
123278,"Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with formoterol. Note: the product label indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
101367,Coadministration has not been studied. Coadministration with ritonavir increased doravirine AUC by 3.5 fold and Cmin by 2.9 fold. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure.,""
101362,Coadministration has not been studied. Doravirine is metabolized by CYP3A4. Cobicistat is a strong inhibitor of CYP3A4 and is expected to increase doravirine exposure by a~ 3.5-fold based on the drug interaction study with ritonavir. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure.&nbsp;,""
123281,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fosinopril is hydrolysed by esterases in the GI mucosa and liver. ,""
123282,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes or renal drug transporters at clinically relevant concentrations.,""
123284,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ganciclovir is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1. Likewise, rilpivirine does not inhibit OAT1.",""
123285,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Garlic supplements have been shown to decrease unboosted saquinavir AUC by 50% in a clinical trial and there is a case report of treatment failure due to garlic cloves (six garlic cloves three times weekly) decreasing ritonavir-boosted atazanavir trough concentrations by ~70%. This interaction likely occurs due to the induction of intestinal P-gp. Garlic was shown to have no effect on intestinal and hepatic CYP3A4. Garlic is unlikely to affect cabotegravir or rilpivirine when administered intramuscularly. ,""
123286,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Gefitinib is metabolized by CYP3A4 and CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123287,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite. Cabotegravir and rilpivirine do not interfere with this metabolic pathway.,""
101401,"Coadministration has not been studied. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Co-administration of delamanid with a strong inhibitor of CYP3A4 (lopinavir/ritonavir) increased DM-6705 exposure by 25-30%. QTc prolongation has been reported with delamanid (and is very closely correlated with the metabolite DM-6705). A similar increase would be expected with cobicistat and caution is advised. If coadministration is considered necessary, frequent monitoring of ECGs is recommended, throughout the full delamanid treatment period (for example, at least fortnightly for the first month and if the QTc interval remains within normal range to reduce this to monthly thereafter).",""
123288,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is mainly glucuronidated by UGT2B7 and in vitro data suggest that it inhibits UGT1A1 and UGT1A3. Gemfibrozil is unlikely to alter cabotegravir exposure to a clinically significant extent. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9 and the coadministration of atazanavir (a strong UGT1A1 inhibitor) was predicted to increase cabotegravir exposure by 11% only. A similar effect is expected with intramuscular cabotegravir. No effect is expected on intramuscular rilpivirine.,""
123290,"Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and gestodene exposures. No interaction is expected with intramuscular rilpivirine.",""
123292,Coadministration has not been studied. No effect is expected on cabotegravir exposure as there is no evidence to suggest that ginger inhibits or induces UGTs. Gingerols moderately inhibit CYP3A4 in vitro and could potentially increase the exposure of rilpivirine although to a limited extent. No dose adjustment is required. ,""
123291,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123293,"Coadministration has not been studied. Ginkgo biloba may reduce rilpivirine exposure via induction of CYP3A4. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. Ginkgo biloba is unlikely to alter cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
123294,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral rilpivirine and glecaprevir/pibrentasvir was shown to increase rilpivirine Cmax, AUC and Cmin by 105%, 84% and 77%, respectively (n=12); this was deemed within safety limits thus no dose adjustment is required for rilpivirine. Glecaprevir and pibrentasvir inhibit intestinal P-glycoprotein but this is not problematic with intramuscular administration of cabotegravir and rilpivirine. ",""
101057,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, doravirine should not be administered with another NNRTI (i.e., rilpivirine).",""
96244,"Coadministration of dolutegravir (50 mg once daily) and darunavir/cobicistat (800/150 mg once daily) decreased dolutegravir Cmax, AUC, and C24 by 11%, 16% and 19%, respectively (n=9). Darunavir Cmax, AUC, and C24 decreased 21%, 13% and 18%, respectively, and cobicistat Cmax, AUC and C24h decreased by 14%, 12% and 2%, respectively. Dolutegravir and darunavir/cobicistat can be administered without dose adjustments.",""
123295,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123296,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123297,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is metabolised by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123298,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is metabolized mainly by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123299,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glyceryl trinitrate is metabolised by aldehyde dehydrogenase-2. ,""
123300,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glycopyrronium bromide is mainly eliminated renally (active secretion via organic cation transporter) and is also partly hydroxylated via multiple CYPs. Cabotegravir and rilpivirine do not cause clinically significant inhibition of renal transporters and do not inhibit or induce CYP enzymes.,""
123310,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123301,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goldenseal has been shown to inhibit CYP3A4 in vitro, however, no significant effect of golden seal root on indinavir pharmacokinetics was observed in a study in HIV-negative subjects. Interactions with other drugs metabolized by CYP3A4 such as rilpivirine are unlikely. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9",""
123312,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as hydralazine is metabolised via primary oxidative metabolism and acetylation.,""
123313,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
123303,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Granisetron is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Likewise, rilpivirine does not inibit or induce CYP3A4. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with granisetron. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123304,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inhibition of intestinal CYP3A4 by grapefruit juice is unlikely to be clinically relevant when rilpivirine is administered intramuscularly. Grapefruit juice is not expected to affect cabotegravir as it undergoes metabolism mainly via UGT1A1 and to a lesser extent by UGT1A9.,""
123305,"Coadministration has not been studied. Griseofulvin undergoes glucuronidation and has inducing properties and therefore has the potential to reduce cabotegravir and rilpivirine exposures. Thus, coadministration is contraindicated as it can alter the therapeutic effect of Cabenuva. ",""
123306,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with halofantrine. However, given the QT prolongation risk associated with halofantrine, caution is recommended",""
123307,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, CYP2D6). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. Rilpivirine does not interact with this metabolic pathway. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with haloperidol. However, given the QT prolongation risk associated with haloperidol, caution is recommended.",""
123308,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that halothane undergoes oxidation (mainly via CYP2E1 and to a lesser extent CYP2A6) and reduction (via CYP2A6 and CYP3A4). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123311,"Coadministration has not been studied. In vitro data indicate that extracts of hops activate PXR and induce expression of CYP3A4, CYP2B6 and MDR1 genes. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. However, hops can potentially reduce rilpivirine exposure.",""
123314,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Cabotegravir and rilpivirine do not inhibit or induce CYP3A4 or CYP2D6 at clinically relevant concentrations.",""
97612,"Coadministration of pravastatin (40 mg single dose) and darunavir/ritonavir (600/100 mg twice daily) increased pravastatin AUC on average by 81%, but up to a 5-fold increase was seen in a limited subset of subjects. When coadministration is required, it is recommended to start with the lowest possible dose of pravastatin and titrate it up to the desired clinical effect while monitoring for safety.",""
123315,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123316,No clinically significant interactions are expected with the topical use of hydrocortisone.,""
123317,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123318,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyurea undergoes metabolism via non-CYP mediated metabolism and is unlikely to affect concentrations of cabotegravir or rilpivirine.,""
123321,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid. However, these recommendations are not applicable when cabotegravir and rilpivirine are administered intramuscularly.",""
123322,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123323,Coadministration has not been studied. In vitro studies have demonstrated the ability of ifosfamide to both inhibit and induce CYP3A4. Clinical data with sunitinib suggests that ifosfamide can decrease sunitinib levels via CYP3A4 induction. Thus coadministration is contraindicated as it may reduce intramuscular rilpivirine leading potentially to the loss of therapeutic effect and development of resistance. Ifosfamide is unlikely to alter cabotegravir concentrations.,""
123324,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with iloperidone. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123326,"Coadministration has not been studied. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9, 2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9, 2C19 and therefore could increase rilpivirine concentrations. Cabotegravir is unlikely to be impacted by imatinib as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
123327,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and, to a lesser extent, by active tubular secretion. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123328,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Imipramine is metabolized by CYPs 3A4, 2C19 and 1A2 to desipramine. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with imipramine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123329,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is eliminated partly unchanged (33%) and partly metabolized by CYP3A4 and UGT1A1. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123330,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP450, however, cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123333,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nonpegylated interferon alpha appears to be metabolized principally in the kidney.,""
123347,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ivabradine is metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with ivabradine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123334,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as interleukin-2 is mainly eliminated via the kidney by glomerular filtration.,""
123335,"Coadministration has not been studied. Alantolactone, a component of Inula racemosa, moderately inhibits CYP3A4 in vitro and could potentially increase the exposure of rilpivirine although to a limited extent. No dose adjustment is needed. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
123337,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva. Iodine can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
123339,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolized by glucuronidation and oxidation (mainly CYP2C9). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123340,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123344,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver, with less than 30% of a dose undergoing subsequent glucuronidation. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123342,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as isoflurane is almost exclusively eliminated unchanged by the lungs. ,""
123345,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123343,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Cabotegravir and rilpivirine are unlikely to interfere with this metabolic pathway. ,""
100474,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, Delstrigo contains lamivudine and tenofovir-DF and should not be administered products containing emtricitabine or additional tenofovir-DF.",""
100441,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) and Delstrigo (doravirine, lamivudine, tenofovir-DF) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, Delstrigo contains lamivudine and tenofovir-DF and should not be administered products containing emtricitabine or additional tenofovir-DF.",""
102330,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Non-PEGylated interferon alpha appears to be metabolized principally in the kidney.,""
101024,"Delstrigo (doravirine, lamivudine, tenofovir-DF) and Juluca (dolutegravir, rilpivirine are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, doravirine should not be administered with another NNRTI (i.e., rilpivirine).",""
100973,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
123346,"Coadministration has not been studied. Itraconazole is a strong inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. No dose adjustment is required for rilpivirine when co-administered with azole antifungal agents, but clinical monitoring for breakthrough fungal infections is recommended when azole antifungals are co-administered with rilpivirine.",""
100482,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products&nbsp;or with additional tenofovir-DF.",""
123348,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest ivermectin is predominantly metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
98654,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, Symtuza contains tenofovir alafenamide and must not be administered with tenofovir-DF.",""
123350,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 2B6 and 2C9 in the range of concentrations used in anaesthesia. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. In addition, cabotegravir does not inhibit or induce other CYP enzymes. Likewise, rilpivirine has no inhibitory or inducing effects on CYP enzymes.",""
123352,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7. Cabotegravir and rilpivirine do inhibit or induce UGT enzymes at clinically relevant concentrations.,""
101820,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolized in the liver and animal studies suggest involvement of flavin-containing monooxygenases. Ethionamide does not affect metabolism mediated by CYP450 enzymes in vitro.,""
123353,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123354,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (approximatively 30% of the dose) and is eliminated unchanged through the kidneys (approximately 40% of the dose). Cabotegravir and rilpivirine do not inhibit or induce CYPs at clinically relevant concentrations.,""
101911,"Coadministration has not been studied. Dulaglutide is degraded by general protein catabolism pathways therefore no metabolic interaction is expected. Dulaglutide delays gastric emptying but interaction studies showed no clinically significant effect on the absorption of concomitantly orally administered drugs. However, caution is needed when coadministering atazanavir and GLP-1 agonists such as dulaglutide due to their potential to inhibit gastric secretion and thereby reduce the absorption of atazanavir. Consider monitoring virological response after initiating dulaglutide.",""
123356,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lamivudine would be possible from a pharmacokinetic standpoint.",""
101938,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Miconazole inhibits CYP2C9 and CYP3A4 but is unlikely to cause a clinically significant increase in atazanavir exposure.,""
123357,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123358,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Lansoprazole is mainly metabolized by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Furthermore, rilpivirine absorption is not impacted by lansoprazole when administered intramuscularly.",""
123359,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lapatinib is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Lapatinib inhibits CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Lapatinib may increase rilpivirine concentrations, but to an extent that is not clinically relevant. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with lapatinib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. ",""
123360,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ledipasvir and sofosbuvir are weak inhibitors of intestinal P-glycoprotein and BCRP, but this is not relevant with intramuscular administration of cabotegravir and rilpivirine. ",""
123361,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lenalidomide undergoes limited metabolism and is eliminated renally. Lenalidomide does not induce or inhibit CYPs. ,""
102073,Coadministration has not been studied. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Coadministration could potentially increase hydroxyzine exposure due to inhibition of CYP3A4. Use with caution due to the risk of QT interval prolongation reported for both drugs.,""
123362,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123363,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123364,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Leuprorelin acetate is a peptide that is primarily degraded by peptidases. Note, androgen deprivation treatment may prolong the QT interval. Caution should be taken when using with antiretroviral drugs that can potentially prolong the QT interval such as rilpivirine. ",""
123365,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism and elimination of levamisole has not been well characterized. Based on limited information, and single dose use of levamisole, clinically significant interactions are not considered likely. ",""
102143,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation.,""
123366,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levetiracetam undergoes enzymatic hydrolysis (non CYP) and is eliminated unchanged in the urine by glomerular filtration. ,""
123367,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters,""
123369,"Coadministration has not been studied. A pharmacokinetic interaction is unlikely as levofloxacin is eliminated renally mainly by glomerular filtration and active secretion (possibly OCT2). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with levofloxacin. However, given the QT prolongation risk associated with levofloxacin, caution is recommended.",""
123370,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with levomepromazine. However, given the QT prolongation risk associated with levomepromazine, caution is recommended",""
102265,"Coadministration has not been studied. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Ambrisentan concentrations may increase due to inhibition of OATP1B1 by atazanavir. Start ambrisentan at 5 mg and closely monitor the patient for tolerability.",""
102247,"Coadministration has not been studied. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest that it could act as an inducer of phase I and phase II metabolic enzymes although the clinical relevance has not been evaluated. In the absence of data, caution is recommended and TDM should be considered if available.",""
123371,"Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and levonorgestrel exposures. No interaction is expected with intramuscular rilpivirine.",""
123372,"Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter levonorgestrel used as emergency contraception. No interaction is expected with intramuscular rilpivirine.",""
102378,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Leuprorelin acetate is a peptide that is primarily degraded by peptidases. Note, androgen deprivation treatment may prolong the QT interval. Caution should be taken when using with antiretroviral drugs that can potentially prolong the QT interval such as atazanavir.",""
123373,"Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter levonorgestrel used as hormone therapy replacement. No interaction is expected with intramuscular rilpivirine.",""
123374,"Coadministration with a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter levonorgestrel used as implant. No interaction is expected with intramuscular rilpivirine.",""
102414,"Coadministration has not been studied but based on metabolism and clearance a pharmacokineticinteraction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes.&nbsp;However, as few data are available, care should be taken when administering oxytocin with antiretrovirals. In addition, use with caution due to the risk of QT interval prolongation reported for both drugs.",""
117097,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme).,""
102415,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic&nbsp; interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.&nbsp;However, use with caution due to the risk of QT interval prolongation reported for both drugs.",""
102499,"Coadministration has not been studied and is not recommended. Dofetilide is metabolized to a small degree by CYP3A4 and therefore atazanavir could potentially increase dofetilide exposure and thereby increase the risk of cardiac arrhythmias. Since atazanavir has also the potential to prolong the QT interval, the risk of cardiac arrhythmias might be enhanced when combining these drugs.",""
123376,"Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter levonorgestrel used as POP. No interaction is expected with intramuscular rilpivirine.",""
102624,"Coadministration has not been studied. Exenatide is primarily eliminated by glomerular filtration therefore no interaction is expected at the level of drug elimination. However, caution is needed when coadministering atazanavir and GLP-1 agonists such as exenatide due to their potential to inhibit gastric secretion and thereby reduce the absorption of atazanavir. Furthermore, exenatide has the potential to slow gastric emptying. Consider taking atazanavir 2-4 hours before the GLP-1 agonist.",""
123377,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
102631,"Coadministration has not been studied. Liraglutide is degraded by endogenous endopeptidases therefore no metabolic interaction is expected. However, caution is needed when coadministering atazanavir and GLP-1 agonists such as liraglutide due to their potential to inhibit gastric secretion and thereby reduce the absorption of atazanavir. Consider taking atazanavir 2-4 hours before the GLP-1 agonist.",""
123378,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123379,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces, with metabolism by CYP3A4 representing a minor elimination pathway. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123381,"Coadministration has not been studied. Glycyrrhizin, the main active component of Glycyrrhiza glabra, is a modest inducer of CYP3A4 and therefore could reduce the exposure of rilpivirine although to a modest extent. No significant effect is expected on cabotegravir based on the drug-drug interaction study with rifabutin (a moderate inducer).",""
102821,Coadministration has not been studied. Caution is warranted as atazanavir could increase concentrations of felodipine. Consider dose titration of felodipine. ECG monitoring is recommended.,""
102823,Caution is warranted as atazanavir could increase concentrations of nifedipine. Consider dose titration of nifedipine. ECG monitoring is recommended.,""
123384,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys and is freely filtered at a rate that is dependent upon the glomerular filtration rate. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with lithium. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
102818,Coadministration has not been studied. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Coadministration with ketoconazole (an inhibitor of CYP3A4 and P-gp) increased vilanterol exposure by 65% but this did not increase the occurrence of beta-adrenergic agonist related systemic effects. A similar magnitude of interaction may occur with atazanavir. No a priori dose adjustment of vilanterol is recommended.,""
102844,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Doxorubicin is mainly eliminated in the bile and&nbsp;does not undergo CYP-mediated metabolism. Doxorubicin is a substrate of P-glycoprotein, but coadministration with protease inhibitors did not modify significantly doxorubicin exposure. However caution is advised due to possible cardiac toxicities (ECG abnormalities and sometimes arrhythmias). Use with caution. ECG monitoring is recommended.",""
123385,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is metabolized by CYP2C8 and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
102912,Atazanavir solubility decreases as pH increases. Coadministration with antacids may reduce atazanavir plasma concentrations. Atazanavir should be administered 2 hours before or 1 hour after antacids.,""
123387,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
102969,Coadministration has not been studied. Seville orange juice inhibits intestinal CYP3A4 but is unlikely to have a significant effect on atazanavir exposure.,""
102987,"Coadministration has not been studied. Doxazosin is metabolized mainly by CYP3A4 and coadministration may increase doxazosin exposure which can result in hypotension. For patients already taking atazanavir, start doxazosin at the lowest dose (i.e., 1 mg daily) and increase dose slowly based on tolerance until an effective dose is reached. For patients already taking doxazosin, monitor blood pressure and reduce doxazosin dose as needed if hypotension occurs on starting atazanavir.",""
123388,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is mainly glucuronidated (by UGTs 2B15, 2B4, 2B7, 1A7, 1A10). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123389,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated (possibly by UGTs 2B15, 1A9 and 2B7). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123390,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
103022,"Coadministration has not been studied. Terazosin is extensively metabolized in the liver possibly via CYP3A4 and concentrations may increase due to inhibition of CYP3A4. For patients already taking atazanavir, start terazosin at the lowest dose (e.g. 1 mg daily) and increase dose slowly based on tolerance until an effective dose is reached. For patients already taking terazosin, monitor blood pressure and reduce terazosin dose as needed if hypotension occurs on starting atazanavir.",""
103059,Coadministration has not been studied. Fluvastatin is partially metabolised by CYP2C9 and is a substrate of OATP1B1 and there is a potential for a moderate increase in fluvastatin exposure when coadministered with atazanavir. Start fluvastatin at the lowest recommended dose and titrate as clinically indicated.,""
123391,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
103043,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Atazanavir is metabolised by CYP3A4. Peginterferon alfa-2a has no effect on CYP3A4. The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
103080,Coadministration has not been studied. Cyproterone acetate is metabolized by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by atazanavir. A dose adjustment of cyproterone may be required.,""
103086,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Goserelin is mainly hydrolyzed. Note, androgen deprivation treatment may prolong the QT interval. Caution should be taken when using with antiretroviral drugs that can potentially prolong the QT interval such as atazanavir.",""
103098,"Coadministration has not been studied. Orlistat should only be used with atazanavir if separated by 4-5 hours. Orlistat reduces dietary fat absorption and may affect the absorption of antiretrovirals (especially if lipophilic). [Note: this interaction is not specific for atazanavir, but for any medication taken with orlistat.]",""
103126,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.&nbsp;However, use with caution due to the risk of QT interval prolongation reported for both drugs.",""
123392,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
103183,"Coadministration has not been studied. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Inhibition of CYP3A4 and CYP2D6 by atazanavir/ritonavir may increase hydrocodone concentrations but decrease concentrations of norhydrocodone and hydromorphone. The clinical significance of this is unclear. Monitor the analgesic effect and for signs of opiate toxicity.",""
103184,"Coadministration has not been studied. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Ritonavir induces glucuronidation and coadministration with atazanavir/ritonavir could potentially decrease the analgesic effect. Monitor the analgesic effect.",""
103188,"Coadministration has not been studied. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7&gt;UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7&gt;UGT1A1). As atazanavir/ritonavir induces glucuronidation, coadministration could potentially decrease morphine concentration but facilitate the formation of the active metabolite morphine-6-glucuronide. Morphine and morphine-6-glucuronide are substrates of P-gp and coadministration may potentiate the effects of opiate in the CNS (via inhibition of P-gp at the blood-brain barrier). Monitor for sign of opiate toxicity.",""
103195,"Coadministration has not been studied. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Metabolism by CYP2D6 is to a metabolite more potent than the parent compound. Atazanavir/ritonavir may increase tramadol exposure but also reduce the conversion to the more potent active metabolite. Monitoring for tramadol related side effects and for the analgesic effect may be required as clinically indicated. Adjust tramadol dosage if needed.",""
123393,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lumefantrine is metabolized predominantly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with lumefantrine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
103264,"Coadministration has not been studied. In vitro studies suggest that sulfadiazine is partly metabolized by CYP2C9. Ritonavir has been found to induce metabolism mediated by CYP2C9 in clinical studies with probe substrates. Coadministration of atazanavir/ritonavir may decrease levels of sulfadiazine to a moderate extent, but the clinical significance of this potential interaction is unknown.",""
123394,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123395,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as magnesium resulting in a reduced absorption of cabotegravir. However, there is no such interaction when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
103303,Coadministration has not been studied. Agomelatine is metabolised predominantly by CYP1A2 which is induced by ritonavir. Coadministration with atazanavir/ritonavir could potentially decrease agomelatine exposure. Monitor clinical effect and increase dosage if needed.,""
103305,Coadministration has not been studied. Bupropion is primarily metabolized by CYP2B6 and in vivo data indicate that ritonavir induces CYP2B6. Atazanavir/ritonavir could potentially decrease bupropion concentrations (due to CYP2B6 induction) although the decrease is predicted to be moderate to weak when ritonavir is used at a dose of 100 mg once daily. No a priori dosage adjustment is required.,""
103292,"Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (~30% of the dose) and is eliminated unchanged through the kidneys (~40% of the dose). However, the impact on the PR interval has not been evaluated for the coadministration of atazanavir/ritonavir and lacosamide and an additive effect cannot be excluded. Note, PR interval monitoring may be warranted in patients with underlying block or those with atrioventricular nodal blocking agents.",""
103334,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is metabolised by UGTs and is a substrate of P-gp, BCRP, OAT3 and OATP1B1/1B3. Although atazanavir/ritonavir inhibits P-gp and OATP, data with verapamil (a P-gp inhibitor) and rifampicin (an OATP1B1/1B3 inhibitor) suggest a clinically relevant effect on empagliflozin is unlikely.",""
103345,"Coadministration has not been studied. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Ritonavir dosed as a pharmacokinetic booster is a weak inhibitor of CYP2C8. Atazanavir/ritonavir could potentially increase pioglitazone exposure, although to a moderate extent. No a priori dosage adjustment is required.",""
103369,"Coadministration has not been studied. Fexofenadine does not undergo CYP mediated metabolism but is a substrate of P-gp/OATP. Atazanavir/ritonavir could potentially increase fexofenadine exposure by inhibition of P-gp/OATP. However, due to the large therapeutic index of fexofenadine, no dosage adjustment is recommended.",""
103387,"Coadministration has not been studied. Lumefantrine is metabolised predominantly by CYP3A4. Coadministration of lopinavir/ritonavir and artemether/lumefantrine to HIV- subjects had no significant effect on lopinavir or ritonavir. Lumefantrine AUC was significantly increased by 2.3-fold and there was trend towards increased Cmax (1.4-fold). There was a trend towards decreased artemether AUC (39%) and Cmax (22%) and a significant decrease in AUC and Cmax (45% and 36%, respectively) of the active metabolite dihydroartemisinin. A similar effect is expected for atazanavir/ritonavir. Use with caution due to the risk of QT interval prolongation.",""
103403,"Coadministration has not been studied. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6). As ritonavir induces CYP1A2 and UGT1A4, atazanavir/ritonavir could potentially decrease asenapine exposure. Monitor the clinical effect and increase dosage if needed.&nbsp;Use with caution due to the risk of QT interval prolongation reported for both drugs.",""
103410,"Coadministration has not been studied. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Ritonavir induces CYP1A2 and UGT1A4. Atazanavir/ritonavir could potentially decrease olanzapine exposure. Monitor the clinical effect and increase dosage if needed.",""
123396,"Coadministration has not been studied. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest it could act as an inducer of phase I and phase II metabolic enzymes although the clinical relevance has not been evaluated. No significant effect is expected on cabotegravir based on the drug interaction study with rifabutin (a moderate inducer). However, malabar could potentially decrease rilpivirine exposure.",""
123397,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Mannitol is metabolised only very slightly, if at all, to glycogen in the liver and is predominantly eliminated unchanged via glomerular filtration. There is little potential for mannitol to affect the disposition of antiretrovirals, or to be altered by antiretrovirals.",""
123398,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Maprotiline is mainly metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with maprotiline. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
103521,"Coadministration has not been studied. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Ritonavir dosed as a pharmacokinetic booster is a weak inhibitor of CYP2C8. Atazanavir/ritonavir could potentially increase montelukast exposure by inhibition of CYP3A4, although to a moderate extent. Due to montelukastâ€™s safety profile, no a priori dosage adjustment is recommended.",""
103514,"Coadministration has not been studied. Timolol is predominantly metabolised in the liver by CYP2D6. Atazanavir/ritonavir could potentially increase timolol concentrations although to a moderate extent. No a priori dosage adjustment is required. Pharmacokinetic studies between atazanavir and drugs that prolong the PR interval including beta blockers (other than atenolol) have not been performed. An additive effect of atazanavir and these drugs cannot be excluded. Note, PR interval monitoring may be warranted in patients with underlying block or those with atrioventricular nodal blocking agents.",""
103530,"Coadministration has not been studied. Amlodipine is metabolized by CYP3A4. Atazanavir/ritonavir is predicted to increase amlodipine exposure by ~2-fold based on drug-drug interactions studies with amlodipine and indinavir/ritonavir or paritaprevir/ritonavir. If coadministration is indicated, consider a dose reduction for amlodipine of 50%. Use with caution as both atazanavir and calcium channel blockers prolong the PR interval. ECG monitoring is recommended.",""
123400,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mebendazole is predominantly metabolized in the liver. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123401,Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Medroxyprogesterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123402,"Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Medroxyprogesterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Likewise, rilpirivine does not inhibit or induce CYP3A4.",""
103555,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Doxorubicin is mainly eliminated in the bile and does not undergo CYP-mediated metabolism. Doxorubicin is a substrate of P-glycoprotein, but coadministration with protease inhibitors did not modify significantly doxorubicin exposure. However caution is advised due to possible cardiac toxicities (ECG abnormalities and sometimes arrhythmias). Use with caution. ECG monitoring is recommended.",""
103622,"Coadministration has not been studied. In vitro data indicate that alosetron is metabolized by CYPs 2C9 (30%), 3A4 (18%) and 1A2 (10%); however, in vivo data suggest that CYP1A2 plays a more prominent role. In vitro data indicate that ritonavir induces CYP1A2, therefore coadministration with atazanavir/ritonavir could potentially decrease alosetron exposure.",""
103614,"Administration of norethisterone (0.35 mg/day, as a progestogen only pill (POP)) was studied in a group of HIV+ women receiving protease inhibitors (atazanavir, atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir; n=16) or no protease inhibitors (n=17). Norethisterone exposure was increased by 50% in the presence of a protease inhibitor. In addition, the contraceptive efficacy of norethisterone was not impaired as no changes were noted in the cervical mucus of women receiving a regimen containing a boosted protease inhibitor versus a regimen without a boosted protease inhibitor.",""
123403,"Cabotegravir is metabolized by UGT1A1 and to a lesser extent by UGT1A9. The interaction with mefenamic acid, a strong UGT1A9 inhibitor, was assessed using a PBPK model. Coadministration is predicted to increase cabotegravir exposure by 11%, which is considered to be not clinically relevant. No drug-drug interaction is expected with rilpivirine, a CYP3A4 substrate.",""
123404,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mefloquine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with mefloquine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123406,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as meglumine antimoniate is predominantly eliminated unchanged via renal glomerular filtration. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with meglumine. However, given the QT prolongation risk associated with meglumine, caution is recommended",""
123407,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely, although due to the lack of available data, vigilance is required if administering melarsoprol with antiretrovirals. It is unknown whether urinary metabolites of melarsoprol, such as arsenic, are excreted via active renal mechanisms. However, a clinical study has reported that urinary pharmacokinetic parameters are not predictive of toxicity or therapeutic efficacy. Cabotegravir and rilpivirine have little potential to affect melarsoprol via competition for renal elimination mechanisms.",""
123408,Coadministration has not been studied. Menthol is a moderate inhibitor of CYP3A4 and therefore could increase rilpivirine to a limited extent. No dose adjustment is needed. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123409,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
103715,Coadministration has not been studied. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. In vitro and in vivo data indicate that ritonavir is a modest inducer of CYP2C9. Atazanavir/ritonavir could potentially increase the conversion to the more pharmacologically active metabolite. No a priori dose adjustment is recommended. Atazanavir alone is unlikely to alter losartan concentrations.,""
103727,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Coadministration of lopinavir/ritonavir (a strong inhibitor of CYP3A4) increased selexipag exposure by two-fold but there was no change in the exposure of the active metabolite. A similar result is expected with atazanavir/ritonavir, but this is unlikely to be clinically relevant as the majority of the pharmacological effect is driven by the active metabolite.",""
103740,"Coadministration has not been studied. Amphetamine is metabolized by CYP2D6 and coadministration with atazanavir/ritonavir could potentially increase amphetamine exposure, although to a moderate extent. However, as dosing of recreational drugs can be variable, caution is advised.",""
103744,Coadministration has not been studied. A case was reported of a patient experiencing a near fatal reaction from a small dose of GHB while on saquinavir and ritonavir (400 mg twice daily). Atazanavir/ritonavir may increase gamma-hydroxybutyrate concentrations. Ensure the patient is aware of signs/symptoms of GHB toxicity.,""
123410,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is predominantly metabolised by xanthine oxidase and cabotegravir or rilpivirine do not interfere with this metabolic pathway.,""
123411,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3. Likewise, rilpivirine does not inhibit these transporters.",""
123412,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase and cabotegravir and rilpivirine do not interfere with this pathway.,""
103789,"Coadministration has not been studied. In vitro studies have suggested that transformation of clomifene to its active metabolite is likely to be mediated via CYP2D6. Atazanavir/ritonavir might increase clomifene exposure, although to a moderate extent, via CYP2D6 inhibition. No a priori dosage adjustment is recommended.",""
123414,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is eliminated renally via OCT2 and MATE1. Cabotegravir and rilpivirine cause clinically relevant inhibition of renal transporters.,""
123415,"Coadministration with cabotegravir/rilpivirine has not been studied. Methadone is metabolized by CYP2B6 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Coadministration of oral rilpivirine (25 mg once daily) and methadone (60-100 mg once daily, individualised doses) had no effect on rilpivirine Cmax, AUC and Cmin, but decreased the AUC of both R- and S- methadone by 16%. No dose adjustment is required when starting coadministration of Cabenuva. However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with methadone. However, given the QT prolongation risk associated with methadone, caution is recommended",""
123416,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123418,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged, and as the mono-O-sulfate conjugate.",""
123420,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123421,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123423,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123424,"Coadministration has not been studied but elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, cyclosporine) with metronidazole. However, metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Since the mechanism of the interaction with CYP3A has not yet been identified, an interaction with rilpivirine cannot be excluded. No effect is expected on cabotegravir.",""
123425,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123426,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123427,"Coadministration has not been studied. Miconazole inhibits CYP2C9 and CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase although to a limited extent. No dose adjustment is needed. ",""
123428,Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral cabotegravir (30 mg once daily) and oral midazolam (3 mg) did not alter midazolam pharmacokinetics to a clinically significant extent. A similar effect is expected with intramuscular cabotegravir and rilpivirine.,""
123429,Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral cabotegravir (30 mg once daily) and oral midazolam (3 mg) did not alter midazolam pharmacokinetics to a clinically significant extent. A similar effect is expected with intramuscular cabotegravir and rilpivirine and parenteral midazolam. ,""
123430,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that mifepristone may inhibit CYP3A4 metabolism. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. A clinically significant interaction is not expected with rilpivirine since mifepristone is administered as a single dose. ,""
115765,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated via UGT1A9, UGT1A8 and is oxidized mainly via CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
123433,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Based on limited data concerning metabolism, elimination and toxicity of miltefosine, there is little potential for interaction. In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely. The main metabolic pathway of miltefosine appears to be mediated by phospholipases.",""
102017,"Coadministration has not been studied. Coadministration is expected to increase rilpivirine concentrations but is not expected to affect cobicistat concentrations. No dose adjustment of rilpivirine is required when atazanavir/cobicistat is used concomitantly with rilpivirine as the expected increase in rilpivirine concentrations is not considered clinically relevant. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent rilpivirine concentrations are unlikely to occur during coadministration with atazanavir/cobicistat. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123434,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Minaxolone undergoes hepatic metabolism. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123435,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123436,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123437,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as misoprostol is predominantly metabolised via fatty acid oxidising systems.,""
123438,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. However, caution is advised due to mitoxantrone related cardiotoxicity.",""
123439,"Coadministration has not been studied. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Modafinil is a moderate inducer of CYP3A4 and therefore could decrease rilpivirine concentrations. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. Modafinil is unlikely to impact cabotegravir as it is metabolized mainly by UGT1A1 and to a lesser extent by UGT1A9.",""
123440,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123441,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123442,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123443,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with moxifloxacin. However, given the QT prolongation risk associated with moxifloxacin, caution is recommended.",""
123445,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Multivitamins may contain polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as magnesium resulting in a reduced absorption of cabotegravir. However, there is no such interaction when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
123446,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mycophenolate is mainly glucuronidated by UGTs 1A9 and 2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123448,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly glucuronidated by UGT2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123451,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123452,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolized by CYP2C9 (70%) and to a lesser extent CYP3A4 (30%). Cabotegravir and rilpivirine do not inhibit or induce CYPs at clinically relevant concentrations.,""
123453,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123454,"Coadministration has not been studied. Nefazodone is metabolized mainly by CYP3A4 and is a moderate inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase although to a limited extent. No dose adjustment is needed. ",""
123457,Coadministration has not been studied. Nicardipine is metabolised mainly by CYP3A4 and inhibits this same enzyme. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Nicardipine could increase rilpivirine concentrations although to a limited extent. No dose adjustment is needed. ,""
123460,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolized by xanthine oxidase and aldehyde oxidase. Renal elimination of unchanged nicotinamide is minimal.,""
123461,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolized by xanthine oxidase and aldehyde oxidase. Renal elimination of unchanged nicotinamide is minimal. Nicotinamide can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
123462,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123463,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifurtimox appears to be biotransformed mostly by NADPH P450 reductase.,""
123464,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nilotinib is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Nilotinib is a moderate inhibitor of CYP3A4 and in vitro data indicate that it inhibits UGT1A1.Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, but it is unlikely to be affected by nilotinib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. Similarly, a non-relevant effect is expected with intramuscular cabotegravir. Nilotinib could increase rilpivirine exposure although to a limited extent. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with nilotinib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123465,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123466,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised mainly by CYP3A4. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123467,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123468,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug. Cabotegravir and rilpivirine do not interfere with nitrofurantoin elimination.,""
123470,"Coadministration with transdermally delivered norelgestromin/ethinylestradiol has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Ethinylestradiol is mainly metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and norelgestromin exposures. No interaction is expected with intramuscular rilpivirine.",""
123471,"Coadministration of a combined oral contraceptive (COC) containing norethisterone and mestranol has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and norethisterone exposures. No interaction is expected with intramuscular rilpivirine.",""
123472,Coadministration with norethisterone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123473,Coadministration of a norethisterone IM depot injection has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123474,Coadministration of a norethisterone progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123475,"Coadministration of a combined oral contraceptive (COC) containing norgestimate has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestimate is deacetylated to the active metabolite norelgestromin which is then metabolised to norgestrel, possibly by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and norgestimate exposures. No interaction is expected with intramuscular rilpivirine.",""
123476,"Coadministration of a combined oral contraceptive (COC) containing norgestrel/ethinylestradiol has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, intramuscular cabotegravir is unlikely to alter ethinylestradiol and norgestrel exposures. No interaction is expected with intramuscular rilpivirine.",""
123477,Coadministration with norgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. ,""
123478,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nortriptyline is metabolized mainly by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with nortriptyline. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123480,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ofloxacin is eliminated unchanged in the kidneys by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with ofloxacin. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123481,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123483,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olodaterol is metabolized by CYP2C8, CYP2C9, is glucuronidated via several UGTs, and is a substrate of P-gp. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes, or P-glycoprotein at clinically relevant concentrations.",""
123484,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied. Ombitasvir and paritaprevir/r are unlikely to significantly alter cabotegravir exposure. Ombitasvir/paritaprevir/ritonavir + dasabuvir were shown to increase oral rilpivirine Cmax, AUC and Cmin by 2.55-, 3.25- and 3.62-fold when administered orally. Coadministration should only be considered in patients without known QT prolongation and without other QT prolongation medications. If treatment is warranted, use with caution and with repeated ECG monitoring. ",""
123485,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied. Ombitasvir, paritaprevir/r and dasabuvir are unlikely to significantly alter cabotegravir exposure. Ombitasvir/paritaprevir/ritonavir + dasabuvir were shown to increase oral rilpivirine Cmax, AUC and Cmin by 2.55-, 3.25- and 3.62-fold when administered orally. Coadministration should only be considered in patients without known QT prolongation and without other QT prolongation medications. If treatment is warranted, use with caution and with repeated ECG monitoring. ",""
123486,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Omeprazole is mainly metabolized by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Furthermore, rilpivirine absorption is not impacted by omeprazole when administered intramuscularly.",""
123487,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with ondansetron. However, given the QT prolongation risk associated with ondansetron, caution is recommended",""
123488,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Orlistat reduces dietary fat absorption and may affect the absorption of antiretrovirals (especially if lipophilic). There is no risk of malabsorption when cabotegravir and rilpivirine are administered intramuscularly.,""
123489,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases. The latter is excreted in the urine by glomerular filtration and tubular secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1. Likewise, rilpivirine does not inhibit OAT1.",""
123490,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with oxaliplatin. However, given the QT prolongation risk associated with oxaliplatin, caution is recommended",""
123491,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Oxamniquine is thought to be predominantly metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123493,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated (by UGTs 2B15, 1A9 and 2B7). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123494,Coadministration has not been studied but is contraindicated. Oxcarbazepine is an inducer and therefore is expected to decrease cabotegravir and rilpivirine exposures and thereby result in loss of therapeutic effect.,""
123495,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised by glucuronidation. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123496,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123497,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally by CYP3A and CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123498,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with oxytocin. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123499,"Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. In vitro data suggest that paclitaxel activates PXR and therefore has potential inducing properties, which may reduce rilpivirine concentrations. No significant effect is expected on cabotegravir based on the drug interaction study with rifabutin (a moderate inducer).",""
123501,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Pantoprazole is mainly metabolized by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Furthermore, rilpivirine absorption is not impacted by pantoprazole when administered intramuscularly.",""
123502,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
123503,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (via UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15) and sulfation and, to a lesser extent, by oxidation. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations. Coadministration of oral rilpivirine (150 mg once daily) and paracetamol (500 mg single dose) increased rilpivirine Cmax, AUC and Cmin by 9%, 16% and 26%. Paracetamol Cmax and AUC decreased by 3% and 8%. These changes are not clinically significant.",""
123505,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYPs 2D6 and 3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123506,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Pazopanib is metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C8. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. In vitro data indicate that pazopanib inhibits UGT1A1. Cabotegravir is unlikely to be impacted by pazopanib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. Pazopanib is a weak inhibitor and therefore could potentially increase rilpivirine exposure although to a limited extent. No dose adjustment is required. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with pazopanib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123507,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is primarily metabolised by UGT1A1, and to a lesser extent by UGT1A9 whereas rilpivirine is mainly metabolized by CYP3A4. These pathways are not affected by peginterferon alfa-2a.The metabolism of peginterferon alfa-2a is not fully characterized, however, studies in rats indicate that the kidney is a major organ for excretion.",""
123508,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is primarily metabolised by UGT1A1, and to a lesser extent by UGT1A9 whereas rilpivirine is mainly metabolized by CYP3A4. These pathways are not affected by peginterferon alfa-2b.",""
123509,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although metabolism of penicillamine is not fully elucidated, multiple mechanisms and sites of metabolism are thought to be involved. There is, therefore, low potential for clinically significant interactions with cabotegravir or rilpivirine.",""
123510,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3. Likewise, rilpivirine does not inhibit OATs.",""
123511,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. The exact metabolic pathway of pentamidine has not been clearly established. Data from animal studies suggest the involvement of CYPs 1A1, 2D6 and 2C19 in the oxidative metabolism of pentamidine. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with pentamidine. However, given the QT prolongation risk associated with pentamidine, caution is recommended",""
123512,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline has not been well described but some studies indicate oxidation by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123513,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. However, caution is needed when combining rilpivirine and perazine as cardiac conduction abnormalities may be seen with perazine.",""
123514,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. However, caution is needed when combining rilpivirine and periciazine as cardiac conduction abnormalities may be seen with periciazine.",""
123516,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Perphenazine is metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with perphenazine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123517,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123518,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4). Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
123520,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. The interaction between phenobarbital (an inducer of UGT1A1) and oral cabotegravir (30 mg once daily) was evaluated using a PBPK model, which predicted a 28% decrease in cabotegravir exposure. Phenobarbital also induces CYP3A4 and is expected to substantially reduce rilpivirine exposure. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
123521,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123522,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir AUC by 59% A similar effect is expected with phenytoin. In addition, phenytoin is expected to substantially reduce rilpivirine exposure. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
123523,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal. No effect is expected on cabotegravir and rilpivirine.,""
123524,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal. Phytomenadione can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
123525,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123526,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Pimozide is metabolized mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with pimozide. However, given the QT prolongation risk associated with pimozide, caution is recommended",""
123528,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123529,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperacillin is eliminated renally via glomerular filtration and active secretion by OAT1/3. Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3. Likewise, rilpivirine does not inhibit OATs.",""
123530,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with piperaquine. However, given the QT prolongation risk associated with piperaquine, caution is recommended.",""
123531,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with pipotiazine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123532,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123533,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123537,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
123538,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123540,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Praziquantel is predominantly metabolised via CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
116534,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diethylcarbamazine is mainly excreted unchanged in the urine. No interaction is expected with dolutegravir, abacavir or lamivudine.",""
123541,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin undergoes extensive hepatic metabolism primarily by demethylation and conjugation. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123542,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone is metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123543,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123546,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied. Primidone is metabolised by CYP3A4 to the active metabolite phenobarbital. The interaction between phenobarbital (an inducer of UGT1A1) and oral cabotegravir (30 mg once daily) was evaluated using a PBPK model, which predicted a 28% decrease in cabotegravir exposure. In addition, phenobarbital is expected to substantially reduce rilpivirine exposure. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
123547,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is metabolized mainly by UGT1A1 and to a lesser extent by UGT1A9. In vitro data suggest that probenecid is a non-selective inhibitor of UGT, however it is unlikely to significantly impact cabotegravir exposure. Coadministration with the strong UGT1A1 inhibitor atazanavir was indeed predicted to minimally increase cabotegravir exposure (11%). No effect is expected on rilpivirine.",""
123548,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and CYP1A) and monoamine oxidase. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123549,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with prochlorperazine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123550,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123551,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123552,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2 and CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123553,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Propofol is glucuronidated via UGT1A9 and UGT1A8, and is oxidized mainly via CYP2B6. Cabotegravir and rilpivirine were shown to have no inhibitory or inducing effects on CYP or UGT enzymes at clinically relevant concentrations. However, rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with propofol. However, given the QT prolongation risk associated with propofol, caution is recommended.",""
123554,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123555,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Propylthiouracil is extensively metabolised, predominantly via glucuronidation, but the exact glucuronidation pathways are unknown. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
115813,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion of the parent drug also eliminated unchanged renally. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
123557,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123560,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Pyridostigmine is mainly eliminated unchanged by the kidney (via glomerular filtration and active tubular secretion most likely by a cation transporter). Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
123562,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. Pyridoxine can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
123564,Coadministration has not been studied. Quercetin has the ability to modulate CYP/P-gp activities although there are inconsistencies in the literature. Use with caution with rilpivirine. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123566,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
123567,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Quinidine is metabolized by CYP3A4, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with quinidine. However, given the QT prolongation risk associated with quinidine, caution is recommended.",""
123569,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Rabeprazole is mainly metabolized by CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Furthermore, rilpivirine absorption is not impacted by rabeprazole when administered intramuscularly.",""
69664,No significant interaction was observed when stavudine (40 mg single dose) and lamivudine (150 mg single dose) was studied in 18 HIV-infected subjects. There was no change in stavudine AUC and a 12% increase in Cmax. Lamivudine AUC and Cmax were unaltered.,""
114184,"Coadministration has not been studied and therefore there are no data available to make dosing recommendations. Based on interactions studies with boosted atazanavir, darunavir and lopinavir, an increase in tenofovir alafenamide absorption (via inhibition of intestinal P-gp and BRCP) and thereby increase in tenofovir exposure is expected. The European SmPC for tenofovir alafenamide does not recommended coadministration with boosted atazanavir, darunavir or lopinavir. This checker reflects the more cautious option.",""
123571,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123572,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Ranitidine is excreted via the kidney, partially by the cationic system. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters. Furthermore, rilpivirine absorption is not impacted by ranitidine when administered intramuscularly.",""
114181,"Coadministration of darunavir/ritonavir (800/100 mg once daily) with emtricitabine/tenofovir alafenamide (200/10 mg, once daily) increased tenofovir AUC and Cmax by 105% and 142% (n=10). No significant effects were observed on darunavir pharmacokinetics relative to historical controls. The European SmPC for tenofovir alafenamide states that coadministration is not recommended but darunavir is not mentioned in the US PI. This checker reflects the more cautious option.",""
114186,"Coadministration with tenofovir alafenamide alone has not been studied. Coadministration of lopinavir/ritonavir (800/200 mg once daily) with tenofovir alafenamide (10 mg once daily, with emtricitabine) increased tenofovir alafenamide AUC and Cmax by 47% and 119%. Tenofovir AUC and Cmax increased by 322% and 275% (n=10). No significant effects were observed on lopinavir pharmacokinetics relative to historical controls. The European SmPC for tenofovir alafenamide states that coadministration is not recommended but lopinavir is not mentioned in the US PI. This checker reflects the more cautious option.",""
114187,"Coadministration has not been studied. Tenofovir alafenamide (the prodrug of tenofovir) is a substrate of P-gp and inhibitors of P-gp such as ritonavir are expected to increase the absorption of tenofovir alafenamide, thereby increasing the systemic concentration. The European SmPC for tenofovir alafenamide does not recommended coadministration with boosted ARVs. This checker reflects the more cautious option.",""
114190,"Delstrigo (doravirine, lamivudine, tenofovir-DF) contains tenofovir-DF and must not be administered with products containing tenofovir alafenamide.",""
114182,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) contains tenofovir alafenamide and must not be administered with other products containing tenofovir alafenamide.",""
114189,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4. Tenofovir alafenamide does not inhibit or induce CYP3A.,""
114191,"Coadministration with tenofovir alafenamide alone has not been studied. Coadministration of efavirenz (600 mg once daily) and tenofovir alafenamide (40 mg once daily, with emtricitabine) decreased tenofovir alafenamide AUC and Cmax by 14% and 22%; tenofovir AUC and Cmax decreased by 20% and 24% (n=11). No effect on efavirenz is expected. No dose adjustment of tenofovir alafenamide or efavirenz is required.&nbsp;",""
114192,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etravirine is metabolised by CYPs 3A4, 2C9 and 2C19; tenofovir alafenamide does not inhibit these enzymes.&nbsp;",""
114193,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tenofovir alafenamide exposure is not expected to be affected by nevirapine nor is it expected to affect the metabolic and excretion pathways relevant to nevirapine. No dose adjustment of tenofovir alafenamide or nevirapine is required.,""
114194,"Coadministration of rilpivirine (25 mg once daily) and tenofovir alafenamide (25 mg once daily) had no significant effect on the pharmacokinetics of rilpivirine (AUC and Cmin increased by 1% and 13%, Cmax decreased by 7%). Tenofovir alafenamide Cmax and AUC were unchanged. Tenofovir Cmax, AUC and Cmin increased by 13%, 11% and 18%, respectively. No dose adjustment of tenofovir alafenamide or rilpivirine is required.",""
123573,"Coadministration has not been studied. Ranolazine is primarily metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Ranolazine is a weak inhibitor of CYP3A4. No effect is expected on cabotegravir and a clinically significant increase in rilpivirine exposure is unlikely. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with ranolazine. However, the product label for rilpivirine indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. ",""
123574,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rasagiline is metabolised predominantly by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
114195,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of tenofovir alafenamide and rilpivirine alone had not effect on the pharmacokinetics of rilpivirine, tenofovir alafenamide or tenofovir. Coadministration of tenofovir alafenamide (with emtricitabine) and dolutegravir alone increased dolutegravir Cmax, AUC and Cmin by 15%, 2% and 5%, respectively. Tenofovir alafenamide Cmax and AUC increased by 24% and 19%; tenofovir Cmax and AUC increased by 10% and 25%. No dose adjustment of tenofovir alafenamide, rilpivirine or dolutegravir is required.",""
114199,Tenofovir alafenamide can be coadministered with emtricitabine. A clinically significant interaction is unlikely.,""
114200,"Descovy (emtricitabine, tenofovir alafenamide) contains tenofovir alafenamide and must not be administered with other products containing tenofovir alafenamide.",""
123575,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Likewise, rilpivirine does not inhibit or induce CYP3A4.",""
123576,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes.,""
123577,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYPs 2C8 and 3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123579,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Retinol can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.",""
123580,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ribavirin is partly metabolized (non CYP mediated) and partly excreted in the urine. Cabotegravir and rilpivirine do not cause clinically significant inhibition of renal transporters.,""
123582,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Riboflavin can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
123583,"Coadministration of rifabutin (300 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 17%, AUC by 21% and Ctrough by 26%. This reduction in cabotegravir exposure is not considered to be clinically relevant. Similarly, no clinically relevant interaction is expected when cabotegravir is administered intramuscularly. However, coadministration of oral rilpivirine (25 mg once daily) and rifabutin (300 mg once daily) decreased rilpivirine Cmax, AUC and Cmin by 31%, 42% and 48%, respectively. When compared to rilpivirine 25 mg once daily, coadministration of oral rifabutin and rilpivirine (50 mg once daily) had no effect on rilpivirine Cmin, and increased AUC and Cmax by 16% and 43%, respectively. Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
123584,"Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 6%, AUC by 59% whereas oral clearance was increased by 2.4 fold. Similarly to oral cabotegravir, concomitant administration with rifampicin is not recommended with intramuscular cabotegravir. Furthermore, significant decreases in rilpivirine plasma concentrations are expected. Coadministration of rilpivirine (150 mg once daily) and rifampicin (600 mg once daily) decreased rilpivirine Cmax, AUC and Cmin by 69%, 80% and 89%, respectively. There was no significant effect on rifampicin. Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
123585,"Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir Cmax by 6%, AUC by 59% whereas oral clearance was increased by 2.4 fold. A similar effect is expected with rifapentine thus coadministration is not recommended with intramuscular cabotegravir. Furthermore, significant decreases in rilpivirine plasma concentrations expected due to induction of CYP3A4. Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
123587,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, if a patient plans to miss a scheduled injection visit by more than 7 days, oral therapy (cabotegravir 30 mg and rilpivirine 25 mg once daily) may be used to replace up to 2 consecutive monthly injection visits. The first dose of oral therapy should be taken approximately 1 month after the last injection dose of Cabenuva. Injection dosing should be resumed on the day oral dosing completes. ",""
123589,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123590,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, CYP2J2 and is also eliminated unchanged in the bile and renally. Riociguat is a substrate of P-gp and BCRP. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes, P-glycoprotein or BCRP at clinically relevant concentrations.",""
123594,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). Cabotegravir and rilpivirine do not inhibit or induce CYPs or P-gp and BCRP at clinically relevant concentrations.",""
123596,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally. P-gp was shown to mediate biliary excretion of rocuronium in a rat model. However cabotegravir and rilpivirine do not inhibit P-gp at clinically relevant concentrations.,""
123597,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Roflumilast is metabolized by CYP3A4 and CYP1A2 to form roflumilast N-oxide, with both roflumilast and roflumilast N-oxide having PDE4 inhibitory activity. Roflumilast N-oxide is subsequently dealkylated by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymesat clinically relevant concentrations.",""
123598,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolised predominantly by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123599,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123602,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-O-sulphate. Cabotegravir and rilpivirine do not interfere with this metabolic pathway.,""
123603,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. ,""
115935,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115936,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioxetine is mainly metabolized by CYP2D6 and to a lesser extent CYP2C9 and CYP3A4/5. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123605,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that Serenoa repens inhibits CYP2C9, CYP2D6 and CYP3A4 activity. However, clinical studies found that administration of Serenoa repens did not alter CYP3A4 or CYP2D6 activity in healthy volunteers. Saw palmetto is unlikely to affect cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. A clinically relevant interaction is unlikely with rilpivirine.",""
123606,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123607,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
86922,"Coadministration has not been studied and is not recommended as concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by cobicistat, thereby increasing the bleeding risk. The product labels for apixaban do not recommend the concomitant use with strong dual CYP3A4 and P-gp inhibitors, although the US label gives the option to use apixaban at a reduced dose (i.e., 2.5 mg) if needed. Of interest, no adverse outcomes were reported in six HIV infected patients treated with a reduced dose of apixaban (2.5 mg twice daily) while on ritonavir or cobicistat boosted regimens which supports the option of dose reduction given in the US label. Based on metabolism and clearance a clinically significant interaction with emtricitabine and tenofovir-DF is unlikely.",""
86921,"Coadministration has not been studied and is not recommended as concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by cobicistat, thereby increasing the bleeding risk. The product labels for apixaban do not recommend the concomitant use with strong dual CYP3A4 and P-gp inhibitors, although the US label gives the option to use apixaban at a reduced dose (i.e., 2.5 mg) if needed. Of interest, no adverse outcomes were reported in six HIV infected patients treated with a reduced dose of apixaban (2.5 mg twice daily) while on ritonavir or cobicistat boosted regimens which supports the option of dose reduction given in the US label.&nbsp;Based on metabolism and clearance a clinically significant interaction with emtricitabine and tenofovir alafenamide is unlikely.",""
114475,"Coadministration has not been studied and is contraindicated. Avanafil is primarily metabolized by CYP3A4. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in presence of atazanavir/cobicistat.",""
95568,"Coadministration has not been studied and is not recommended as concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by cobicistat, thereby increasing the bleeding risk. The product labels for apixaban do not recommend the concomitant use with strong dual CYP3A4 and P-gp inhibitors, although the US label gives the option to use apixaban at a reduced dose (i.e., 2.5 mg) if needed. Of interest, no adverse outcomes were reported in six HIV infected patients treated with a reduced dose of apixaban (2.5 mg twice daily) while on ritonavir or cobicistat boosted regimens which supports the option of dose reduction given in the US label.",""
97148,"Coadministration has not been studied and is not recommended as concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by ritonavir, thereby increasing the bleeding risk. The product labels for apixaban do not recommend the concomitant use with strong dual CYP3A4 and P-gp inhibitors, although the US label for apixaban gives the option to use apixaban at a reduced dose (i.e., 2.5 mg) if needed. Of interest, no adverse outcomes were reported in six HIV infected patients treated with a reduced dose of apixaban (2.5 mg twice daily) while on ritonavir or cobicistat boosted regimens which supports the option of dose reduction given in the US label.",""
114472,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of saquinavir.",""
114474,"Coadministration has not been studied and is contraindicated. Avanafil is primarily metabolized by CYP3A4. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of lopinavir/ritonavir.",""
114507,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with dolutegravir and potentially decrease the amount of dolutegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of dolutegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation. No interaction is expected with rilpivirine.",""
123609,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
114476,"Coadministration has not been studied and is contraindicated. Avanafil is primarily metabolized by CYP3A4. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of darunavir/cobicistat.",""
114477,"Coadministration has not been studied and is contraindicated. Avanafil is primarily metabolized by CYP3A4. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in presence of darunavir/ritonavir.",""
114478,"Coadministration has not been studied and is contraindicated. Avanafil is primarily metabolized by CYP3A4. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of darunavir/cobicistat. Emtricitabine and tenofovir alafenamide do not interact with this pathway.",""
114473,"Coadministration has not been studied. Avanafil is primarily metabolized by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated in the product labels for avanafil. Coadministration with ritonavir (600 mg twice daily) increased avanafil AUC by 13-fold. Similarly, a large increase in avanafil exposure is predicted in the presence of tipranavir.",""
114508,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with raltegravir and potentially decrease the amount of raltegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of raltegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation.",""
73738,"Coadministration has not been studied. Based on metabolism and clearance a pharmacokinetic interaction is unlikely but coadministration could potentially result in increased risk of nephrotoxicity. The risk is increased if an NSAID is used for a long duration, if the patient has a pre-existing renal dysfunction, has a low body weight, or receives other drugs that may increase tenofovir exposure. Cases of acute renal failure after initiation of high dose or multiple NSAIDs have been reported in patients treated with tenofovir-DF and with risk factors for renal dysfunction. Alternatives to NSAIDs should be considered in patients at risk for renal dysfunction. If tenofovir-DF is co-administered with an NSAID, renal function should be monitored adequately.",""
123610,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sevelamer is a resin not absorbed from the GI tract. No interaction is expected with cabotegravir/rilpivirine when administered intramuscularly.,""
114503,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with elvitegravir and potentially decrease the amount of elvitegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of elvitegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation. No interaction is expected with cobicistat, emtricitabine or tenofovir alafenamide.",""
114504,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with elvitegravir and potentially decrease the amount of elvitegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of elvitegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation. No interaction is expected with cobicistat, emtricitabine or tenofovir-DF.",""
114505,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with bictegravir and potentially decrease the amount of bictegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of bictegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation. No interaction is expected with emtricitabine or tenofovir alafenamide.",""
114506,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with dolutegravir and potentially decrease the amount of dolutegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of dolutegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation.",""
83854,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%).",""
123611,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Seville orange juice inhibits intestinal CYP3A4. However, this is not problematic with intramuscular administration of rilpivirine and cabotegravir. ",""
123612,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as sevoflurane is almost exclusively eliminated unchanged by the lungs. However, rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with sevoflurane. However, given the QT prolongation risk associated with sevoflurane, caution is recommended.",""
115785,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7, whereas dolutegravir is glucuronidated by UGT1A1. No interaction is expected with lamivudine.",""
123613,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral rilpivirine (75 mg once daily) and sildenafil (50 mg single dose) did not significantly alter the pharmacokinetics of sildenafil, a CYP3A4 substrate. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers and is unlikely to alter sildenafil pharmacokinetics.",""
116178,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gefitinib is metabolized by CYP3A4 and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123614,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Coadministration of oral rilpivirine (75 mg once daily) and a single dose of sildenafil (50 mg, as used for the treatment of erectile dysfunction) decreased rilpivirine Cmax and AUC by 8% and 2%, and increased Cmin by 4%. Sildenafil Cmax and AUC decreased by 7% and 3%; N-desmethyl sildenafil Cmax and AUC decreased by 10% and 8%, respectively.",""
93943,"Coadministration has not been studied. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). There is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
84150,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as levofloxacin is metabolised to a very small extent&nbsp;and is eliminated renally mainly by glomerular filtration and active secretion (possibly OCT2).",""
123615,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simeprevir is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Coadministration of oral rilpivirine (25 mg once daily for 11 days) and simeprevir (150 mg once daily for 11 days) was studied in 21 subjects. Simeprevir Cmax and AUC increased by 10% and 6%, but Cmin decreased by 4%. Rilpivirine Cmax, AUC and Cmin increased by 4%, 12% and 25%, respectively. No dose adjustment is required.",""
75077,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally (via glomerular filtration and possibly active secretion by OCT). There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in amisulprideâ€™s elimination.,""
101645,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acamprosate is eliminated unchanged in the urine&nbsp;both via glomerular filtration and active secretion (exact transporter unknown, possibly OATs or OCTs).",""
90346,"Coadministration has not been studied. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase trospium exposure, but the clinical relevance of this is unknown.",""
99826,"Coadministration has not been studied. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase trospium exposure, but the clinical relevance of this is unknown.&nbsp;Rilpivirine does not interfere with this elimination pathway.",""
123616,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4. Cabotegravir and rilpivirine have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123617,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123618,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp), with metabolism by CYP3A4 representing a minor elimination pathway. Cabotegravir and rilpivirine do not inhibit these transporters at clinically relevant concentrations. ",""
115426,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Bictegravir, emtricitabine and tenofovir alafenamide do not interact with ciclesonide metabolism.",""
115427,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Doravirine, lamivudine and tenofovir-DF do not interact with ciclesonide metabolism.",""
115428,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Dolutegravir does not interact with ciclesonide metabolism.,""
115429,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Dolutegravir/rilpivirine does not interact with ciclesonide metabolism.,""
115430,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Doravirine does not interact with ciclesonide metabolism.,""
115431,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Rilpivirine does not interact with ciclesonide metabolism.,""
115433,"No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
115434,"Coadministration has not been studied. Ciclesonide can be administered with atazanavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with atazanavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
115435,"Coadministration has not been studied. Ciclesonide can be administered with atazanavir/cobicistat without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with atazanavir/cobicistat would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
115436,"Coadministration has not been studied. Ciclesonide can be administered with atazanavir/ritonavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with atazanavir/ritonavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
115437,"Coadministration has not been studied. Ciclesonide can be administered with darunavir/cobicistat without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with darunavir/cobicistat would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
115438,"Coadministration has not been studied. Ciclesonide can be administered with darunavir/ritonavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with darunavir/ritonavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
75453,"Coadministration has not been studied. Ciclesonide can be administered with fosamprenavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with fosamprenavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
75454,"Coadministration has not been studied. Ciclesonide can be administered with indinavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with indinavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
75458,"Coadministration has not been studied. Ciclesonide can be administered with saquinavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with saquinavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
115439,"Coadministration has not been studied. Ciclesonide can be administered with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with elvitegravir/cobicistat would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration. Emtricitabine and tenofovir alafenamide do not interfere with ciclesonide metabolism.",""
115462,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with atazanavir/cobicistat, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115440,"Coadministration has not been studied. Ciclesonide can be administered with elvitegravir/cobicistat/emtricitabine/tenofovir-DF without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with elvitegravir/cobicistat would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration. Emtricitabine and tenofovir-DF do not interfere with ciclesonide metabolism.",""
115441,"Coadministration has not been studied. Ciclesonide can be administered with darunavir/cobicistat/emtricitabine/tenofovir alafenamide without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with darunavir/cobicistat would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration. Emtricitabine and tenofovir alafenamide do not interfere with ciclesonide metabolism.",""
75459,"Coadministration has not been studied. Ciclesonide can be administered with tipranavir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used, or in case of prolonged administration, or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 Âµg once daily) did not alter ciclesonide but resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide. Ciclesonide is mainly absorbed by the lungs, has a high protein binding and a high clearance resulting in a lower potential to cause systemic effects compared to some other inhaled corticosteroids. Hence, any interaction with tipranavir would not require any dosage/therapy adjustments, particularly if ciclesonide is administered at lower or medium clinical doses, but close monitoring for Cushingâ€™s syndrome signs is required when using a higher dose or with prolonged administration.&nbsp;",""
115442,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism.,""
115451,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Doravirine, lamivudine and tenofovir-DF do not interact with flunisolide metabolism.",""
115452,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Bictegravir, emtricitabine and tenofovir alafenamide do not interact with flunisolide metabolism.",""
115463,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with atazanavir/ritonavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115464,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with darunavir/cobicistat, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115465,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with darunavir/ritonavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115466,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with fosamprenavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115467,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with indinavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115468,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with lopinavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115469,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with ritonavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115470,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with saquinavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115471,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with tipranavir, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects.",""
115472,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with elvitegravir/cobicistat, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects. Emtricitabine and tenofovir alafenamide do not interfere with flunisolide metabolism.",""
115473,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with elvitegravir/cobicistat, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects. Emtricitabine and tenofovir-DF do not interfere with flunisolide metabolism.",""
115474,"Coadministration has not been studied. Flunisolide undergoes CYP3A4-mediated metabolism and coadministration may increase flunisolide concentrations. Flunisolide has properties (low binding affinity to glucocorticoid receptors, low lipophilicity and short elimination half-life) associated with a lower propensity to cause a Cushing syndrome. If coadministered with darunavir/cobicistat, it is recommended to use the lowest possible flunisolide dose with monitoring for corticosteroid side effects. Emtricitabine and tenofovir alafenamide do not interfere with flunisolide metabolism.",""
115498,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Atazanavir/cobicistat could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with atazanavir/cobicistat.&nbsp;",""
115499,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Atazanavir/ritonavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with atazanavir/ritonavir. ",""
115500,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Darunavir/cobicistat could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with darunavir/cobicistat.&nbsp;",""
115501,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Darunavir/ritonavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with darunavir/ritonavir.&nbsp;",""
115502,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Fosamprenavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with fosamprenavir.&nbsp;",""
115503,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Indinavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with indinavir.&nbsp;",""
115504,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Lopinavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with lopinavir.&nbsp;",""
115505,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Ritonavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with ritonavir.&nbsp;",""
115506,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Saquinavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with saquinavir.&nbsp;",""
115507,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Tipranavir could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with tipranavir.&nbsp;",""
115508,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Emtricitabine and tenofovir alafenamide do not interfere with monacolin K metabolism. Elvitegravir/cobicistat could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.&nbsp;",""
115509,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Emtricitabine and tenofovir-DF do not interfere with monacolin K metabolism. Elvitegravir/cobicistat could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with elvitegravir/cobicistat/emtricitabine/tenofovir-DF.&nbsp;",""
115510,"Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Emtricitabine and tenofovir alafenamide do not interfere with monacolin K metabolism. Darunavir/cobicistat could significantly increase the exposure of monacolin K due to inhibition of CYP3A4. There are two case reports of rhabdomyolysis resulting from drug-drug interactions with red yeast rice (one with ciclosporin; one with sertraline and rosuvastatin). Since coadministration with lovastatin is contraindicated due to the potential for serious reactions such as myopathy including rhabdomyolysis, red yeast rice should not be coadministered with darunavir/cobicistat/emtricitabine/tenofovir alafenamide.&nbsp;",""
115511,Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Efavirenz induces CYP3A4 and coadministration could potentially decrease monacolin K exposure and reduce its effect.&nbsp;,""
115512,Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Etravirine induces CYP3A4 and coadministration could potentially decrease monacolin K exposure and reduce its effect.&nbsp;,""
115513,Coadministration has not been studied. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Nevirapine induces CYP3A4 and coadministration could potentially decrease monacolin K exposure and reduce its effect.&nbsp;,""
123620,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely with both cabotegravir and rilpivirine. Elimination of sodium stibogluconate is predominantly via renal glomerular filtration. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with sodium stibogluconate. However, given the QT prolongation risk associated with sodium stibogluconate, caution is recommended",""
123621,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir is a weak inhibitor of intestinal P-glycoprotein and BCRP, but this not relevant with intramuscular administration of cabotegravir and rilpivirine. Coadministration of oral rilpivirine (25 mg once daily) and sofosbuvir (400 mg single dose) was studied in 17 subjects. Sofosbuvir Cmax and AUC increased by 21% and 9%, whereas GS-331007 Cmax and AUC increased by 6% and 1%. Rilpivirine Cmax and AUC increased by 5% and 6%, but Cmin decreased by 1%. No dose adjustment of sofosbuvir or rilpivirine is required.",""
123622,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir and velpatasvir are inhibitors of intestinal P-glycoprotein and BCRP, but this is not relevant with intramuscular administration of cabotegravir and rilpivirine. Coadministration of oral rilpivirine (25 mg once daily and emtricitabine/tenofovir-DF) and sofosbuvir/velpatasvir (400/100 mg once daily) decreased rilpivirine Cmax, AUC and Cmin by 7%, 5% and 4%, respectively (n=24). No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed.",""
123623,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sofosbuvir, velpatasvir and voxilaprevir are inhibitors of intestinal P-glycoprotein and BCRP, but this is not relevant with intramuscular administration of cabotegravir and rilpivirine. Coadministration of oral rilpivirine (25 mg once daily with emtricitabine and tenofovir-alafenamide) and sofosbuvir/velpatasvir/voxilaprevir had no clinically significant effect on pharmacokinetic parameters.",""
123624,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123625,"Coadministration has not been studied but based on metabolism and a pharmacokinetic interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. Sorafenib inhibits UGT1A1 and UGT1A9. Cabotegravir is unlikely to be impacted by sorafenib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. Sorafenib is unlikely to impact rilpivirine as it is metabolized by CYP3A4. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with sorafenib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123627,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases. Cabotegravir and rilpivirine do not interfere with this metabolic pathway.,""
123628,"St Johnâ€™s Wort is an inducer and therefore can reduce rilpivirine and cabotegravir exposure. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. However, a recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (<1 mg/day) of St Johnâ€™s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp). Coadministration may be considered with St Johnâ€™s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of 1 mg or less.",""
115783,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123629,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
102133,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. &nbsp;Doxorubicin is mainly eliminated in the bile and does not undergo CYP-mediated metabolism. Doxorubicin is a substrate of P-glycoprotein, but coadministration with protease inhibitors did not modify significantly doxorubicin exposure. However caution is advised due to possible cardiac toxicities (ECG abnormalities and sometimes arrhythmias). Use with caution. ECG monitoring is recommended.",""
97422,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;Doxorubicin is mainly eliminated in the bile and&nbsp;does not undergo CYP-mediated metabolism. Doxorubicin is a substrate of P-glycoprotein, however, coadministration with protease inhibitors did not modify significantly doxorubicin exposure.",""
115784,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115754,"Coadministration has not been studied. Alcuronium is predominantly excreted unchanged via the kidneys. As there are no available data determining whether excretion is via active tubular secretion or glomerular filtration, there is some potential for exposure of alcuronium to be increased since dolutegravir inhibits the renal transporter OCT2. There is also potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of alcuronium or lamivudine. Caution is advised as alcuronium has a narrow therapeutic window.",""
115755,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupivacaine is predominantly metabolized via CYP3A4, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Renal excretion of unchanged bupivacaine is thought to account for approximately 1% of a dose and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115758,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly CYP2A Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115759,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enflurane is predominantly metabolized by CYP2E1, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115760,"Coadministration has not been studied. Ephedrine is predominantly eliminated unchanged via the kidneys possibly via the renal transporter OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase the exposure of ephedrine. There is also potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
115761,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that halothane undergoes oxidation (mainly via CYP2E1 and to a lesser extent CYP2A6) and reduction (via CYP2A6 and CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115763,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 2B6 and 2C9 in the range of concentrations used in anaesthesia. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115766,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally. P-gp was shown to mediate biliary excretion of rocuronium in a rat model, however, in vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115768,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sufentanil undergoes extensive CYP3A4 metabolism, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115769,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Suxamethonium is hydrolysed by plasma cholinesterase and there is little potential for an interaction with dolutegravir via modulation of or competition for metabolic pathways. Renal elimination of unchanged suxamethonium is minimal and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
115771,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although pentobarbital (a potent inducer of hepatic microsomal drug metabolism) is formed during thiopental metabolism, levels do not reach the therapeutic range. Therefore, dolutegravir pharmacokinetics are unlikely to be affected significantly by coadministration with thiopental. Renal excretion of unchanged thiopental is thought to be minimal so there is little potential for an interaction with lamivudine due to competition for renal elimination pathways.",""
115772,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Tizanidine is metabolised by CYP1A2 which is not inhibited or induced by dolutegravir. No interaction is expected with lamivudine.",""
115774,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes CYP3A4 metabolism, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115775,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6). Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115777,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is metabolised mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115778,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115779,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolized by CYP3A. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115780,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115781,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9 (catalyzes the major route of diclofenac oxidative metabolism). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115814,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115782,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) via CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
123633,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir. Strontium is a divalent cation and can chelate with the integrase inhibitor cabotegravir thereby reducing its absorption. However, there is no such interaction when cabotegravir or rilpivirine are administered intramuscularly.",""
123634,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sufentanil undergoes extensive CYP3A4 metabolism, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
115786,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115787,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and additionally glucuronidated by UGT2B7 and 1A9. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115789,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115790,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. Naproxen and its metabolites are primarily eliminated by the kidney. In vitro data suggest that naproxen is a weak inhibitor of the renal transporter OCT2. No interaction is expected with lamivudine.,""
115791,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115792,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally by CYP3A and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115793,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (via UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15) and sulfation and, to a lesser extent, by oxidation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115794,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115795,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115796,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol is mainly glucuronidated by UGT1A6, UGT1A9 and UGT2B7 and does not induce or inhibit CYP450 enzymes in the range of doses in clinical use. Dolutegravir is glucuronidated by other UGTs. No interaction is expected with lamivudine.",""
115797,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115798,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized by CYP3A4 and by the flavine-containing monooxygenase system. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. There is little potential for an interaction via competition with lamivudine for renal elimination pathways.",""
115799,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diethylcarbamazine is mainly excreted unchanged in the urine. No interaction is expected with dolutegravir or lamivudine.,""
115800,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest ivermectin is predominantly metabolised by CYP3A4 and does not inhibit metabolic enzymes at clinically relevant concentrations. Similarly, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. There is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115801,"Coadministration has not been studied. Metabolism and elimination of levamisole has not been well characterized. Based on limited information, and single dose use of levamisole, clinically significant interactions are not considered likely. ",""
115802,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mebendazole is predominantly metabolized in the liver. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. Renal excretion of unchanged mebendazole appears to be minimal and there is little potential for an interaction with lamivudine via competition for active renal elimination pathways.,""
123635,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that sulfadiazine is metabolized in part by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYPs at clinically relevant concentrations.,""
115804,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Oxamniquine is thought to be predominantly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Renal excretion of unchanged oxamniquine is minimal and there little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115805,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Praziquantel is predominantly metabolised via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Renal excretion of unchanged praziquantel appears to be minimal and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
115806,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrantel is metabolized by CYP2D6 in vitro, however, absorption of an oral dose is minimal and over 50% of a dose is excreted unchanged in the faeces. Renal excretion of unchanged pyrantel is minimal (<7%) and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115807,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Suramin appears to be eliminated predominantly unchanged via renal glomerular filtration. No interaction is expected with dolutegravir and there is little potential for an interaction with lamivudine via competition for renal transport pathways.,""
115808,"Coadministration has not been studied. In vitro data suggest that, triclabendazole and its active sulfoxide metabolite are inhibitors of CYP3A4. Coadministration may increase dolutegravir concentrations although to a moderate extent as CYP3A4 does not play a major role in dolutegravir metabolism. Furthermore, due to short term dosing of triclabendazole, the effect on antiretrovirals is likely to be minimal. Renal excretion of unchanged triclabendazole appears to be minimal (<10%) and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115809,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Amiodarone is metabolized by CYP3A4 and in vitro data suggest it is only a weak inhibitor of CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115810,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Bepridil is metabolized by CYP2D6 (major) and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115811,"Coadministration has not been studied. Disopyramide is metabolized by CYP3A4 (25%) whereas 50% of the drug is eliminated unchanged in the urine (possibly via OCT2). In vitro data indicate that dolutegravir inhibits OCT2 and may increase disopyramide exposure. Caution is warranted and clinical monitoring is recommended if coadministered. Data from animal studies indicate that disopyramide is a weak inhibitor of the renal transporter OCT2. Since OCT2 may contribute to the renal elimination of disopyramide, there is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
115815,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115820,"Coadministration has not been studied. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion; it is reduced by probenecid. About 20 to 40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60 to 80% is excreted in the urine within 6 hours. No interaction is expected with dolutegravir. As lamivudine is eliminated by renal tubular secretion, there is potential for competition with ampicillin for renal transporters, which could lead to increased levels of either drug when ampicillin is administered intravenously. When administered orally, there is little potential for significant interaction. ",""
115821,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-glycoprotein and MRP2. In vitro data indicate that dolutegravir does not inhibit P-glycoprotein and MRP2 at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115822,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. Concentrations are unlikely to be affected by dolutegravir or lamivudine. There are no clinical data on the safety and efficacy of bedaquiline when co-administered with antiretroviral agents.,""
115823,"Coadministration has not been studied. Capreomycin is predominantly excreted via the kidneys as unchanged drug, partly by glomerular filtration and possibly partly by tubular secretion (renal transporter not identified). There is some potential for exposure of capreomycin to be increased since dolutegravir inhibits the renal transporter OCT2. As capreomycin may potentially compete with lamivudine for renal elimination transport mechanisms, levels of capreomycin or lamivudine may hypothetically be raised. Renal function should be monitored as clinically appropriate.",""
115824,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged via the kidneys (by glomerular filtration and tubular secretion via OAT1 and MATE1). Dolutegravir is not expected to inhibit these renal transporters and lamivudine is eliminated by different renal transporters.,""
123637,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. There is, therefore, low potential for clinically significant interactions with cabotegravir or rilpivirine.",""
123638,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as sulpiride is mainly excreted in the urine and faeces as unchanged drug. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with sulpiride. However, given the QT prolongation risk associated with sulpiride, caution is recommended",""
115825,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by other renal transporters.",""
115826,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration, with no significant active renal tubular secretion. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal elimination transport mechanisms.",""
115827,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine (about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite). In vitro studies indicate that OATs participate to the renal elimination of cefotaxime. Dolutegravir is not expected to inhibit these renal transporters and lamivudine is eliminated by other renal transporters.",""
115828,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
115829,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
115830,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly metabolized by glucuronidation via UGT2B7 whereas dolutegravir is mainly eliminated by glucuronidation via UGT1A1. Dolutegravir is not expected to inhibit UGTs at clinically relevant concentrations. Although, in vitro studies have shown that chloramphenicol inhibits CYP3A4 and CYP2C19, CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the concentrations used are unlikely to cause a clinically significant interaction.",""
115831,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged through the kidneys (by glomerular filtration and tubular secretion via OAT3. Ciprofloxacin is also metabolized and partially cleared through the bile and intestine. Dolutegravir is not expected to inhibit OAT3 and lamivudine is eliminated by other renal transporters.,""
115832,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clarithromycin is a strong inhibitor of CYP3A4, but CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
115834,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4 with some metabolites having antibacterial activity. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115835,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. Three metabolites, two glucuronides, have been identified in urine, As glucuronidation has a minor role in clofazimine elimination, an interaction with dolutegravir via this mechanism is unlikely. An interaction with lamivudine via competition for renal elimination pathways is unlikely as renal excretion has a minor role in clofazimine elimination.",""
115836,"Coadministration has not been studied. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted via glomerular filtration and tubular secretion. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction as total renal elimination of cloxacillin represents approximately 35% of a dose. There is little potential for significant interactions with lamivudine via competition for renal transport.",""
115837,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly excreted renally via glomerular filtration. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
115838,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapsone is mainly metabolized by N-acetylation with a component of N-hydroxylation, and is via multiple CYP P450 enzymes. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115839,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Dolutegravir does not affect CYP enzymes. No interaction is expected with lamivudine.",""
123640,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sunitinib is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with sunitinib. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
115840,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No significant metabolism of doxycycline occurs and it is cleared intact by renal and biliary mechanisms. No interaction is expected with dolutegravir and there is little potential for a clinically significant interaction with lamivudine via competition for renal elimination transport mechanisms.,""
115842,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erythromycin is considered to be a moderate inhibitor of CYP3A4 but CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
115844,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolized in the liver with animal studies suggesting involvement of flavin-containing monooxygenases. No interaction is expected with dolutegravir. There is little potential for an interaction with lamivudine via competition for renal elimination pathways as less than 1% of the oral dose is excreted as ethionamide in urine.,""
115846,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
115847,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and, to a lesser extent, by active tubular secretion. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms as probenecid (an inhibitor of renal tubular excretion) had minimal effect on plasma levels of imipenem. ",""
115850,"Coadministration has not been studied. Levofloxacin is metabolised to a very small extent and is eliminated renally mainly by glomerular filtration and active secretion (possibly OCT2). No interaction is expected with dolutegravir. In vitro data indicate that levofloxacin inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown given the good tolerability of lamivudine.",""
115855,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug. In vitro studies indicate that dolutegravir does not inhibit UGTs at clinically relevant concentrations. As renal excretion is not the predominant mechanism of elimination, there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115856,"Coadministration has not been studied. Ofloxacin is eliminated unchanged in the kidneys by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with ofloxacin. Lamivudine is eliminated by OCT2 and in vitro data indicate that ofloxacin inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown given the good tolerability of lamivudine.",""
115857,"Coadministration has not been studied. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that dolutegravir inhibits OCT2 and may increase the exposure of para-aminosalicylic acid. In addition, as para-aminosalicylic acid and lamivudine are predominantly renally eliminated, including by active tubular secretion, there is potential for competition for elimination via renal transport proteins, which may lead to increased concentrations of either drug. The clinical relevance of this interaction is unknown.",""
115858,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Dolutegravir is not expected to inhibit OAT and lamivudine is eliminated by different transporters.,""
123643,Coadministration has not been studied. Tacrolimus inhibits CYP3A4 and OATP1B1 in vitro but produced modest inhibition of CYP3A4 and OATP1B1 in the range of clinical concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Rilpivirine is metabolised mainly by CYP3A4 and is transported by OATP1B1 and concentrations could potentially increase but not to a clinically relevant extent.,""
115866,"Coadministration has not been studied. Sulfadiazine is metabolized in part by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Sulfadiazine has been associated with crystalluria leading to renal toxicity and in some cases renal failure, and case reports in immunocompromised patients have suggested that AIDS patients may be particularly prone to sulfadiazine-induced renal toxicity. As lamivudine is predominantly excreted via active renal transport, monitoring of renal function is warranted if sulfadiazine is administered with lamivudine.",""
115867,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telithromycin is metabolized by CYP3A4. Dolutegravir does not affect CYP enzymes. No interaction is expected with lamivudine.,""
115862,"Coadministration with dolutegravir/lamivudine has not been studied. No significant interaction is expected with lamivudine. However, coadministration may substantially decrease dolutegravir concentrations as rifapentine has a comparable inducing effect to rifampicin. Although no dosing recommendations are provided for rifapentine, the European and US labels for Dovato recommend that an additional dolutegravir 50 mg tablet, separated by 12 hours from Dovato, should be taken with rifampicin. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.&nbsp;In healthy volunteers receiving weekly rifapentine and isoniazid, the addition of dolutegravir resulted in flu-like symptoms and LFT elevations in 2 out of 4 patients, leading to study termination. Intolerance was hypothesized be related to rifapentine (+/- healthy volunteer status) rather than isoniazid, since in the INSPIRING study the addition of dolutegravir to daily rifampicin and isoniazid was well tolerated in HIV-TB co-infected adults. Thus, the coadministration of dolutegravir (50 mg once daily) and rifapentine/isoniazid once weekly was evaluated again in HIV infected individuals and was well tolerated in persons living with HIV (no Grade &gt;3 adverse effects). Dolutegravir Ctrough and AUC were reduced by ~50% and ~30% but median values at all time points were above 300 ng/ml. Virologic suppression was maintained throughout the TB treatment.&nbsp;Close monitoring of HIV infection is also recommended when using rifapentine once weekly with a daily dose of Dovato considering the limited experience when coadministering inducers with dual antiretroviral regimens.",""
115870,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via renal glomerular filtration. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
115871,Coadministration has not been studied but based on metabolism and clearance a significant interaction is unlikely. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115872,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Dolutegravir is mainly metabolized by UGT1A1 and is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115873,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of dolutegravir or lamivudine.",""
115875,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betrixaban is largely eliminated unchanged through biliary secretion via P-gp. Dolutegravir does not inhibit or induce P-gp and no interaction is expected with lamivudine.,""
115876,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115877,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP450 isoenzymes and is mainly cleared by glomerular filtration. The prodrug of dabigatran is a substrate of P-gp and in vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. There is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
115879,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Dolutegravir does not inhibit or induce these UGTs. No interaction is expected with lamivudine.",""
123644,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123645,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123646,"Coadministration has not been studied. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. However, tamoxifen induces CYP3A4 and could potentially decrease rilpivirine exposure. No significant effect is expected on cabotegravir based on the drug interaction study with rifabutin (a moderate inducer).",""
115880,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is eliminated primarily as unchanged drug in urine. Edoxaban is minimally metabolised by hydrolysis (mediated by carboxylesterase 1), conjugation, or oxidation by CYP3A4/5 (<10%). Edoxaban is a substrate for P-gp but dolutegravir does not inhibit or induce P-gp. There is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
115881,"Coadministration has not been studied. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8) and in vitro data indicate it is an inhibitor of UGTs 1A1 and 1A3. Although eltrombopag could potentially increase dolutegravir exposure, this is unlikely to be of clinical significance. No interaction is expected with lamivudine.",""
115885,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115887,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). In vitro data indicate that dolutegravir does not inhibit P450 isoenzymes or the efflux transporters P-gp, BCRP at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115888,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Renal elimination of unchanged streptokinase is minimal. No interaction is expected with dolutegravir and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
115890,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYP1A2 and 3A4. S-warfarin (more potent) is metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115892,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4 and does not induce metabolizing enzymes. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115894,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is mainly metabolized by CYP3A4 and does not induce metabolizing enzymes. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115896,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (approximatively 30% of the dose) and is eliminated unchanged through the kidneys (approximately 40% of the dose). ,""
115897,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115941,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3. Dolutegravir is unlikely to affect the metabolism of empagliflozin and empagliflozin is unlikely to affect dolutegravir concentrations as it does not inhibit or induce CYPs and does not inhibit UGTs. No interaction is expected with lamivudine.",""
115893,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied but is expected to decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by eslicarbazepine. Although no dosing recommendations are provided for eslicarbazepine, the US Prescribing Information for Dovato does not recommend coadministration with carbamazepine, another anticonvulsant with inducing properties. However, the European label for Dovato recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Dovato, can be taken in presence of carbamazepine. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.&nbsp;No significant interaction is expected with lamivudine.",""
115904,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolised by CYP3A4/5. Neither dolutegravir nor tiagabine induce or inhibit CYP450 enzymes. No interaction is expected with lamivudine.,""
115905,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Weak induction of CYP isozymes has been observed with higher doses of topiramate but this is not considered to be of clinical relevance with dolutegravir. No interaction is expected with lamivudine.,""
115908,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. Zonisamide is a weak inhibitor of P-gp but is unlikely to have a significant effect on dolutegravir exposure. No interaction is expected with lamivudine.,""
115909,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115910,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115911,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolized by CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115912,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115913,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115914,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115915,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115916,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115917,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolized by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115918,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by CYPs 2C19 and 3A4 to form norfluoxetine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115919,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123647,"Coadministration has not been studied, but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
115943,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115944,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115945,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is metabolised by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115946,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipazide is metabolized mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115948,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces, with metabolism by CYP3A4 representing a minor elimination pathway. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115949,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Liraglutide is degraded by endogenous endopeptidases.,""
115951,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolized by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115952,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115953,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYPs 2C8 and 3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115954,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115955,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115956,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp), with metabolism by CYP3A4 representing a minor elimination pathway. Dolutegravir is not expected to inhibit these transporters at clinically relevant concentrations. Although metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD), a clinically significant increase is unlikely as sitagliptin is mainly eliminated unchanged and has a large safety window, and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115957,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115961,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. In vitro data indicate that caspofungin is a substrate of the hepatic transporter OATP1B1, but there is no evidence that dolutegravir inhibits OATP1B1. No interaction is expected with lamivudine.",""
115962,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is mainly eliminated renally by glomerular filtration and is a moderate inhibitor of CYP3A4. A clinically significant interaction is not expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
115963,Coadministration has not been studied. Flucytosine is metabolised to 5-flurouracil which is further metabolised by dihydropyrimidine dehydrogenase. This enzyme is also involved in the catabolic pathway of pyrimidine analogs (such as lamivudine) and competition could potentially increase haematological toxicity. Monitor haematological parameters and consider dose reduction if required. No interaction is expected with dolutegravir.,""
115964,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Griseofulvin is a liver microsomal enzyme inducer but a clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys and there is little potential for an interaction via competition with lamivudine for renal elimination pathways. ,""
115965,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Itraconazole is metabolized by CYP3A4 and is a strong inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
115966,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketoconazole is metabolized by CYP3A4 and is a strong inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
115967,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Miconazole inhibits CYP2C9 and CYP3A4 but a clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
115969,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4). Posaconazole is a strong inhibitor of CYP3A4. A clinically significant interaction is not expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115970,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYP2C8 and 2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115971,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Voriconazole is metabolised by CYPs 2C19, 2C9 and 3A4 and is a strong inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115974,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized in the liver via CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Approximately 22% of a chlorphenamine dose is excreted unchanged in the urine and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
115975,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115976,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine does not undergo CYP-mediated metabolism but is a substrate of P-glycoprotein. In vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115978,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115979,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123648,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol is mainly glucuronidated by UGT1A6, UGT1A9 and UGT2B7. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
115980,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115982,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroergotamine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115983,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115987,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolised via UGT1A9 and 2B7. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
115989,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Benznidazole undergoes non-CYP mediated metabolism and partly CYP mediated metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Renal elimination of unchanged benznidazole appears to be minimal and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
115990,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Due to the multiple elimination pathways, a clinically significant interaction with lamivudine is unlikely.",""
116006,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinine is extensively metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115992,"Coadministration has not been studied. Approximately 80% of oral/intravenous doses of eflornithine are excreted unchanged via the kidneys. No interaction is expected with dolutegravir. As there are no available data determining whether excretion is via active tubular secretion or glomerular filtration, there is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. Clinically significant interactions are not expected with topical preparations as <1% of topically applied eflornithine is systemically absorbed.",""
115993,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115995,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
115996,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meglumine antimoniate is predominantly eliminated unchanged via renal glomerular filtration. No interaction is expected with dolutegravir and there is little potential for an interaction via completion with lamivudine for active renal transport mechanisms.,""
115997,"Coadministration has not been studied. Based on limited data concerning metabolism, elimination and toxicity of melarsoprol, there is little potential for interaction, although due to the lack of available data, vigilance is required if administering melarsoprol with antiretrovirals. It is unknown whether urinary metabolites of melarsoprol, such as arsenic, are excreted via active renal mechanisms, however a clinical study has reported that urinary pharmacokinetic parameters are not predictive of toxicity or therapeutic efficacy. Therefore lamivudine has little potential to effect melarsoprol treatment via competition for renal elimination mechanisms.",""
116014,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123649,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is only minimally metabolised and is eliminated renally via glomerular filtration and active secretion by OAT1/3. Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3. Likewise, rilpivirine does not inhibit OATs.",""
123651,"Coadministration has not been studied. Telithromycin metabolised by and is a strong inhibitor of CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with telithromycin. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
115998,"Coadministration has not been studied. Based on limited data concerning metabolism, elimination and toxicity of miltefosine, there is little potential for interaction. In vitro studies have shown that interactions between miltefosine and drugs which are metabolised by cytochrome P450, glucuronidated or otherwise conjugated are unlikely. The main metabolic pathway of miltefosine appears to be mediated by phospholipases. Only a very small proportion of an administered dose of miltefosine is excreted in the unchanged form, therefore there is little potential for an interaction with lamivudine via competition for renal elimination pathways. A case report describes two patients who were taking a regimen of stavudine, lamivudine and nevirapine who were safely and effectively treated with miltefosine.",""
115999,"Coadministration has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, there is little potential for interaction, although due to the lack of data, vigilance is required if administering nifurtimox with antiretrovirals. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase, with <1% of a dose excreted unchanged via the kidneys. No interaction is expected with dolutegravir and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116000,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paromomycin is not metabolized and is eliminated unchanged by renal glomerular filtration. No interaction with dolutegravir is expected and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116001,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The exact metabolic pathway of pentamidine has not been clearly established. Data from animal studies suggest the involvement of CYPs 1A1, 2D6 and 2C19 in the oxidative metabolism of pentamidine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116002,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperaquine is mainly metabolized by CYP3A4 and is a modest inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is unlikely as CYP3A4 plays a minor role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116003,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116004,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116005,Coadministration has not been studied. No interaction is expected with dolutegravir but in vitro data suggest that pyrimethamine inhibits the renal transporters OCT2 and MATE1 and may increase concentrations of lamivudine. No a priori dosage adjustment is recommended in patients with normal renal function.,""
116007,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elimination of sodium stibogluconate is predominantly via renal glomerular filtration. No interaction is expected with dolutegravir. Renal elimination of sodium stibogluconate has been found to be similar to the rate of glomerular filtration and there is little potential for an interaction with lamivudine via competition for active renal transport mechanisms.,""
116008,"Coadministration has not been studied. Sulfadoxine is rarely used alone, but is usually given in combination with pyrimethamine. No interaction is expected with dolutegravir, however, in vitro data suggest that pyrimethamine inhibits the renal transporters OCT2 and MATE1 and may increase concentrations of lamivudine. No a priori dosage adjustment is recommended in patients with normal renal function.",""
116009,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally, possibly via OCT. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with amisulpride. There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in amisulprideâ€™s elimination.",""
116010,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolized by CYP3A4 and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116011,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (CYP1A2 (major) and CYP3A4, 2D6 (minor)). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116012,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116013,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116015,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116016,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116017,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116018,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116019,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly OCT), with minimal metabolism occurring via CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with paliperidone. There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in paliperidoneâ€™s elimination.",""
116020,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116021,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116022,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116030,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116031,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. Dolutegravir undergoes only minimal metabolism via CYP3A4 and does not inhibit or induce CYPs. No interaction is expected with lamivudine.,""
116032,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116088,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simeprevir is metabolized by CYP3A4. Dolutegravir is mainly metabolised by UGT1A1 with limited CYP3A4 involvement. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123652,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123653,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated. Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123654,Coadministration has not been studied. Temsirolimus is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Temsirolimus inhibits CYP3A4 and may increase rilpivirine although to a limited extent. No dose adjustment is required. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
116083,"Coadministration has not been studied. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and dolutegravir alone (50 mg once daily) or abacavir/lamivudine alone (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, dolutegravir or lamivudine. No dose adjustment is required.",""
123655,"Coadministration with intramuscular cabotegravir and rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of oral rilpivirine (25 mg once daily) and tenofovir alafenamide (25 mg once daily) had no significant effect on the pharmacokinetics of rilpivirine (AUC and Cmin increased by 1% and 13%, Cmax decreased by 7%). Tenofovir alafenamide Cmax and AUC were unchanged. Tenofovir Cmax, AUC and Cmin increased by 13%, 11% and 18%, respectively. No dose adjustment of tenofovir alafenamide or oral rilpivirine is required. Similarly, no dose adjustment is needed with intramuscular rilpivirine and cabotegravir.",""
116179,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite. No interaction is expected with dolutegravir or lamivudine.,""
116052,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. Dovato contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine.",""
116070,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by different renal transporters.,""
116071,"Coadministration with dolutegravir/lamivudine has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter. Coadministration of adefovir dipivoxil (10 mg) and lamivudine (100 mg) did not alter the pharmacokinetic profile of either drug. However, as adefovir is nephrotoxic, renal function should be monitored.",""
116072,"Coadministration has not been studied. Amantadine is mainly eliminated in the kidney by glomerular filtration and active secretion via OCT2. There is potential for dolutegravir to increase amantadine exposure via inhibition of OCT2 but the clinical relevance of this is unknown. There is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
116074,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1 and OAT3. Dolutegravir is not expected to inhibit these renal transporters. No interaction is expected with lamivudine.,""
116077,"Coadministration with dolutegravir/lamivudine has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anions and cations transporters. Dolutegravir is not expected to inhibit OATs. In vitro data indicate that dolutegravir inhibits OCT, but is unlikely to cause a clinically relevant drug interaction with entecavir. No pharmacokinetic interactions were observed between entecavir and lamivudine.",""
116078,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase which is then eliminated in the urine, possibly by OAT1. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by different transporters.",""
116080,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ganciclovir is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OAT1. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by different transporters.,""
116136,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116068,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. If intensification of HIV treatment is needed, alternatives to saquinavir should be considered.&nbsp;",""
116101,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116102,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116075,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of dolutegravir (50 mg once daily) and daclatasvir (60 mg once daily) had no significant effect on daclatasvir AUC (2% decrease), Cmax (3% increase) or Cmin (6% increase). There was no clinically relevant change in dolutegravir exposure (AUC, Cmax and Cmin increased by 33%, 29% and 45%, respectively). No interaction with lamivudine is expected.",""
116082,"Coadministration with dolutegravir/lamivudine has not been studied. Although concentrations of dolutegravir may increase due to inhibition of P-gp and BCRP by ledipasvir, any increase is unlikely to be clinically significant. Coadministration of lamivudine (in combination with abacavir) and ledipasvir/sofosbuvir had no effect on the pharmacokinetic parameters of lamivudine, ledipasvir or sofosbuvir. Lamivudine Cmax and AUC decreased by 7% and 6% and Cmin increased by 12%; abacavir Cmax and AUC decreased by 8% and 10%. Ledipasvir Cmax, AUC and Cmin increased by 10%, 18% and 26%; sofosbuvir Cmax and AUC increased by 8% and 21%; AUC and Cmin of GS-331007 increased by 5% and 8% with no change in Cmax. No dose adjustment is required.",""
116085,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases. The latter is excreted in the urine by glomerular filtration and tubular secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by different transporters.,""
116087,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated. Dolutegravir is not expected to inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116091,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No clinically significant drug interactions have been observed with dolutegravir and sofosbuvir/velpatasvir and no additional effect is likely with the addition of voxilaprevir. Lamivudine is not expected to inhibit or induce any relevant metabolic enzymes or transporters of sofosbuvir, velpatasvir or voxilaprevir.",""
116094,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by different transporters.,""
116096,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116097,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Drug-drug interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116098,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116092,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily by urinary excretion as unchanged drug. The renal clearance of telbivudine approaches normal glomerular filtration rate, suggesting that filtration is the main mechanism of excretion. No interaction is expected with dolutegravir. Coadministration of telbivudine (200 mg once daily) and lamivudine (100 mg once daily) to 16 subjects had no significant effect on telbivudine Cmax and AUC (both increased by ~6%) or lamivudine Cmax and AUC (decreased by 14% and 1%). Although doses studied were lower than used in clinical practice, no interaction is expected at clinically relevant doses.",""
116103,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116104,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116105,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116106,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116107,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is mainly glucuronidated (by UGTs 2B15, 2B4, 2B7, 1A7, 1A10). Dolutegravir is mainly glucuronidated by UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116108,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated (possibly by UGTs 2B15, 1A9 and 2B7). Dolutegravir is mainly glucuronidated by UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116111,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated (by UGTs 2B15, 1A9 and 2B7). Dolutegravir is mainly glucuronidated by UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116112,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated, but there is no evidence that temazepam is a substrate of UGT1A1, the major enzyme involved in dolutegravir metabolism. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116113,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116114,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116115,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116116,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116133,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olodaterol is metabolized by CYP2C8, CYP2C9, is glucuronidated via several UGTs, and is a substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116117,"Coadministration has not been studied. Atenolol is mainly eliminated by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. There is potential for dolutegravir to increase atenolol exposure via inhibition of OCT2. Based on the drug-drug interaction study with metformin (another drug transported by OCT2 and MATE1), the increase in atenolol exposure is expected to be ~80% or ~110% when dolutegravir is administered once daily and twice daily, respectively. There is potential for competition with atenolol and lamivudine for elimination via renal transport proteins, which may lead to increased concentrations of either drug. It is recommended to start atenolol at a lower dose and adjust dosage until the desired clinical effect is achieved.",""
116137,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116118,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Lamivudine is eliminated by OCT2 and in vitro data indicate that bisoprolol inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown given the good tolerability of lamivudine.",""
116119,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116120,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116121,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116122,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised by glucuronidation. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116123,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116124,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116125,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when timolol is used either orally or as eye drops. Timolol is predominantly metabolised by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116127,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Theophylline is mainly metabolized by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116128,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116130,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is eliminated partly unchanged (33%) and partly metabolized by CYP3A4 and UGT1A1, and is a weak substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116132,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116134,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Roflumilast is metabolized by CYP3A4 and CYP1A2 to form roflumilast N-oxide, with both roflumilast and roflumilast N-oxide having PDE4 inhibitory activity. Roflumilast N-oxide is subsequently dealkylated by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116135,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4â€™-O-sulphate. No interaction is expected with dolutegravir or lamivudine.,""
116138,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiotropium bromide is predominantly excreted unchanged in the urine. Metabolism by CYP2D6 and CYP3A4 is only a minor role in its elimination. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116139,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Umeclidinium bromide is mainly metabolized by CYP2D6 and is a substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116140,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116141,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116142,Coadministration has not been studied. Diltiazem is metabolized by CYP3A4 and is a moderate inhibitor of CYP3A4. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116143,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116144,"Coadministration has not been studied. Nicardipine is metabolised mainly by CYP3A4, and to a lesser extent by CYPs 2D6 and 2C8, and inhibits CYP3A4. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116145,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116146,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116147,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116148,Coadministration has not been studied. Verapamil is metabolised mainly by CYP3A4 and is a moderate inhibitor of CYP3A4. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116149,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116150,Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Limited data suggest that asparaginase is likely to be eliminated by the reticulo endothelial system. Less than 0.1% of a total injected dose is recovered in urine.,""
116154,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent CYP1A2, 2D6 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116155,Coadministration has not been studied. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as lamivudine may compete for these metabolic pathways. The clinical relevance of this interaction is unknown. No interaction is expected with dolutegravir.,""
116156,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carboplatin is excreted primarily by renal glomerular filtration and there is little potential for a pharmacokinetic interaction.,""
116177,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Dolutegravir is not expected to induce or inhibit UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116159,"Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1. In vitro data indicate that dolutegravir is a moderate inhibitor of OCT2. Inhibition of OCT2 will lead to lower concentrations of cisplatin inside the tubular cell which represents an advantage as this may reduce the risk of cisplatin related nephrotoxicity. However, cisplatin and lamivudine could potentially compete for OCT2 which could slow their elimination. Furthermore, cisplatin may impair the renal function. Closely monitor creatinine clearance.",""
116160,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116161,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cytarabine is metabolized by cytidine deaminase. No interaction is expected with dolutegravir or lamivudine.,""
116162,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine is activated to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116163,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dactinomycin is minimally metabolized.,""
116164,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dasatinib is metabolized by CYP3A4 and inhibits this same enzyme. A clinically significant interaction is not expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116166,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Docetaxel is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116168,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Droloxifene is mainly glucuronidated. Dolutegravir is not expected to induce or inhibit UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116169,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Epirubicin is glucuronidated by UGT2B7. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116170,"Coadministration has not been studied. Erlotinib is mainly metabolized by CYP3A4, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Erlotinib is a strong inhibitor of UGT1A1 in vitro and could increase dolutegravir concentrations, however, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with lamivudine.",""
116172,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. Furthermore, etoposide is partly glucuronidated by UGT1A1. Dolutegravir is not expected to inhibit or induce CYPs or UGTs enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116173,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Everolimus is metabolized by CYP3A4 and is a modest inhibitor of CYP3A4 in vivo. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116174,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116176,"Coadministration has not been studied. Fluorouracil is metabolised via the same mechanisms as endogenous uracil, including via dihydropyrimidine dehydrogenase. There is little potential for an interaction with dolutegravir via modulation of, or competition for, metabolic pathways. However, nucleoside analogues such as lamivudine may compete for this metabolic pathway. The clinical relevance of this interaction is unknown.",""
123657,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terazosin is extensively metabolized in the liver possibly via CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123658,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYPs 2C8 and 2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123659,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Terfenadine undergoes extensive metabolism by CYP3A4. Cabotegravir and rilpivirine have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with terfenadine. However, given the QT prolongation risk associated with terfenadine, caution is recommended.",""
116180,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ifosfamide is predominantly metabolized by CYP3A4 and CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116181,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent CYPs 1A2, 2D6, 2C9, 2C19. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9, 2C19. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116182,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. SN38 is further inactivated by several UGTs. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116183,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lapatinib is metabolized by CYP3A4 and inhibits this same enzyme. Lapatinib does not significantly inhibit renal transporters (OAT, OCT). A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116184,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116185,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is predominantly metabolised by xanthine oxidase. No interaction is expected with dolutegravir or lamivudine.,""
116186,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesna is rapidly oxidised to its only metabolite, mesna disulphide via the physiological cysteine system. Approximately 32% and 33% of an administered dose is eliminated in the urine in 24 hours as mesna and mesna disulphide respectively. No interaction is expected with dolutegravir. In vitro data suggest that mesna is a substrate of the OAT1, OAT3 and OAT4 renal transporters whereas lamivudine is transported by OCT2. ",""
116201,"Coadministration has not been studied. Vinblastine is metabolized by CYP3A4 and is excreted primarily by the biliary route. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. However, in vitro data suggest that vinblastine activates PXR and therefore could potentially decrease dolutegravir concentrations via induction of UGT1A1. Monitor response to antiretroviral therapy. No interaction is expected with lamivudine.",""
116188,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116189,"Coadministration has not been studied. Nilotinib is metabolized by CYP3A4 and inhibits this same enzyme. Furthermore, in vitro data indicate that nilotinib inhibits UGT1A1. Nilotinib could potentially increase dolutegravir concentrations via UGT1A1 and CYP3A4 inhibition. However, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with lamivudine.",""
116190,"Coadministration has not been studied. Oxaliplatin undergoes non enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. In vitro data indicate that dolutegravir is a moderate inhibitor of OCT2. Although inhibition of OCT2 may represent an advantage in terms of nephrotoxicity, inhibition may impair the response to oxaliplatin chemotherapy. OCT2 is expressed in some tumour cells where it will facilitate the entry of cytostatic agents such as oxaliplatin (but not cisplatin) inside the tumour cell. Dolutegravir, an inhibitor of OCT2, could potentially decrease the efficacy of oxaliplatin. Oxaliplatin and lamivudine could potentially compete for OCT2 which could slow their elimination. Monitor side effects. ",""
116191,Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. In vitro data suggest that paclitaxel activates PXR and therefore could potentially decrease dolutegravir concentrations via induction of UGT1A1. Monitor response to antiretroviral therapy. No interaction is expected with lamivudine.,""
123660,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
116192,"Coadministration has not been studied. Pazopanib is metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C8. Dolutegravir is not expected to inhibit or induce CYPs enzymes at clinically relevant concentrations. In vitro data indicate that pazopanib inhibits UGT1A1 and therefore could potentially increase dolutegravir concentrations. However, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with lamivudine.",""
116193,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and 1A) and monoamine oxidase. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116195,"Coadministration has not been studied. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Sorafenib inhibits UGT1A1 and UGT1A9 and therefore could potentially increase dolutegravir concentrations, however, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with lamivudine.",""
116196,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sunitinib is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116197,"Coadministration has not been studied but based on the metabolic profiles of the drugs there is little potential for pharmacokinetic interaction. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4.",""
116198,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4 and inhibits CYP3A4. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116199,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration. Topotecan is a substrate for P-gp and BCRP and concomitant use of P-gp and BCRP inhibitors has been shown to increase topotecan exposure. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116200,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116203,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated). Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116204,Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116205,Coadministration with a desogestrel-containing progestogen-only pill (POP) has not been but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116206,Coadministration with a drospirenone-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir does not interact with these metabolic pathways and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116207,Coadministration with drospirenone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
123664,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116208,Coadministration with dydrogesterone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116209,"Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116211,Coadministration with an etonogestrel-containing progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116212,Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116213,Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir does not inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine,""
116214,Coadministration with a levonorgestrel-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116215,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116216,Coadministration with levonorgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116217,Coadministration with a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116219,Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116221,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116222,Coadministration with transdermally delivered norelgestromin/ethinylestradiol has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116223,Coadministration of a combined oral contraceptive (COC) containing norethisterone and mestranol or ethinylestradiol has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Mestranol is rapidly and almost completely converted to ethinylestradiol by CYP2C9; ethinylestradiol is mainly metabolised by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116388,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116224,Coadministration with norethisterone as hormone replacement therapy (HRT) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116225,Coadministration of a norethisterone IM depot injection has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116226,Coadministration of a norethisterone progestogen-only pill (POP) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116228,Coadministration of a combined oral contraceptive (COC) containing norgestrel/ethinylestradiol has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir does not inhibit or induce CYP450 or UGT enzymes and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with lamivudine.,""
116229,Coadministration with norgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116230,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is metabolized mainly by CY3A4 and to a lesser extent by CYPs 1A2 and 2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116231,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Dolutegravir is mainly metabolized by UGT1A1 and is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116239,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisapride is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116244,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is metabolized by CYP2C8 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116245,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase. No interaction is expected with dolutegravir or lamivudine.,""
116241,Coadministration has not been studied. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%). Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with lamivudine.,""
116268,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Echinacea has a selective effect on CYP3A4 activity (inhibition of intestinal CYP3A4 and induction of hepatic CYP3A4) and its effect on the net exposure of a CYP3A4 substrate will depend on the extraction of the drug at the intestinal and hepatic sites. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
116269,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence to suggest that eucalyptus impacts UGTs. ,""
116272,"Coadministration has not been studied. Garlic has been shown to induce intestinal CYP3A4 and/or P-gp and garlic supplements decreased unboosted saquinavir AUC by 50% in a clinical trial and there is a case report of treatment failure due to garlic cloves (six garlic cloves three times weekly) decreasing ritonavir-boosted atazanavir trough concentrations by ~70%. Similarly, concentrations of dolutegravir could be decreased via induction of CYP3A4 and/or P-gp. Patients should be advised against the use of garlic supplements. No interaction is expected with lamivudine.",""
116273,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence to suggest that ginger inhibits or induces UGTs.,""
116274,"Coadministration has not been studied. Ginkgo biloba induces CYP3A4 and may decrease dolutegravir concentrations, but the magnitude and clinical relevance of this potential interaction is difficult to predict as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine. ",""
116238,Coadministration with dolutegravir/lamivudine has not been studied. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction was observed with lamivudine.,""
116247,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with lamivudine.,""
116253,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116254,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Domperidone is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. ,""
116255,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116256,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Granisetron is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116257,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116258,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116259,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116260,Coadministration has not been studied. African potato was shown to inhibit CYP3A4 and P-gp in vitro and to activate PXR suggesting that inhibition may occur initially followed by induction of CYP3A4 and P-gp when used for extended periods. Use with caution as African potato could decrease concentrations of dolutegravir. Therapeutic drug monitoring of dolutegravir is recommended. No interaction is expected with lamivudine.,""
116264,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Catâ€™s claw was demonstrated to strongly inhibit CYP3A4 in vitro but CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
116266,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence to suggest that Piper cubeba impacts UGTs.,""
123666,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Thiamine can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
116275,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goldenseal has been shown to inhibit CYP3A4 in vitro but not in vivo. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
116276,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inhibition of intestinal CYP3A4 by grapefruit juice is unlikely to alter significantly dolutegravir concentrations as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
116277,"Coadministration has not been studied. In vitro data indicate that extracts of hops activate PXR and induce expression of CYP3A4, CYP2B6 and MDR1 genes to a degree similar to that of St John's wort. The magnitude and clinical relevance of a potential interaction with dolutegravir is difficult to predict as CYP3A4 does not play a major role in dolutegravir metabolism. Patients should be monitored carefully regarding their HIV infection. No interaction is expected with lamivudine.",""
116281,"Coadministration has not been studied. Glycyrrhizin, the main active component of Glycyrrhiza glabra, is a modest inducer of CYP3A4 and could potentially decrease the exposure of dolutegravir, although to a modest extent as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
116282,"Coadministration has not been studied. Magnesium is eliminated in kidney, mainly by glomerular filtration. Dolutegravir binds to divalent cations, such as magnesium, and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed. No interaction is expected with lamivudine. When taken with food, Dovato (dolutegravir/lamivudine) and supplements containing magnesium can be taken at the same time. Under fasting conditions, Dovato should be taken 2 hours before or 6 hours after taking supplements containing magnesium.",""
116382,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of bezafibrate dose is eliminated unchanged in the urine and in vitro data suggest that bezafibrate inhibits the renal transporter OAT1. No interaction is expected with dolutegravir or with lamivudine as it is excreted by different renal transporters.,""
116283,"Coadministration has not been studied. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest it could act as an inducer of phase I and phase II metabolic enzymes although the clinical relevance has not been evaluated. In the absence of data, caution is recommended and TDM of dolutegravir should be considered if available. No interaction is expected with lamivudine.",""
116284,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence to suggest that menthol impacts UGTs or P-gp.,""
116290,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inconsistencies in the literature regarding the ability of quercetin to modulate CYP/P-gp activities make it difficult to predict the nature and magnitude of any interaction. However, quercetin is unlikely to produce a large effect on dolutegravir pharmacokinetics as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
116291,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K, a natural component with the same chemical structure as lovastatin. Monacolin K is metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and no interaction is expected with lamivudine.",""
116295,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Seville orange juice inhibits intestinal CYP3A4 but is unlikely to cause a significant effect on dolutegravir exposure as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
123667,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although pentobarbital (a potent inducer of hepatic microsomal drug metabolism) is formed during thiopental metabolism, levels do not reach the therapeutic range. Therefore, cabotegravir and rilpivirine pharmacokinetics are unlikely to be affected significantly by coadministration with thiopental.",""
123668,"Coadministration has not been studied. Thioridazine is a moderate inducer of CYP3A4. Based on the drug-drug interaction study with rifabutin (also a moderate inducer), the decrease in cabotegravir exposure after intramuscular administration is expected to be not clinically relevant. However, thioridazine has the potential to significantly reduce rilpivirine exposure. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. ",""
116301,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability. Dolutegravir is not expected to inhibit or induce CYP450 enzymes and does not inhibit or induce P-glycoprotein in the range of clinically relevant concentrations. No interaction is expected with lamivudine.,""
116302,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116303,Coadministration has not been studied. Amiloride is eliminated unchanged by the kidney and in vitro data indicate that it is a substrate of OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase amiloride exposure. Amiloride may potentially compete with lamivudine for renal elimination transport mechanisms which may lead to increased concentrations of either drug.,""
116304,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%, exact pathway not known) and excreted unchanged in the urine (30%) via OAT1 and OAT3. There is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes. Similarly, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. A drug interaction with lamivudine is unlikely as lamivudine and bendroflumethiazide are eliminated by different renal transporters.",""
116305,Coadministration has not been studied. Bosentan is a substrate and inducer of CYP3A4 and CYP2C9. Bosentan could potentially decrease dolutegravir exposure although to a moderate extent as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.,""
116307,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1 (40-50% as unchanged drug, the rest as disulfide and other metabolites). No interaction is expected with dolutegravir or with lamivudine as it is eliminated by different renal transporters.",""
116310,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose). No interaction is expected with dolutegravir. Clonidine is a weak inhibitor of OCT2 and is unlikely to cause a clinically relevant interaction with lamivudine.",""
116311,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as digoxin is eliminated renally via the renal transporters OATP4C1 and P-glycoprotein. In vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. Lamivudine is excreted by different renal transporters.,""
116312,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Renal elimination of unchanged dopamine is minimal. There is little potential for dopamine to affect the disposition of antiretrovirals, or to be affected if co-administered with antiretrovirals.",""
116313,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116314,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is eliminated renally (possibly via OATs). Dolutegravir is not expected to inhibit OATs and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116319,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations, or to inhibit OATs. No interaction is expected with lamivudine as lamivudine is excreted by different renal transporters.",""
116320,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Renal elimination of unchanged hydralazine is minimal. No interaction is expected with dolutegravir and there is little potential for interaction with lamivudine via competition for renal elimination pathways.,""
116321,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. No interaction is expected with dolutegravir or with lamivudine which is excreted by different renal transporters.,""
123669,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolised by CYP3A4/5. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
116322,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloprost is extensively metabolized via beta oxidation of the carboxyl side chain with only a minor role for CYP metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116323,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP450. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. In vitro data suggest that indapamide inhibits OAT3 but lamivudine is excreted by different renal transporters.,""
116324,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Irbesartan is metabolized by glucuronidation and oxidation (mainly CYP2C9). Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116325,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver, with less than 30% of a dose undergoing subsequent glucuronidation. There is little potential for clinically significant interaction with dolutegravir via competition for glucuronidation pathways. As renal elimination of unchanged drug is a minor pathway, there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116326,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116327,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7. Dolutegravir does not induce or inhibit UGTs in the range of clinical concentrations. No interaction is expected with lamivudine.,""
116328,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116329,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116331,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116332,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116333,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged, and as the mono-O-sulfate conjugate. No interaction is expected with dolutegravir and there is little potential for interaction with lamivudine for active renal transport mechanisms.",""
116334,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. No interaction is expected with dolutegravir and there is no evidence that metolazone inhibits the renal transporters involved in the elimination of lamivudine.,""
116339,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Dolutegravir is not expected to interfere with these metabolic pathways. No interaction is expected with lamivudine.",""
116340,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116341,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, CYP2J2 and is also eliminated unchanged in the bile and renally. Riociguat is a substrate of P-gp and BCRP. Dolutegravir and lamivudine do not interfere with riociguat metabolism.",""
123670,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as tiapride is excreted largely unchanged in the urine. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with tiapride. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
123671,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticagrelor undergoes extensive CYP3A4 metabolism and is only a mild inhibitor of CYP3A4. Cabotegravir and rilpivirine have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. ,""
116343,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Dolutegravir and lamivudine do not interfere with selexipag metabolism.,""
116345,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little or no renal elimination of unchanged drug. There is little potential for sodium nitroprusside to affect the disposition of antiretrovirals, or to be affected if coadministered with antiretrovirals.",""
116346,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolized by the flavin containing monooxygenases. ,""
116348,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Dolutegravir undergoes glucuronidation mainly via UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116349,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terazosin is extensively metabolized in the liver possibly via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116350,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolized mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116352,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116355,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4, however, no interaction with dolutegravir is expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
116356,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amphetamine is metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116357,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tetrahydrocannabinol (THC, the psychoactive component of cannabis), is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116358,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cocaine is metabolized by several non CYP mediated pathways, with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116359,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. MDMA is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116360,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116466,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolised predominantly by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116361,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Dolutegravir and lamivudine do not affect these metabolic pathways.",""
116363,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116364,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116365,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116367,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyurea undergoes metabolism via non-CYP mediated metabolism and is unlikely to affect concentrations of dolutegravir or lamivudine. However, hydroxyurea is not licensed for use in combination with stavudine and didanosine as toxicities including pancreatitis and hepatitis (in some cases fatal) in HIV patients have been reported via post marketing surveillance. Thus, caution and monitoring for side effects is recommended if coadministered with other NRTIs such as lamivudine.",""
116370,"Coadministration with dolutegravir/lamivudine has not been studied. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. These pathways are not affected by peginterferon alfa-2a. Results from pharmacokinetic substudies of phase III trials demonstrated no effect of lamivudine on the pharmacokinetics of peginterferon alfa-2a in HBV patients. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
116371,"Coadministration with dolutegravir/lamivudine has not been studied. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. These pathways are not affected by peginterferon alfa-2b. In a trial with another pegylated interferon alfa, no evidence of a pharmacokinetic or pharmacodynamic (e.g., loss of HIV/HCV virologic suppression) interaction was seen when lamivudine and ribavirin were co-administered to 18 HIV/HCV co-infected subjects as part of a multidrug regimen. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
116383,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Dolutegravir is not expected to inhibit OAT1. No interaction is expected with lamivudine as it is excreted by different renal transporters.",""
116385,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116386,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolyzed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. No interaction is expected with dolutegravir. A clinically relevant drug interaction is unlikely with lamivudine as it is excreted by different renal transporters.",""
123672,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116389,"Coadministration has not been studied. Dolutegravir is mainly glucuronidated by UGT1A1 whereas gemfibrozil is mainly glucuronidated by UGT2B7. In vitro data suggest that gemfibrozil inhibits UGT1A1 and UGT1A3 and therefore could potentially increase dolutegravir concentrations. However, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with lamivudine.",""
116390,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116391,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116394,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116395,"Coadministration has not been studied. Acamprosate is eliminated unchanged in the urine both via glomerular filtration and active secretion (exact transporter unknown, possibly OATs or OCTs). No interaction is expected with dolutegravir. There is little potential for a clinically relevant interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in acamprosateâ€™s elimination and the therapeutic index of lamivudine and acamprosate.",""
116396,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion and in vitro studies have shown it may competitively inhibit the renal transporters OAT1, OAT3 and OAT4. No interaction is expected with dolutegravir. A clinically relevant drug interaction is unlikely with lamivudine as it is excreted by different renal transporters.",""
116397,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acitretin undergoes isomerisation and glucuronidation. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116400,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolised mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116402,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. No interaction is expected with dolutegravir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
116405,"Coadministration has not been studied but based on limited information concerning the metabolism and clearance of biperiden, there is little potential for a clinically significant interaction. Limited human data suggest biperiden undergoes hydroxylation in the liver.",""
116406,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caffeine is mainly metabolized by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116407,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. No interaction is expected with lamivudine. In theory, calcium could chelate with dolutegravir and potentially decrease the amount of dolutegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of dolutegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation.",""
123673,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinidazole is partly metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
116409,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole). Despite this potential hepatic metabolism very few data exist on carbimazole drug interactions and a marked interaction is not expected with dolutegravir or lamivudine.",""
116410,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP2D6 is thought to have a role in clomifene metabolism and renal excretion of clomifene is thought to account for approximately 8% of an oral dose. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. There is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
116411,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is a substrate of CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116412,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116413,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway. (Note, caution is required if denosumab is given with calcium supplements as dolutegravir may be subject to chelation by high concentrations of divalent cations which may result in reduced dolutegravir concentrations.)",""
116415,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116416,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116417,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and has been shown to moderately increase the exposure of simvastatin, a CYP3A4 substrate. No interaction is expected with dolutegravir as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A4 plays a minor role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
116421,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116423,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116426,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116428,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly glucuronidated by UGT2B7 and does not induce or inhibit CYP450 enzymes. Dolutegravir is not expected to inhibit or induce UGT enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116468,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4 and is a moderate inducer of CYP3A4. A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentration and CYP3A does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
116430,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Neostigmine is thought to undergo a degree of hepatic metabolism, although the mechanisms are unknown. Metabolism also occurs via hydrolysis by cholinesterase and up to 50% of a dose is excreted unchanged via the kidneys. There is little potential for a clinically significant interaction with antiretrovirals via liver enzyme modification and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
116432,"Coadministration has not been studied. Orlistat should only be used with dolutegravir/lamivudine if separated by 4-5 hours. Orlistat reduces dietary fat absorption and may affect the absorption of antiretrovirals (especially if lipophilic). [Note: this interaction is not specific for dolutegravir/lamivudine, but for any medication taken with orlistat.]",""
116433,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although metabolism of penicillamine is not fully elucidated, multiple mechanisms and sites of metabolism are thought to be involved. There is, low potential for clinically significant interactions with dolutegravir or with lamivudine via competition for active renal elimination pathways.",""
116435,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases. Renal elimination of unchanged pilocarpine is minimal. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
116437,"Coadministration has not been studied. In vitro data suggest that probenecid is a non-selective inhibitor of UGT and coadministration could increase dolutegravir concentrations, but this is unlikely to be of clinical significance. However, probenecid is an inhibitor of tubular secretion and coadministration is likely to increase lamivudine concentrations.",""
116438,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propylthiouracil is extensively metabolised, predominantly via glucuronidation, but the exact glucuronidation pathways are unknown. Renal elimination of unchanged propylthiouracil is minor. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116440,"Coadministration has not been studied. Pyridostigmine is predominantly excreted unchanged via the kidneys, with up to 74% of renal clearance attributed to active tubular secretion (most likely by a cation transporter). In vitro data indicate that dolutegravir inhibits OCT2 and could potentially increase pyridostigmine concentrations. There is also potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. The clinical relevance is unknown.",""
116441,"Coadministration has not been studied. A pharmacokinetic interaction with lamivudine is unlikely as strontium is predominantly eliminated unchanged by the kidneys. However, strontium is a divalent cation and can chelate with dolutegravir thereby reducing its absorption. Separating administration of dolutegravir/lamivudine and strontium ranelate by at least 4 hours is recommended.",""
116442,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. Renal elimination of unchanged sulfasalazine is minimal. There is, therefore, low potential for clinically significant interactions with dolutegravir or with lamivudine via competition for renal elimination pathways.",""
116443,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116447,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Varenicline is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion by OCT2. No interaction is expected with dolutegravir (via inhibition of OCT2) or lamivudine (via competition for active renal transport mechanisms as cimetidine (an inhibitor of renal transporters) was shown to increase varenicline exposure to a limited extent (29%).,""
116450,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116451,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116452,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116453,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116454,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116455,"Coadministration has not been studied. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase trospium exposure, but the clinical relevance of this is unknown. Trospium could potentially compete with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
116457,Coadministration has not been studied. CYP3A4 is thought to be the main enzyme involved in mifepristone metabolism and in vitro studies suggest that mifepristone may inhibit CYP3A4. Renal excretion of mifepristone is thought to account for approximately 10% of an oral dose A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentration and CYP3A does not play a major role in dolutegravir metabolism. There is little potential for interaction with lamivudine via competition for renal elimination pathways.,""
116458,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Misoprostol is predominantly metabolised via fatty acid oxidising systems.,""
116459,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes. However, as few data are available, care should be taken when administering oxytocin with antiretrovirals",""
116464,Coadministration has not been studied. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase pramipexole exposure. Pramipexole may compete with lamivudine for renal elimination transport mechanisms which may lead to increased concentrations of either drug. No a priori dosage adjustment of pramipexole is required unless if the patient presents pramipexole related side effects.,""
116465,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rasagiline is metabolised predominantly by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
123675,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, tipranavir has inducing properties and therefore has the potential to reduce cabotegravir and rilpivirine exposures. ",""
123676,"Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. Tizanidine is metabolised by CYP1A2, which is not inhibited or induced by cabotegravir or rilpivirine. However, rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with tizanidine. Note: the product label indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
116469,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116470,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4 mediated metabolism. Dolutegravir is not expected to interact with ciclesonide metabolism. No interaction is expected with lamivudine.,""
116472,"Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4 and a moderate inducer of this enzyme. Dexamethasone and its metabolites are excreted in the urine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Dexamethasone could potentially decrease dolutegravir concentrations, but this is unlikely to be of clinical significance as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with lamivudine.",""
116473,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116474,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide is metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
116489,"Coadministration has not been studied. Alcuronium is predominantly excreted unchanged via the kidneys. As there are no available data determining whether excretion is via active tubular secretion or glomerular filtration, there is some potential for exposure of alcuronium to be increased since dolutegravir inhibits the renal transporter OCT2. There is also potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of alcuronium or lamivudine. Caution is advised as alcuronium has a narrow therapeutic window. No interaction is expected with abacavir.",""
116493,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly CYP2A Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116494,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enflurane is predominantly metabolized by CYP2E1, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116495,"Coadministration has not been studied. Ephedrine is predominantly eliminated unchanged via the kidneys possibly via the renal transporter OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase the exposure of ephedrine. There is also potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. No interaction is expected with abacavir.",""
116496,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that halothane undergoes oxidation (mainly via CYP2E1 and to a lesser extent CYP2A6) and reduction (via CYP2A6 and CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116532,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116498,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 2B6 and 2C9 in the range of concentrations used in anaesthesia. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116500,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is glucuronidated via UGT1A9, UGT1A8 and is oxidized mainly via CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116501,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally. P-gp was shown to mediate biliary excretion of rocuronium in a rat model, however, in vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116503,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sufentanil undergoes extensive CYP3A4 metabolism, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116504,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Suxamethonium is hydrolysed by plasma cholinesterase and there is little potential for an interaction with dolutegravir or abacavir via modulation of or competition for metabolic pathways. Renal elimination of unchanged suxamethonium is minimal and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
116506,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although pentobarbital (a potent inducer of hepatic microsomal drug metabolism) is formed during thiopental metabolism, levels do not reach the therapeutic range. Therefore, dolutegravir or abacavir pharmacokinetics are unlikely to be affected significantly by coadministration with thiopental. Renal excretion of unchanged thiopental is thought to be minimal so there is little potential for an interaction with lamivudine due to competition for renal elimination pathways.",""
116507,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Tizanidine is metabolised by CYP1A2 which is not inhibited or induced by dolutegravir. No interaction is expected with abacavir or lamivudine.",""
116509,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes CYP3A4 metabolism, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116510,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to salicylic acid and then further metabolized mainly by glucuronidation (by several UGT, major UGT1A6). Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116512,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is metabolised mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116513,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116514,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolized by CYP3A. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116533,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized by CYP3A4 and by the flavine-containing monooxygenase system. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. There is little potential for an interaction via competition with lamivudine for renal elimination pathways.",""
116515,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116516,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9 (catalyzes the major route of diclofenac oxidative metabolism). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116517,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) via CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116518,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116519,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116520,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7, whereas dolutegravir is glucuronidated by UGT1A1. No interaction is expected with abacavir or lamivudine.",""
116521,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116522,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and additionally glucuronidated by UGT2B7 and 1A9. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116524,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116525,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. Naproxen and its metabolites are primarily eliminated by the kidney. In vitro data suggest that naproxen is a weak inhibitor of the renal transporter OCT2. No interaction is expected with abacavir or lamivudine.,""
116526,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116527,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally by CYP3A and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116528,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (via UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15) and sulfation and, to a lesser extent, by oxidation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116529,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116530,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116531,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol is mainly glucuronidated by UGT1A6, UGT1A9 and UGT2B7 and does not induce or inhibit CYP450 enzymes in the range of doses in clinical use. Dolutegravir is glucuronidated by other UGTs. No interaction is expected with abacavir or lamivudine.",""
116535,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest ivermectin is predominantly metabolised by CYP3A4 and does not inhibit metabolic enzymes at clinically relevant concentrations. Similarly, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. There is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116537,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mebendazole is predominantly metabolized in the liver. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Renal excretion of unchanged mebendazole appears to be minimal and there is little potential for an interaction with lamivudine via competition for active renal elimination pathways.,""
116539,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Oxamniquine is thought to be predominantly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Renal excretion of unchanged oxamniquine is minimal and there little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116540,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Praziquantel is predominantly metabolised via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Renal excretion of unchanged praziquantel appears to be minimal and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
116542,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Suramin appears to be eliminated predominantly unchanged via renal glomerular filtration. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction with lamivudine via competition for renal transport pathways.,""
116543,"Coadministration has not been studied. In vitro data suggest that, triclabendazole and its active sulfoxide metabolite are inhibitors of CYP3A4. Coadministration may increase dolutegravir concentrations although to a moderate extent as CYP3A4 does not play a major role in dolutegravir metabolism. Furthermore, due to short term dosing of triclabendazole, the effect on antiretrovirals is likely to be minimal. No interaction is expected with abacavir. Renal excretion of unchanged triclabendazole appears to be minimal (<10%) and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116544,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Amiodarone is metabolized by CYP3A4 and in vitro data suggest it is only a weak inhibitor of CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116545,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Bepridil is metabolized by CYP2D6 (major) and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116546,"Coadministration has not been studied. Disopyramide is metabolized by CYP3A4 (25%) whereas 50% of the drug is eliminated unchanged in the urine (possibly via OCT2). In vitro data indicate that dolutegravir inhibits OCT2 and may increase disopyramide exposure. Caution is warranted and clinical monitoring is recommended if coadministered. No interaction is expected with abacavir Data from animal studies indicate that disopyramide is a weak inhibitor of the renal transporter OCT2. Since OCT2 may contribute to the renal elimination of disopyramide, there is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
123678,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Vitamin E can be found in multivitamin preparations containing polyvalent cations but there is no risk of chelation when cabotegravir is administered intramuscularly. No interaction is expected with rilpivirine.,""
123679,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123680,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. However, multiple oral therapeutic (4 mg) and supratherapeutic (8 mg) doses of tolterodine have been shown to prolong the QTc interval. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with tolterodine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
116548,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion of the parent drug also eliminated unchanged renally. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116589,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. In vitro studies indicate that dolutegravir does not inhibit UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116549,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116550,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116551,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116560,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Dolutegravir is not expected to inhibit this renal transporter and lamivudine is eliminated by other renal transporters. No interaction is expected with abacavir.",""
116561,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration, with no significant active renal tubular secretion. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal elimination transport mechanisms.",""
116562,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine (about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite). In vitro studies indicate that OATs participate to the renal elimination of cefotaxime. Dolutegravir is not expected to inhibit these renal transporters and lamivudine is eliminated by other renal transporters. No interaction is expected with abacavir.",""
116563,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116564,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
116565,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly metabolized by glucuronidation via UGT2B7 whereas dolutegravir is mainly eliminated by glucuronidation via UGT1A1. Dolutegravir is not expected to inhibit UGTs at clinically relevant concentrations. Although, in vitro studies have shown that chloramphenicol inhibits CYP3A4 and CYP2C19, CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the concentrations used are unlikely to cause a clinically significant interaction.",""
116566,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged through the kidneys (by glomerular filtration and tubular secretion via OAT3. Ciprofloxacin is also metabolized and partially cleared through the bile and intestine. Dolutegravir is not expected to inhibit OAT3 and lamivudine is eliminated by other renal transporters. No interaction is expected with abacavir.,""
116567,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clarithromycin is a strong inhibitor of CYP3A4, but CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
116569,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4 with some metabolites having antibacterial activity. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116570,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. Three metabolites, two glucuronides, have been identified in urine, As glucuronidation has a minor role in clofazimine elimination, an interaction with dolutegravir via this mechanism is unlikely. No interaction is expected with abacavir. An interaction with lamivudine via competition for renal elimination pathways is unlikely as renal excretion has a minor role in clofazimine elimination.",""
116640,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Weak induction of CYP isozymes has been observed with higher doses of topiramate but this is not considered to be of clinical relevance with dolutegravir. No interaction is expected with abacavir or lamivudine.,""
116571,"Coadministration has not been studied. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted via glomerular filtration and tubular secretion. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction as total renal elimination of cloxacillin represents approximately 35% of a dose. No interaction is expected with abacavir. There is little potential for significant interactions with lamivudine via competition for renal transport.",""
116572,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly excreted renally via glomerular filtration. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116573,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapsone is mainly metabolized by N-acetylation with a component of N-hydroxylation, and is via multiple CYP P450 enzymes. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir lamivudine.",""
116574,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Dolutegravir does not affect CYP enzymes. No interaction is expected with abacavir or lamivudine.",""
116575,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No significant metabolism of doxycycline occurs and it is cleared intact by renal and biliary mechanisms. No interaction is expected with dolutegravir or abacavir and there is little potential for a clinically significant interaction with lamivudine via competition for renal elimination transport mechanisms.,""
116577,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erythromycin is considered to be a moderate inhibitor of CYP3A4 but CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir lamivudine.,""
116579,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolized in the liver with animal studies suggesting involvement of flavin-containing monooxygenases. No interaction is expected with dolutegravir or abacavir. There is little potential for an interaction with lamivudine via competition for renal elimination pathways as less than 1% of the oral dose is excreted as ethionamide in urine.,""
116580,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally partly by glomerular filtration and partly by active secretion via OAT1. No pharmacokinetic interaction is expected with dolutegravir, abacavir or lamivudine. However, HLA-5701 has been identified as the main genetic risk factor for flucloxacillin induced liver injury and patients should be genotyped before receiving abacavir or flucloxacillin.",""
116581,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116582,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and, to a lesser extent, by active tubular secretion. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms as probenecid (an inhibitor of renal tubular excretion) had minimal effect on plasma levels of imipenem. ",""
116585,"Coadministration has not been studied. Levofloxacin is metabolised to a very small extent and is eliminated renally mainly by glomerular filtration and active secretion. No interaction is expected with dolutegravir or abacavir. In vitro data indicate that levofloxacin inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown given the good tolerability of lamivudine.",""
116587,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. Dolutegravir is not expected to inhibit these renal transporters and no interaction is expected with abacavir. Lamivudine is excreted by different renal transporters.,""
116588,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interaction is expected with dolutegravir or lamivudine. Although abacavir concentrations may increase due to inhibition of alcohol dehydrogenase by metronidazole, no a priori dosage adjustment is required as abacavir has a large therapeutic index.",""
123681,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Weak induction of CYP isozymes has been observed with higher doses of topiramate but this is not considered to be of clinical relevance with rilpivirine or with cabotegravir.,""
116590,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug. In vitro studies indicate that dolutegravir does not inhibit UGTs at clinically relevant concentrations and no interaction is expected with abacavir. As renal excretion is not the predominant mechanism of elimination, there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116591,"Coadministration has not been studied. Ofloxacin is eliminated unchanged in the kidneys by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with ofloxacin. No interaction is expected with abacavir Lamivudine is eliminated by OCT2 and in vitro data indicate that ofloxacin inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown given the good tolerability of lamivudine.",""
116592,"Coadministration has not been studied. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that dolutegravir inhibits OCT2 and may increase the exposure of para-aminosalicylic acid. In addition, as para-aminosalicylic acid and lamivudine are predominantly renally eliminated, including by active tubular secretion, there is potential for competition for elimination via renal transport proteins, which may lead to increased concentrations of either drug. The clinical relevance of this interaction is unknown. No interaction is expected with abacavir.",""
116593,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Dolutegravir is not expected to inhibit OAT and no interaction is expected with abacavir. Lamivudine is eliminated by different transporters.,""
116601,"Coadministration has not been studied. Sulfadiazine is metabolized in part by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and no interaction is expected with abacavir. Sulfadiazine has been associated with crystalluria leading to renal toxicity and in some cases renal failure, and case reports in immunocompromised patients have suggested that AIDS patients may be particularly prone to sulfadiazine-induced renal toxicity. As lamivudine is predominantly excreted via active renal transport, monitoring of renal function is warranted if sulfadiazine is administered with lamivudine.",""
116608,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. In vitro studies indicate that CYP3A4 plays a role in argatroban metabolism, however, human drug-drug interactions studies suggest that metabolism via CYP3A4 is not a major elimination pathway in vivo. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of dolutegravir, abacavir or lamivudine.",""
116610,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betrixaban is largely eliminated unchanged through biliary secretion via P-gp. Dolutegravir does not inhibit or induce P-gp and no interaction is expected with abacavir or lamivudine.,""
116612,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP450 isoenzymes and is mainly cleared by glomerular filtration. The prodrug of dabigatran is a substrate of P-gp and in vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. No interaction is expected with abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116614,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Dolutegravir does not inhibit or induce these UGTs. No interaction is expected with abacavir or lamivudine.",""
123682,"Coadministration has not been studied. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration. Topotecan is a substrate for P-gp and BCRP. In vitro data indicate that rilpivirine is an inhibitor of BCRP and thus may increase the risk and severity of topotecan-related side effects. No effect is expected on cabotegravir.",""
123683,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolized mainly by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123684,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. However, rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with toremifene. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
116656,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys and is freely filtered at a rate that is dependent upon the glomerular filtration rate. No interactions is expected with dolutegravir, abacavir or lamivudine.",""
116615,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is eliminated primarily as unchanged drug in urine. Edoxaban is minimally metabolised by hydrolysis (mediated by carboxylesterase 1), conjugation, or oxidation by CYP3A4/5 (<10%). Edoxaban is a substrate for P-gp but dolutegravir does not inhibit or induce P-gp. No interaction is expected with abacavir and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
116616,"Coadministration has not been studied. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8) and in vitro data indicate it is an inhibitor of UGTs 1A1 and 1A3. Although eltrombopag could potentially increase dolutegravir exposure, this is unlikely to be of clinical significance. No interaction is expected with abacavir or lamivudine.",""
116620,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116621,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116622,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). In vitro data indicate that dolutegravir does not inhibit P450 isoenzymes or the efflux transporters P-gp, BCRP at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116623,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Renal elimination of unchanged streptokinase is minimal. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116625,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYP1A2 and 3A4. S-warfarin (more potent) is metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116627,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4 and does not induce metabolizing enzymes. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116629,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is mainly metabolized by CYP3A4 and does not induce metabolizing enzymes. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116632,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116639,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolised by CYP3A4/5. Neither dolutegravir nor tiagabine induce or inhibit CYP450 enzymes. No interaction is expected with abacavir or lamivudine.,""
123685,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
116628,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine)&nbsp;has not been studied but is expected to decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by eslicarbazepine. Although no dosing recommendations are provided for eslicarbazepine, the European product label for Triumeq does not recommend coadministration with carbamazepine, another anticonvulsant with inducing properties. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, can be taken in presence of carbamazepine.&nbsp; A significant effect on abacavir is unlikely as abacavir is only partly metabolised by glucuronidation. No significant interaction is expected with lamivudine.",""
116638,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine)&nbsp;has not been studied but is expected to substantially decrease dolutegravir exposure.&nbsp;Primidone is metabolised by CYP3A4 to the active metabolite phenobarbital which is an inducer of CPY3A4 and UGT1A1. The European and the US product labels for Triumeq do not recommend coadministration with phenobarbital. However, the US product label for Triumeq mentions that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, can be taken in presence of carbamazepine, another anticonvulsant with inducing properties. A significant effect on abacavir is unlikely as abacavir is only partly metabolised by glucuronidation.&nbsp;No significant interaction is expected with lamivudine.",""
116643,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. Zonisamide is a weak inhibitor of P-gp but is unlikely to have a significant effect on dolutegravir exposure. No interaction is expected with abacavir or lamivudine.,""
116644,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116645,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116646,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolized by CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116647,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116648,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116649,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116650,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116651,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116652,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolized by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116653,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by CYPs 2C19 and 3A4 to form norfluoxetine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116654,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116655,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolized by CYPs 3A4, 2C19 and 1A2 to desipramine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116657,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116658,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116660,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116661,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nefazodone is metabolized mainly by CYP3A4 and is also an inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
116662,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116663,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116665,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116666,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116668,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116669,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116670,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116671,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioxetine is mainly metabolized by CYP2D6 and to a lesser extent CYP2C9 and CYP3A4/5. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116673,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is primarily metabolised by UGT1A9 and UGT2B4. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116674,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is primarily metabolised by UGT1A9. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116740,Coadministration has not been studied. No interaction is expected with dolutegravir or abacavir but in vitro data suggest that pyrimethamine inhibits the renal transporters OCT2 and MATE1 and may increase concentrations of lamivudine. No a priori dosage adjustment is recommended in patients with normal renal function.,""
116676,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3. Dolutegravir is unlikely to affect the metabolism of empagliflozin and empagliflozin is unlikely to affect dolutegravir concentrations as it does not inhibit or induce CYPs and does not inhibit UGTs. No interaction is expected with abacavir or lamivudine.",""
116678,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116679,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116680,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is metabolised by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116681,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipazide is metabolized mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116683,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces, with metabolism by CYP3A4 representing a minor elimination pathway. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116686,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolized by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116687,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolized by mainly CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116688,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Repaglinide is metabolized by CYPs 2C8 and 3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116689,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized mainly by CYP2C8 and to a lesser extent by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116690,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116706,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Voriconazole is metabolised by CYPs 2C19, 2C9 and 3A4 and is a strong inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116855,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116691,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, P-gp), with metabolism by CYP3A4 representing a minor elimination pathway. Dolutegravir is not expected to inhibit these transporters at clinically relevant concentrations. No interaction is expected with abacavir. Although metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal impairment or end-stage renal disease (ESRD), a clinically significant increase is unlikely as sitagliptin is mainly eliminated unchanged and has a large safety window, and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116692,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116696,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. In vitro data indicate that caspofungin is a substrate of the hepatic transporter OATP1B1, but there is no evidence that dolutegravir inhibits OATP1B1. No interaction is expected with abacavir or lamivudine.",""
116697,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is mainly eliminated renally by glomerular filtration and is a moderate inhibitor of CYP3A4. A clinically significant interaction is not expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
116698,Coadministration has not been studied. Flucytosine is metabolised to 5-flurouracil which is further metabolised by dihydropyrimidine dehydrogenase. This enzyme is also involved in the catabolic pathway of pyrimidine analogs (such as lamivudine) and competition could potentially increase haematological toxicity. Monitor haematological parameters and consider dose reduction if required. No interaction is expected with dolutegravir or abacavir.,""
116699,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Griseofulvin is a liver microsomal enzyme inducer but a clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir. As less than 1% of a griseofulvin dose is excreted unchanged via the kidneys, there is little potential for an interaction via competition with lamivudine for renal elimination pathways. ",""
116700,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Itraconazole is metabolized by CYP3A4 and is a strong inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
116701,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketoconazole is metabolized by CYP3A4 and is a strong inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
116702,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Miconazole inhibits CYP2C9 and CYP3A4 but a clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
116704,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4). Posaconazole is a strong inhibitor of CYP3A4. A clinically significant interaction is not expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116705,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYP2C8 and 2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116707,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Astemizole is metabolized by CYP2D6, CYP2J2 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116708,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. No interaction is expected with dolutegravir or abacavir. Lamivudine is eliminated by OCT2 and in vitro data indicate that cetirizine inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown and given the good tolerability of lamivudine, no a priori dose adjustment of lamivudine is needed.",""
116709,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized in the liver via CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Approximately 22% of a chlorphenamine dose is excreted unchanged in the urine and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
116710,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116711,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine does not undergo CYP-mediated metabolism but is a substrate of P-glycoprotein. In vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116713,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116714,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116715,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116717,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroergotamine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116718,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116722,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYP3s A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolised via UGT1A9 and 2B7. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116724,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Benznidazole undergoes non-CYP mediated metabolism and partly CYP mediated metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Renal elimination of unchanged benznidazole appears to be minimal and there is little potential for an interaction with lamivudine via competition for renal elimination pathways. ,""
116725,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Due to the multiple elimination pathways, a clinically significant interaction with lamivudine is unlikely.",""
116727,"Coadministration has not been studied. Approximately 80% of oral/intravenous doses of eflornithine are excreted unchanged via the kidneys. No interaction is expected with dolutegravir or abacavir.. As there are no available data determining whether excretion is via active tubular secretion or glomerular filtration, there is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. Clinically significant interactions are not expected with topical preparations as <1% of topically applied eflornithine is systemically absorbed.",""
116728,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116730,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116731,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meglumine antimoniate is predominantly eliminated unchanged via renal glomerular filtration. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction via completion with lamivudine for active renal transport mechanisms.,""
116734,"Coadministration has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, there is little potential for interaction, although due to the lack of data, vigilance is required if administering nifurtimox with antiretrovirals. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase, with <1% of a dose excreted unchanged via the kidneys. No interaction is expected with dolutegravir or abacavir and there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
116735,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paromomycin is not metabolized and is eliminated unchanged by renal glomerular filtration. No interaction with dolutegravir or abacavir is expected and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
116736,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The exact metabolic pathway of pentamidine has not been clearly established. Data from animal studies suggest the involvement of CYPs 1A1, 2D6 and 2C19 in the oxidative metabolism of pentamidine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116737,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperaquine is mainly metabolized by CYP3A4 and is a modest inhibitor of CYP3A4. A clinically significant interaction with dolutegravir is unlikely as CYP3A4 plays a minor role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116738,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116739,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123690,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trastuzumab emtansine is a monoclonal antibody-drug conjugate. Trastuzumab does not undergo CYP mediated metabolism, whereas DM1 (an active component of emtansine) is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.",""
116741,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinine is extensively metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116742,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elimination of sodium stibogluconate is predominantly via renal glomerular filtration. No interaction is expected with dolutegravir or abacavir. Renal elimination of sodium stibogluconate has been found to be similar to the rate of glomerular filtration and there is little potential for an interaction with lamivudine via competition for active renal transport mechanisms.,""
116743,"Coadministration has not been studied. Sulfadoxine is rarely used alone, but is usually given in combination with pyrimethamine. No interaction is expected with dolutegravir or abacavir, however, in vitro data suggest that pyrimethamine inhibits the renal transporters OCT2 and MATE1 and may increase concentrations of lamivudine. No a priori dosage adjustment is recommended in patients with normal renal function.",""
116744,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally, possibly via OCT. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with amisulpride. No interaction is expected with abacavir. There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in amisulprideâ€™s elimination.",""
116745,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolized by CYP3A4 and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116746,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (CYP1A2 (major) and CYP3A4, 2D6 (minor)). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116747,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116748,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116749,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116750,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116751,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116752,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116753,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116754,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily eliminated renally (possibly OCT), with minimal metabolism occurring via CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with paliperidone. No interaction is expected with abacavir. There is little potential for an interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in paliperidoneâ€™s elimination.",""
116755,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
123692,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116856,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116756,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116757,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116758,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pimozide is metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116759,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116760,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116761,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116763,"Coadministration has not been studied. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. No effect on thioridazine is expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Thioridazine is a moderate inducer of CYP3A4 and could potentially decrease dolutegravir concentrations, but this is unlikely to be of clinical significance as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
116765,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116766,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. Dolutegravir undergoes only minimal metabolism via CYP3A4 and does not inhibit or induce CYPs. No interaction is expected with abacavir or lamivudine.,""
116767,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116851,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123693,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
123694,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
116776,"Triumeq (dolutegravir, abacavir, lamivudine) can be used as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with enfuvirtide would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
116854,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
123695,"Coadministration has not been studied. Triclabendazole and its active sulfoxide metabolite were shown to inhibit CYP3A4 and therefore may increase rilpivirine concentrations. However, due to the short term dosing of triclabendazole (usually single dose), this interaction is not clinically relevant. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. ",""
123696,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
116784,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. Triumeq contains abacavir and should not be taken with additional abacavir.",""
116857,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised by glucuronidation. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116790,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
116772,"Triumeq (dolutegravir, abacavir, lamivudine) and Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. In addition, Triumeq contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine. Furthermore, coadministering two integrase inhibitors (i.e., elvitegravir and dolutegravir) is unlikely to be of clinical benefit.",""
116774,"Triumeq (dolutegravir/abacavir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with maraviroc (dosed at 300 mg twice daily) would be possible from a pharmacokinetic standpoint.&nbsp;Maraviroc is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and no interaction is expected with abacavir. Coadministration of maraviroc (300 mg twice daily) and lamivudine/zidovudine (150/300 mg twice daily) increased lamivudine AUC (14%) and Cmax (16%), but is not considered to be clinically significant. Maraviroc concentrations were not measured, but no effect is expected.",""
116805,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter, no interaction is expected with abacavir, and lamivudine is eliminated by different renal transporters.",""
116806,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter. No interaction is expected with abacavir. Coadministration of adefovir dipivoxil (10 mg) and lamivudine (100 mg) did not alter the pharmacokinetic profile of either drug. However, as adefovir is nephrotoxic, renal function should be monitored.",""
116807,"Coadministration has not been studied. Amantadine is mainly eliminated in the kidney by glomerular filtration and active secretion via OCT2. There is potential for dolutegravir to increase amantadine exposure via inhibition of OCT2 but the clinical relevance of this is unknown. No interaction is expected with abacavir. There is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
116809,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1 and OAT3. Dolutegravir is not expected to inhibit these renal transporters. No interaction is expected with abacavir or lamivudine.,""
116812,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anions and cations transporters. Dolutegravir is not expected to inhibit OATs. In vitro data indicate that dolutegravir inhibits OCT, but is unlikely to cause a clinically relevant drug interaction with entecavir. No interaction is expected with abacavir. No pharmacokinetic interactions were observed between entecavir and lamivudine.",""
116813,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase which is then eliminated in the urine, possibly by OAT1. Dolutegravir is not expected to inhibit this renal transporter, no interaction is expected with abacavir, and lamivudine is eliminated by different transporters.",""
116815,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ganciclovir is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OAT1. Dolutegravir is not expected to inhibit this renal transporter, no interaction is expected with abacavir, and lamivudine is eliminated by different transporters.",""
123699,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.",""
116858,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolized to hydroxymetabolites (possibly by CYP2D6) and partly eliminated unchanged in the urine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116816,"Coadministration of glecaprevir/pibrentasvir and dolutegravir/lamivudine/abacavir (Triumeq) was evaluated as part of a Phase 1 study and showed no clinically significant interaction with glecaprevir/pibrentasvir. Cmax and AUC for glecaprevir and pibrentasvir decreased by 25-28%, but there was no impact on Cmax and AUC for abacavir, dolutegravir or lamivudine. No dose adjustment is required.",""
116811,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of multiple doses of elbasvir/grazoprevir and dolutegravir had no clinically relevant effect on the pharmacokinetics of grazoprevir, elbasvir or dolutegravir. Coadministration of dolutegravir (50 mg single dose) and elbasvir + grazoprevir (50 + 200 mg once daily) to 12 subjects decreased elbasvir AUC, Cmax and C24 by 2%, 3% and 2%, respectively, and decreased grazoprevir AUC, Cmax and C24 by 19%, 36% and 14%, respectively. Dolutegravir AUC, Cmax and Ctrough increased by 16%, 22% and14%, respectively. No interaction with abacavir or lamivudine is expected.",""
116817,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Although concentrations of dolutegravir may increase due to inhibition of P-gp and BCRP by ledipasvir, any increase is unlikely to be clinically significant. Coadministration of abacavir/lamivudine and ledipasvir/sofosbuvir had no effect on the pharmacokinetic parameters of abacavir, lamivudine, ledipasvir or sofosbuvir. Abacavir Cmax and AUC decreased by 8% and 10%; lamivudine Cmax and AUC decreased by 7% and 6% and Cmin increased by 12%. Ledipasvir Cmax, AUC and Cmin increased by 10%, 18% and 26%; sofosbuvir Cmax and AUC increased by 8% and 21%; AUC and Cmin of GS-331007 increased by 5% and 8% with no change in Cmax. No dose adjustment is required.",""
116820,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases. The latter is excreted in the urine by glomerular filtration and tubular secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter, no interaction is expected with abacavir, and lamivudine is eliminated by different transporters.",""
116822,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated. Dolutegravir is not expected to inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116824,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is metabolised by UGT1A1 (major) and CYP3A (minor), neither of which is affected by sofosbuvir. No interaction is expected with abacavir. An interaction with lamivudine is unlikely as lamivudine is predominately cleared unchanged by renal excretion. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.",""
116826,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No clinically significant drug interactions have been observed with dolutegravir and sofosbuvir/velpatasvir and no additional effect is likely with the addition of voxilaprevir. No interaction is expected with abacavir. Lamivudine is not expected to inhibit or induce any relevant metabolic enzymes or transporters of sofosbuvir, velpatasvir or voxilaprevir.",""
116829,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Dolutegravir is not expected to inhibit this renal transporter, no interaction is expected with abacavir, and lamivudine is eliminated by different transporters.",""
116852,"Coadministration has not been studied. Atenolol is mainly eliminated by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. There is potential for dolutegravir to increase atenolol exposure via inhibition of OCT2. Based on the drug-drug interaction study with metformin (another drug transported by OCT2 and MATE1), the increase in atenolol exposure is expected to be ~80% or ~110% when dolutegravir is administered once daily and twice daily, respectively. No interaction is expected with abacavir. There is potential for competition with atenolol and lamivudine for elimination via renal transport proteins, which may lead to increased concentrations of either drug. It is recommended to start atenolol at a lower dose and adjust dosage until the desired clinical effect is achieved.",""
116853,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abavavir. Lamivudine is eliminated by OCT2 and in vitro data indicate that bisoprolol inhibits OCT2. However, the clinical relevance of an interaction via OCT is unknown given the good tolerability of lamivudine.",""
123700,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Data from pharmacokinetic studies suggest that curcuminoids (derived from turmeric extract) are unlikely to affect UGT or CYP3A4-mediated metabolism.,""
116825,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Based on drug interaction studies conducted with sofosbuvir/velpatasvir, no clinically significant drug interactions have been observed with dolutegravir. Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) and dolutegravir (50 mg once daily) had no effect on the pharmacokinetic parameters of sofosbuvir (AUC and Cmax decreased by 8% and 12%), GS-331007 (AUC and Cmin both decreased by 1%, Cmax increased by 1%), velpatasvir (AUC, Cmax and Cmin decreased by 9%, 6% and 12%) or dolutegravir (AUC, Cmax and Cmin increased by 6%, 6% and 4%) was observed. No interaction is expected with abacavir. Lamivudine is not expected to inhibit or induce any relevant metabolic enzymes or transporters of sofosbuvir or velpatasvir.",""
116823,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simeprevir is metabolized by CYP3A4. Dolutegravir is mainly metabolised by UGT1A1 with limited CYP3A4 involvement. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116837,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYP3A4 and 2C19) and to temazepam (mainly by CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116838,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116839,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYP3A4 and CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116840,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116841,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116842,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is mainly glucuronidated (by UGTs 2B15, 2B4, 2B7, 1A7, 1A10). Dolutegravir is mainly glucuronidated by UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116843,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated (possibly by UGTs 2B15, 1A9 and 2B7). Dolutegravir is mainly glucuronidated by UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116846,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly glucuronidated (by UGTs 2B15, 1A9 and 2B7). Dolutegravir is mainly glucuronidated by UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116847,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is mainly glucuronidated, but there is no evidence that temazepam is a substrate of UGT1A1, the major enzyme involved in dolutegravir metabolism. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116848,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116849,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116850,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123701,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is metabolized mainly by CY3A4 and to a lesser extent by CYPs 1A2 and 2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123702,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Umeclidinium bromide is mainly metabolized by CYP2D6 and is a substrate of P-gp. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes or P-glycoprotein at clinically relevant concentrations.,""
116859,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is metabolized by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116860,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when timolol is used either orally or as eye drops. Timolol is predominantly metabolised by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116862,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Theophylline is mainly metabolized by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116863,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116865,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is eliminated partly unchanged (33%) and partly metabolized by CYP3A4 and UGT1A1, and is a weak substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116867,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116868,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olodaterol is metabolized by CYP2C8, CYP2C9, is glucuronidated via several UGTs, and is a substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116869,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Roflumilast is metabolized by CYP3A4 and CYP1A2 to form roflumilast N-oxide, with both roflumilast and roflumilast N-oxide having PDE4 inhibitory activity. Roflumilast N-oxide is subsequently dealkylated by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116870,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4â€™-O-sulphate. No interaction is expected with dolutegravir, abacavir or lamivudine.",""
116871,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123703,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valaciclovir is converted to aciclovir which is eliminated renally via glomerular filtration and active renal secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition. Likewise, rilpivirine does not inhibit OAT1.",""
116872,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116873,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiotropium bromide is predominantly excreted unchanged in the urine. Metabolism by CYP2D6 and CYP3A4 is only a minor role in its elimination. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116874,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Umeclidinium bromide is mainly metabolized by CYP2D6 and is a substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116914,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite. No interaction is expected with dolutegravir, abacavir, or lamivudine.",""
116875,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116876,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116877,Coadministration has not been studied. Diltiazem is metabolized by CYP3A4 and is a moderate inhibitor of CYP3A4. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116878,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116879,"Coadministration has not been studied. Nicardipine is metabolised mainly by CYP3A4, and to a lesser extent by CYPs 2D6 and 2C8, and inhibits CYP3A4. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116880,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116881,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116882,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116883,Coadministration has not been studied. Verapamil is metabolised mainly by CYP3A4 and is a moderate inhibitor of CYP3A4. No interaction is expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116884,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116889,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent CYP1A2, 2D6 and 2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116890,Coadministration has not been studied. Capecitabine is activated by sequential enzyme reactions to fluorouracil. Dihydropyrimidine dehydrogenase plays a role in fluorouracil metabolism. Nucleoside analogues such as lamivudine may compete for these metabolic pathways. The clinical relevance of this interaction is unknown. No interaction is expected with dolutegravir or abacavir.,""
123704,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of valerian with probe substrates for CYP3A4 (alprazolam) and CYP2D6 (dextromethorphan) modestly increased alprazolam Cmax and AUC (~20%) and had no effect on dextromethorphan. A clinically significant interaction is unlikely with rilpivirine. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123705,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19. Valproate has no inducing effects on metabolism. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
116894,"Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1. In vitro data indicate that dolutegravir is a moderate inhibitor of OCT2. Inhibition of OCT2 will lead to lower concentrations of cisplatin inside the tubular cell which represents an advantage as this may reduce the risk of cisplatin related nephrotoxicity. However, cisplatin and lamivudine could potentially compete for OCT2 which could slow their elimination. Furthermore, cisplatin may impair the renal function. Closely monitor creatinine clearance. No interaction is expected with abacavir.",""
116895,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116896,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cytarabine is metabolized by cytidine deaminase. No interaction is expected with dolutegravir, abacavir, or lamivudine.",""
116897,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine is activated to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116899,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dasatinib is metabolized by CYP3A4 and inhibits this same enzyme. A clinically significant interaction is not expected with dolutegravir as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116901,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Docetaxel is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116903,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Droloxifene is mainly glucuronidated. Dolutegravir is not expected to induce or inhibit UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116904,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Epirubicin is glucuronidated by UGT2B7. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116905,"Coadministration has not been studied. Erlotinib is mainly metabolized by CYP3A4, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Erlotinib is a strong inhibitor of UGT1A1 in vitro and could increase dolutegravir concentrations, however, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with abacavir or lamivudine.",""
116907,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. Furthermore, etoposide is partly glucuronidated by UGT1A1. Dolutegravir is not expected to inhibit or induce CYPs or UGTs enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116908,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Everolimus is metabolized by CYP3A4 and is a modest inhibitor of CYP3A4 in vivo. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116909,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116911,"Coadministration has not been studied. Fluorouracil is metabolised via the same mechanisms as endogenous uracil, including via dihydropyrimidine dehydrogenase. There is little potential for an interaction with dolutegravir via modulation of, or competition for, metabolic pathways and no interaction is expected with abacavir. However, nucleoside analogues such as lamivudine may compete for this metabolic pathway. The clinical relevance of this interaction is unknown.",""
116912,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Dolutegravir is not expected to induce or inhibit UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116913,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gefitinib is metabolized by CYP3A4 and CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116915,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ifosfamide is predominantly metabolized by CYP3A4 and CYP2B6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116916,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent CYPs 1A2, 2D6, 2C9, 2C19. In vitro data indicate that imatinib inhibits CYPs 3A4, 2D6, 2C9, 2C19. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116917,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. SN38 is further inactivated by several UGTs. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116918,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lapatinib is metabolized by CYP3A4 and inhibits this same enzyme. Lapatinib does not significantly inhibit renal transporters (OAT, OCT). A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116919,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116920,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is predominantly metabolised by xanthine oxidase. No interaction is expected with dolutegravir, abacavir, or lamivudine.",""
116921,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesna is rapidly oxidised to its only metabolite, mesna disulphide via the physiological cysteine system. Approximately 32% and 33% of an administered dose is eliminated in the urine in 24 hours as mesna and mesna disulphide respectively. No interaction is expected with dolutegravir or abacavir. In vitro data suggest that mesna is a substrate of the OAT1, OAT3 and OAT4 renal transporters whereas lamivudine is transported by OCT2. ",""
116923,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116924,"Coadministration has not been studied. Nilotinib is metabolized by CYP3A4 and inhibits this same enzyme. Furthermore, in vitro data indicate that nilotinib inhibits UGT1A1. Nilotinib could potentially increase dolutegravir concentrations via UGT1A1 and CYP3A4 inhibition. However, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with abacavir or lamivudine.",""
116925,"Coadministration has not been studied. Oxaliplatin undergoes non enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. In vitro data indicate that dolutegravir is a moderate inhibitor of OCT2. Although inhibition of OCT2 may represent an advantage in terms of nephrotoxicity, inhibition may impair the response to oxaliplatin chemotherapy. OCT2 is expressed in some tumour cells where it will facilitate the entry of cytostatic agents such as oxaliplatin (but not cisplatin) inside the tumour cell. Dolutegravir, an inhibitor of OCT2, could potentially decrease the efficacy of oxaliplatin. Oxaliplatin and lamivudine could potentially compete for OCT2 which could slow their elimination. Monitor side effects. No interaction is expected with abacavir.",""
123708,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
116926,Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. In vitro data suggest that paclitaxel activates PXR and therefore could potentially decrease dolutegravir concentrations via induction of UGT1A1. Monitor response to antiretroviral therapy. No interaction is expected with abacavir or lamivudine.,""
116927,"Coadministration has not been studied. Pazopanib is metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C8. Dolutegravir is not expected to inhibit or induce CYPs enzymes at clinically relevant concentrations. In vitro data indicate that pazopanib inhibits UGT1A1 and therefore could potentially increase dolutegravir concentrations. However, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with abacavir or lamivudine.",""
116928,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and 1A) and monoamine oxidase. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116930,"Coadministration has not been studied. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Sorafenib inhibits UGT1A1 and UGT1A9 and therefore could potentially increase dolutegravir concentrations, however, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with abacavir or lamivudine.",""
116931,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sunitinib is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116933,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4 and inhibits CYP3A4. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism and dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116934,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration. Topotecan is a substrate for P-gp and BCRP and concomitant use of P-gp and BCRP inhibitors has been shown to increase topotecan exposure. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116935,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116936,"Coadministration has not been studied. Vinblastine is metabolized by CYP3A4 and is excreted primarily by the biliary route. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. However, in vitro data suggest that vinblastine activates PXR and therefore could potentially decrease dolutegravir concentrations via induction of UGT1A1. Monitor response to antiretroviral therapy. No interaction is expected with abacavir or lamivudine.",""
116937,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vincristine is metabolized by CYP3A5/4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116938,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated). Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116939,Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
123709,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Varenicline is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion by OCT2. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters.,""
116940,Coadministration with a desogestrel-containing progestogen-only pill (POP) has not been but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116941,Coadministration with a drospirenone-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir does not interact with these metabolic pathways and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
116942,Coadministration with drospirenone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116943,Coadministration with dydrogesterone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116944,"Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116946,Coadministration with an etonogestrel-containing progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116947,Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
116948,Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir does not inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine,""
116995,Coadministration has not been studied. African potato was shown to inhibit CYP3A4 and P-gp in vitro and to activate PXR suggesting that inhibition may occur initially followed by induction of CYP3A4 and P-gp when used for extended periods. Use with caution as African potato could decrease concentrations of dolutegravir. Therapeutic drug monitoring of dolutegravir is recommended. No interaction is expected with abacavir or lamivudine.,""
116949,Coadministration with a levonorgestrel-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
116950,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116951,Coadministration with levonorgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116952,Coadministration with a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116954,Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116956,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116957,Coadministration with transdermally delivered norelgestromin/ethinylestradiol has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
116958,Coadministration of a combined oral contraceptive (COC) containing norethisterone and mestranol or ethinylestradiol has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Mestranol is rapidly and almost completely converted to ethinylestradiol by CYP2C9; ethinylestradiol is mainly metabolised by hydroxylation. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
116959,Coadministration with norethisterone as hormone replacement therapy (HRT) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116960,Coadministration of a norethisterone IM depot injection has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116961,Coadministration of a norethisterone progestogen-only pill (POP) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116963,Coadministration of a combined oral contraceptive (COC) containing norgestrel/ethinylestradiol has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is mainly metabolized by hydroxylation. Dolutegravir does not inhibit or induce CYP450 or UGT enzymes and had no clinically relevant effect on the pharmacokinetics of ethinylestradiol when administered with a COC containing ethinylestradiol/norgestimate. No interaction is expected with abacavir or lamivudine.,""
116964,Coadministration with norgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116965,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is metabolized mainly by CY3A4 and to a lesser extent by CYPs 1A2 and 2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116966,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Dolutegravir is mainly metabolized by UGT1A1 and is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116967,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine. ,""
116968,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine. ,""
116969,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine. ,""
116970,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
123712,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Verapamil is metabolised mainly by CYP3A4 and is a moderate inhibitor of CYP3A4. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Verapamil could increase rilpivirine concentrations although to a limited extent. No dosage adjustment is needed. ,""
116974,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisapride is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117018,"Coadministration has not been studied. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest it could act as an inducer of phase I and phase II metabolic enzymes although the clinical relevance has not been evaluated. In the absence of data, caution is recommended and TDM of dolutegravir should be considered if available. No interaction is expected with abacavir or lamivudine.",""
116976,Coadministration has not been studied. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%). Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir or lamivudine.,""
116979,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is metabolized by CYP2C8 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116980,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase. No interaction is expected with dolutegravir or abacavir or lamivudine.,""
116987,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116988,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116989,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Domperidone is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine. ,""
116990,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116991,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Granisetron is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116992,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116993,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117017,"Coadministration has not been studied. Magnesium is eliminated in kidney, mainly by glomerular filtration. Dolutegravir binds to divalent cations, such as magnesium, and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed. Dolutegravir should be administered 2 hours before or 6 hours after taking medications containing magnesium. No interaction is expected with abacavir or lamivudine.",""
123714,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes or P-glycoprotein at clinically relevant concentrations.,""
117061,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
116982,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pantoprazole is mainly metabolized by CYP2C19 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir or lamivudine.,""
116999,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Catâ€™s claw was demonstrated to strongly inhibit CYP3A4 in vitro but CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
117003,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Echinacea has a selective effect on CYP3A4 activity (inhibition of intestinal CYP3A4 and induction of hepatic CYP3A4) and its effect on the net exposure of a CYP3A4 substrate will depend on the extraction of the drug at the intestinal and hepatic sites. A clinically significant interaction with dolutegravir is not expected as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
117007,"Coadministration has not been studied. Garlic has been shown to induce intestinal CYP3A4 and/or P-gp and garlic supplements decreased unboosted saquinavir AUC by 50% in a clinical trial and there is a case report of treatment failure due to garlic cloves (six garlic cloves three times weekly) decreasing ritonavir-boosted atazanavir trough concentrations by ~70%. Similarly, concentrations of dolutegravir could be decreased via induction of CYP3A4 and/or P-gp. Patients should be advised against the use of garlic supplements. No interaction is expected with abacavir or lamivudine.",""
117009,"Coadministration has not been studied. Ginkgo biloba induces CYP3A4 and may decrease dolutegravir concentrations, but the magnitude and clinical relevance of this potential interaction is difficult to predict as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine. ",""
117000,"Coadministration has not been studied. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. No interaction is expected with abacavir or lamivudine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with dolutegravir and vitamin D given as a single agent (i.e. not with calcium or in a multivitamin preparation) or as an injection. However, colecalciferol can be found in multivitamin preparations. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
117012,"Coadministration has not been studied. In vitro data indicate that extracts of hops activate PXR and induce expression of CYP3A4, CYP2B6 and MDR1 genes to a degree similar to that of St John's wort. The magnitude and clinical relevance of a potential interaction with dolutegravir is difficult to predict as CYP3A4 does not play a major role in dolutegravir metabolism. Patients should be monitored carefully regarding their HIV infection. No interaction is expected with abacavir or lamivudine.",""
117016,"Coadministration has not been studied. Glycyrrhizin, the main active component of Glycyrrhiza glabra, is a modest inducer of CYP3A4 and could potentially decrease the exposure of dolutegravir, although to a modest extent as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
123716,"Coadministration has not been studied. Vinblastine is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. In vitro data suggest that vinblastine activates PXR and therefore has potential inducing properties. Intramuscular cabotegravir is unlikely to be significantly impacted by vinblastine based on the drug-drug interaction study with rifabutin showing a modest reduction in cabotegravir exposure. However, vinblastine has the potential to significantly decrease intramuscular rilpivirine. Thus, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance.",""
117025,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inconsistencies in the literature regarding the ability of quercetin to modulate CYP/P-gp activities make it difficult to predict the nature and magnitude of any interaction. However, quercetin is unlikely to produce a large effect on dolutegravir pharmacokinetics as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
117026,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K, a natural component with the same chemical structure as lovastatin. Monacolin K is metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and no interaction is expected with abacavir or lamivudine.",""
117030,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Seville orange juice inhibits intestinal CYP3A4 but is unlikely to cause a significant effect on dolutegravir exposure as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
117036,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability. Dolutegravir is not expected to inhibit or induce CYP450 enzymes and does not inhibit or induce P-glycoprotein in the range of clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117024,"Coadministration has not been studied. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. No interaction is expected with abacavir and lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and pyridoxine itself. However, pyridoxine administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
117037,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117038,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged by the kidney and in vitro data indicate that it is a substrate of OCT2. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with amiloride. No interaction is expected with abacavir. Although lamivudine is eliminated by the same renal transporter, a drug-drug interaction is unlikely as amiloride does not inhibit OCT2.",""
117039,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%, exact pathway not known) and excreted unchanged in the urine (30%) via OAT1 and OAT3. There is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes. Similarly, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. A drug interaction with lamivudine is unlikely as lamivudine and bendroflumethiazide are eliminated by different renal transporters.",""
117040,Coadministration has not been studied. Bosentan is a substrate and inducer of CYP3A4 and CYP2C9. Bosentan could potentially decrease dolutegravir exposure although to a moderate extent as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.,""
123717,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vincristine is metabolized by CYP3A5/4. Cabotegravir and rilpivirine have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123718,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vinorelbine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
117042,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1 (40-50% as unchanged drug, the rest as disulfide and other metabolites). No interaction is expected with dolutegravir or abacavir. There is little potential for an interaction with lamivudine as it is eliminated by different renal transporters.",""
117045,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose). No interaction is expected with dolutegravir or abacavir. Clonidine is a weak inhibitor of OCT2 and is unlikely to cause a clinically relevant interaction with lamivudine.",""
117046,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as digoxin is eliminated renally via the renal transporters OATP4C1 and P-glycoprotein. In vitro data indicate that dolutegravir does not inhibit P-gp at clinically relevant concentrations. No interaction is expected with abacavir. Lamivudine is excreted by different renal transporters.,""
117048,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolized mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117049,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is eliminated renally (possibly via OATs). Dolutegravir is not expected to inhibit OATs and no interaction is expected with abacavir. There is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.,""
117050,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eplerenone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117054,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations, or to inhibit OATs. No interaction is expected with abacavir. There is little potential for an interaction with lamivudine as lamivudine is excreted by different renal transporters.",""
117055,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Renal elimination of unchanged hydralazine is minimal. No interaction is expected with dolutegravir or abacavir, and there is little potential for interaction with lamivudine via competition for renal elimination pathways.",""
117056,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. No interaction is expected with dolutegravir or abacavir, and with lamivudine which is excreted by different renal transporters.",""
117057,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloprost is extensively metabolized via beta oxidation of the carboxyl side chain with only a minor role for CYP metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117058,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP450. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. In vitro data suggest that indapamide inhibits OAT3 but lamivudine is excreted by different renal transporters.,""
117059,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Irbesartan is metabolized by glucuronidation and oxidation (mainly CYP2C9). Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117060,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver, with less than 30% of a dose undergoing subsequent glucuronidation. There is little potential for clinically significant interaction with dolutegravir via competition for glucuronidation pathways. No interaction is expected with abacavir. As renal elimination of unchanged drug is a minor pathway, there is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
117062,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7. Dolutegravir does not induce or inhibit UGTs in the range of clinical concentrations. No interaction is expected with abacavir or lamivudine.,""
117063,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117064,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117066,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117067,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117068,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged, and as the mono-O-sulfate conjugate. No interaction is expected with dolutegravir or abacavir, and there is little potential for interaction with lamivudine for active renal transport mechanisms.",""
117069,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. No interaction is expected with dolutegravir or abacavir, and there is no evidence that metolazone inhibits the renal transporters involved in the elimination of lamivudine.",""
117073,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily by renal excretion via OAT3. Dolutegravir is not expected to inhibit OATs and no interaction is expected with abacavir. Lamivudine is eliminated by other renal transporters.,""
117074,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolized to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Dolutegravir is not expected to interfere with these metabolic pathways. No interaction is expected with abacavir or lamivudine.",""
117075,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ranolazine is primarily metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117076,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, CYP2J2 and is also eliminated unchanged in the bile and renally. Riociguat is a substrate of P-gp and BCRP. Dolutegravir, abacavir and lamivudine do not interfere with riociguat metabolism.",""
123720,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Vorinostat is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated). Cabotegravir and rilpivirine do not inhibit or induce UGT enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with vorinostat. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123721,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioxetine is mainly metabolized by CYP2D6 and to a lesser extent by CYP2C9 and CYP3A4/5. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
117078,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Dolutegravir, abacavir and lamivudine do not interfere with selexipag metabolism.",""
117083,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Dolutegravir undergoes glucuronidation mainly via UGT1A1 and is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117084,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terazosin is extensively metabolized in the liver possibly via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117085,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolized mainly by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117087,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117091,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amphetamine is metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117092,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tetrahydrocannabinol (THC, the psychoactive component of cannabis), is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117093,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cocaine is metabolized by several non CYP mediated pathways, with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117094,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. MDMA is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117095,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117096,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Dolutegravir, abacavir and lamivudine do not affect these metabolic pathways.",""
123722,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Warfarin is a mixture of enantiomers which are metabolized by different cytochromes. R-warfarin is primarily metabolized by CYP1A2 and CYP3A4. S-warfarin (more potent) is metabolized by CYP2C9. Cabotegravir and rilpivirine do not inhibit or induce CYPs at clinically relevant concentrations.,""
117098,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117099,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117100,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117102,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyurea undergoes metabolism via non-CYP mediated metabolism and is unlikely to affect concentrations of dolutegravir, abacavir or lamivudine. However, hydroxyurea is not licensed for use in combination with stavudine and didanosine as toxicities including pancreatitis and hepatitis (in some cases fatal) in HIV patients have been reported via post marketing surveillance. Thus, caution and monitoring for side effects is recommended if coadministered with other NRTIs such as abacavir and lamivudine.",""
117105,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. These pathways are not affected by peginterferon alfa-2a. No pharmacokinetic interaction is expected with abacavir. Results from pharmacokinetic substudies of phase III trials demonstrated no effect of lamivudine on the pharmacokinetics of peginterferon alfa-2a in HBV patients. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
117106,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Dolutegravir is primarily metabolised by UGT1A1, with some contribution from CYP3A. These pathways are not affected by peginterferon alfa-2b. No pharmacokinetic interaction is expected with abacavir. In a trial with another pegylated interferon alfa, no evidence of a pharmacokinetic or pharmacodynamic (e.g., loss of HIV/HCV virologic suppression) interaction was seen when lamivudine and ribavirin were co-administered to 18 HIV/HCV co-infected subjects as part of a multidrug regimen. However, hepatic decompensation (some fatal) has occurred rarely in cirrhotic HIV/HCV co-infected patients receiving NRTI-containing HIV therapy and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and NRTIs should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anaemia.",""
117114,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117115,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tacrolimus is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117116,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atorvastatin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117117,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of bezafibrate dose is eliminated unchanged in the urine and in vitro data suggest that bezafibrate inhibits the renal transporter OAT1. No interaction is expected with dolutegravir or abacavir, or with lamivudine as it is excreted by different renal transporters.",""
117158,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117118,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Dolutegravir is not expected to inhibit OAT1. No interaction is expected abacavir and there is little potential for an interaction with lamivudine as it is excreted by different renal transporters.",""
117120,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117121,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolyzed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. No interaction is expected with dolutegravir or abacavir. A clinically relevant drug interaction is unlikely with lamivudine as it is excreted by different renal transporters.",""
117123,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolized by CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117124,"Coadministration has not been studied. Dolutegravir is mainly glucuronidated by UGT1A1 whereas gemfibrozil is mainly glucuronidated by UGT2B7. In vitro data suggest that gemfibrozil inhibits UGT1A1 and UGT1A3 and therefore could potentially increase dolutegravir concentrations. However, this is unlikely to be clinically significant due to the wide therapeutic window of dolutegravir. No interaction is expected with abacavir or lamivudine.",""
117125,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lovastatin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117126,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Dolutegravir is not expected to inhibit or induce UGT or CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117129,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Simvastatin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117130,"Coadministration has not been studied. Acamprosate is eliminated unchanged in the urine both via glomerular filtration and active secretion (exact transporter unknown, possibly OATs or OCTs). No interaction is expected with dolutegravir or abacavir. There is little potential for a clinically relevant interaction with lamivudine via competition for active renal transport mechanisms given the possible limited role of OCT in acamprosateâ€™s elimination and the therapeutic index of lamivudine and acamprosate.",""
117131,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion and in vitro studies have shown it may competitively inhibit the renal transporters OAT1, OAT3 and OAT4. No interaction is expected with dolutegravir or abacavir. A clinically relevant drug interaction is unlikely with lamivudine as it is excreted by different renal transporters.",""
117132,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acitretin undergoes isomerisation and glucuronidation. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117135,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolised mainly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117137,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. No interaction is expected with dolutegravir or abacavir, and there is little potential for an interaction via competition with lamivudine for active renal transport mechanisms.",""
117141,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caffeine is mainly metabolized by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117142,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. No interaction is expected with abacavir or lamivudine. In theory, calcium could chelate with dolutegravir and potentially decrease the amount of dolutegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of dolutegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation.",""
117144,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (also known as methimazole). Despite this potential hepatic metabolism very few data exist on carbimazole drug interactions and a marked interaction is not expected with dolutegravir, abacavir or lamivudine.",""
117145,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP2D6 is thought to have a role in clomifene metabolism and renal excretion of clomifene is thought to account for approximately 8% of an oral dose. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. There is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
117147,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117150,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is mainly metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117151,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117152,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and has been shown to moderately increase the exposure of simvastatin, a CYP3A4 substrate. No interaction is expected with dolutegravir as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A4 plays a minor role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
117161,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117163,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly glucuronidated by UGT2B7 and does not induce or inhibit CYP450 enzymes. Dolutegravir is not expected to inhibit or induce UGT enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117220,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of prednisone (60 mg once daily with taper) and dolutegravir (50 mg once daily) to 12 subjects had no clinically significant effect on the pharmacokinetics of dolutegravir (Cmax, AUC and Ctrough increased by 6%, 11% and 17%, respectively). No interaction is expected with abacavir or lamivudine.",""
117167,"Coadministration has not been studied. Orlistat should only be used with dolutegravir/abacavir/lamivudine if separated by 4-5 hours. Orlistat reduces dietary fat absorption and may affect the absorption of antiretrovirals (especially if lipophilic). [Note: this interaction is not specific for dolutegravir/abacavir/lamivudine, but for any medication taken with orlistat.]",""
117168,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although metabolism of penicillamine is not fully elucidated, multiple mechanisms and sites of metabolism are thought to be involved. There is, low potential for clinically significant interactions with dolutegravir and abacavir, or with lamivudine via competition for active renal elimination pathways.",""
117170,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when pilocarpine is used either orally or as eye drops. Pilocarpine is primarily metabolized by CYP2A6 and serum esterases. Renal elimination of unchanged pilocarpine is minimal. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and no interaction is expected with abacavir. There is little potential for an interaction with lamivudine via competition for renal elimination pathways.,""
117172,"Coadministration has not been studied. In vitro data suggest that probenecid is a non-selective inhibitor of UGT and coadministration could increase dolutegravir and abacavir concentrations, but this is unlikely to be of clinical significance. However, probenecid is an inhibitor of tubular secretion and coadministration is likely to increase lamivudine concentrations.",""
117173,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propylthiouracil is extensively metabolised, predominantly via glucuronidation, but the exact glucuronidation pathways are unknown. Renal elimination of unchanged propylthiouracil is minor. Dolutegravir is not expected to inhibit or induce UGTs at clinically relevant concentrations and no interaction is expected with abacavir. There is little potential for an interaction with lamivudine via competition for renal elimination pathways.",""
123724,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolized by aldehyde oxidase and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
117175,"Coadministration has not been studied. Pyridostigmine is predominantly excreted unchanged via the kidneys, with up to 74% of renal clearance attributed to active tubular secretion (most likely by a cation transporter). In vitro data indicate that dolutegravir inhibits OCT2 and could potentially increase pyridostigmine concentrations. There is also potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. The clinical relevance is unknown. No interaction is expected with abacavir.",""
117176,"Coadministration has not been studied. A pharmacokinetic interaction with abacavir or lamivudine is unlikely as strontium is predominantly eliminated unchanged by the kidneys. However, strontium is a divalent cation and can chelate with dolutegravir thereby reducing its absorption. Separating administration of dolutegravir/abacavir/lamivudine and strontium ranelate by at least 4 hours is recommended.",""
117177,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Multiple mechanisms are thought to be involved in sulfasalazine metabolism including acetylation, hydroxylation, and glucuronidation. Renal elimination of unchanged sulfasalazine is minimal. There is, therefore, low potential for clinically significant interactions with dolutegravir and abacavir, or with lamivudine via competition for renal elimination pathways.",""
117178,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117182,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Varenicline is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion by OCT2. No interaction is expected with dolutegravir (via inhibition of OCT2) or lamivudine (via competition for active renal transport mechanisms as cimetidine (an inhibitor of renal transporters) was shown to increase varenicline exposure to a limited extent (29%). No interaction is expected with abacavir.,""
117185,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117186,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117187,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117188,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117189,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 having a major role in CYP2D6 poor metabolisers. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117190,"Coadministration has not been studied. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. In vitro data indicate that dolutegravir inhibits OCT2 and may increase trospium exposure, but the clinical relevance of this is unknown. Trospium could potentially compete with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. No interaction is expected with abacavir.",""
117191,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123727,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). However, coadministration is not recommended with rilpivirine due to the potential of life threatening arrhythmias such as torsade de pointes and sudden death. The US Prescribing information contraindicates ziprasidone in the presence of other drugs that prolong the QT interval.",""
123728,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zoledronic acid is eliminated unchanged renally. ,""
117208,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117192,Coadministration has not been studied. CYP3A4 is thought to be the main enzyme involved in mifepristone metabolism and in vitro studies suggest that mifepristone may inhibit CYP3A4. Renal excretion of mifepristone is thought to account for approximately 10% of an oral dose A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentration and CYP3A does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir. There is little potential for interaction with lamivudine via competition for renal elimination pathways.,""
117219,Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. When prednisone (more than 80% of which is converted to prednisolone by first pass hepatic metabolism) was coadministered with dolutegravir there was no clinically significant effect on the pharmacokinetics of dolutegravir. No interaction is expected with abacavir or lamivudine.,""
117199,Coadministration has not been studied. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. No interaction is expected with abacavir. In vitro data indicate that dolutegravir inhibits OCT2 and may increase pramipexole exposure. Pramipexole may compete with lamivudine for renal elimination transport mechanisms which may lead to increased concentrations of either drug. No a priori dosage adjustment of pramipexole is required unless if the patient presents pramipexole related side effects.,""
117200,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Rasagiline is metabolised predominantly by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
117201,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolised predominantly by CYP1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117203,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4 and is a moderate inducer of CYP3A4. A clinically significant interaction with dolutegravir is not expected as dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations and CYP3A does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
117204,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117205,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4 mediated metabolism. Dolutegravir is not expected to interact with ciclesonide metabolism. No interaction is expected with abacavir or lamivudine.,""
117207,"Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4 and a moderate inducer of this enzyme. Dexamethasone and its metabolites are excreted in the urine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Dexamethasone could potentially decrease dolutegravir concentrations, but this is unlikely to be of clinical significance as CYP3A4 does not play a major role in dolutegravir metabolism. No interaction is expected with abacavir or lamivudine.",""
117209,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide is metabolised by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117211,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117212,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117215,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
117216,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.,""
123729,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123730,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. Zonisamide is a weak inhibitor of P-gp but is unlikely to have a significant effect on cabotegravir exposure. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123731,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C8. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123732,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with zotepine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
116034,"The dolutegravir dose (50 mg) in Dovato is insufficient when coadministered with some medications that may decrease dolutegravir concentrations. An additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato (dolutegravir/lamivudine), is recommended with these medications.",""
116054,Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with additional lamivudine.,""
123733,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (by CYP2D6 and CYP3A4) and glucuronidation. Cabotegravir and rilpivirine do not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur when coadministered with zuclopenthixol. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes",""
116045,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with etravirine would be possible from a pharmacokinetic standpoint. The European product label for Dovato recommends an additional 50 mg tablet of dolutegravir should be administered, approximately 12 hours after Dovato, during coadministration with etravirine without boosted protease inhibitors but no dose adjustment is necessary for etravirine with boosted protease inhibitors. Coadministration of dolutegravir and etravirine (without boosted protease inhibitors) decreased dolutegravir AUC, Cmax and Cmin by 71%, 52% and 88%, respectively. There was no change in etravirine pharmacokinetics. Coadministration of etravirine (with lopinavir/ritonavir) increased dolutegravir AUC, Cmax and Cmin by 11%, 7% and 28%, respectively; there was no change in lopinavir, ritonavir or etravirine pharmacokinetics. Coadministration of etravirine (with darunavir/ritonavir) decreased dolutegravir AUC, Cmax and Cmin by 25%, 12% and 36%, respectively; there was no change in darunavir, ritonavir or etravirine pharmacokinetics. No interaction is expected with lamivudine.",""
116055,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
116048,"Dovato (dolutegravir/lamivudine) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, products containing emtricitabine should not be administered with products containing lamivudine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.",""
116067,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ritonavir would be possible from a pharmacokinetic standpoint. Based on studies with boosted PIs, ritonavir is not expected to significantly affect dolutegravir pharmacokinetics. Using cross-study comparisons to historical pharmacokinetic data, dolutegravir did not appear to affect the pharmacokinetics of ritonavir. No interaction is expected with lamivudine.",""
116049,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment with abacavir is needed, dolutegravir and lamivudine are available coformulated with abacavir as a fixed dose combination (Triumeq).",""
116036,"Dovato (dolutegravir/lamivudine) and Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. In addition, Dovato contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine. Furthermore, coadministering two integrase inhibitors (i.e., elvitegravir and dolutegravir) is unlikely to be of clinical benefit.",""
115901,"Coadministration with Dovato (dolutegravir/lamivudine)&nbsp;has not been studied but is expected to substantially decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by phenytoin. The US Prescribing Information advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato (dolutegravir/lamivudine), should be taken. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.&nbsp;No significant interaction is expected with lamivudine.&nbsp;",""
115891,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. No significant interaction is expected with lamivudine. However, the dolutegravir dose (50 mg) in Dovato is insufficient when coadministered with certain drugs (such as carbamazepine) that may decrease dolutegravir concentrations.&nbsp;Coadministration of carbamazepine (300 mg twice daily) and dolutegravir alone (50 mg once daily) decreased dolutegravir Cmax, AUC and Cmin by 33%, 49% and 73%, respectively. The European and US product labels for Dovato recommend that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.",""
115812,"Coadministration has not been studied and is contraindicated in the US product label for Dovato. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). Dolutegravir is an inhibitor of OCT2 and therefore can increase dofetilide exposure and thereby increase the risk of cardiac arrhythmias. There is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug.",""
115950,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. Metformin is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. A clinically relevant drug interaction with lamivudine is unlikely in the range of observed clinical concentrations. Coadministration of metformin (500 mg twice daily) was studied with dolutegravir alone (50 mg once or twice daily) in 15 subjects. Coadministration with once daily dolutegravir increased metformin Cmax and AUC by 66% and 79%, whereas coadministration with twice daily dolutegravir increased metformin Cmax and AUC by 111% and 145%. A dose adjustment of metformin should be considered when starting and stopping coadministration of Dovato with metformin in order to maintain glycaemic control. Monitoring renal function during coadministration and monitoring blood glucose when starting and stopping coadministration is recommended. As metformin is eliminated renally, patients with moderate renal impairment may be at increased risk for lactic acidosis due to increased metformin concentrations.",""
116424,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. Mannitol is metabolised only very slightly, if at all, to glycogen in the liver and is predominantly eliminated unchanged via glomerular filtration. No interaction is expected with dolutegravir. However, coadministration may decrease lamivudine concentrations. When possible, avoid chronic coadministration of Dovato with medicinal products containing osmotic acting poly-alcohols or monosaccharide alcohols (e.g., mannitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.",""
116250,"Coadministration with dolutegravir/lamivudine has not been studied. Ranitidine is excreted via the kidney, partially by the cationic system. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction was observed with lamivudine.",""
116263,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. Calcium is eliminated through faeces, urine and sweat. No interaction with lamivudine is expected. Simultaneous coadministration of calcium carbonate (1200 mg) and dolutegravir (50 mg single dose) to fasting subjects decreased dolutegravir Cmax, AUC and Cmin by 37%, 39% and 39%, respectively. Simultaneous coadministration to fed subjects increased dolutegravir Cmax, AUC and Cmin by 7%, 9% and 8%, respectively. Coadministration of calcium carbonate 2 h after dolutegravir had no effect on dolutegravir Cmax and decreased dolutegravir AUC and Cmin by 6% and 10%, respectively. When taken with food, Dovato and supplements containing calcium can be taken at the same time. Under fasting conditions, Dovato should be taken 2 hours before or 6 hours after taking supplements containing calcium.",""
116280,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. No interaction is expected with lamivudine. Administration of an iron supplement (ferrous fumarate 324 mg) simultaneously under fed conditions or 2 hours after dolutegravir had no significant effect on dolutegravir exposure. However, when coadministered simultaneously in the fasted state, dolutegravir AUC and Cmax decreased by 54% and 57%, respectively. When taken with food, Dovato and supplements containing iron can be taken at the same time. Under fasting conditions, Dovato should be taken 2 hours before or 6 hours after taking supplements containing iron.",""
116286,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. No interaction is expected with lamivudine. Dolutegravir binds to divalent cations such as magnesium, iron or calcium and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed. Divalent cations can be found in multivitamins. The simultaneous coadministration of a multivitamin preparation decreased dolutegravir AUC by 33%. When taken with food, Dovato and multivitamins can be taken at the same time. Under fasting conditions, Dovato should be taken 2 hours before or 6 hours after taking supplements containing calcium or iron.",""
123737,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Cabotegravir was shown to have no inhibitory or inducing effects on CYP1A2, CYP2C9 and CYP2C19 at clinically relevant concentrations.",""
123738,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion and in vitro studies have shown it may competitively inhibit the renal transporters OAT1, OAT3 and OAT4. Cabotegravir does not cause clinically relevant inhibition of renal transporters and is unlikely to be affected by inhibition of OATs.",""
116076,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of multiple doses of elbasvir/grazoprevir and dolutegravir had no clinically relevant effect on the pharmacokinetics of grazoprevir, elbasvir or dolutegravir. Coadministration of dolutegravir (50 mg single dose) and elbasvir + grazoprevir (50 + 200 mg once daily) to 12 subjects decreased elbasvir AUC, Cmax and C24 by 2%, 3% and 2%, respectively, and decreased grazoprevir AUC, Cmax and C24 by 19%, 36% and 14%, respectively. Dolutegravir AUC, Cmax and Ctrough increased by 16%, 22% and14%, respectively. No interaction with lamivudine is expected.",""
116089,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is metabolised by UGT1A1 (major) and CYP3A (minor), neither of which is affected by sofosbuvir. Coadministration of sofosbuvir (400 mg once daily) and dolutegravir (50 mg once daily) decreased sofosbuvir Cmax and AUC by 12% and 8%. GS-331007 (sofosbuvir metabolite) Cmax increased by 1%, whereas AUC and Cmin both decreased by 1%. An interaction with lamivudine is unlikely as lamivudine is predominately cleared unchanged by renal excretion. Sofosbuvir is a prodrug and formation of its active metabolite is unlikely to be affected by comedications.",""
116109,Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of midazolam (3 mg) and dolutegravir alone (25 mg once daily) to 10 subjects had no clinically relevant effect on the pharmacokinetics of midazolam (AUC decreased by 5%). No interaction is expected with lamivudine.,""
116485,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of prednisone (60 mg once daily with taper) and dolutegravir (50 mg once daily) had no clinically significant effect on the pharmacokinetics of dolutegravir (Cmax, AUC and Ctrough increased by 6%, 11% and 17%, respectively). No interaction is expected with lamivudine.",""
123739,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.,""
123740,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as acitretin undergoes isomerisation and glucuronidation. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
116227,"Coadministration with dolutegravir/lamivudine has not been studied. Coadministration of dolutegravir (50 mg twice daily) and a combined oral contraceptive (COC) containing norgestimate/ethinylestradiol (0.25/0.035 mg) had no clinically relevant effect on the pharmacokinetics of norgestimate, norgestromin (the active metabolite of norgestimate) or ethinylestradiol. Dolutegravir had no pharmacodynamic effect on luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone. No interaction is expected with lamivudine.",""
116210,"Coadministration with dolutegravir/lamivudine has not been studied. Coadministration of ethinyl estradiol (0.035 mg) and dolutegravir (50 mg twice daily) had no clinically relevant effect on the pharmacokinetics of ethinyl estradiol (Cmax decreased by 1%, AUC and Ctrough increased by 3% and 2%). Dolutegravir had no pharmacodynamic effect on luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone. No interaction is expected with lamivudine.",""
123743,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.,""
123744,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Adrenaline is rapidly inactivated, mostly in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Cabotegravir does not interfere with this metabolic pathway.",""
123745,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. African potato was shown to inhibit CYP3A4 and P-gp in vitro and to activate PXR suggesting that inhibition may occur initially followed by induction of CYP3A4 and P-gp when used for extended periods. Inhibition of CYP3A4 is not problematic because cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Furthermore, inhibition of P-glycoprotein is unlikely to significantly impact cabotegravir intestinal absorption due to its high permeability. Finally, moderate inducers like rifabutin were shown to cause a not clinically significant effect on cabotegravir exposure.",""
123746,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123747,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized by CYP3A4 and by the flavine-containing monooxygenase system. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116547,"Coadministration has not been studied and is contraindicated in the US Prescribing Information for Triumeq. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). Dolutegravir is an inhibitor of OCT2 and therefore can increase dofetilide exposure and thereby increase the risk of cardiac arrhythmias. There is potential for competition with lamivudine for active renal transport mechanisms, which may lead to increased levels of either drug. No interaction is expected with abacavir.",""
123749,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123750,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcuronium is predominantly excreted unchanged via the kidneys possibly via active tubular secretion. However, cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
116780,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with etravirine would be possible from a pharmacokinetic standpoint, but only if also coadministered with atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir.&nbsp;Etravirine significantly reduced plasma concentrations of dolutegravir, but the effect of etravirine was mitigated by coadministration of lopinavir/ritonavir or darunavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir. Coadministration of etravirine (200 mg twice daily) and dolutegravir (50 mg once daily) decreased dolutegravir Cmax, AUC and Ctrough by 52%, 71% and 88%, respectively. When the same doses were coadministered in the presence of ritonavir-boosted darunavir or lopinavir, dolutegravir Cmax, AUC and Ctrough decreased by 12%, 25% and 37%, respectively, with darunavir/lopinavir and increased by 7%, 11% and 28%, respectively, with lopinavir/ritonavir. When compared to historical data, dolutegravir did not appear to affect the pharmacokinetics of etravirine. No interaction is expected with abacavir or lamivudine.",""
116788,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. Triumeq contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine.",""
116771,"Triumeq (dolutegravir, abacavir, lamivudine) and Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. In addition, Triumeq contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine. Furthermore, coadministering two integrase inhibitors (i.e., elvitegravir and dolutegravir) is unlikely to be of clinical benefit.",""
116769,"The dolutegravir dose (50 mg) in Triumeq is insufficient when coadministered with some medications that may decrease dolutegravir concentrations. The European product label for Triumeq does not recommend coadministration with these medications. However, the US product label for Triumeq recommends that if additional dolutegravir is required, a dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken.",""
123752,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes CYP3A4 metabolism, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
123753,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Alfuzosin is metabolised mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
123754,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized by CYP450 but is a substrate of P-glycoprotein. Cabotegravir does not inhibit or induce CYP enzymes or P-glycoprotein at clinically relevant concentrations.,""
116810,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of dolutegravir (50 mg once daily) and daclatasvir (60 mg once daily) had no significant effect on daclatasvir AUC (2% decrease), Cmax (3% increase) or Cmin (6% increase). There was no clinically relevant change in dolutegravir exposure (AUC, Cmax and Cmin increased by 33%, 29% and 45%, respectively). No interaction with abacavir or lamivudine is expected.",""
123755,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Cabotegravir does not interfere with this metabolic pathway.,""
123756,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized (mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123757,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro but this is not problematic because cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
116973,Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir and no interaction was observed with lamivudine.,""
116635,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine)&nbsp;has not been studied but is expected to substantially decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by phenobarbital. The European and the US product labels for Triumeq do not recommend coadministration with phenobarbital. However, the US product label for Triumeq mentions that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, can be taken in presence of carbamazepine, another anticonvulsant with inducing properties. A significant effect on abacavir is unlikely as abacavir is only partly metabolised by glucuronidation.&nbsp;No significant interaction is expected with lamivudine.",""
117156,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. There is a possible interaction with abacavir given the common pathway of elimination via alcohol dehydrogenase, however, there are insufficient data to recommend dosage adjustment.",""
123758,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2, with in vivo data suggesting that CYP1A2 plays a more prominent role. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
117159,"Coadministration with Triumeq (dolutegravir, lamnivudine, abacavir) has not been studied. Mannitol is metabolised only very slightly, if at all, to glycogen in the liver and is predominantly eliminated unchanged via glomerular filtration. No interaction is expected with dolutegravir or abacavir. However, coadministration may decrease lamivudine concentrations. When possible, avoid chronic coadministration of Triumeq with medicinal products containing osmotic acting poly-alcohols or monosaccharide alcohols (e.g., mannitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided.",""
116998,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Calcium is eliminated through faeces, urine and sweat. No interaction with abacavir or lamivudine is expected. Simultaneous coadministration of calcium carbonate (1200 mg) and dolutegravir (50 mg single dose) to fasting subjects decreased dolutegravir Cmax, AUC and Cmin by 37%, 39% and 39%, respectively. Simultaneous coadministration to fed subjects increased dolutegravir Cmax, AUC and Cmin by 7%, 9% and 8%, respectively. Coadministration of calcium carbonate 2 h after dolutegravir had no effect on dolutegravir Cmax and decreased dolutegravir AUC and Cmin by 6% and 10%, respectively. Triumeq should be administered 2 hours before or 6 hours after taking medications containing polyvalent cations, such as calcium supplements. The US product label for Triumeq suggests that, alternatively, Triumeq and calcium supplements can be taken together with food.",""
116971,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Triumeq (dolutegravir/abacavir lamivudine) should be administered 2 hours before or 6 hours after taking medications containing polyvalent cations, such as antacids. Simultaneous coadministration of dolutegravir (50 mg once daily) and a magnesium/aluminium containing antacid (Maalox) decreased dolutegravir Cmax, AUC and Ctrough by 72%, 74% and 74%, respectively. When antacid was administered 2 hours after dolutegravir (50 mg once daily, n=16), dolutegravir Cmax, AUC and Ctrough decreased by 18%, 26% and 30%, respectively. No interaction is expected with abacavir or lamivudine. Coadministration with antacids containing calcium carbonate has not been studied.",""
117015,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. No interaction is expected with abacavir or lamivudine. Administration of an iron supplement (ferrous fumarate 324 mg) simultaneously under fed conditions or 2 hours after dolutegravir had no significant effect on dolutegravir exposure. However, when coadministered simultaneously in the fasted state, dolutegravir AUC and Cmax decreased by 54% and 57%, respectively. Administer Triumeq 2 hours before or 6 hours after taking supplements containing iron. The US product information for Triumeq suggests that, alternatively, Triumeq and supplements containing iron can be taken together with food.",""
123759,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
116685,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Metformin is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. No interaction is expected with abacavir and a clinically relevant drug interaction with lamivudine is unlikely in the range of observed clinical concentrations. However, coadministration with dolutegravir increased metformin exposure. Coadministration of metformin (500 mg twice daily) was studied with dolutegravir alone (50 mg once or twice daily) in 15 subjects. Coadministration with once daily dolutegravir increased metformin Cmax and AUC by 66% and 79%, whereas coadministration with twice daily dolutegravir increased metformin Cmax and AUC by 111% and 145%. A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin in order to maintain glycaemic control. The US product label for Triumeq suggests limiting the total daily dose of metformin to 1000 mg when starting metformin or Triumeq. Monitoring renal function during coadministration and monitoring blood glucose when starting and stopping coadministration is recommended. As metformin is eliminated renally, patients with moderate renal impairment may be at increased risk for lactic acidosis due to increased metformin concentrations.",""
117006,"Coadministration has not been studied. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. A pharmacokinetic interaction is unlikely with folic acid itself and dolutegravir, abacavir or lamivudine. However, folic acid may be administered in a multivitamin preparation which may also contain polyvalent cations. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116981,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Omeprazole is mainly metabolized by CYP2C19 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of omeprazole (40 mg once daily) and dolutegravir (50 mg single dose) had no clinically significant effect on the pharmacokinetics of dolutegravir (Cmax, AUC and Ctrough decreased by 8%, 3% and 5%, respectively). No interaction is expected with abacavir or lamivudine.",""
116844,Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of midazolam (3 mg) and dolutegravir alone (25 mg once daily) to 10 subjects had no clinically relevant effect on the pharmacokinetics of midazolam (AUC decreased by 5%). No interaction is expected with abacavir or lamivudine.,""
123760,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated in the kidney by glomerular filtration and active secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
123761,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Cabotegravir does not inhibit or induce CYP or UGT enzymes, P-glycoprotein, or OATP1B1 at clinically relevant concentrations.",""
116945,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Coadministration of ethinyl estradiol (0.035 mg) and dolutegravir (50 mg twice daily) had no clinically relevant effect on the pharmacokinetics of ethinyl estradiol (Cmax decreased by 1%, AUC and Ctrough increased by 3% and 2%). Dolutegravir had no pharmacodynamic effect on luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone. No interaction is expected with abacavir or lamivudine.",""
123763,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged by the kidney with in vitro data indicating that it is a substrate of OCT2. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
123764,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Theophylline is mainly metabolized by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123765,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Amiodarone inhibits intestinal P-gp but this is unlikely to significantly alter cabotegravir absorption due to its high permeability.",""
117090,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. The chronic use of alcohol may induce CYP2E1 and to a lesser extent CYP3A4, however, no interaction with dolutegravir is expected as CYP3A4 does not play a major role in dolutegravir metabolism. Abacavir has no effect on the pharmacokinetics of alcohol, but alcohol increase abacavir AUC by 41%, however, this is unlikely to be clinically significant. No interaction is expected with lamivudine.",""
123766,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally, possibly via OCT. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
123767,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123768,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
116611,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. No pharmacokinetic interaction is expected with abacavir, however, abacavir has been shown to potentiate platelet activation in vitro and thereby may reduce the pharmacodynamic effect of clopidogrel. An alternative NRTI or antiplatelet agent should be considered.",""
123769,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is metabolized mainly by CYP2C8. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123770,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion via OAT3. Cabotegravir does not cause clinically relevant inhibition of renal transporters,""
116058,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with atazanavir. Coadministration of atazanavir alone and dolutegravir increased dolutegravir AUC, Cmax and Ctrough by 91%, 50% and 180%, respectively. No significant effect on lamivudine and zidovudine concentrations was observed when atazanavir (400 mg once daily) was coadministered with lamivudine/zidovudine (150/300 mg twice daily).",""
116922,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methotrexate is predominantly eliminated via the kidneys, including active tubular secretion (OAT1, OAT3 mediate methotrexate transport in the kidney whereas MRP4 and BCRP mediate methotrexate efflux in the urine). No interaction is expected with dolutegravir or abacavir. There is no risk for competition for active renal transport mechanisms as lamivudine is eliminated by other renal transporters. Note, some methotrexate product labels contraindicate its use or advise caution in immunodeficiency and some contraindicate its use in HIV infection.",""
117113,Coadministration has not been studied. Mycophenolate is mainly glucuronidated by UGT1A9 and 2B7. No interaction is expected with dolutegravir as it is primarily glucuronidated by UGT1A1 and is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine. Mycophenolate had no significant effect on abacavir plasma concentrations or intracellular phosphorylated metabolites. NRTIs which are also glucuronidated (i.e. abacavir or zidovudine) could alter mycophenolate levels. Concentration monitoring of mycophenolate may be considered.,""
116523,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Coadministration of methadone (16-150 mg) and dolutegravir (50 mg twice daily) had no effect on methadone Cmax, and decreased AUC and Ctrough by 2% and 1%, respectively. No effect on methadone pharmacokinetics was observed following a single dose of lamivudine/zidovudine (150/300 mg) to subjects stable on methadone maintenance therapy (AUC and Cmax increased by ~2% and Cmin decreased by ~3%). Coadministration of abacavir (600 mg twice daily) and methadone had no clinically significant effect on abacavir pharmacokinetics but methadone clearance increased by 22%. A methadone dose modification will not be required in the majority of patients; however, an increased methadone dose may be required in a small number of patients.",""
116084,"Coadministration with dolutegravir/lamivudine has not been studied. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and dolutegravir alone (50 mg once daily) or abacavir/lamivudine alone (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, dolutegravir or lamivudine. No dose adjustment is required.",""
116818,"Coadministration has not been studied. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and dolutegravir alone (50 mg once daily) or abacavir/lamivudine alone (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, dolutegravir, abacavir, or lamivudine. No dose adjustment is required.",""
115776,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Norbuprenorphine, an active metabolite, can further undergo glucuronidation (via UGT1A3 and UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations. Coadministration of buprenorphine and lamivudine (with didanosine and tenofovir-DF) had no significant effect on buprenorphine pharmacokinetics or NRTI concentrations when compared to control data.",""
116511,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Norbuprenorphine, an active metabolite, can further undergo glucuronidation (via UGT1A3 and UGT1A1). Dolutegravir is not expected to inhibit or induce CYP450 or UGT enzymes at clinically relevant concentrations and no interaction is expected with abacavir. Coadministration of buprenorphine and lamivudine (with didanosine and tenofovir-DF) had no significant effect on buprenorphine pharmacokinetics or NRTI concentrations when compared to control data.",""
116801,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lopinavir/ritonavir would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of lopinavir and dolutegravir decreased dolutegravir AUC and C24 by 4% and 6% and had no effect on Cmax; there was no effect on lopinavir or ritonavir. Coadministration of lopinavir and abacavir decreased abacavir AUC by 32%. No change in the pharmacokinetics of lopinavir was observed with lamivudine in clinical studies.",""
116791,"Triumeq (dolutegravir, abacavir, lamivudine) can be used as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with tenofovir-DF would be possible from a pharmacokinetic standpoint.&nbsp;No clinically significant pharmacokinetic interaction was observed between tenofovir-DF and dolutegravir, abacavir or lamivudine. Coadministration of tenofovir-DF (300 mg once daily) and dolutegravir (50 mg once daily) decreased dolutegravir Cmax and Ctrough by 3% and 8%, and increased AUC by 1%. Tenofovir Cmax, AUC and Ctrough increased by 9%, 12% and 19%, respectively. No significant pharmacokinetic interaction was observed when tenofovir-DF (300 mg once daily) and lamivudine (150 mg twice daily for 7 days) were coadministered. There was no change in AUC, Cmax or Cmin of tenofovir. Lamivudine AUC and Cmin were unaltered, and there was a 24% decrease in Cmax. Coadministration of tenofovir-DF (300 mg once daily) and abacavir (300 mg single dose) had no effect on tenofovir AUC or Cmax, and abacavir AUC; abacavir Cmax increased by 12%.",""
116900,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interaction is expected with dolutegravir or abacavir. A clinical study reported that antiretroviral regimens containing lamivudine had no effect on the pharmacokinetics of liposomal daunorubicin.,""
116165,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interaction is expected with dolutegravir. A clinical study reported that antiretroviral regimens containing lamivudine had no effect on the pharmacokinetics of liposomal daunorubicin.,""
123771,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Amphetamine is metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116081,Coadministration with dolutegravir/lamivudine alone has not been studied. Coadministration of glecaprevir/pibrentasvir and dolutegravir/lamivudine/abacavir (Triumeq) was evaluated as part of a Phase 1 study and showed no clinically significant interaction with glecaprevir/pibrentasvir. No dose adjustment is required.,""
116368,Coadministration with dolutegravir/lamivudine has not been studied. Nonpegylated interferon alpha appears to be metabolized principally in the kidney. No interaction is expected with dolutegravir and no pharmacokinetic interaction was observed with lamivudine.,""
116955,Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Coadministration of medroxyprogesterone and lamivudine (with zidovudine and efavirenz) did not the affect the pharmacokinetics of medroxyprogesterone. Coadministration with a medroxyprogesterone sub-cutaneous depot injection has not been studied.,""
116220,Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of medroxyprogesterone and lamivudine (with zidovudine and efavirenz) did not the affect the pharmacokinetics of medroxyprogesterone. Coadministration with a medroxyprogesterone sub-cutaneous depot injection has not been studied.,""
116187,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methotrexate is predominantly eliminated via the kidneys, including active tubular secretion (OAT1, OAT3 mediate methotrexate transport in the kidney whereas MRP4 and BCRP mediate methotrexate efflux in the urine). No interaction is expected with dolutegravir. There is no risk for competition for active renal transport mechanisms as lamivudine is eliminated by other renal transporters. Note, some methotrexate product labels contraindicate its use or advise caution in immunodeficiency and some contraindicate its use in HIV infection.",""
116827,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily by urinary excretion as unchanged drug. The renal clearance of telbivudine approaches normal glomerular filtration rate, suggesting that filtration is the main mechanism of excretion. No interaction is expected with dolutegravir or abacavir. Coadministration of telbivudine (200 mg once daily) and lamivudine (100 mg once daily) to 16 subjects had no significant effect on telbivudine Cmax and AUC (both increased by ~6%) or lamivudine Cmax and AUC (decreased by 14% and 1%). Although doses studied were lower than used in clinical practice, no interaction is expected at clinically relevant doses.",""
116069,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. If intensification of HIV treatment is needed, alternatives to tipranavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of dolutegravir have not been established. Coadministration with other antiretroviral drugs for the treatment of HIV-1 infection is not recommended in the US Prescribing Information for Dovato. However, the European product label for Dovato recommends an additional 50 mg tablet of dolutegravir should be administered, approximately 12 hours after Dovato, during coadministration with tipranavir. Coadministration of dolutegravir and tipranavir decreased dolutegravir AUC, Cmax and Cmin by 59%, 47% and 76%, respectively. There was no change in tipranavir or ritonavir pharmacokinetics.",""
116086,Coadministration has not been studied. Ribavirin is partly metabolized (non CYP mediated) and partly excreted in the urine. Based on metabolism and clearance a pharmacokinetic interaction is unlikely with dolutegravir and no pharmacokinetic interaction was observed with lamivudine.,""
115869,"Coadministration with dolutegravir/lamivudine has not been studied. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with trimethoprim and sulfamethoxazole. In vitro data indicate that trimethoprim inhibits the renal transporters OCT2 and MATE1. Coadministration with trimethoprim increased lamivudine exposure by 43%, but lamivudine had no effect on trimethoprim or sulfamethoxazole. Note, the bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in liquid formulations such trimethoprim/sulfamethoxazole paediatric suspension.",""
116236,"Coadministration with Dovatoa (dolutegravir/lamivudine) has not been studied. Dovato should be administered 2 hours before or 6 hours after taking medications containing polyvalent cations, such as antacids. Simultaneous coadministration of dolutegravir (50 mg once daily) and a magnesium/aluminium containing antacid (Maalox) decreased dolutegravir Cmax, AUC and Ctrough by 72%, 74% and 74%, respectively. When antacid was administered 2 hours after dolutegravir (50 mg once daily), dolutegravir Cmax, AUC and Ctrough decreased by 18%, 26% and 30%, respectively. Coadministration with antacids containing calcium carbonate has not been studied. No interaction is expected with lamivudine.",""
116721,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Amodiaquine is mainly metabolized by CYP2C8 to N-desethylamodiaquine, an active metabolite but less potent than the parent compound. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of dolutegravir and artesunate-amodiaquine had no significant effect on the AUC of amodiaquine or on the AUCs of artesunate and its metabolites. No interaction is expected with abacavir or lamivudine. Standard doses of artesunate-amodiaquine can be used in patients receiving 50 mg dolutegravir once daily.",""
117143,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19 and is unlikely to significantly inhibit CYP3A4, UGT1A1 or intestinal transporters in the range of doses in clinical use. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir or lamivudine.",""
116408,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19 and is unlikely to significantly inhibit CYP3A4, UGT1A1 or intestinal transporters in the range of doses in clinical use. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.",""
116265,"Coadministration has not been studied. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. No interaction is expected with lamivudine. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with dolutegravir and vitamin D given as a single agent (i.e. not with calcium or in a multivitamin preparation) or as an injection. However, colecalciferol can be found in multivitamin preparations. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
117021,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. No interaction is expected with abacavir or lamivudine. Dolutegravir binds to divalent cations such as magnesium, iron or calcium and forms a complex at the level of the gastro-intestinal tract which results in less dolutegravir being absorbed. Divalent cations can be found in multivitamins. The simultaneous coadministration of a multivitamin preparation decreased dolutegravir AUC by 33%. Triumeq should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
123773,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ampicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters,""
116962,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Coadministration of dolutegravir (50 mg twice daily) and a combined oral contraceptive (COC) containing norgestimate/ethinylestradiol (0.25/0.035 mg) had no clinically relevant effect on the pharmacokinetics of norgestimate, norgestromin (the active metabolite of norgestimate) or ethinylestradiol. Dolutegravir had no pharmacodynamic effect on luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone. No interaction is expected with abacavir or lamivudine.",""
116583,"Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Dolutegravir is unlikely to interfere with this metabolic pathway and no interaction is expected with abacavir or lamivudine. However, a study of coadministration of dolutegravir and isoniazid with rifapentine was ended early due to intolerance. In healthy volunteers receiving weekly isoniazid and rifapentine, the addition of dolutegravir resulted in flu-like symptoms and LFT elevations in 2 out of 4 patients (with higher than expected isoniazid concentrations), leading to study termination. Limited pharmacokinetic data suggested lower dolutegravir exposure. Intolerance is likely to be related to rifapentine (+/- healthy volunteer status) rather than isoniazid, since in the INSPIRING study, the addition of dolutegravir to daily isoniazid and rifampicin was well tolerated in 69 HIV-TB coinfected adults at 24 week analysis.",""
123774,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated by UGT1A4. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
116978,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir or lamivudine.,""
116975,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is mainly metabolized by CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir or lamivudine.,""
116240,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is mainly metabolized by CYP2C19. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with lamivudine.,""
123776,"Coadministration has not been studied. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations contained in antacids resulting in a reduced absorption of cabotegravir. Antacids containing divalent cations should be administered at least 2 hours before or 4 hours after oral cabotegravir. ",""
123778,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apixaban is metabolized by CYP3A4 and to a lesser extent CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
116271,"Coadministration has not been studied. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. A pharmacokinetic interaction is unlikely with folic acid itself and dolutegravir or lamivudine. However, folic acid may be administered in a multivitamin preparation which may also contain polyvalent cations. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
123779,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
115848,"Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Dolutegravir is unlikely to interfere with this metabolic pathway and no interaction is expected with lamivudine. However, a study of coadministration of dolutegravir and isoniazid with rifapentine was ended early due to intolerance. In healthy volunteers receiving weekly isoniazid and rifapentine, the addition of dolutegravir resulted in flu-like symptoms and LFT elevations in 2 out of 4 patients (with higher than expected isoniazid concentrations), leading to study termination. Limited pharmacokinetic data suggested lower dolutegravir exposure. Intolerance is likely to be related to rifapentine (+/- healthy volunteer status) rather than isoniazid, since in the INSPIRING study, the addition of dolutegravir to daily isoniazid and rifampicin was well tolerated in 69 HIV-TB coinfected adults at 24 week analysis.",""
116243,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor). Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with lamivudine.,""
116729,Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Lumefantrine is metabolized predominantly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of dolutegravir alone (50 mg once daily) and artemether-lumefantrine to 7 subjects had no clinically significant effect on the pharmacokinetics of artemether or lumefantrine (Cmax and AUC increased by 12% and 10%). No interaction is expected with abacavir or lamivudine. Standard doses of artemether-lumefantrine can be used in patients receiving 50 mg dolutegravir once daily.,""
115788,"Coadministration with dolutegravir/lamivudine has not been studied. Coadministration of methadone (16-150 mg) and dolutegravir (50 mg twice daily) had no effect on methadone Cmax, and decreased AUC and Ctrough by 2% and 1%, respectively. No effect on methadone pharmacokinetics was observed following a single dose of lamivudine/zidovudine (150/300 mg) to subjects stable on methadone maintenance therapy (AUC and Cmax increased by ~2% and Cmin decreased by ~3%). No dose adjustment is necessary for methadone, dolutegravir or lamivudine.",""
115994,Coadministration with dolutegravir/lamivudine has not been studied. Lumefantrine is metabolized predominantly by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of dolutegravir alone (50 mg once daily) and artemether-lumefantrine to 7 subjects had no clinically significant effect on the pharmacokinetics of artemether or lumefantrine (Cmax and AUC increased by 12% and 10%). No interaction is expected with lamivudine. Standard doses of artemether-lumefantrine can be used in patients receiving 50 mg dolutegravir once daily.,""
123780,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
117022,"Coadministration has not been studied. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which is then metabolized by xanthine oxidase and aldehyde oxidase. Renal elimination of unchanged nicotinamide is minimal.&nbsp;No interaction is expected with abacavir or lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and nicotinamide itself. However, nicotinamide administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116819,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and dolutegravir alone (50 mg once daily) or abacavir/lamivudine alone (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, dolutegravir, abacavir or lamivudine. No dose adjustment is required.",""
123781,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
116246,"Coadministration with dolutegravir/lamivudine has not been studied. Omeprazole is mainly metabolized by CYP2C19 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of omeprazole (40 mg once daily) and dolutegravir (50 mg single dose) had no clinically significant effect on the pharmacokinetics of dolutegravir (Cmax, AUC and Ctrough decreased by 8%, 3% and 5%, respectively). No interaction is expected with lamivudine.",""
116289,"Coadministration has not been studied. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and pyridoxine itself. However, pyridoxine administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116249,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolized by CYP2C19 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with lamivudine.,""
116984,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rabeprazole is mainly metabolized by CYP2C19 and CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir or lamivudine.,""
116985,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Ranitidine is excreted via the kidney, partially by the cationic system. Data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction was observed with abacavir or lamivudine.",""
116595,Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifabutin is mainly metabolized by CYP3A4 and cholinesterase. Coadministration of rifabutin (300 mg once daily) and dolutegravir alone (50 mg once daily) had no clinically significant effect on the pharmacokinetics of dolutegravir (Cmax increased by 16%; AUC and Ctrough decreased by 5% and 30%). No interaction is expected with abacavir or lamivudine.,""
115860,Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifabutin is mainly metabolized by CYP3A4 and cholinesterase. Coadministration of rifabutin (300 mg once daily) and dolutegravir alone (50 mg once daily) had no clinically significant effect on the pharmacokinetics of dolutegravir (Cmax increased by 16%; AUC and Ctrough decreased by 5% and 30%). No interaction is expected with lamivudine.,""
123782,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aripiprazole is metabolized by CYP3A4 and CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123783,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemisinins undergo rapid metabolism via several CYP450 (CYP3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolised via UGTs 1A9 and 2B7. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123784,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. Cabotegravir does not interfere with this metabolic pathway. ,""
116596,"Coadministration decreases dolutegravir exposure. The European product label for Triumeq does not recommend coadministration with rifampicin. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken. Coadministration of rifampicin (600 mg once daily) and twice daily dolutegravir (50 mg twice daily) decreased dolutegravir Cmax, AUC and Ctrough by 43%, 54% and 72%, respectively, compared to twice daily dolutegravir alone. When coadministration of these doses was compared to once daily dolutegravir (50 mg once daily), dolutegravir Cmax, AUC and Ctrough increased by 18%, 33% and 22%, respectively. Further studies are required as to whether administering dolutegravir once daily at a dose of 100 mg can mitigate the reduction in dolutegravir exposure seen with rifampicin. Abacavir concentrations may decrease due to induction of UGTs by rifampicin, although to a moderate extent. This is unlikely to be clinically relevant as abacavir has a large therapeutic index. The interaction between lamivudine and rifampicin is unlikely to be of clinical significance as estimated population pharmacokinetic parameters for lamivudine during and after rifampicin were similar once between-occasional variability in bioavailability and absorption rate constant were accounted for.",""
116090,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Based on drug interaction studies conducted with sofosbuvir/velpatasvir, no clinically significant drug interactions have been observed with dolutegravir. Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) and dolutegravir (50 mg once daily) had no effect on the pharmacokinetic parameters of sofosbuvir (AUC and Cmax decreased by 8% and 12%), GS-331007 (AUC and Cmin both decreased by 1%, Cmax increased by 1%), velpatasvir (AUC, Cmax and Cmin decreased by 9%, 6% and 12%) or dolutegravir (AUC, Cmax and Cmin increased by 6%, 6% and 4%) was observed. Lamivudine is not expected to inhibit or induce any relevant metabolic enzymes or transporters of sofosbuvir or velpatasvir.",""
123785,"Coadministration has not been studied. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. A pharmacokinetic interaction is unlikely with vitamin C itself. However, vitamin C can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir. ",""
116828,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Coadministration of tenofovir alafenamide (10 mg once daily, with emtricitabine) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Cmin by 15%, 2% and 5%, respectively. Tenofovir alafenamide Cmax and AUC increased by 24% and 19%; tenofovir Cmax and AUC increased by 10% and 25%. No pharmacokinetic interaction is expected with lamivudine.",""
116093,"Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Coadministration of tenofovir alafenamide (10 mg once daily, with emtricitabine) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Cmin by 15%, 2% and 5%, respectively. Tenofovir alafenamide Cmax and AUC increased by 24% and 19%; tenofovir Cmax and AUC increased by 10% and 25%. No interaction is expected with lamivudine.",""
117032,"Coadministration has not been studied. No interaction is expected with abacavir or lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and thiamine itself. However, thiamine can be found in multivitamin preparations; simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
115986,"Coadministration with dolutegravir/lamivudine has not been studied. Amodiaquine is mainly metabolized by CYP2C8 to N-desethylamodiaquine, an active metabolite but less potent than the parent compound. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of dolutegravir and artesunate-amodiaquine had no significant effect on the AUC of amodiaquine or on the AUCs of artesunate and its metabolites. No interaction is expected with lamivudine. Standard doses of artesunate-amodiaquine can be used in patients receiving 50 mg dolutegravir once daily.",""
123786,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (CYP1A2 (major) and CYP3A4, 2D6 (minor)). Cabotegravir does not inhibit or induce UGT or CYP enzymes at clinically relevant concentrations.",""
123788,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetylsalicylic acid is deacetylated to form salicylic acid which is further glucuronidated. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123790,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Astemizole is metabolized by CYP2D6, CYP2J2 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123794,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated by the kidney, both by glomerular filtration and active secretion via the renal transporters OCT2 and MATE1. Cabotegravir does not cause clinically significant inhibition of renal transporters.",""
123795,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atorvastatin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
116040,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. If intensification of HIV treatment is needed, alternatives to raltegravir should be considered as coadministering two integrase inhibitors (i.e., raltegravir and dolutegravir) is unlikely to be of clinical benefit.",""
123797,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. There is, therefore, little potential for clinically significant interactions with cabotegravir.",""
123798,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4 and does not inhibit or induce CYPs or UGTs. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123799,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolized analogously to natural purines. Cabotegravir does not interfere with this metabolic pathway.,""
117243,"Dovato (dolutegravir/lamivudine) and Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) are indicated for use as complete regimens for the treatment of HIV 1 infection and should not be administered with other antiretroviral products. In addition, Dovato contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine. Furthermore, coadministering two integrase inhibitors (i.e., elvitegravir and dolutegravir) is unlikely to be of clinical benefit.",""
117235,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. Coadministration with other antiretroviral drugs for the treatment of HIV-1 infection is not recommended in the US Prescribing Information for Dovato. However, the European product label for Dovato advises that no dose adjustment is necessary with darunavir/ritonavir. Coadministration of darunavir/ritonavir and dolutegravir decreased dolutegravir AUC, Cmax and Ctrough by 22%, 11% and 38%, respectively; there was no effect on darunavir or ritonavir. No interaction is expected with lamivudine.",""
123800,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-glycoprotein and MRP2. Cabotegravir does not inhibit these transporters.,""
117227,"Dovato (dolutegravir, lamivudine) and Triumeq (dolutegravir, abacavir, lamivudine) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, both Dovato and Triumeq contain dolutegravir and lamivudine and should not be taken with any other medicinal products also containing dolutegravir and lamivudine.",""
117261,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with tenofovir-DF would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with tenofovir. No clinically significant pharmacokinetic interaction was observed between tenofovir-DF and dolutegravir or lamivudine. Coadministration of tenofovir-DF (300 mg once daily) and dolutegravir (50 mg once daily) decreased dolutegravir Cmax and Ctrough by 3% and 8%, and increased AUC by 1%. Tenofovir Cmax, AUC and Ctrough increased by 9%, 12% and 19%, respectively. Coadministration of tenofovir-DF (300 mg once daily) and lamivudine (150 mg twice daily for 7 days) had no effect on AUC, Cmax or Cmin of tenofovir. Lamivudine AUC and Cmin were unaltered, and there was a 24% decrease in Cmax.",""
117238,"Juluca (dolutegravir, rilpivirine) and Dovato (dolutegravir/lamivudine) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, both Juluca and Dovato contain dolutegravir and should not be taken with any other medicinal products also containing dolutegravir.",""
123804,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
117263,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with zidovudine. No interaction is expected with dolutegravir. No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed with coadministration of zidovudine (200 mg, single dose) and lamivudine (300 mg single dose).",""
123807,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is eliminated by hepatic metabolism (70%, exact pathway not known) and excreted unchanged in the urine (30%). There is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes. Cabotegravir does not inhibit or induce CYPs or UGT enzymes or renal drug transporters at clinically relevant concentrations.",""
117266,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/cobicistat would be possible from a pharmacokinetic standpoint.&nbsp;Atazanavir/cobicistat is expected to increase dolutegravir plasma concentrations, but dolutegravir is not expected to affect the pharmacokinetics of atazanavir/cobicistat. No interaction is expected with abacavir or lamivudine. However, cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. Atazanavir/cobicistat should not be coadministered with lamivudine in patients with creatinine clearance less than 70 ml/min.",""
117239,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with doravirine would be possible from a pharmacokinetic standpoint. Doravirine is metabolized by CYP3A4. Coadministration of dolutegravir (50 mg once daily) and doravirine (200 mg once daily) did not significantly alter doravirine exposure. Dolutegravir AUC, Cmax and Cmin were increased by 36%, 43% and 27%, respectively (n=11). These changes are not considered as clinically significant No interaction is expected with lamivudine.",""
117275,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with doravirine would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of dolutegravir (50 mg once daily) and doravirine (200 mg once daily) did not significantly alter doravirine exposure. Dolutegravir AUC, Cmax and Cmin were increased by 36%, 43% and 27%, respectively (n=11). These changes are not considered as clinically significant No interaction is expected with abacavir or lamivudine.",""
117277,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with efavirenz is expected to decrease dolutegravir exposure.&nbsp;The European product label for Triumeq does not recommend coadministration with efavirenz. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken. Coadministration of efavirenz (600 mg once daily) and dolutegravir (50 mg once daily) decreased dolutegravir Cmax, AUC and Ctrough by 39%, 57% and 75%, respectively. When compared to historical data, dolutegravir did not appear to affect the pharmacokinetics of efavirenz. Coadministration of lamivudine (150 mg twice daily) with efavirenz (600 mg once daily) increased lamivudine Cmin by 265%, but had no effect on lamivudine Cmax or AUC. Abacavir had no effect on efavirenz pharmacokinetics when abacavir, efavirenz and indinavir were coadministered.",""
117274,"Juluca (dolutegravir, rilpivirine) and Triumeq (dolutegravir, abacavir, lamivudine) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, both Juluca and Triumeq contain dolutegravir and should not be taken with any other medicinal products also containing dolutegravir.",""
123810,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bepridil is metabolized by CYP2D6 (major) and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
117250,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with indinavir or indinavir/ritonavir would be possible from a pharmacokinetic standpoint. Based on studies with other boosted PIs, indinavir/ritonavir is not expected to significantly affect dolutegravir pharmacokinetics. Coadministration of indinavir alone with lamivudine/zidovudine showed no clinically significant interactions.",""
79258,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp; An in vitro study has shown that daunorubicin was able to inhibit metabolism mediated by CYP3A4, but was unlikely to cause clinically significant drug interactions via this mechanism.",""
123812,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Betamethasone is metabolized by CYP3A4 and is a moderate inducer of CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
123813,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betrixaban is largely eliminated unchanged through biliary secretion via P-gp. Cabotegravir does not inhibit or induce P-gp.,""
123815,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123818,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited human data suggest biperiden undergoes hydroxylation in the liver. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123820,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is partly metabolized by CYP3A4 and CYP2D6 and partly eliminated unchanged in the urine. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123822,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bortezomib is mainly metabolized by CYP3A4 and 2C19 and to a lesser extent CYP1A2, 2D6 and 2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123823,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bosentan is a substrate and inducer of CYP3A4 and CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. ONo effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123824,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Drug-drug interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may also play a role. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123825,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. ,""
123826,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupivacaine is predominantly metabolized via CYP3A4, however cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
123827,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buprenorphine is mainly metabolized by CYP3A4 to form the active metabolite norbuprenorphine. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123828,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolized by CYP2B6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123829,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123830,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caffeine is mainly metabolized by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123831,"Coadministration has not been studied. Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid, an active metabolite of folinic acid. In theory, calcium could chelate with cabotegravir and potentially decrease the amount of cabotegravir available to bind to the active site of the HIV integrase. However, given that the extent of chelation is dependent on the amount of calcium, this risk is predicted to be low when administering calcium folinate in small doses at frequent intervals. Since calcium is distributed rapidly, separating the intake of cabotegravir from the IV administration of calcium folinate by 2 hours should eliminate any risk of chelation.",""
123832,"Coadministration has not been studied. Calcium is eliminated through faeces, urine and sweat. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as calcium resulting in a reduced absorption of cabotegravir. Calcium should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
123833,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is primarily metabolised by UGT1A9 and UGT2B4. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123835,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19 and is unlikely to significantly inhibit CYP3A4, UGT1A1 or intestinal transporters in the range of doses in clinical use. Cabotegravir does not inhibit or induce CYP or intestinal transporters at clinically relevant concentrations.",""
123836,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Tetrahydrocannabinol (THC, the psychoactive component of cannabis), is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123838,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug, partly by glomerular filtration and possibly partly by tubular secretion (renal transporter not identified). Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
123840,"Coadministration has not been studied. Coadministration of rifampicin (600 mg once daily) and oral cabotegravir (30 mg once daily) decreased cabotegravir AUC by 59%. A similar effect is expected with carbamazepine. Therefore, coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. ",""
123844,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123857,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly metabolized by glucuronidation via UGT2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123845,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. In vitro data indicate that caspofungin is a substrate of the hepatic transporter OATP1B1, however cabotegravir does not inhibit OATP1B1.",""
123846,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Catâ€™s claw was demonstrated to strongly inhibit CYP3A4 in vitro. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123847,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged via the kidneys (by glomerular filtration and tubular secretion via OAT1 and MATE1). Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
123848,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
123850,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine (about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite). In vitro studies indicate that OATs participate to the renal elimination of cefotaxime, but cabotegravir was shown to cause not clinically relevant inhibition of OATs.",""
123851,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ceftazidime is excreted predominantly by renal glomerular filtration,",""
123853,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is metabolised mainly by CYP2C9, however, cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
82191,"Based on metabolism and clearance, a pharmacokinetic interaction is unlikely. [Dolutegravir is available coformulated with lamivudine&nbsp;for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.]",""
123859,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123860,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized in the liver by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
69737,"Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive drugs (e.g. amphotericin) may also increase the risk of adverse reactions to zidovudine. Monitor renal function and haematological parameters and consider dose reduction if required.",""
68089,No change in the pharmacokinetics of lopinavir was observed when Kaletra was given alone or in combination with stavudine and lamivudine in clinical studies.,""
123861,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123863,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4 mediated metabolism. Cabotegravir does not interact with ciclesonide metabolism. ,""
123864,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclosporin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. ,""
123865,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1 and OAT3. Cabotegravir does not cause clinically relevant inhibition of OAT1.,""
123867,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cimetidine is primarily eliminated by the kidneys. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. ,""
106854,"Coadministration of abacavir (600 mg once daily) and atazanavir/ritonavir (300/100 mg once daily) had no effect on atazanavir or ritonavir pharmacokinetics, but decreased abacavir AUC (17%) and Cmax (20%). These changes are unlikely to be clinically significant.",""
123868,"Ciprofloxacin is primarily eliminated unchanged through the kidneys (by glomerular filtration and tubular secretion via OAT3). Cabotegravir has been shown to inhibit OAT3 in vitro. The interaction between cabotegravir and ciprofloxacin was evaluated using a PBPK model. Coadministration was shown to cause a minimal effect on ciprofloxacin exposure thus, no dosage adjustment is needed.",""
123869,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisapride is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
69608,Coadministration with didanosine gastro-resistant capsules has not been studied.&nbsp;Coadministration with didanosine buffered tablets had no effect on didanosine AUC and Cmax; zidovudine AUC and Cmax decreased by 10% and 17%. No dose adjustment is necessary.,""
69601,Coadministration with didanosine gastro-resistant capsules had no significant effect on ketoconazole AUC and Cmax.,""
69594,Coadministration with didanosine gastro-resistant capsules has not been studied.&nbsp;Coadministration with didanosine buffered tablets increased didanosine AUC and Cmax by 13% and 17%. No dose adjustment is necessary.,""
69679,Coadministration of ganciclovir and stavudine (40 mg twice daily) had no statistically significant effect on the pharmacokinetics of ganciclovir or stavudine.&nbsp;In vitro studies indicate that ganciclovir has no effect on the activation of stavudine.,""
123871,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Cisplatin is eliminated renally via OCT2 and MATE1. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
123872,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123873,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clarithromycin is a strong inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. ,""
123875,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123876,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clobazam is metabolised by CYP3A4 (major) and CYP2B6 and CYP2C19 (minor) to the active metabolite N-desmethylclobazam, which is metabolised by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Clobazam is a weak inducer. However, drug-drug interaction studies with rifabutin (a moderate inducer) have shown no clinically significant decrease in cabotegravir exposure.",""
69746,"Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive drugs (e.g. systemic pentamidine) may also increase the risk of adverse reactions to zidovudine. Monitor renal function and haematological parameters and consider dose reduction if required.&nbsp;Limited data from clinical trials do not indicate a significantly increased risk of adverse reactions to zidovudine with aerosolised pentamidine at doses used in prophylaxis.",""
106842,"Coadministration has not been studied and is not recommended.&nbsp;Coadministration of atazanavir alone (400 mg once daily) and etravirine decreased atazanavir Cmax, AUC and Cmin by 3%, 17% and 47%, respectively. Etravirine Cmax, AUC and Cmin increased by 47%, 50% and 58%, respectively, but this is not considered clinically relevant.&nbsp;Atazanavir should only be used with etravirine in the presence of low dose ritonavir.",""
69751,Coadministration of zidovudine (200 mg single dose) and lamivudine (300 mg twice daily) to 12 asymptomatic HIV-infected adult patients increased zidovudine Cmax and AUC by 28% and 13%. Zidovudine had no effect on the pharmacokinetics of lamivudine. No dose adjustments are necessary.,""
123878,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. ",""
123879,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
69752,"Coadministration should be avoided. Zidovudine and stavudine are phosphorylated by thymidine kinase which preferentially phosphorylates zidovudine, thereby decreasing the phosphorylation of stavudine to its active triphosphate form. ",""
70426,"Coadministration of lumefantrine/artemether and etravirine decreased lumefantrine AUC and Cmin by 13% and 3%, and increased Cmax by 7%. Etravirine AUC, Cmin and Cmax increased by 10%, 8% and 11%. Concentrations of artemether and dihydroartemisinin decreased.&nbsp;Caution and close monitoring of antimalarial response is warranted when co-administering etravirine and lumefantrine/artemether as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin could result in decreased antimalarial efficacy. No dose adjustment is needed for etravirine.&nbsp;",""
70317,"Coadministration with didanosine gastro-resistant capsules has not been studied. Coadministration with didanosine buffered tablets increased etravirine Cmax, AUC and Cmin by 16%, 11% and 5%, respectively; didanosine Cmax decreased by 9% and there was no change in AUC. No dose adjustment is needed for either drug.",""
123880,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. CYP2D6 is thought to have a role in clomifene metabolism. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123881,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
70320,"Coadministration of etravirine with fosamprenavir/ritonavir significantly increased amprenavir Cmax, AUC and Cmin by 62%, 69% and 77%, respectively. Coadministration is not recommended in the etravirine US product label, but the European product labels for etravirine and fosamprenavir&nbsp;advise that dose reduction of fosamprenavir may be required. [This checker reflects the more cautious option.]",""
123882,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolized by CYP3A4 and does not induce metabolizing enzymes. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123884,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites via CYPs 3A4, 2B6, 2C19 and 1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123885,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam, which is then metabolized to oxazepam by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.",""
123886,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted via glomerular filtration and tubular secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
123887,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123888,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Cocaine is metabolized by several non CYP mediated pathways, with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123889,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism. Cabotegravir does not inhibit or induce UGT or CYP enzymes at clinically relevant concentrations.",""
123890,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Colchicine is a substrate of CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects",""
123891,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for an interaction with cabotegravir.",""
123892,"Coadministration has not been studied. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. There is little potential for interaction with cabotegravir via modulation of, or competition for, metabolic pathways. No interaction is expected with vitamin D when given as a single agent (i.e. not with calcium or in a multivitamin preparation) or as an injection. However, vitamin D can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
123893,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Several constituents of Piper cubeba were shown to inhibit CYP3A4 in vitro, but there is no evidence to suggest that Piper cubeba impacts UGTs.",""
123895,"Coadministration has not been studied. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine. No interaction is expected with vitamin B12 when given as a single agent (i.e. not in a multivitamin preparation) or as an injection. However, vitamin B12 can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
123896,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
77548,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cisapride is metabolized by CYP3A4, but rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with cisapride. However, given the QT prolongation risk associated with cisapride, caution is recommended.",""
123933,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123898,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123899,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Cytarabine is metabolized by cytidine deaminase and cabotegravir does not interfere with this metabolic pathway.",""
123900,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The prodrug of dabigatran is a substrate of P-gp. Cabotegravir does not inhibit P-gp at clinically relevant concentrations.,""
123901,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Dacarbazine is activated to MTIC primarily via CYP1A2 and to a lesser extent by CYP2E1, with CYP1A1 having a role in extrahepatic metabolism. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123902,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Daclatasvir is partly metabolized by CYP3A4 and is eliminated for a large part unchanged in the bile. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. ,""
77558,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with terfenadine. However, given the QT prolongation risk associated with terfenadine, caution is recommended.",""
123934,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) whereas 50% of the drug is eliminated unchanged in the urine (possibly via OCT2). Cabotegravir does not cause clinically relevant inhibition of renal transporters and does not inhibit or induce CYP3A4.,""
123905,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is primarily metabolised by UGT1A9. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123906,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapsone is mainly metabolized by N-acetylation with a component of N-hydroxylation, and is via multiple CYP P450 enzymes. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123907,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darifenacin is metabolized by CYP3A4 and CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123908,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Induction of UGTs by ritonavir used to boost darunavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. ",""
114600,"Coadministration has not been studied. Piperaquine is a modest inhibitor of CYP3A4 and may increase rilpivirine concentrations. Rilpivirine should be used with caution when coadministered with a drug that has a potential risk to prolong the QT interval. In healthy subjects, supratherapeutic doses of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QT interval.&nbsp;",""
123911,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Dasatinib is metabolized by CYP3A4 and inhibits this same enzyme. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
123913,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123914,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway. (Note, caution is required if given with calcium supplements as cabotegravir may be subject to chelation which may result in reduced cabotegravir concentrations.)",""
123916,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123917,"Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter desogestrel exposure.",""
123918,Coadministration with a desogestrel-containing progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolised by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
70591,Coadministration has not been studied but is expected to decrease maraviroc concentrations due to induction of CYP3A4. Maraviroc dose should be increased to 600 mg twice daily when co-administered with phenobarbital in the absence of a potent CYP3A4 inhibitor. The US Prescribing Information contraindicates coadministration in patients with creatinine clearance less than 30 ml/min or on haemodialysis.,""
70042,Coadministration of a non-licensed dose of maraviroc (100 mg twice daily) and an oral contraceptive (ethinylestradiol/levonorgestrel 0.03/0.15 mg once daily) had no effect on the AUC and Cmax of either ethinylestradiol or levonorgestrel. Maraviroc pharmacokinetics were with in the range seen in male subjects.,""
123919,Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4 and a moderate inducer of this enzyme. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. No significant effect is expected on cabotegravir as indicated by a drug-drug interaction study with rifabutin (a moderate inducer).,""
123920,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGTs 1A4 and 2B10) and cytochrome P450 (mainly 2A6). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
123921,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is mainly metabolized by CYP3A, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
70912,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Maraviroc is metabolised by CYP3A4 which is not affected by peginterferon alfa. The metabolism of peginterferon alfa-2a is not fully characterized, however studies in rats indicate that the kidney is a major organ for excretion.",""
84682,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8.&nbsp;No dose adjustment of maraviroc required.,""
123922,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
123923,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolized to nordiazepam (by CYPs 3A4 and 2C19) and to temazepam (mainly by CYP3A4). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123924,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9 (catalyzes the major route of diclofenac oxidative metabolism). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
70546,"<em></em>Coadministration of ritonavir (100 mg twice daily) and a non-licensed dose of maraviroc (100 mg twice daily) increased maraviroc concentrations. The recommended dose of maraviroc when coadministered is 150 mg twice daily (except with tipranavir/ritonavir).&nbsp;The European SmPC for maraviroc recommends when coadministering potent CYP3A inhibitors and maraviroc to patients with impaired renal function (creatinine clearance less than 80 ml/min), maraviroc should be reduced to 150 mg once daily. The US Prescribing Information recommends 150 mg twice daily for patients with creatinine clearance of 30-80 ml/min and contraindicates coadministration in patients with creatinine clearance less than 30 ml/min or on haemodialysis.",""
123927,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The elimination of digoxin is dependent on P-glycoprotein, which is not inhibited by cabotegravir. ",""
88950,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with abacavir would be possible from a pharmacokinetic standpoint. Based on metabolism and clearance a clinically significant interaction with abacavir and rilpivirine, emtricitabine or tenofovir alafenamide is unlikely.",""
123928,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) via CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine via CYP3A4. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123929,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroergotamine is a substrate and inhibitor of CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. On the other hand, cabotegravir is metabolized by UGT1A1 and UGT1A9.",""
123931,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diltiazem is metabolized by CYP3A4 and is a moderate inhibitor of CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123932,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
106886,"Coadministration of raltegravir (400 mg twice daily) and atazanavir/ritonavir increased raltegravir AUC (41%), Cmax (24%) and Cmin (77%). However, concomitant use of twice daily raltegravir and atazanavir/ritonavir did not result in a unique safety signal in clinical studies, therefore, no dose adjustment of raltegravir is required when given twice daily. Coadministration of raltegravir (1200 mg single dose) and atazanavir alone increased raltegravir AUC (67%), Cmax (16%) and Cmin (26%).&nbsp;The US product label for raltegravir states that no dose adjustment is required with atazanavir/ritonavir and once daily raltegravir, however, the European label does not recommend coadministration with once daily raltegravir.",""
123935,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Disulfiram is reduced to diethyldithiocarbamic acid, is conjugated with glucuronic acid, oxidised to sulphate, methylated and decomposed to diethylamine and carbon disulphide.",""
123936,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Docetaxel is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.",""
123937,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). Cabotegravir does not cause clinically relevant inhibition of renal transporters,""
75985,"Coadministration with raltegravir (400 mg twice daily) decreased midazolam AUC by 8% and increased Cmax by 3%. No dosage adjustment is required for twice daily or once daily raltegravir, or for midazolam",""
123938,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
96981,"Coadministration with twice daily raltegravir has not been studied. Population PK analysis showed emtricitabine/tenofovir-DF had minimal effect on the&nbsp;pharmacokinetics of once daily raltegravir (12% increase in relative bioavailability). Coadministration of tenofovir-DF and raltegravir (400 mg twice daily) increased raltegravir AUC (49%) and Cmax (64%), but had no effect on Cmin; tenofovir AUC, Cmax and Cmin decreased by 10%, 23% and 13%, respectively. The safety profile observed in patients who used atazanavir and/or tenofovir-DF (both agents that increase raltegravir concentrations) was generally similar to that of patients who did not use these agents. No clinically significant interaction is expected with emtricitabine.&nbsp;No dose adjustment is required when coadministered with twice daily or once daily raltegravir.",""
72334,"Coadministration of raltegravir (400 mg twice daily) and maraviroc (300 mg twice daily) decreased maraviroc AUC (14%), Cmax (21%) and Cmin (10%). Raltegravir AUC, Cmax and Cmin were decreased by 37%, 33% and 28%, respectively. The maraviroc average concentration was greater than 100 ng/ml (the apparent threshold for increased risk of virologic failure) in all subjects. The 28% decrease in raltegravir Cmin was not considered clinically relevant. No dose adjustments are required for twice daily or once daily raltegravir, or for maraviroc.",""
75474,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Raltegravir does not interact with ciclesonide metabolism.,""
115458,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Raltegravir does not interact with flunisolide metabolism.,""
123943,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Domperidone is mainly metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
97714,"No dose adjustment is required when raltegravir 400 mg twice daily or 1200 mg once daily is coadministered. Population data from HIV+ subjects suggest that coadministration of raltegravir and darunavir/ritonavir is associated with lower darunavir trough concentrations. However, the effect of raltegravir on darunavir plasma concentrations did not appear to be clinically meaningful.&nbsp;Limited data from 6 healthy subjects indicate that coadministration with darunavir/ritonavir decreased raltegravir AUC (29%) and Cmax (33%), but increased Cmin by 38%. Darunavir pharmacokinetics were similar to historical data. Contrary to clinical experience in HIV+ patients, 8/18 subjects presented with a clinical adverse experience of rash, which progressed from mild/moderate to serious in one subject and only six subjects completed the PK study.",""
123947,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolized mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123948,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123951,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Droloxifene is mainly glucuronidated. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
93891,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and dolutegravir) is unlikely to be of clinical benefit.",""
123952,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
99080,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, both products contain emtricitabine and tenofovir alafenamide and must not be administered with other products containing emtricitabine and tenofovir alafenamide.",""
101059,"Delstrigo (doravirine, lamivudine, tenofovir-DF) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, products containing emtricitabine should not be administered with products containing lamivudine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine. Furthermore, products containing tenofovir-DF should not be coadministered with products containing tenofovir alafenamide.",""
98646,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, both products contain emtricitabine and tenofovir alafenamide and must not be administered with other products containing emtricitabine and tenofovir alafenamide.",""
123953,"Coadministration with a drospirenone-containing combined oral contraceptive (COC) has not been studied. Drospirenone is metabolized to a minor extent via CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter drospirenone exposure.",""
123954,Coadministration with drospirenone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolized to a minor extent via CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123956,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
114196,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) contains tenofovir alafenamide and must not be administered with other products containing tenofovir alafenamide. Coadministration of rilpivirine (25 mg once daily) and tenofovir alafenamide (25 mg once daily) had no significant effect on the pharmacokinetics of rilpivirine (AUC and Cmin increased by 1% and 13%, Cmax decreased by 7%). Tenofovir alafenamide Cmax and AUC were unchanged. Tenofovir Cmax, AUC and Cmin increased by 13%, 11% and 18%, respectively.",""
123957,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Dutasteride is mainly metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123958,Coadministration with dydrogesterone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123959,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Echinacea has a selective effect on CYP3A4 activity (inhibition of intestinal CYP3A4 and induction of hepatic CYP3A4) and its effect on the net exposure of a CYP3A4 substrate will depend on the extraction of the drug at the intestinal and hepatic sites. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123960,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. MDMA is metabolized mainly by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123961,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is a substrate for P-gp. Cabotegravir does not inhibit or induce P-gp.,""
123963,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eflornithine is predominantly eliminated unchanged via the kidneys.,""
123964,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elbasvir/grazoprevir are substrate of CYP3A4 and P-glycoprotein. Cabotegravir does not inhibit or induce CYP3A4 and P-glycoprotein. ,""
123965,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eletriptan is metabolised by CYP3A4 and does not induce or inhibit CYPs. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123966,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (UGTs 1A1 and 1A3) and oxidation (CYPs 1A2 and 2C8) and in vitro data indicate it is an inhibitor of UGTs 1A1 and 1A3. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Inhibition of UGT1A1 by eltrombopag is unlikely to significantly alter cabotegravir exposure as coadministration of atazanavir (a strong inhibitor of UGT1A1) was predicted to increase cabotegravir exposure by 11%.,""
93903,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, both products contain emtricitabine and tenofovir alafenamide and must not be administered with other products containing emtricitabine and tenofovir alafenamide.",""
123969,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3. Cabotegravir does not inhibit or induce UGTs or P-gp or BCRP at clinically relevant concentrations.",""
123973,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is eliminated renally (possibly via OATs). Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
123974,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enflurane is predominantly metabolized by CYP2E1, however, cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123977,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anions and cations transporters. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
123978,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ephedrine is predominantly excreted unchanged via renal pathways. There are no available data to determine whether excretion is via active tubular secretion or glomerular filtration. However, cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
123979,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Epirubicin is glucuronidated by UGT2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
123980,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Eplerenone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123983,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects,""
123984,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is a substrate and inhibitor of CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123985,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erlotinib is mainly metabolized by CYP3A4, but cabotegravir does not inhibit or induce CYP450 enzymes at clinically relevant concentrations. Erlotinib is a strong inhibitor of UGT1A1. However, based on the drug interaction study with atazanavir (another strong inhibitor of UGT1A1) this is unlikely to alter cabotegravir exposure to a clinically significant extent.",""
123987,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Erythromycin is a moderate inhibitor of CYP3A4 but No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
123988,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolized by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123989,Coadministration has not been studied. Eslicarbazepine is partly eliminated unchanged renally and partly glucuronidated by UGT2B4. Eslicarbazepine is an inducer of UGT and is expected to decrease the exposure of cabotegravir. Coadministration is contraindicated due to the potential for loss of therapeutic effect and development of resistance. ,""
123990,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Esomeprazole is mainly metabolized by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. ,""
123991,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolized to its major metabolite 4-hydroxyestazolam via CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
123992,"Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
123993,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine phosphate undergoes rapid dephosphorylation to estramustine which is then oxidized by 17beta-hydroxysteroid dehydrogenases to estromustine. Estramustine and estromustine are subsequently hydrolyzed to estradiol and estrone, respectively. Estradiol is then hydroxylated by CYPs 1A1, 1A2 and 3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
123995,Coadministration of cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. ,""
123997,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is mainly metabolized by CYP3A4 and does not induce metabolizing enzymes. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123998,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etidocaine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
123999,Coadministration with an etonogestrel-containing progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124000,"Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter etonogestrel exposure.",""
124001,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Etoposide is partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. Furthermore, etoposide is partly glucuronidated by UGT1A1. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124003,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eucalyptus is only a weak inhibitor of CYP3A4 and there is no evidence to suggest that eucalyptus impacts UGTs.",""
124004,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Everolimus is metabolized by CYP3A4 and is a modest inhibitor of CYP3A4 in vivo. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
124006,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124008,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
124009,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase, which is then eliminated in the urine, possibly by OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.",""
124010,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famotidine is eliminated by renal excretion via OAT3 (65-70%) and by metabolic routes (30-35%). Cabotegravir does not inhibit renal transporters to a clinically significant extent. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. ,""
124011,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
114573,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab but based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
114585,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab but based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Piperaquine undergoes CYP3A4 metabolism whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
114509,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Calcium folinate does not interfere with this pathway.",""
124013,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism, however, cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
69657,No pharmacokinetic or pharmacodynamic interaction was observed when ribavirin and lamivudine were coadministered as part of a multi-drug regimen to HIV-1/HCV co-infected subjects.,""
116821,"Coadministration has not been studied. Ribavirin is partly metabolized (non CYP mediated) and partly excreted in the urine. Based on metabolism and clearance a pharmacokinetic interaction is unlikely with dolutegravir. A possible intracellular interaction had been suggested as abacavir and ribavirin share the same phosphorylation pathways. However, a well-designed study to evaluate the effects of abacavir on intracellular ribavirin triphosphate and plasma ribavirin concentrations failed to show any significant effect. While some initial data suggested HIV/HCV co-infected patients receiving abacavir-containing regimens may be at risk of lower response to ribavirin therapy, this has not been confirmed in more recent studies. No pharmacokinetic interaction was observed with lamivudine.",""
124014,"Coadministration has not been studied. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as iron resulting in a reduced absorption of cabotegravir. Ferrous fumarate should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
84679,"Coadministration has not been studied. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Etravirine is a weak inhibitor of CYP2C9 but is unlikely to increase pitavastatin concentrations to a clinically significant extent. [Note, the US product label for etravirine indicates that dose adjustments for pitavastatin may be necessary.]",""
70322,"Etravirine and indinavir/ritonavir can be coadministered, however, unboosted indinavir should not be coadministered with etravirine. Coadministration of etravirine (1600 mg twice daily, phase II formulation) and indinavir (800 mg three times daily) increased etravirine AUC and Cmax both by 51%, however, indinavir AUC and Cmax decreased by 46% and 28%.",""
117103,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Nonpegylated interferon alpha appears to be metabolized principally in the kidney. No pharmacokinetic interaction is expected with dolutegravir or abacavir and no pharmacokinetic interaction was observed with lamivudine. While some initial data suggested that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/ribavirin therapy, this has not been confirmed in more recent studies.",""
100791,"Coadministration with doravirine/lamivudine/tenofovir-DF has not been studied. Nonpegylated interferon alpha appears to be metabolized principally in the kidney. No interaction is expected with doravirine and tenofovir-DF, and no pharmacokinetic interaction was observed with lamivudine.",""
124015,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124016,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine does not undergo CYP-mediated metabolism but is a substrate of P-glycoprotein. Cabotegravir does not inhibit or induce P-gp at clinically relevant concentrations.",""
124018,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects,""
124020,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion of the parent drug also eliminated unchanged renally. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124021,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flibanserin is primarily metabolized by CYP3A4 and has been shown to moderately increase the exposure of simvastatin, a CYP3A4 substrate. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
124022,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally partly by glomerular filtration and partly by active secretion via OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.,""
124023,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is a moderate inhibitor of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124026,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.",""
124027,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide is metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124028,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunitrazepam is metabolized mainly via CYPs 3A4 and 2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124030,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluorouracil is metabolised via the same mechanisms as endogenous uracil, including via dihydropyrimidine dehydrogenase. There is therefore little potential for an interaction with cabotegravir via modulation of, or competition for, metabolic pathways.",""
124031,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by CYPs 2C19 and 3A4 to form norfluoxetine. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124032,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124033,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flurazepam is most likely CYP-mediated. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124034,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124035,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolized by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124036,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124038,"Coadministration has not been studied. Folic acid is metabolized to dihydrofolic acid and tetrahydrofolic acid with the aid of reduced diphosphopyridine nucleotide and folate reductases. Cabotegravir does not interfere with this metabolic pathway. A pharmacokinetic interaction is unlikely with folic acid itself. However, folic acid can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124040,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Cabotegravir does not interfere with formestaneâ€™s metabolic pathway. ,""
124041,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation being another pathway. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124042,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost fosamprenavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. ",""
124045,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). Cabotegravir does not inhibit or induce UGT enzymes or renal drug transporters at clinically relevant concentrations.,""
124047,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ganciclovir is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1.,""
124048,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although garlic has been shown to induce intestinal P-gp, this is unlikely to affect cabotegravir exposure.",""
124049,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Gefitinib is metabolized by CYP3A4 and 2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124050,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite. Cabotegravir does not interfere with this metabolic pathway.,""
124051,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is mainly glucuronidated by UGT2B7 and in vitro data suggest that it inhibits UGT1A1 and UGT1A3. Gemfibrozil is unlikely to alter cabotegravir exposure to a clinically significant extent. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9 and the coadministration of atazanavir (a strong UGT1A1 inhibitor) was predicted to increase cabotegravir exposure by 11% only.,""
124053,"Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter gestodene exposure.",""
124054,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124055,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Gingerols moderately inhibit CYP3A4 in vitro but there is no evidence to suggest that they inhibit or induce UGTs.",""
124056,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ginkgo biloba induces CYP3A4 but is unlikely to alter cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124057,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir and pibrentasvir inhibit P-glycoprotein. Cabotegravir is a substrate of P-glycoprotein but inhibition of this transporter is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.,""
124058,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124059,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124060,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is metabolised by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124061,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is metabolized mainly by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124063,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glycopyrronium bromide is mainly eliminated renally (active secretion via organic cation transporter) and is also partly hydroxylated via multiple CYPs. Cabotegravir does not cause clinically significant inhibition of renal transporters and does not inhibit or induce CYP enzymes.,""
124064,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Goldenseal has been shown to inhibit CYP3A4 in vitro but is unlikely to alter cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124066,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Granisetron is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124067,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inhibition of intestinal CYP3A4 by grapefruit juice is not expected to affect cabotegravir as it undergoes metabolism mainly via UGT1A1 and to a lesser extent by UGT1A9.,""
124068,"Coadministration has not been studied. Griseofulvin undergoes glucuronidation and has inducing properties. Given the limited drug-drug interaction data, it is unclear whether griseofulvin can cause a clinically significant decrease in cabotegravir exposure. Therefore coadministration should be avoided.",""
124069,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124070,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGT2B7>1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, 2D6). Cabotegravir does not inhibit or induce UGT or CYP enzymes at clinically relevant concentrations.",""
124071,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that halothane undergoes oxidation (mainly via CYP2E1 and to a lesser extent CYP2A6) and reduction (via CYP2A6 and CYP3A4). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124073,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant pharmacokinetic interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorhine (6-MAM) and subsequently to morphine by plasma and liver esterase, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124074,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data indicate that extracts of hops activate PXR and induce expression of CYP3A4, CYP2B6 and MDR1 genes to a degree similar to that of St John's wort. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
124076,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised and is cleared by the kidneys via OAT1. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
124077,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Cabotegravir does not inhibit or induce CYP3A4 or CYP2D6 at clinically relevant concentrations.",""
124078,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124080,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124081,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyurea undergoes metabolism via non-CYP mediated metabolism and is unlikely to affect concentrations of cabotegravir.,""
124082,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124085,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
124086,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Ifosfamide is predominantly metabolized by CYP3A4 and CYP2B6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124087,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolised by CYP3A4 and CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124089,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent CYP1A2, 2D6, 2C9, 2C19. In vitro data indicate that imatinib inhibits CYP3A4, 2D6, 2C9, 2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
124090,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and, to a lesser extent, by active tubular secretion. Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
124091,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolized by CYPs 3A4, 2C19 and 1A2 to desipramine. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124092,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indacaterol is eliminated partly unchanged (33%) and partly metabolized by CYP3A4 and UGT1A1. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
124093,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP450, however, cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124094,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost indinavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. ",""
124098,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Alantolactone, a component of Inula racemosa, moderately inhibits CYP3A4 in vitro, but there is no evidence that Inula racemosa affects UGTs or P-gp.",""
124100,"Coadministration has not been studied. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva. A pharmacokinetic interaction is unlikely with iodine itself. However, iodine can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124102,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Irbesartan is metabolized by glucuronidation and oxidation (mainly CYP2C9). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124103,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.",""
124104,"Coadministration has not been studied. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as iron resulting in a reduced absorption of cabotegravir. Iron supplements should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124106,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Cabotegravir is unlikely to interfere with this metabolic pathway. ,""
124107,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isosorbide dinitrate undergoes extensive first past metabolism, predominantly in the liver, with less than 30% of a dose undergoing subsequent glucuronidation. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124108,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isotretinoin is metabolised mainly by CYP2C8 and CYP3A4 with the participation of CYP2B6 and CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
81020,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K.&nbsp;However, the European SPC for lopinavir advises caution when coprescribing with drugs known to induce QT interval prolongation.",""
79454,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes. However, as few data are available, care should be taken when administering oxytocin with antiretrovirals. In addition, the European SPC for lopinavir advises caution when coprescribing with drugs known to induce QT interval prolongation.",""
77575,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Quinidine is metabolized by CYP3A4. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with quinidine. However, given the QT prolongation risk associated with quinidine, caution is recommended.",""
124109,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Itraconazole is a strong inhibitor of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124110,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124111,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest ivermectin is predominantly metabolised by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
77544,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bepridil is metabolized by CYP2D6 (major) and CYP3A4. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with bepridil. However, given the QT prolongation risk associated with bepridil, caution is recommended.",""
124113,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYPs 2B6 and 2C9 in the range of concentrations used in anaesthesia. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. In addition, cabotegravir does not inhibit or induce other CYP enzymes.",""
124114,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketoconazole is a strong inhibitor of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124115,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated by UGTs 1A1 and 2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
124116,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124117,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (approximatively 30% of the dose) and is eliminated unchanged through the kidneys (approximately 40% of the dose). Cabotegravir does not inhibit or induce CYPs at clinically relevant concentrations.,""
124120,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
124121,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lansoprazole is mainly metabolized by CYP2C19. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.,""
84939,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as tiapride is excreted largely unchanged in urine. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with tiapride. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124122,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Lapatinib is metabolized by CYP3A4 and inhibits this same enzyme. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124123,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ledipasvir and sofosbuvir are weak inhibitors of intestinal P-glycoprotein and BCRP. Cabotegravir is a substrate of P-glycoprotein and BCRP but inhibition of these transporters is unlikely to significantly affect cabotegravir intestinal absorption due to its high permeability.,""
124124,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lenalidomide undergoes limited metabolism and is eliminated renally. ,""
84248,"Coadministration has not been studied. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. In vitro inhibition of P450 was shown to improve mitoxantrone cytotoxicity, however the impact on the antitumoral effect is unknown. Rilpivirine is not expected to inhibit or induce CYP enzymes at clinically relevant concentrations.&nbsp;Caution is advised due to mitoxantrone related cardiotoxicity. ECG monitoring is recommended.",""
124125,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124126,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol, an inactive metabolite. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124132,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as levofloxacin is eliminated renally mainly by glomerular filtration and active secretion (possibly OCT2). Cabotegravir does not cause clinically relevant inhibition of renal transporters.",""
124133,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
81029,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Oxaliplatin undergoes non-enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. Rilpivirine does not interfere with oxaliplatin elimination. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with oxaliplatin. However, given the QT prolongation risk associated with oxaliplatin, caution is recommended.",""
124134,Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. ,""
124135,Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Cabotegravir is unlikely to alter levonorgestrel used as emergency contraception.,""
124136,Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Cabotegravir is unlikely to alter levonorgestrel used as hormone therapy replacement.,""
124137,Coadministration with a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Cabotegravir is unlikely to alter levonorgestrel used as implant.,""
124139,Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. ,""
124140,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Levothyroxine is metabolized by deiodination (by enzymes of deiodinase family) and glucuronidation. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124141,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124142,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces, with metabolism by CYP3A4 representing a minor elimination pathway. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
79465,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase; the plasma half-life is approximately five minutes. Renal excretion of unchanged oxytocin is thought to be minimal. No interaction is expected with rilpivirine. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with oxytocin. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. As few data are available, care should be taken when administering oxytocin with antiretrovirals.",""
77673,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic&nbsp;interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with apomorphine. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124144,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glycyrrhizin, the main active component of Glycyrrhiza glabra, is a modest inducer of CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.",""
115861,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. The dolutegravir dose (50 mg) in Dovato is insufficient when coadministered with certain drugs, such as rifampicin, that may decrease dolutegravir concentrations. The European and US product labels for Dovato recommend that an&nbsp;additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. Coadministration of rifampicin (600 mg once daily) and twice daily dolutegravir (50 mg twice daily) decreased dolutegravir Cmax, AUC and Ctrough by 43%, 54% and 72%, respectively, compared to twice daily dolutegravir alone. When coadministration of these doses was compared to once daily dolutegravir (50 mg once daily), dolutegravir Cmax, AUC and Ctrough increased by 18%, 33% and 22%, respectively. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.&nbsp;Further studies are required as to whether administering dolutegravir once daily at a dose of 100 mg can mitigate the reduction in dolutegravir exposure seen with rifampicin. The interaction between lamivudine and rifampicin is unlikely to be of clinical significance. Estimated population pharmacokinetic parameters for lamivudine during and after rifampicin were similar once between-occasional variability in bioavailability and absorption rate constant were accounted for.",""
116626,"Coadministration substantially decreases dolutegravir exposure. The European product label for Triumeq (dolutegravir/abacavir/lamivudine) does not recommend coadministration with carbamazepine. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken. Coadministration of carbamazepine (300 mg twice daily) and dolutegravir alone (50 mg once daily) decreased dolutegravir Cmax, AUC and Cmin by 33%, 49% and 73%, respectively. Abacavir may increase carbamazepine concentrations due to competition for glucuronidation (carbamazepine is glucuronidated by UGT2B7), but the clinical relevance of this interaction is unknown as the importance of glucuronidation in the overall metabolic process of carbamazepine is controversial. Abacavir concentrations may decrease due to induction of UGTs by rifampicin, although to a moderate extent. This is unlikely to be clinically relevant as abacavir has a large therapeutic index. No interaction is expected with lamivudine.",""
116634,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine)&nbsp;has not been studied but is expected to decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by oxcarbazepine. The European and the US product labels for Triumeq do not recommend coadministration with oxcarbazepine. However, the US product label for Triumeq mentions that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, can be taken in presence of carbamazepine, another anticonvulsant with inducing properties.&nbsp;No significant interaction is expected with abacavir or lamivudine.",""
115899,"Coadministration with Dovato (dolutegravir/lamivudine)&nbsp;has not been studied but is expected to decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by oxcarbazepine. The US Prescribing Information for Dovato advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.&nbsp;No significant interaction is expected with lamivudine.&nbsp;",""
116636,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine)&nbsp;has not been studied but is expected to substantially decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by phenytoin. The European and the US product labels for Triumeq do not recommend coadministration with phenytoin. However, the US product label for Triumeq mentions that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, can be taken in presence of carbamazepine, another anticonvulsant with inducing properties. A significant effect on abacavir is unlikely as abacavir is only partly metabolised by glucuronidation.&nbsp;No significant interaction is expected with lamivudine.",""
124148,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is metabolized by CYP2C8 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124149,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Induction of UGTs by ritonavir used to boost lopinavir is unlikely to cause a clinically relevant decrease in cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. ",""
124150,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
115900,"Coadministration with Dovato (dolutegravir/lamivudine)&nbsp;has not been studied but is expected to substantially decrease dolutegravir exposure due to induction of UGT1A1 and CYP3A by phenobarbital. The US Prescribing Information for Dovato advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato (dolutegravir/lamivudine), should be taken.&nbsp;Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended.&nbsp;No significant interaction is expected with lamivudine.&nbsp;",""
115903,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied but is expected to substantially decrease dolutegravir exposure.&nbsp;Primidone is metabolised by CYP3A4 to the active metabolite phenobarbital which is an inducer of CPY3A4 and UGT1A1. The US Prescribing Information for Dovato advises to avoid coadministration with phenobarbital due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken with phenobarbital.&nbsp;Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended. No significant interaction is expected with lamivudine.",""
124151,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is mainly glucuronidated (by UGTs 2B15, 2B4, 2B7, 1A7, 1A10). Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
116597,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine) has not been studied. No interaction is expected with abacavir or lamivudine. However, coadministration may substantially decrease dolutegravir concentrations due to CYP3A4 induction. The magnitude of rifapentine-mediated CYP3A4 induction is predicted to be comparable to rifampicin. Although no dosing recommendations are provided for rifapentine, the European product label for Triumeq does not recommend coadministration with rifampicin. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken.&nbsp;In healthy volunteers receiving weekly rifapentine and isoniazid, the addition of dolutegravir resulted in flu-like symptoms and LFT elevations in 2 out of 4 patients, leading to study termination. Intolerance was hypothesized be related to rifapentine (+/- healthy volunteer status) rather than isoniazid, since in the INSPIRING study the addition of dolutegravir to daily rifampicin and isoniazid was well tolerated in HIV-TB co-infected adults. Thus, the coadministration of dolutegravir (50 mg once daily) and rifapentine/isoniazid once weekly was evaluated again in HIV infected individuals and was well tolerated in persons living with HIV (no Grade &gt;3 adverse effects). Dolutegravir Ctrough and AUC were reduced by ~50% and ~30% but median values at all time points were above 300 ng/ml. Virologic suppression was maintained throughout the TB treatment.",""
116604,"Coadministration with dolutegravir/abacavir/lamivudine has not been studied. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. In vitro data indicate that dolutegravir inhibits OCT2 but is unlikely to cause a clinically relevant drug interaction with trimethoprim/sulfamethoxazole. No interaction is expected with abacavir. In vitro data indicate that trimethoprim inhibits the renal transporters OCT2 and MATE1. Coadministration with trimethoprim increased lamivudine exposure by 43%, but lamivudine had no effect on trimethoprim or sulfamethoxazole. Note, the bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in liquid formulations such trimethoprim/sulfamethoxazole paediatric suspension.",""
124152,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is mainly glucuronidated (possibly by UGTs 2B15, 1A9 and 2B7). Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.",""
124153,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124155,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124156,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lumefantrine is metabolized predominantly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124157,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolized mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124158,"Coadministration has not been studied. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as magnesium resulting in a reduced absorption of cabotegravir. Magnesium supplements should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124159,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data are available on the effect of malabar nut tree on drug metabolism. In vitro data with leaf extracts suggest it could act as an inducer of phase I and phase II metabolic enzymes although the clinical relevance has not been evaluated. No significant effect is expected on cabotegravir based on the drug interaction study with rifabutin (a moderate inducer).,""
124161,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124163,Coadministration has not been studied but based on metabolism and clearance a clinically significantinteraction is unlikely. Mebendazole is predominantly metabolized in the liver. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
124164,Coadministration has not been studied but based on the metabolic profiles of both drugs there is little potential for pharmacokinetic interaction. Medroxyprogesterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124166,"Cabotegravir is metabolized by UGT1A1 and to a lesser extent by UGT1A9. The interaction with mefenamic acid, a strong UGT1A9 inhibitor, was assessed using a PBPK model. Coadministration is predicted to increase cabotegravir exposure by 11%, which is considered to be not clinically relevant.",""
124167,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefloquine is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124169,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as meglumine antimoniate is predominantly eliminated unchanged via renal glomerular filtration.,""
124171,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Menthol is a moderate inhibitor of CYP3A4 but there is no evidence to suggest that menthol affects UGTs.",""
124172,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124173,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is predominantly metabolised by xanthine oxidase and cabotegravir does not interfere with this metabolic pathway.,""
124174,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. Cabotegravir does not cause clinically relevant inhibition of OAT1/OAT3.,""
124175,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase and cabotegravir does not interfere with this pathway.,""
124177,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is eliminated renally via OCT2 and MATE1. Cabotegravir does not cause clinically relevant inhibition of renal transporters.,""
124178,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methadone is metabolized by CYP2B6 and CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124179,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6. Cabotegravir does not inhibit or induce CY enzymes at clinically relevant concentrations.",""
124181,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged, and as the mono-O-sulfate conjugate.",""
124183,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects.,""
124184,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116262,"Coadministration has not been studied. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. Large doses of ascorbic acid may cause the urine to become acidic causing unexpected renal tubular reabsorption of acidic drugs, thus producing an exaggerated response. Conversely basic drugs may exhibit decreased reabsorption resulting in a decreased therapeutic effect. Lamivudine is predominantly eliminated unchanged via active renal tubular secretion, however unless treatment with ascorbic acid involves large doses of prolonged duration, significant interactions are not expected. A pharmacokinetic interaction is unlikely with dolutegravir and vitamin C itself as dolutegravir does not interfere with this metabolic pathway. However, vitamin C can be found in multivitamin preparations. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
124186,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
116997,"Coadministration has not been studied. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. No interaction is expected with abacavir. Large doses of ascorbic acid may cause the urine to become acidic causing unexpected renal tubular reabsorption of acidic drugs, thus producing an exaggerated response. Conversely basic drugs may exhibit decreased reabsorption resulting in a decreased therapeutic effect. Lamivudine is predominantly eliminated unchanged via active renal tubular secretion, however unless treatment with ascorbic acid involves large doses of prolonged duration, significant interactions are not expected. A pharmacokinetic interaction is unlikely with dolutegravir and vitamin C itself as dolutegravir does not interfere with this metabolic pathway and no interaction is expected with abacavir. However, vitamin C can be found in multivitamin preparations. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
102941,"Coadministration has not been studied. No interaction is expected with vitamin D when given with calcium or in a multivitamin preparation. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. In vitro studies have shown rifampicin (an enzyme inducer) increased metabolism of vitamin D and introduction of 6',7'-dihydroxybergamottin (a CYP3A4 inhibitor in grapefruit juice) reversed the effects of rifampicin on vitamin D clearance. Inhibition of CYP3A by atazanavir is not expected to reduce the effect of vitamin D, but the consequence of CYP3A inhibition on the clinical effect of vitamin D is not known. However, no effect of antiretroviral therapy on the response to vitamin D supplementation was found in a PK modelling study",""
70628,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with cyanocobalamin when given alone or in multivitamins. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine.&nbsp;,""
116267,"Coadministration has not been studied. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine. No interaction is expected with vitamin B12 when given as a single agent (i.e. not in a multivitamin preparation) or as an injection. However, vitamin B12 can be found in multivitamin preparations and simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations. No interaction is expected with lamivudine.",""
124188,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent CYP1A2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124189,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
117014,"Coadministration has not been studied. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva. No interaction is expected with abacavir or lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and iodine itself.&nbsp;However, iodine administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116279,"Coadministration has not been studied. Iodine is converted to iodide, which is trapped in the thyroid gland. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and iodine itself.&nbsp;However, iodine administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116287,"Coadministration has not been studied. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which is then metabolized by xanthine oxidase and aldehyde oxidase. Renal elimination of unchanged nicotinamide is minimal. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and nicotinamide itself. However, nicotinamide administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116288,"Coadministration has not been studied. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal, therefore, there is little potential for an interaction with lamivudine via competition for renal elimination pathways. There is little potential for an interaction with dolutegravir and phytomenadione itself via competition for glucuronidation pathways as glucuronidation is not the sole route of elimination. However, phytomenadione administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.&nbsp;",""
117023,"Coadministration has not been studied. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal, therefore, there is little potential for an interaction with lamivudine via competition for renal elimination pathways. There is little potential for an interaction with phytomenadione itself and dolutegravir or abacavir via competition for glucuronidation pathways as glucuronidation is not the sole route of elimination. However, phytomenadione administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
124190,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Miconazole inhibits CYP2C9 and CYP3A4 but no effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
125514,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Alogliptin was shown to have no inhibitory or inducing effect on CYPs at concentrations achieved with the recommended dose of 25 mg alogliptin.,""
117027,"Coadministration has not been studied. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. No interaction is expected with abacavir or lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and retinol itself. However, retinol administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
95212,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with thiamine when given alone or in multivitamins. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
124191,Coadministration of cabotegravir (30 mg once daily) and oral midazolam (3 mg) did not alter midazolam pharmacokinetics to a clinically significant extent. ,""
116293,"Coadministration has not been studied. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and riboflavin itself. However, riboflavin can be found in multivitamin preparations; simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
117028,"Coadministration has not been studied. No interaction is expected with abacavir or lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and riboflavin itself. However, riboflavin can be found in multivitamin preparations; simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116297,"Coadministration has not been studied. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and thiamine itself. However, thiamine can be found in multivitamin preparations; simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
116300,"Coadministration has not been studied. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and vitamin E itself. However, vitamin E can be found in multivitamin preparations; simultaneouscoadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
117035,"Coadministration has not been studied. No interaction is expected with abacavir or lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and vitamin E itself. However, vitamin E can be found in multivitamin preparations; simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
117002,"Coadministration has not been studied. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine. No interaction is expected with vitamin B12 when given as a single agent (i.e. not in a multivitamin preparation) or as an injection. However, vitamin B12 can be found in multivitamin preparations and simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations. No interaction is expected with abacavir or lamivudine.",""
125536,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism.,""
124192,Coadministration with parenteral midazolam has not been studied. Coadministration of cabotegravir (30 mg once daily) and oral midazolam (3 mg) did not alter midazolam pharmacokinetics to a clinically significant extent. A similar effect is expected with i parenteral midazolam.,""
125008,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of sofosbuvir, velpatasvir and, in particular, voxilaprevir. Use an alternative HCV regimen if possible.",""
125049,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes,""
116292,"Coadministration has not been studied. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. No interaction is expected with lamivudine. A pharmacokinetic interaction is unlikely with dolutegravir and retinol itself. However, retinol administered in multivitamin preparations may decrease dolutegravir exposure. Simultaneous coadministration of a multivitamin preparation decreased dolutegravir exposure by ~33%. Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations, such as multivitamin preparations.",""
125050,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olodaterol is metabolized by CYP2C8, CYP2C9, is glucuronidated via several UGTs, and is a substrate of P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes, and does not inhibit P-gp.",""
125051,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Roflumilast is metabolized by CYP3A4 and CYP1A2 to form roflumilast N-oxide, with both roflumilast and roflumilast N-oxide having PDE4 inhibitory activity. Roflumilast N-oxide is subsequently dealkylated by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes",""
124193,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that mifepristone may inhibit CYP3A4 metabolism. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
125052,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolized to the inactive salbutamol-4â€™-O-sulphate. Fostemsavir does not interfere with salbutamolâ€™s metabolic pathway. ,""
125053,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125054,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolized by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125055,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiotropium bromide is predominantly excreted unchanged in the urine. Metabolism by CYP2D6 and CYP3A4 is only a minor role in its elimination. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes,""
125056,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Umeclidinium bromide is mainly metabolized by CYP2D6 and is a substrate of P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes, and does not inhibit P-gp.",""
125057,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes and does not inhibit P-gp.,""
125058,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amlodipine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124197,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Minaxolone undergoes hepatic metabolism. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
125060,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Felodipine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125061,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Nicardipine is a moderate inhibitor of CYP3A4 but is not expected to cause a clinically significant increase in temsavir. Coadministration of fostemsavir with cobicistat (a strong CYP3A4) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.,""
124198,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124199,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124201,Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124202,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects,""
124203,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. ,""
124204,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is mainly metabolized by CYP2C8 and to a lesser extent by CYPs 3A4 and 2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124205,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.",""
124206,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
125062,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125063,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125064,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125065,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Verapamil is a moderate inhibitor of CYP3A4 and P-gp but is not expected to cause a clinically significant increase in temsavir. Coadministration of fostemsavir with cobicistat (a strong CYP3A4) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.,""
124208,"Coadministration has not been studied. Multivitamins may contain polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations such as magnesium resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir. ",""
124209,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mycophenolate is mainly glucuronidated by UGTs 1A9 and 2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
121362,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for dolutegravir and lamivudine, but for any medication taken with sevelamer.]",""
121363,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for dolutegravir and rilpivirine, but for any medication taken with sevelamer.]",""
124211,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxone is mainly glucuronidated by UGT2B7. Cabotegravir does not inhibit or induce UGT enzymes at clinically relevant concentrations.,""
121364,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for doravirine, but for any medication taken with sevelamer.]",""
121365,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for doravirine, lamivudine and tenofovir-DF, but for any medication taken with sevelamer.]",""
121366,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for efavirenz, but for any medication taken with sevelamer.]",""
121367,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, but for any medication taken with sevelamer.]",""
121368,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for elvitegravir, cobicistat, emtricitabine, tenofovir-DF, but for any medication taken with sevelamer.]",""
121369,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for emtricitabine, but for any medication taken with sevelamer.]",""
124214,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
124215,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolized by CYP2C9 (70%) and to a lesser extent CYP3A4 (30%). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124216,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124217,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nefazodone is metabolized mainly by CYP3A4 and is also an inhibitor of CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
124220,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicardipine is metabolised mainly by CYP3A4 and inhibits this same enzyme. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9.,""
121370,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for emtricitabine and tenofovir alafenamide, but for any medication taken with sevelamer.]",""
121371,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for emtricitabine and tenofovir-DF, but for any medication taken with sevelamer.]",""
121372,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for etravirine, but for any medication taken with sevelamer.]",""
121373,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for fosamprenavir, but for any medication taken with sevelamer.]",""
121374,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for indinavir, but for any medication taken with sevelamer.]",""
121375,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for lamivudine, but for any medication taken with sevelamer.]",""
121376,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for lopinavir, but for any medication taken with sevelamer.]",""
121377,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for maraviroc, but for any medication taken with sevelamer.]",""
121378,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for nevirapine, but for any medication taken with sevelamer.]",""
121379,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for raltegravir, but for any medication taken with sevelamer.]",""
121380,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for rilpivirine, emtricitabine and tenofovir alafenamide, but for any medication taken with sevelamer.]",""
121381,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for rilpivirine, but for any medication taken with sevelamer.]",""
121382,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for ritonavir, but for any medication taken with sevelamer.]",""
121383,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for saquinavir, but for any medication taken with sevelamer.]",""
121384,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for stavudine, but for any medication taken with sevelamer.]",""
121385,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for tenofovir-DF, but for any medication taken with sevelamer.]",""
121386,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for tipranavir, but for any medication taken with sevelamer.]",""
121387,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for zidovudine, but for any medication taken with sevelamer.]",""
124224,"Coadministration has not been studied. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolized by xanthine oxidase and aldehyde oxidase. A pharmacokinetic interaction is unlikely with nicotinamide itself. However, nicotinamide can be found in multivitamin preparations containing polyvalent cations. Cabotegravir, similarly to other integrase inhibitors, chelates with polyvalent cations resulting in a reduced absorption of cabotegravir. Multivitamin preparations containing polyvalent cations should be administered at least 2 hours before or 4 hours after taking oral cabotegravir.",""
124225,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised mainly by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124227,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Nilotinib is metabolized by CYP3A4 and inhibits this same enzyme. Furthermore, in vitro data indicate that nilotinib inhibits UGT1A1. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, but it is unlikely to be affected by nilotinib as coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. ",""
124228,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
121388,"Coadministration has not been studied but based on metabolism and clearance, as well as limited drug-drug interaction data, a clinically significant interaction is unlikely. Sevelamer is a resin not absorbed from the GI tract. Albuvirtide is a peptide administered intravenously and eliminated by catabolism to its constituent amino acids.",""
121389,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sevelamer is a resin not absorbed from the GI tract. Ibalizumab is monoclonal antibody administered intravenously and eliminated via intracellular catabolism similarly to other monoclonal antibodies.,""
124229,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised mainly by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124230,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is extensively metabolized mainly by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124231,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug. Cabotegravir does not interfere with nitrofurantoin elimination.,""
124233,"Coadministration with transdermally delivered norelgestromin/ethinylestradiol has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Ethinylestradiol is mainly metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter norelgestromin exposure.",""
124234,"Coadministration of a combined oral contraceptive (COC) containing norethisterone and mestranol has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter norethisterone exposure.",""
124235,Coadministration with norethisterone as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124236,Coadministration of a norethisterone IM depot injection has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124237,Coadministration of a norethisterone progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers.,""
124238,"Coadministration of a combined oral contraceptive (COC) containing norgestimate has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestimate is deacetylated to the active metabolite norelgestromin which is then metabolised to norgestrel, possibly by CYP3A4. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter norgestimate exposure.",""
77470,"Rilpivirine and products containing St John's wort should not be coadministered as significant decreases in rilpivirine plasma concentrations may occur which&nbsp;may result in loss of therapeutic effect of rilpivirine. Coadministration is not recommended in the product labels for rilpivirine. However, a recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (&lt;1 mg/day) of St Johnâ€™s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp). Coadministration may be considered with St Johnâ€™s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of 1 mg or less.",""
86332,"Coadministration is contraindicated in the product labels for Stribild as St Johnâ€™s wort is expected to substantially decrease elvitegravir/cobicistat concentrations and may result in suboptimal levels.&nbsp;However, a recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (&lt;1 mg/day) of St Johnâ€™s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp). Coadministration may be considered with St Johnâ€™s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of 1 mg or less.",""
117031,"Coadministration with Triumeq (dolutegravir/abacavir/lamivudine) has not been studied but is expected to decrease dolutegravir exposure. The European and the US product labels for Triumeq do not recommend coadministration with St Johnâ€™s Wort. However, the US product label for Triumeq mentions that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, can be taken in presence of other inducers such as carbamazepine or rifampicin. No significant interaction is expected with abacavir or lamivudine.&nbsp;A recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (&lt;1 mg/day) of St Johnâ€™s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp).",""
116296,"Coadministration with Dovato (dolutegravir/lamivudine) has not been studied but is expected to decreased dolutegravir exposure. The US Prescribing Information for Dovato advises to avoid coadministration due to insufficient data to make dosing recommendations. However, the European product label for Dovato recommends an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended. No significant interaction is expected with lamivudine.&nbsp;A recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (&lt;1 mg/day) of St Johnâ€™s Wort (hyperforin is the constituent responsible for induction of CYPs and P-gp).",""
121351,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for abacavir, but for any medication taken with sevelamer].&nbsp;",""
121360,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for dolutegravir, abacavir and lamivudine, but for any medication taken with sevelamer.]",""
121361,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for dolutegravir, but for any medication taken with sevelamer.]",""
121352,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for atazanavir, but for any medication taken with sevelamer.]&nbsp;",""
121353,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for atazanavir/cobicistat, but for any medication taken with sevelamer.]",""
121354,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for atazanavir and ritonavir, but for any medication taken with sevelamer.]",""
121355,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for bictegravir, emtricitabine and tenofovir alafenamide, but for any medication taken with sevelamer.]&nbsp;",""
121356,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for darunavir/cobicistat, but for any medication taken with sevelamer.]",""
121357,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for darunavir, cobicistat, emtricitabine and tenofovir alafenamide, but for any medication taken with sevelamer.]",""
121358,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for darunavir and ritonavir, but for any medication taken with sevelamer.]&nbsp;",""
121359,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for didanosine, but for any medication taken with sevelamer.]&nbsp;",""
124239,"Coadministration of a combined oral contraceptive (COC) containing norgestrel/ethinylestradiol has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Ethinylestradiol is metabolized by hydroxylation and glucuronidation. Coadministration of oral cabotegravir (30 mg once daily) with ethinylestradiol (0.03 mg) + levonorgestrel (0.15 mg) did not significantly affect the hormones levels. Similarly, cabotegravir is unlikely to alter norgestrel exposure.",""
124240,Coadministration with norgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Cabotegravir does not inhibit or induce CYP or UGT enzymes at clinically relevant concentrations.,""
124241,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolized mainly by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
124574,"Cabenuva (cabotegravir LA, rilpivirine LA) and Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration would be possible from a pharmacokinetic standpoint.",""
124570,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. Similarly, no significant effect is expected when cabotegravir is administered intramuscularly. Atazanavir may increase rilpivirine concentrations. However, no dose adjustment of rilpivirine is required. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with atazanavir. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a risk of QT interval prolongation.",""
124571,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/cobicistat would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. A comparable effect is expected with atazanavir/cobicistat. Similarly, no significant effect is expected when cabotegravir is administered intramuscularly. Atazanavir/cobicistat may increase rilpivirine concentrations. However, no dose adjustment of rilpivirine is required. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with atazanavir/cobicistat. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a risk of QT interval prolongation.",""
124569,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/ritonavir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Coadministration with the strong UGT1A1 inhibitor atazanavir was predicted to increase oral cabotegravir (30 mg once daily) exposure by 11% which is considered to be not clinically relevant. A comparable effect is expected with atazanavir/ritonavir. Similarly, no significant effect is expected when cabotegravir is administered intramuscularly. Atazanavir/ritonavir may increase rilpivirine concentrations, but no dose adjustment of rilpivirine is required. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with atazanavir/ritonavir. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a risk of QT interval prolongation.",""
124573,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with darunavir/cobicistat would be possible from a pharmacokinetic standpoint.",""
124572,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with darunavir/ritonavir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Induction of UGTs by ritonavir used to boost darunavir is unlikely to cause a clinically relevant decrease of cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. Coadministration of oral rilpivirine (150 mg once daily) and darunavir/ritonavir (800/100 mg once daily) was studied in 14 subjects. Rilpivirine Cmax increased by 79% and AUC and Cmin increased by 2.3- and 2.78-fold, respectively. Darunavir Cmax, AUC and Cmin decreased by 10%, 11% and 11%, respectively. [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug]. No dose adjustment of rilpivirine is required.",""
124576,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with indinavir would be possible from a pharmacokinetic standpoint.",""
124575,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to fosamprenavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of fosamprenavir have not been established.",""
124577,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lopinavir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9. Induction of UGTs by ritonavir used to boost lopinavir is unlikely to cause a clinically relevant decrease of cabotegravir exposure based on drug-drug interaction studies with rifabutin, another moderate inducer. Coadministration of oral rilpivirine (150 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) increased rilpivirine Cmax, AUC and Cmin by 29%, 52% and 74%, respectively. Lopinavir Cmax, AUC and Cmin decreased by 4%, 1% and 11%, respectively. [Note: this interaction study has been performed with a dose higher than the licensed dose for rilpivirine assessing the maximal effect on the co-administered drug]. No dose adjustment of rilpivirine is required. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with lopinavir/ritonavir. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a risk of QT interval prolongation.",""
124578,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ritonavir would be possible from a pharmacokinetic standpoint.",""
124562,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with emtricitabine would be possible from a pharmacokinetic standpoint.",""
124579,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to saquinavir should be considered.",""
124561,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to didanosine should be considered.",""
124563,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with emtricitabine and tenofovir alafenamide would be possible from a pharmacokinetic standpoint. When given with Cabenuva, the recommended dose of Descovy (emtricitabine/tenofovir alafenamide) is 200/25 mg once daily.",""
124565,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
124567,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with tenofovir-DF would be possible from a pharmacokinetic standpoint. Coadministration with cabotegravir LA or rilpivirine LA has not been studied. Coadministration of oral rilpivirine (150 mg once daily) and tenofovir-DF (300 mg once daily) decreased rilpivirine Cmax and Cmin by 4% and 1%, and increased AUC by 1%. Tenofovir Cmax, AUC and Cmin increased by 19%, 23% and 24%.",""
124568,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.",""
124636,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) and is a substrate of P-gp. In vitro data indicate that efavirenz does not induce or inhibit P-gp in the range of clinical concentrations. No effect on efavirenz is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.,""
124638,Coadministration has not been studied. Cabergoline is extensively metabolized by the liver predominantly via hydrolysis (non-CYP mediated metabolism) and is a substrate of P-gp. Etravirine is a weak inhibitor of P-gp and could increase cabergoline exposure although to a limited extent. No effect on etravirine is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;,""
124633,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with darunavir/cobicistat is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on darunavir, cobicistat, emtricitabine or tenofovir alafenamide is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124676,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sevoflurane is almost exclusively eliminated unchanged by the lungs. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with sevoflurane. However, given the known QT prolongation risk associated with sevoflurane, ECG monitoring is recommended when coadministering both drugs.",""
124622,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with atazanavir/ritonavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on atazanavir or ritonavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124623,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with darunavir/cobicistat is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on darunavir or cobicistat is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124624,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with darunavir/ritonavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on darunavir or ritonavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124625,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with fosamprenavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on fosamprenavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124626,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with indinavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on indinavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124627,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with lopinavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on lopinavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124628,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with ritonavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on ritonavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124629,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with saquinavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on saquinavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124630,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with tipranavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on tipranavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124621,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with atazanavir/cobicistat is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on atazanavir or cobicistat is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124620,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with atazanavir is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on atazanavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124631,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with elvitegravir/cobicistat is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on elvitegravir, cobicistat, emtricitabine or tenofovir alafenamide is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124632,"Coadministration has not been studied. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure increased by&nbsp;2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Similarly, coadministration with elvitegravir/cobicistat is expected to increase cabergoline exposure. Consider a reduction in cabergoline dose if the patient presents with adverse drug effects. No effect on elvitegravir, cobicistat, emtricitabine or tenofovir-DF is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.&nbsp;",""
124661,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcuronium is predominantly eliminated unchanged via the kidneys. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to significantly inhibit renal elimination of alcuronium.,""
124662,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupivacaine is predominantly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124665,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexmedetomidine undergoes extensive hepatic metabolism through direct glucuronidation (mainly via UGT1A4, 2B10) and cytochrome P450 (mainly CYP2A6). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ",""
124666,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enflurane is predominantly metabolized by CYP2E1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124667,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ephedrine is predominantly eliminated unchanged via the kidneys possibly via the renal transporter OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2. ,""
124668,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etidocaine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124669,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halothane undergoes both oxidative (mainly via CYP2E1 and to a lesser extent CYP2A6) and reductive (via CYP2A6 and CYP3A4) metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124671,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketamine is mainly metabolized by CYP3A4 and to a lesser extent by CYP2B6 and CYP2C9 in the range of concentrations used in anaesthesia. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124672,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Minaxolone undergoes hepatic metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce drug metabolizing enzymes. ,""
124673,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Most inhaled nitrous oxide is rapidly eliminated unchanged through the lungs. ,""
124675,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rocuronium is mostly cleared in the bile although up to 30% may be excreted renally. P-glycoprotein was shown to mediate biliary excretion of rocuronium in a rat model. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit P-gp. ,""
124674,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Propofol is glucuronidated via UGT1A9, UGT1A8 and is oxidized mainly via CYP2B6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with propofol. However, given the known QT prolongation risk associated with propofol, ECG monitoring is recommended when coadministering both drugs.",""
124684,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid which is further glucuronidated by several UGTs (major UGT1A6). Fostemsavir and its active metabolite temsavir do not interfere with this metabolic pathway. ,""
124720,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Disopyramide is metabolized by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine possibly via OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes and does not inhibit OCT2. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with disopyramide. However, given the known QT prolongation risk associated with disopyramide, ECG monitoring is recommended when coadministering both drugs.",""
124686,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolized by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124687,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine undergoes predominantly direct glucuronidation with CYP3A4 mediated metabolism accounting for only 10-15% of the overall metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ,""
124688,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dextropropoxyphene is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124689,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diamorphine is rapidly metabolized by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7 >UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7 >UGT1A1). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. ",""
124690,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidized by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. ,""
124691,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) via CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine via CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ",""
124692,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124693,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ",""
124694,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. ",""
124695,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ,""
124696,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and additionally glucuronidated by UGT2B7 and UGT1A9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ,""
124718,"Coadministration has not been studied. Amiodarone is metabolized by CYPs 3A4 and 2C8, but temsavir (the active metabolite of fostemsavir) does not inhibit or induce CYP enzymes. Amiodarone is a P-gp inhibitor and coadministration is expected to increase temsavir concentrations but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with amiodarone. However, given the known QT prolongation risk associated with amiodarone, ECG monitoring is recommended when coadministering both drugs.",""
124698,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7 >UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7 >UGT1A1). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. ",""
124699,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ,""
124700,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolized in the liver following multiple pathways including CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124701,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxycodone is metabolised principally to noroxycodone by CYP3A and oxymorphone by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124702,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is mainly metabolized by glucuronidation (via UGT1A9 (major), UGT1A6, UGT1A1, UGT2B15) and sulfation and, to a lesser extent, by oxidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. ",""
124703,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolized mainly by CYP2B6 and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124704,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolized by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124705,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol is mainly glucuronidated by UGT1A6, UGT1A9 and UGT2B7 and does not induce or inhibit CYP450 enzymes in the range of doses in clinical use. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. ",""
124706,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolized by CYPs 3A4, 2B6, and 2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ",""
124707,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized by CYP3A4 and by the flavine-containing monooxygenase system. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124708,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diethylcarbamazine is mainly excreted unchanged in the urine. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to significantly inhibit diethylcarbamazine renal elimination.,""
124709,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivermectin is predominantly metabolised by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124710,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism and elimination of levamisole has not been well characterized. Based on limited information, and single dose use of levamisole, a clinically significant interaction is unlikely. ",""
124711,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mebendazole is predominantly metabolized in the liver. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
124712,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After oral administration, absorption of niclosamide is considered minimal. ",""
124713,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxamniquine is thought to be predominantly metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124714,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro, praziquantel is metabolised predominantly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124715,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrantel is metabolized by CYP2D6 in vitro, however, absorption of an oral dose is minimal and over 50% of a dose is excreted unchanged in the faeces. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124716,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Suramin appears to be eliminated predominantly unchanged via renal glomerular filtration. ,""
124717,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. In vitro, triclabendazole and its active sulfoxide metabolite are inhibitors of CYP3A4, and therefore may increase temsavir exposure. However, due to short term dosing of triclabendazole (usually single dose), the clinical relevance of this interaction is low. ",""
124719,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bepridil is metabolized by CYPs 2D6 (major) and 3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with bepridil. However, given the QT prolongation risk associated with bepridil, ECG monitoring is recommended when coadministering both drugs.",""
124721,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dofetilide is mainly excreted unchanged in urine. Renal elimination involves both glomerular filtration and active tubular secretion (via cation transport system). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit the organic cation transporters. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with dofetilide. However, given the known QT prolongation risk associated with dofetilide, ECG monitoring is recommended when coadministering both drugs.",""
124723,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124724,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes,""
124725,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes,""
124751,"Coadministration has not been studied. Erythromycin is a moderate inhibitor of CYP3A4 and P-gp and coadministration may increase temsavir (the active metabolite of fostemsavir) but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with erythromycin. However, given the known QT prolongation risk associated with erythromycin, ECG monitoring is recommended when coadministering both drugs.",""
124727,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amikacin is eliminated by glomerular filtration therefore no interaction is expected with fostemsavir.,""
124728,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT3.,""
124729,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and tubular secretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to interfere with ampicillin renal elimination.,""
124731,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bedaquiline is metabolised by CYP3A4 and mainly eliminated in faeces. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Bedaquiline has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with bedaquiline.,""
124732,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug, partly by glomerular filtration and partly by tubular secretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to interfere with renal elimination of capreomycin.",""
124733,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1 and its metabolite (BMS-930644) is unlikely to cause a clinically significant interaction via MATE1. ,""
124734,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion by OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT3.",""
124735,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cefixime is renally excreted predominantly by glomerular filtration. ,""
124736,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolized by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT3.",""
124737,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ceftazidime is excreted predominantly by renal glomerular filtration. ,""
124738,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. ",""
124739,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloramphenicol is predominantly metabolised via UDP-glucuronyltransferases, in particular UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125066,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is mainly oxidized to hydroxyanastrozole by CYP3A4 (major) and glucuronidated via UGT1A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
125067,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data suggest that asparaginase is likely to be eliminated by the reticulo-endothelial system. Less than 0.1% of a total injected dose is recovered in urine. ,""
124759,"Coadministration has not been studied but based on metabolism and clearance, a pharmacokinetic interaction is unlikely. Levofloxacin is eliminated renally mainly by glomerular filtration and active secretion (possibly OCT2). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with levofloxacin. However, given the known QT prolongation risk associated with levofloxacin, ECG monitoring is recommended when coadministering both drugs.",""
124742,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolized (likely non-CYP mediated pathway) and excreted in the urine by glomerular filtration. ,""
124743,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124744,"Coadministration has not been studied. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Clofazimine is a moderate inhibitor of CYP3A4 and may increase temsavir but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Clofazimine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with clofazimine.",""
124745,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent and renal elimination represents approximately 35% of a dose. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is unlikely to interfere with cloxacillin elimination.,""
124746,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly excreted renally via glomerular filtration. ,""
124747,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP enzymes. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124748,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Delamanid has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with delamanid.",""
124749,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40%-60% of an administered dose can be accounted for in the urine. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to interfere with doxycycline elimination.,""
124750,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor component. ,""
124752,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and in the urine (50%). ,""
124753,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolized in the liver and animal studies suggest involvement of flavin-containing monooxygenases. ,""
124754,Coadministration has not been studied. Flucloxacillin is mainly eliminated renally (partly by OAT1) and was shown to induce CYP3A4 and P-gp but is unlikely to cause a clinically significant effect. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with the moderate inducer rifabutin was shown to reduce the exposure of temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with flucloxacillin. ,""
124755,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. ,""
124756,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem/cilastatin are eliminated by glomerular filtration and to a lesser extent, active tubular secretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to interfere with imipenem/cilastatin renal elimination.",""
124757,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Fostemsavir does not interfere with isoniazidâ€™s metabolic pathway. ",""
124758,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration. ,""
124760,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Linezolid undergoes non CYP mediated metabolism. ",""
124761,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3 and OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs.,""
124764,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolized in the liver via glucuronidation and N-acetylation and partly eliminated in the urine as unchanged drug (30-40%). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
124726,"Coadministration has not been studied. Quinidine is metabolized by CYP3A4 but temsavir (the active metabolite of fostemsavir) does not inhibit or induce CYP enzymes. Quinidine is a P-gp inhibitor and coadministration is expected to increase temsavir concentrations but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with quinidine. However, given the known QT prolongation risk associated with quinidine, ECG monitoring is recommended when coadministering both drugs.",""
124730,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-gp and MRP2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit MRP2 and P-gp. Azithromycin is not a significant inhibitor of CYP3A4 or P-gp and is not expected to impact temsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with azithromycin. However, given the known QT prolongation risk associated with azithromycin, ECG monitoring is recommended when coadministering both drugs.",""
124740,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged through the kidneys by glomerular filtration and tubular secretion via OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT3. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with ciprofloxacin. However, given the known QT prolongation risk associated with ciprofloxacin, ECG monitoring is recommended when coadministering both drugs.",""
124765,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ofloxacin is eliminated unchanged renally by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit cationic and anionic renal transporters. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Ofloxacin has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with ofloxacin. ,""
124766,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit cationic and anionic renal transporters.,""
124767,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs transporters.,""
124768,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperacillin is eliminated renally via glomerular filtration and active renal secretion by OAT1/3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs transporters.,""
124769,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolized by xanthine oxidase. ,""
124803,"Coadministration has not been studied but is contraindicated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with rifampicin (another strong inducer) substantially decreased temsavir Cmax and AUC by 76% and 88%. A similar effect is expected with the strong inducer carbamazepine, therefore, coadministration is contraindicated as it may result in a potential loss of therapeutic effect.",""
124772,"Coadministration has not been studied but and is not recommended. Coadministration of fostemsavir with rifampicin (another strong inducer) substantially decreased temsavir Cmax and AUC by 76% and 88%. A similar effect is expected with the strong inducer rifapentine, therefore coadministration is not recommended as it may result in a potential loss of therapeutic effect.",""
124773,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, mostly as unchanged drug. ",""
124775,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as streptomycin is excreted rapidly in the urine by glomerular filtration. ,""
124776,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124777,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is only minimally metabolised and is eliminated renally via glomerular filtration and active renal secretion by OAT1/3. Temsavir does not inhibit OATs transporters.,""
124779,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracyclines are eliminated unchanged primarily by glomerular filtration. ,""
124780,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinidazole is partly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124781,Coadministration has not been studied. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir is unlikely to affect trimethoprim/sulfamethoxazole elimination.,""
124782,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vancomycin is excreted unchanged via renal glomerular filtration. ,""
124783,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolized by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124784,"Coadministration has not been studied. Apixaban is metabolized by CYP3A4 and to a lesser extent by CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Apixaban is preferentially transported by BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. However, fostemsavir has been shown to increase tenofovir alafenamide exposure to a modest extent, likely due to intestinal inhibition of BCRP. An increase in apixaban exposure cannot be excluded, however, the apixaban product label indicates that no dose adjustment is required when coadministered with drugs that are not strong inhibitors. ",""
124785,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Argatroban undergoes metabolism in the liver via hydroxylation and aromatization. Drug-drug interactions studies performed with substrates of different cytochromes and P-glycoprotein (i.e., acetaminophen, lidocaine, warfarin, digoxin) indicate that argatroban has a low potential to cause drug-drug interactions and therefore is unlikely to alter the exposure of fostemsavir and its active metabolite temsavir.",""
124786,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid which is further glucuronidated by several UGTs (major UGT1A6). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not interfere with aspirinâ€™s metabolic pathway.,""
124787,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betrixaban is largely eliminated unchanged through biliary secretion via P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit P-gp. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Betrixaban has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with betrixaban.,""
124788,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug and is converted to its active metabolite via CYPs 3A4, 2B6, 2C19 and 1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124789,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dabigatran is not metabolized by CYP enzymes and is a substrate of P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes or P-gp.,""
124790,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. ",""
124791,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
124792,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Edoxaban is eliminated primarily as unchanged drug in urine and is minimally metabolised by hydrolysis (mediated by carboxylesterase 1), conjugation, or oxidation by CYP3A4/5 (<10%). Edoxaban is a substrate of P-gp. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce P-gp.",""
124793,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Eltrombopag is metabolised by cleavage conjugation (by UGT1A1, UGT1A3) and oxidation (by CYP1A2 and CYP2C8). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
124794,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is excreted predominantly renally. ",""
124796,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. ",""
124797,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124798,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124799,"Coadministration has not been studied. Rivaroxaban is partly metabolized in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes or P-gp. However, fostemsavir has been shown to increase tenofovir alafenamide exposure to a modest extent, likely due to intestinal inhibition of BCRP. It is unclear whether fostemsavir can cause a significant inhibition of renal BCRP. ",""
124778,Coadministration has not been studied. Telithromycin is metabolized by CYP3A4 and is a strong inhibitor of CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration is expected to increase temsavir but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Telithromycin has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with telithromycin.,""
124806,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is mainly oxidized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124807,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. ,""
124808,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolized to O-desmethyl-lacosamide mainly by CYP2C19 (~30% of the dose) and is eliminated unchanged through the kidneys (~40% of the dose). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124809,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is mainly glucuronidated by UGT1A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
124811,Coadministration has not been studied and is not recommended. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Oxcarbazepine is an inducer and has the potential to substantially reduce temsavir which may result in a potential loss of therapeutic effect.,""
124812,Coadministration has not been studied but is contraindicated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with rifampicin (another strong inducer) substantially decreased temsavir Cmax and AUC by 76% and 88%. A similar effect is expected with the strong inducer phenobarbital therefore coadministration is contraindicated as it may result in a potential loss of therapeutic effect.,""
124814,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pregabalin is cleared mainly by glomerular filtration. ,""
124815,Coadministration has not been studied and is not recommended. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Primidone is metabolised by CYP3A4 to the active metabolite phenobarbital. Phenobarbital induces CYP34A and has the potential to substantially reduce temsavir which may result in a potential loss of therapeutic effect.,""
124816,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolised by CYP3A4/5 and has no inducing properties. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124817,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Weak induction of CYP isozymes has been observed with higher doses of topiramate but this is unlikely to be of clinical relevance with fostemsavir.,""
124818,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19. Valproate has no inducing effects on metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
124819,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vigabatrin is cleared mainly by glomerular filtration. ,""
124820,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zonisamide is metabolized partly by CYP3A4 and also by N-acetyl-transferases and conjugation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
124821,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124822,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124823,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolized by CYP2B6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124825,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. In addition, clomipramine and desmethylclomipramine are metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ",""
124826,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Desipramine is metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Desipramine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with desipramine.,""
124827,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolized to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. In addition, doxepin and nordoxepin are metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124828,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124830,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolized by CYPs 2D6 and 2C9 and to a lesser extent by CYPs 2C19 and 3A4 to form norfluoxetine. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124831,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolized mainly by CYP2D6 and to a lesser extent by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124832,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Imipramine is metabolized by CYPs 3A4, 2C19 and 1A2 to desipramine. Imipramine and desipramine are both metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Imipramine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with imipramine.",""
124833,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Lithium has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with lithium.,""
124834,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Maprotiline is mainly metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Maprotiline has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with maprotiline.,""
124835,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124836,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). ",""
124837,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124839,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nortriptyline is metabolized mainly by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Nortriptyline has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with nortriptyline.,""
124840,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is mainly metabolized by CYP2D6 and CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124841,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolized by oxidation via monoamine oxidase and to a lesser extent acetylation. Fostemsavir does not interfere with phenelzineâ€™s metabolic pathway.,""
124842,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Reboxetine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124843,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolized by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124844,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Fostemsavir does not interact with tranylcypromineâ€™s metabolic pathway. ,""
124845,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124813,"Coadministration has not been studied but is contraindicated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with rifampicin (another strong inducer) substantially decreased temsavir Cmax and AUC by 76% and 88%. A similar effect is expected with the strong inducer phenytoin, therefore, coadministration is contraindicated as it may result in a potential loss of therapeutic effect.",""
124824,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Citalopram is metabolized by CYP2C19 (38%), 2D6 (31%) and 3A4 (31%). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with citalopram. However, given the known QT prolongation risk associated with citalopram, ECG monitoring is recommended when coadministering both drugs.",""
124829,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Escitalopram is metabolized by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with escitalopram. However, given the known QT prolongation risk associated with escitalopram, ECG monitoring is recommended when coadministering both drugs.",""
124846,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Trimipramine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with trimipramine.,""
124847,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Venlafaxine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with venlafaxine.",""
124848,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioxetine is mainly metabolized by CYP2D6 and to a lesser extent by CYP2C9 and CYP3A4/5. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124849,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and by the microbial flora. ",""
124850,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is primarily metabolised by UGT1A9 and UGT2B4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
124851,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is primarily metabolised by UGT1A9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
124853,"Coadministration has not been studied Empagliflozin is mainly glucuronidated by UGTs 1A3, 1A8, 1A9 and 2B7. It is a substrate of P-gp and BCRP, and also a substrate of the renal transporter OAT3 and the hepatic transporters OATP1B1 and OATP1B3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes but is an inhibitor of BCRP and OATPs and therefore has the potential to increase empagliflozin exposure, but to an extent that would be considered not to be clinically relevant. (Coadministration of gemfibrozil, a strong inhibitor of OATPs, increased empagliflozin Cmax by 15% and AUC by 59%; these changes were not considered to be clinically meaningful).",""
124854,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is cleared mainly by glomerular filtration. ,""
124855,"Coadministration has not been studied. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9, and is a substrate of OATP1B3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and therefore has the potential to increase glibenclamide exposure. Monitor glucose.",""
124856,"Coadministration has not been studied. Gliclazide is metabolized mainly by CYP2C9 and to a lesser extent by CYP2C19, and is a substrate of OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and therefore has the potential to increase gliclazide exposure. Monitor glucose.",""
124857,Coadministration has not been studied. Glimepiride is mainly metabolized by CYP2C9 and is a substrate of OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and therefore has the potential to increase glimepiride exposure. Monitor glucose.,""
124858,Coadministration has not been studied. Glipizide is mainly metabolized by CYP2C9 and is a substrate of OATP1B3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and therefore has the potential to increase glipizide exposure. Monitor glucose.,""
124860,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor elimination pathway. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124884,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Astemizole is metabolized by CYPs 2D6, 2J2 and 3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with astemizole. However, given the known QT prolongation risk associated with astemizole, ECG monitoring is recommended when coadministering both drugs.",""
124877,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Itraconazole is a strong inhibitor of CYP3A4 and P-gp and coadministration is expected to increase temsavir, but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124887,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is mainly metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124888,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fexofenadine undergoes negligible metabolism and is mainly eliminated unchanged in the faeces. ,""
124889,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised and levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. ,""
124890,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolized mainly by CYP3A4 and to a lesser extent by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124891,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Promethazine is metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124920,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elimination of sodium stibogluconate is predominantly via renal glomerular filtration. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with sodium stibogluconate. However, given the known QT prolongation risk associated with sodium stibogluconate, ECG monitoring is recommended when coadministering both drugs.",""
124893,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Almotriptan is partly eliminated unchanged in the urine and partly metabolized mainly via monoamine oxidase-A and to a lesser extent by CYP3A4, CYP2D6 and flavin monooxygenase. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124894,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydroergotamine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124895,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eletriptan is metabolised by CYP3A4 and does not induce or inhibit CYPs. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124896,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergotamine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124897,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rizatriptan is metabolized by oxidative deamination by monoamine oxidase-A (MAO-A). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. ,""
124898,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sumatriptan is eliminated primarily by metabolism mediated by monoamine oxidase A. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. ,""
124899,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is metabolized mainly by CYP2C8. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124900,"Coadministration has not been studied. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, 2B6) and the active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolism via UGTs 1A9 and 2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGTs enzymes. Artemisinins induce CYP3A4 and/or CYP2C19 but are unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce exposure of temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with artemisinin.",""
124901,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atovaquone is mainly eliminated unchanged in the faeces. Fostemsavir does not interact with atovaquoneâ€™s metabolic pathway. ,""
124914,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Pentamidine is metabolized by CYP1A2 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with pentamidine. However, given the known QT prolongation risk associated with pentamidine, ECG monitoring is recommended when coadministering both drugs.",""
124904,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diloxanide furoate is largely hydrolysed under the combined action of bacterial and gut esterases and subsequently glucuronidated. No clinically significant drug interactions are known, and significant interactions with antiretrovirals are unlikely. ",""
124905,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eflornithine is predominantly eliminated unchanged via the kidneys but fostemsavir is unlikely to significantly inhibit eflornithine renal elimination.,""
124907,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lumefantrine is metabolized predominantly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with lumefantrine. However, the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124908,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Mefloquine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with mefloquine. However, the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124909,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Meglumine antimoniate is predominantly eliminated unchanged via renal glomerular filtration. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with meglumine. However, given the QT prolongation risk associated with meglumine, ECG monitoring is recommended when coadministering both drugs.",""
124910,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely, although due to the lack of available data, vigilance is required if administering melarsoprol with antiretrovirals. It is unknown whether urinary metabolites of melarsoprol, such as arsenic, are excreted via active renal mechanisms. However, a clinical study has reported that urinary pharmacokinetic parameters are not predictive of toxicity or therapeutic efficacy. ",""
124911,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that interactions between miltefosine and drugs which are metabolized by cytochrome P450, glucuronidated or otherwise conjugated are unlikely. ",""
124912,"Coadministration has not been studied. Based on limited data concerning metabolism, elimination and toxicity of nifurtimox, a clinically significant interaction is unlikely. Nifurtimox appears to be biotransformed partially at a cytochrome P450 level but mostly by NADPH P450 reductase therefore no interaction is expected with fostemsavir. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124913,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paromomycin is not metabolised but is eliminated unchanged by renal glomerular filtration. ,""
124925,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Chlorpromazine is metabolized mainly by CYP2D6, but also by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with chlorpromazine. However, given the known QT prolongation risk associated with chlorpromazine, ECG monitoring is recommended when coadministering both drugs.",""
124915,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Piperaquine is a modest inhibitor of CYP3A4 but is unlikely to significantly increase temsavir exposure. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with piperaquine. However, given the QT prolongation risk associated with piperaquine, ECG monitoring is recommended when coadministering both drugs.",""
124916,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450. Fostemsavir does not interfere with primaquine elimination. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Primaquine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with primaquine.,""
124917,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is partly excreted unchanged and partly metabolized to its more active metabolite cycloguanil by CYP2C19 and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124919,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Quinine is extensively metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with sodium quinine. However, given the QT prolongation risk associated with sodium quinine, ECG monitoring is recommended when coadministering both drugs.",""
124922,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolized and is primarily eliminated renally (possibly via OCT). Temsavir (the active metabolite of fostemsavir) does not inhibit OCTs. ,""
124923,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Aripiprazole is metabolized by CYP3A4 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Aripiprazole has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with aripiprazole.,""
124924,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (CYP1A2 (major) and CYP3A4, CYP2D6 (minor)). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Asenapine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with asenapine.",""
124926,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clozapine is metabolized by CYPs 1A2, 2C19, 3A4, and to a lesser extent by CYPs 2C9 and 2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Clozapine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with clozapine.",""
124892,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Terfenadine undergoes extensive metabolism mainly by CYP3A4 to form azacyclonol and terfenadine alcohol. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with terfenadine. However, given the known QT prolongation risk associated with terfenadine, ECG monitoring is recommended when coadministering both drugs.",""
125069,Coadministration has not been studied. Bexarotene is mainly metabolized by CYP3A4 and induces CYP3A4 (after repeated administration and especially at doses greater than 300 mg/m2/day). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Bexarotene is unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) decreased temsavir exposure by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with bexarotene.,""
125070,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Bleomycin is inactivated by a cytosolic enzyme, bleomycin hydrolase, and approximately 67% of the administered drug is excreted unchanged in urine probably by glomerular filtration. ",""
125071,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bortezomib is mainly metabolized by CYPs 3A4 and 2C19 and to a lesser extent by CYPs 1A2, 2D6 and 2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Bortezomib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with bortezomib.",""
125072,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is activated by sequential enzyme reactions to fluorouracil. ,""
124903,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with chloroquine. However, given the known QT prolongation risk associated with chloroquine, ECG monitoring is recommended when coadministering both drugs.",""
124906,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Halofantrine is extensively metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with halofantrine. However, given the known QT prolongation risk associated with halofantrine, ECG monitoring is recommended when coadministering both drugs.",""
124927,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Fluphenazine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with fluphenazine.,""
124929,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Iloperidone is metabolized by CYP3A4 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Iloperidone has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with iloperidone.,""
124940,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with sulpiride. However, given the known QT prolongation risk associated with pimozide, ECG monitoring is recommended when coadministering both drugs.",""
124931,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolized mainly by CYP1A2, but also by glucuronidation (UGT1A4). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
124932,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Paliperidone is primarily eliminated renally (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Paliperidone has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with paliperidone.,""
124933,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is demethylated by CYP3A4 and to a lesser extent by CYP2C9, and oxidated by FMO3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124934,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124935,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Perphenazine is metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Perphenazine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with perphenazine.,""
124937,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with pipotiazine. However, the product label for fostemsavir indicates that pipotiazine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124938,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Quetiapine is primarily metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124939,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
124950,"Triumeq (dolutegravir/abacavir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. No interaction is expected with lamivudine or abacavir.",""
124942,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as tiapride is excreted largely unchanged in urine. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Tiapride has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with tiapride.,""
124943,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with ziprasidone. However, given the QT prolongation risk associated with ziprasidone, ECG monitoring is recommended when coadministering both drugs.",""
124944,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Zotepine is mainly metabolized by CYP3A4 and to a lesser extent CYP1A2 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Zotepine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with zotepine.,""
124945,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Zuclopenthixol is metabolized by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Zuclopenthixol has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with zuclopenthixol.",""
124962,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Efavirenz is a moderate inducer. Based on a drug-drug interaction study with etravirine, another moderate inducer, coadministration is not expected to result in a clinically significant interaction. Coadministration of fostemsavir with etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124947,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, and does not inhibit or induce CYP enzymes at clinically relevant concentrations. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
124949,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dolutegravir is mainly metabolized by UGT1A1 and to a lesser extent CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
124951,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. No interaction is expected with lamivudine.",""
124965,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Rilpivirine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir and rilpivirine have been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration. However, the product labels indicate that these antiretroviral drugs should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124964,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.&nbsp;Nevirapine is a weak inducer. Based on a drug-drug interaction study with etravirine, a moderate inducer, coadministration is not expected to result in a clinically significant interaction. Coadministration of fostemsavir with etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124955,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Dose modifications of ibalizumab are not required when administered with any other antiretroviral.",""
124958,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
124960,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
124967,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Abacavir does not interfere with fostemsavir metabolic pathway.,""
124928,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGT2B7 &gt;1A4, 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4, CYP2D6). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with haloperidol. However, given the known QT prolongation risk associated with haloperidol, ECG monitoring is recommended when coadministering both drugs.",""
124930,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Levomepromazine is metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with levomepromazine. However, given the known QT prolongation risk associated with levomepromazine, ECG monitoring is recommended when coadministering both drugs.",""
125073,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carboplatin is excreted primarily by renal glomerular filtration and therefore there is little potential for a pharmacokinetic interaction. ,""
125075,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorambucil is almost completely metabolized (little is known about chlorambucil metabolism in humans, most probably non-CYP mediated) and has extremely low urinary excretion. ",""
125076,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisplatin is eliminated renally via OCT2 and MATE1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2 or MATE1 to a clinically significant extent.,""
125077,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is metabolized by two pathways. Activation (major pathway) to 4-hydroxycyclophosphamide is catalyzed by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124936,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as pimozide is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with pimozide. However, given the known QT prolongation risk associated with pimozide, ECG monitoring is recommended when coadministering both drugs.",""
124968,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Didanosine does not interfere with fostemsavir metabolic pathway.,""
124969,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Emtricitabine does not interfere with fostemsavir metabolic pathway.,""
124970,"Coadministration with emtricitabine/tenofovir alafenamide has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir), but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine.",""
124971,"Coadministration with emtricitabine/tenofovir-DF has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of fostemsavir and tenofovir-DF had no significant effect on temsavir pharmacokinetics, but increased tenofovir Cmax, AUC and Cmin by 18%, 19% and 28%. These changes were not considered to be clinically relevant. No interaction is expected with emtricitabine.",""
124972,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Lamivudine does not interfere with fostemsavir metabolic pathway.,""
124973,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Stavudine does not interfere with fostemsavir metabolic pathway.,""
124986,"Coadministration with saquinavir has not been studied but is not expected to result in a pharmacokinetic interaction based on drug-drug interaction studies with other protease inhibitors. For example, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. The pharmacokinetics of darunavir or ritonavir were not significantly altered by fostemsavir (darunavir Cmax, AUC and Cmin decreased by 2%, 6% and 5%; ritonavir AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.&nbsp;Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with lopinavir/ritonavir. However, the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124975,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Zidovudine does not interfere with fostemsavir metabolic pathway.,""
124979,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes are not considered to be clinically significant and warrant a dose adjustment of fostemsavir. Fostemsavir did not significantly alter the pharmacokinetics of darunavir (Cmax, AUC and Cmin decreased by 2%, 6% and 5%) or ritonavir (AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Of interest, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) plus etravirine (200 mg twice daily) increased temsavir Cmax, AUC and Cmin by 53%, 34% and 33%. These changes were also not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir had no significant effect on the pharmacokinetics of darunavir (Cmax, AUC and Cmin decreased by 5%, 6% and 12%), ritonavir (Cmax, AUC and Cmin increased by 14%, 9% and 7%) or etravirine (Cmax, AUC and Cmin increased by 18%, 28% and 28%).",""
124982,"Coadministration has not been studied but is not expected to result in a clinically significant interaction based on drug-drug interaction studies with other protease inhibitors. For example, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. The pharmacokinetics of darunavir or ritonavir were not significantly altered by fostemsavir (darunavir Cmax, AUC and Cmin decreased by 2%, 6% and 5%; ritonavir AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124987,"Coadministration has not been studied but is not expected to result in a clinically significant interaction based on a drug-drug interaction study with etravirine, another inducer. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.&nbsp;Coadministration of fostemsavir with etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124983,"Coadministration with indinavir or indinavir/ritonavir has not been studied but is not expected to result in a clinically significant interaction based on drug-drug interaction studies with other protease inhibitors. For example, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. The pharmacokinetics of darunavir or ritonavir were not significantly altered by fostemsavir (darunavir Cmax, AUC and Cmin decreased by 2%, 6% and 5%; ritonavir AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
124984,"<p>Coadministration with lopinavir/ritonavir has not been studied but is not expected to result in a pharmacokinetic interaction based on drug-drug interaction studies with other protease inhibitors. For example, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. The pharmacokinetics of darunavir or ritonavir were not significantly altered by fostemsavir (darunavir Cmax, AUC and Cmin decreased by 2%, 6% and 5%; ritonavir AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with lopinavir/ritonavir. However, the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.
</p>",""
124993,Coadministration with elbasvir/grazoprevir has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase grazoprevir exposure and thereby increase the risk of ALT elevations. Use an alternative HCV regimen if possible.,""
124988,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.,""
124989,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Adefovir is eliminated renally via glomerular filtration and active renal secretion by OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.,""
124990,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is mainly eliminated in the kidney by glomerular filtration and active secretion via OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2.,""
124991,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1, OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs.",""
124992,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Daclatasvir is partly metabolized by CYP3A4 and mainly eliminated unchanged in bile. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124994,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Entecavir is eliminated renally via glomerular filtration and active renal secretion by both organic anions and cations transporters. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCTs or OATs transporters.,""
124995,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Famciclovir is converted to penciclovir by aldehyde oxidase. Penciclovir is secreted in the urine possibly by OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1. ,""
124996,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Foscarnet is cleared mainly by glomerular filtration. ,""
124997,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ganciclovir is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.,""
124998,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of glecaprevir and pibrentasvir, but an extent that is not clinically relevant.",""
124999,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of ledipasvir and sofosbuvir, but to an extent that is not clinically relevant.",""
125000,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of ombitasvir, paritaprevir and ritonavir, but an extent that is not clinically relevant. In contrast, paritaprevir/ritonavir may increase the exposure of temsavir. Coadministration of fostemsavir with ritonavir increased temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
125001,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of ombitasvir, paritaprevir, ritonavir and dasabuvir, but an extent that is not clinically relevant. In contrast, paritaprevir/ritonavir may increase the exposure of temsavir. Coadministration of fostemsavir with ritonavir increased temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
125002,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases. The latter is excreted in the urine by glomerular filtration and tubular secretion by OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.,""
125004,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Rimantadine is both hydroxylated and glucuronidated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce P450 or UGT enzymes.,""
125005,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of simeprevir, but to an extent that is not clinically relevant.",""
125006,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of sofosbuvir, but to an extent that is not clinically relevant.",""
125007,"Coadministration has not been studied. Temsavir (the active metabolite of fostemsavir) inhibits BCRP and OATPs and may increase the exposure of sofosbuvir and velpatasvir, but to an extent that is not clinically relevant.",""
124977,"Coadministration of fostemsavir and atazanavir alone has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (600 mg twice daily) and atazanavir/ritonavir (300/100 mg once daily) increased temsavir Cmax, AUC and Cmin by 68%, 54% and 57%, but did not alter significantly atazanavir (Cmax, AUC and Cmin increased by 3%, 9% and 19%) and ritonavir (Cmax, AUC and Cmin increased by 2%, 7% and 22%). The increase in fostemsavir exposure was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. A similar effect is expected with atazanavir alone.",""
124974,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir and tenofovir-DF had no significant effect on temsavir pharmacokinetics, but increased tenofovir Cmax, AUC and Cmin by 18%, 19% and 28%. These changes were not considered to be clinically relevant.",""
125009,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Telbivudine is eliminated primarily by urinary excretion as unchanged drug. The renal clearance of telbivudine approaches normal glomerular filtration rate, suggesting that filtration is the main mechanism of excretion. ",""
125010,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir), but to a modest extent with no clinically relevant impact.",""
125059,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Diltiazem is a strong inhibitor of CYP3A4 but is not expected to cause a clinically significant increase in temsavir. Coadministration of fostemsavir with cobicistat (a strong CYP3A4) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.,""
125089,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoposide is partly metabolized by CYP3A4 to reactive catechol metabolites. Conversion to reactive metabolites can also be mediated by prostaglandin synthase or myeloperoxidase. Furthermore, etoposide is partly glucuronidated by UGT1A1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
125090,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Everolimus is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Everolimus is a weak inhibitor of CYP3A4 but is unlikely to significantly increase temsavir exposure. ,""
125091,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolized by CYP3A4 and aldoketoreductase. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125092,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed to 2F-ara-A, the principal metabolite (non CYP mediated metabolism) which is then eliminated renally. ",""
125093,"Coadministration has not been studied. Fluorouracil is metabolised by the same mechanisms as endogenous uracil, including by dihydropyrimidine dehydrogenase. Fostemsavir does not interfere with this metabolic pathway. ",""
125094,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formestane undergoes reductive metabolism by hepatic hydroxysteroid dehydrogenase and glucuronidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125095,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gefitinib is metabolized by CYP3A4 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125096,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemcitabine is metabolized in the liver by cytidine deaminase to an inactive metabolite. Fostemsavir does not interfere with this metabolic pathway. ,""
125097,"Coadministration has not been studied. In vitro studies have demonstrated the ability of ifosfamide to both inhibit and induce CYP3A4. Clinical data with sunitinib suggests that ifosfamide can decrease sunitinib levels via CYP3A4 induction. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. There is potential for ifosfamide to alter levels of temsavir via modulation of CYP3A4 activity, but to a limited extent. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with ifosfamide.",""
125098,"Coadministration has not been studied. Imatinib is primarily metabolized by CYP3A4 and to a lesser extent by CYPs 1A2, 2D6, 2C9, and 2C19. Imatinib is a substrate of BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Imatinib is a moderate inhibitor of CYP3A4 but is unlikely to increase temsavir exposure to a clinically significant extent. Coadministration of fostemsavir with ritonavir (a strong CYP3A4 inhibitor) increased temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. In contrast, fostemsavir has been shown to increase tenofovir alafenamide exposure to a modest extent (likely due to intestinal inhibition of BCRP). An increase in imitanib exposure cannot be excluded. Caution is advised.",""
125099,"Coadministration has not been studied. Irinotecan is converted to its active metabolite SN38 via tissue carboxylesterase and to inactive metabolites (APC, NPC) via CYP3A4. SN38 is further inactivated by several UGTs. Irinotecan is a substrate of BCRP and OATP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. However, temsavir does inhibit BCRP and OATP and has the potential to increase irinotecan exposure. Caution is advised.",""
125100,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lapatinib is metabolized by CYP3A4 and is a weak inhibitor of both CYP3A4 and UGT1A1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Lapatinib is unlikely to increase temsavir exposure to a clinically significant extent. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Lapatinib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with lapatinib.,""
125101,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lenalidomide undergoes limited metabolism and is eliminated renally. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Lenalidomide does not induce or inhibit CYPs or UGTs and no interaction is expected with fostemsavir. ,""
125102,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised by CYP3A4 and CYP2A6 to carbinol (inactive metabolite). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125103,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is predominantly metabolised by xanthine oxidase. Fostemsavir does not interfere with this metabolic pathway. ,""
125104,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesna is rapidly oxidised to its only metabolite, mesna disulphide via the physiological cysteine system. Approximately 32% and 33% of an administered dose is eliminated in the urine in 24 hours as mesna and mesna disulphide respectively. Fostemsavir does not interfere with mesnaâ€™s metabolic pathway. ",""
125105,"Coadministration has not been studied. Methotrexate is predominantly eliminated via the kidneys, including active tubular secretion (OAT1, OAT3 mediate methotrexate transport in the kidney whereas MRP4 and BCRP mediate methotrexate efflux in the urine). Methotreaxate is also a substrate of OATP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs, however, it does inhibit BCRP and OATP and has the potential to increase methotrexate exposure. Caution is advised.",""
125106,"Coadministration has not been studied. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly via CYP450. Mitoxantrone is a substrate of BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. However, fostemsavir has been shown to increase tenofovir alafenamide exposure (likely due to intestinal inhibition of BCRP), but to a modest extent. An increase in mitoxantrone exposure cannot be excluded. Caution is advised. ",""
125107,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nilotinib is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Nilotinib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with nilotinib.,""
125109,"Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Paclitaxel is a substrate of OATP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes, but does inhibit OATP and therefore has the potential to increase paclitaxel exposure. Caution is advised. In vitro data suggest that paclitaxel activates PXR, however, no clinically significant decrease in temsavir is expected. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation does also apply when fostemsavir is coadministered with paclitaxel. ",""
125110,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Pazopanib is metabolized by CYP3A4 and to a lesser extent by CYPs 1A2 and 2C8. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Pazopanib is a weak inhibitor of CYP3A4 and is a weak inhibitor (in vivo) of UGT1A1 but is unlikely to cause a significant increase in temsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Pazopanib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with pazopanib.,""
125111,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Procarbazine is metabolized to azoprocarbazine by CYP450 (mainly CYP2B and 1A) and monoamine oxidase. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125112,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rituximab is a monoclonal IgG antibody. Elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body. ,""
125113,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sorafenib is metabolized to a moderate extent by CYP3A4 and UGT1A9, UGT1A1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Sorafenib is a moderate inhibitor of UGT1A1 but is unlikely to affect temsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Sorafenib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with sorafenib.",""
125114,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sunitinib is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Sunitinib has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with sunitinib.,""
125115,"Coadministration has not been studied. Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 >2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. No effect on tamoxifen is expected as temsavir does not inhibit or induce CYP enzymes. Tamoxifen induces CYP3A4 but is expected to have a limited effect of temsavir. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with tamoxifen.",""
125116,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temsirolimus is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Temsirolimus has been reported to inhibit CYP3A4 in vitro but is unlikely to cause a clinically significant interaction with temsirolimus.,""
125117,"Coadministration has not been studied. Topotecan undergoes both hepatic and renal elimination. Hepatic elimination involves mainly a non-enzymatic hydrolysis and, to a minor extent, CYP mediated N-demethylation as well as a glucuronidation. Renal elimination is by both active secretion (mainly via OAT3) and glomerular filtration. Topotecan is a substrate for P-gp and BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibits BCRP and has the potential to increase topotecan exposure. Caution is advised.",""
125118,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Toremifene is mainly metabolized by CYP3A4 to N-demethyltoremifene. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Toremifene has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with toremifene.,""
125120,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trastuzumab emtansine is a monoclonal antibody-drug conjugate. Trastuzumab does not undergo CYP mediated metabolism, whereas DM1 (an active component of emtansine) is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125121,Coadministration has not been studied. Vinblastine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In vitro data suggest that vinblastine induces CYP3A4 partly via PXR mediated activation but is expected to have a limited effect of temsavir. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with vinblastine.,""
125122,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vincristine is metabolized by CYP3A5/4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125123,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vinorelbine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125124,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Vorinostat metabolism is mainly metabolised by glucuronidation (UGT2B17) and hydrolysis followed by B oxidation (non CYP-mediated). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Vorinostat has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with vorinostat.,""
125125,"Coadministration with a desogestrel-containing combined oral contraceptive (COC) has not been studied. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). When desogestrel is administered as COC, ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125126,Coadministration with a desogestrel-containing progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that is activated to etonogestrel by CYP2C9 (and possible CYP2C19) which is then metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on exposure of norethindrone (1.5 mg once daily).,""
125127,"Coadministration with a drospirenone-containing combined oral contraceptive (COC) has not been studied. Drospirenone is metabolized to a minor extent via CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). When drospirenone is administered as COC, ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125128,"Coadministration with drospirenone as hormone replacement therapy (HRT) has not been studied. Drospirenone is metabolized to a minor extent via CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Similarly, an increase in estradiol exposure cannot be excluded. The use of estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. ",""
125129,"Coadministration with dydrogesterone as hormone replacement therapy (HRT) has not been studied. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Similarly, an increase in estradiol exposure cannot be excluded. The use of estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
125108,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Oxaliplatin undergoes non enzymatic biotransformation and is eliminated renally via OCT2 and MATE2-K. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2 or MATE2-K to a clinically significant extent. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with oxaliplatin. However, given the known QT prolongation risk associated with oxaliplatin, ECG monitoring is recommended when coadministering both drugs.",""
125130,"Coadministration with estradiol as hormone replacement therapy (HRT) has not been studied. Estradiol is metabolized by CYP3A4, CYP1A2 and is glucuronidated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Similarly, an increase in estradiol exposure cannot be excluded. The use of estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated",""
125147,Coadministration of a norethisterone progestogen-only pill (POP) has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of norethindrone (1.5 mg once daily).,""
125132,Coadministration with an etonogestrel-containing progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of oral norethindrone (1.5 mg once daily).,""
125133,"Coadministration with etonogestrel as a combined vaginal ring (CVR) has not been studied. Etonogestrel is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on exposure of oral norethindrone (1.5 mg once daily). However, fostemsavir increased oral ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). The use of estrogen alone or in combination with a progestogen for hormone replacement therapy should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated",""
125134,"Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125135,"Coadministration with a levonorgestrel-containing combined oral contraceptive (COC) has not been studied. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125136,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of norethindrone (1.5 mg once daily).,""
125137,Coadministration with levonorgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of norethindrone (1.5 mg once daily).,""
125138,Coadministration with a levonorgestrel progestogen-only implant has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of oral norethindrone (1.5 mg once daily).,""
125140,Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of norethindrone (1.5 mg once daily).,""
125141,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of oral norethindrone (1.5 mg once daily).,""
125142,"Coadministration has not been studied. Medroxyprogesterone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Similarly, an increase in estradiol exposure cannot be excluded. The use of estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
125143,"Coadministration with transdermally delivered norelgestromin/ethinylestradiol has not been studied. Norelgestromin is metabolized to norgestrel (possibly by CYP3A4). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125145,"Coadministration with norethisterone as hormone replacement therapy (HRT) has not been studied. Norethisterone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Similarly, an increase in estradiol exposure cannot be excluded. The use of estrogen alone or in combination with a progestogen should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.",""
125160,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cisapride is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with cisapride. However, given the known QT prolongation risk associated with cisapride, ECG monitoring is recommended when coadministering both drugs.",""
125148,"Coadministration of a combined oral contraceptive (COC) containing norgestimate/ethinylestradiol has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125149,"Coadministration of a combined oral contraceptive (COC) containing norgestrel/ethinylestradiol has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir had no significant effect on norethindrone (1.5 mg once daily) exposure, but increased ethinylestradiol (0.030 mg once daily) Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). Ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125150,Coadministration with norgestrel as hormone replacement therapy (HRT) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of norethindrone (1.5 mg once daily).,""
125151,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ulipristal is mainly metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125152,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avanafil is primarily metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125153,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolised by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125154,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125155,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125156,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. In vitro data indicate that alosetron is metabolized by CYPs 2C9, 3A4 and 1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ",""
125157,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir solubility is not impacted by changes in pH. Coadministration of fostemsavir 2 hours after famotidine (40 mg single dose) under fasted conditions did not significantly alter temsavir pharmacokinetics (Cmax increased by 1%, AUC increased by 4%, Cmin decreased by 10%). ",""
125158,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Significant interactions are not expected with fostemsavir.,""
125159,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. In vitro data indicate that cimetidine inhibits OAT1 and OCT2 at concentrations much higher than the observed clinical concentrations and therefore no effect on temsavir is expected. In addition, coadministration of fostemsavir 2 hours after famotidine (40 mg single dose) under fasted conditions did not significantly alter temsavir pharmacokinetics (Cmax increased by 1%, AUC increased by 4%, Cmin decreased by 10%). Thus, temsavir solubility is not impacted by changes in pH and can be coadministered with PPIs or H2-antagonists without dose adjustment or separation.",""
125161,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir 2 hours after famotidine (40 mg single dose) under fasted conditions did not significantly alter temsavir pharmacokinetics (Cmax increased by 1%, AUC increased by 4%, Cmin decreased by 10%). Thus, temsavir solubility is not impacted by changes in pH and can be coadministered with PPIs or H2-antagonists without dose adjustment or separation.",""
125165,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is metabolized by CYP3A4 and CYP2C8. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
125166,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolized to N-acetyl-mesalazine by N-acetyltransferase. Fostemsavir does not interfere with this pathway. ,""
125169,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly eliminated renally, partly by active secretion by renal transporters (of note no clinically relevant interactions were observed when prucalopride was coadministered with inhibitors of renal P-gp, OAT and OCT transporters). ",""
125131,"Coadministration of fostemsavir and an oral contraceptive containing ethinylestradiol (0.03 mg once daily, with norethisterone) increased ethinylestradiol Cmax and AUC by 39% and 40% (possibly due to BCRP inhibition). The daily dose of ethinylestradiol should not exceed 30 Âµg. Caution is advised, particularly in patients with additional risk factors for thromboembolic events.",""
125146,Coadministration of a norethisterone IM depot injection has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been shown to have no significant effect on exposure of oral norethindrone (1.5 mg once daily).,""
125172,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces and also in other secretions. No clinically significant drug interactions are known. ,""
125173,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
125174,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolized by CYP2D6 (10-20%) and CYP3A4 (<1%). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Dolasetron has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with dolasetron.",""
125176,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolized by CYP2C9 and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
125177,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Granisetron is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Granisetron has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with granisetron.,""
125178,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolized by CYP450 system (mainly CYP2D6). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
125180,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with prochlorperazine. However, the product labels for fostemsavir indicate that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125181,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. African potato was shown to inhibit CYP3A4 and P-gp in vitro and to activate PXR suggesting that inhibition may occur initially followed by induction of CYP3A4 and P-gp when used for extended periods. However African potato is expected to have a limited effect on temsavir. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with African potato.,""
125182,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. ",""
125183,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ascorbic acid is oxidised to dehydroascorbic acid where some is metabolised to oxalic acid and the inactive ascorbate-2-sulphate. Large doses are rapidly excreted in the urine when in excess of the requirements of the body. Fostemsavir does not interfere with this metabolic pathway.,""
125187,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of vitamin D to active metabolites occurs in the liver and kidneys, and is thought to involve CYP3A4 and CYP24A1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.",""
125189,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Several constituents of Piper cubeba were shown to inhibit CYP3A4 in vitro but are unlikely to significantly increase temsavir.,""
125192,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Echinacea has a selective effect on CYP3A4 activity (inhibition of intestinal CYP3A4 and induction of hepatic CYP3A4) and its effect on the net exposure of a CYP3A4 substrate will depend on the extraction of the drug at the intestinal and hepatic sites. However, echinacea is unlikely to significantly reduce temsavir.",""
125193,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. ",""
125197,Coadministration has not been studied. Garlic supplements have been shown to decrease unboosted saquinavir AUC by 50% in a clinical trial and there is a case report of treatment failure due to garlic cloves (six garlic cloves three times weekly) decreasing ritonavir-boosted atazanavir trough concentrations by ~70%. This effect has been attributed to the induction of intestinal CYP3A4 and/or P-gp by garlic. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Patients should be advised against the use of garlic supplements.,""
125198,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Gingerols moderately inhibit CYP3A4 in vitro but are unlikely to significantly affect temsavir.",""
125199,Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Ginkgo biloba induces of CYP3A4 but it is expected to have a limited effect on temsavir. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with ginkgo biloba.,""
125200,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Goldenseal has been shown to inhibit CYP3A4 in vitro, however, no significant effect of golden seal root on indinavir pharmacokinetics was observed in a study in HIV-negative subjects. Interactions with other drugs metabolized by CYP3A4 are unlikely. ",""
125201,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Grapefruit juice is unlikely to increase temsavir exposure to a clinically significant extent. ,""
125203,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Alantolactone, a component of Inula racemosa, moderately inhibits CYP3A4 in vitro but is not expected to significantly increase temsavir exposure. Coadministration of fostemsavir with ritonavir (a strong CYP3A4 inhibitor) was shown to increase temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
125207,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Glycyrrhizin, the main active component of Glycyrrhiza glabra, is a modest inducer of CYP3A4 and is expected to have a limited effect on temsavir. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with liquorice. ",""
125208,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in kidney, mainly by glomerular filtration.Â ",""
125175,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Domperidone is mainly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with domperidone. However, given the known QT prolongation risk associated with domperidone, ECG monitoring is recommended when coadministering both drugs.",""
125179,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ondansetron is metabolized mainly by CYP1A2 and CYP3A4 and to a lesser extent by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with ondansetron. However, given the known QT prolongation risk associated with ondansetron, ECG monitoring is recommended when coadministering both drugs.",""
125202,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. In vitro data indicate that extracts of hops activate PXR and induce expression of CYP3A4, CYP2B6 and MDR1 genes to a degree similar to that of St John's wort and could decrease exposure of temsavir. Avoid coadministration.",""
125211,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug-drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, P-gp, UGT and OATP. ",""
125213,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is metabolized by nicotinamide methyltransferase to N-methylnicotinamide which is then metabolized by xanthine oxidase and aldehyde oxidase. Renal elimination of unchanged nicotinamide is minimal. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.,""
125215,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of phytomenadione is thought to involve CYP4F2 and glucuronidation. Renal elimination of phytomenadione is minimal. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
125217,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.,""
125218,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyridoxine is absorbed from the GI tract and is converted to the active form pyridoxal phosphate. It is excreted in the urine as 4-pyridoxic acid. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. ,""
125219,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Quercetin inhibits CYP3A4 and P-gp in vitro but is unlikely to cause a clinically significant increase in temsavir exposure. ",""
125220,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Red yeast rice contains monacolin K (a natural component with the same chemical structure as lovastatin) which is metabolised by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125221,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver. Retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
125226,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Seville orange juice inhibits intestinal CYP3A4 but this is unlikely to cause a clinically significant inhibition of temsavir. ",""
125232,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Data from pharmacokinetic studies suggest that turmeric and curcuminoids (derived from turmeric extract) are unlikely to affect CYP3A4- and UGT-mediated metabolism. ",""
125233,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of valerian with probe substrates for CYP3A4 (alprazolam) and CYP2D6 (dextromethorphan) modestly increased alprazolam Cmax and AUC (~20%) and had no effect on dextromethorphan. A clinically significant interaction is unlikely with drugs metabolised by CYP3A4 or CYP2D6.",""
125234,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aliskiren is minimally metabolized and is mainly excreted unchanged in faeces. P-glycoprotein is a major determinant of aliskiren bioavailability. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit P-glycoprotein.,""
125235,"Coadministration has not been studied. Ambrisentan is mainly glucuronidated by UGT1A9, UGT2B7, UGT1A3 and is metabolized to a lesser extent by CYP3A4. Ambrisentan is also a substrate of P-gp and OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir inhibits OATP and has the potential to increase ambrisentan exposure. Start ambrisentan at 5 mg and closely monitor the patient for tolerability.",""
125236,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged by the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2.,""
125238,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%, exact pathway not known) and excreted unchanged in the urine (30%) via OAT1 and OAT3. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1 and OAT3.",""
125240,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. ,""
125241,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.,""
125242,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. ,""
125243,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys. ,""
125244,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in form of the unchanged parent drug (40-60% of the dose). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit renal transporters to a clinically significant extent.",""
125245,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Digoxin is eliminated renally via the renal transporters OATP4C1 and P-glycoprotein. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit P-gp or OATP4C1. ,""
125246,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. Fostemsavir does not interact with this metabolic pathway. ",""
125247,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is metabolized mainly by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125248,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is eliminated renally (possibly via OATs). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs.,""
125249,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eplerenone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125225,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. In vitro data indicate that Serenoa repens inhibits CYP2C9, CYP2D6 and CYP3A4 activity. However, studies found that administration of Serenoa repens did not alter CYP3A4 or CYP2D6 activity in healthy volunteers. A clinically relevant interaction is unlikely with substrates of CYP3A4 and CYP2D6.",""
125227,"Coadministration has not been studied but is contraindicated. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. St Johnâ€™s wort may substantially decrease temsavir exposure, which may result in loss of therapeutic effect and development of resistance.",""
125239,"Coadministration has not been studied. Bosentan is a substrate CYP3A4 and OATP1B1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATP1B1 and has the potential to increase bosentan exposure. When coadministered patients should be closely monitored for bosentan toxicity, especially during the first week of co-administration. Bosentan is a moderate inducer of CYP3A4 but is unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce the exposure of the active metabolite temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation does also apply when fostemsavir is coadministered with bosentan.",""
125251,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as eprosartan is largely excreted in bile and urine as unchanged drug. ,""
125253,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125254,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP3A4 or UGT enzymes.,""
125255,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolized and is cleared by the kidneys via OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.,""
125256,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloprost is extensively metabolized via beta oxidation of the carboxyl side chain with only a minor role for CYP metabolism. Fostemsavir does not interact with iloprostâ€™s metabolic pathway.,""
125257,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is extensively metabolized by CYP450. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125258,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Irbesartan is metabolized by glucuronidation and oxidation (mainly CYP2C9). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
125259,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125261,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Labetalol is mainly glucuronidated (via UGT1A1 and 2B7). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125262,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125260,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ivabradine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with ivabradine. However, the product labels for fostemsavir indicate that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125275,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ranolazine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Ranolazine inhibits P-gp and has the potential to increase temsavir although to a limited extent. Coadministration of fostemsavir with cobicistat (a strong inhibitor of P-gp) increased temsavir Cmax, AUC and Cmin by 71%, 93% and 136%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with ranolazine. However, the product labels for fostemsavir indicate that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125292,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetrahydrocannabinol (THC, the psychoactive component of cannabis) is metabolized mainly by CYP2C9 and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125326,Coadministration has not been studied. Pitavastatin is metabolized by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes but does inhibit OATPs and BCRP and has the potential to increase pitavastatin exposure. Use the lowest possible starting dose and monitor for statin associated adverse events.,""
125294,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. MDMA is metabolized mainly by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125295,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gamma-hydroxybutyrate undergoes first pass metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125296,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. When used illicitly, heroin is mainly injected or inhaled through the nose and goes directly in the bloodstream. Heroin is then rapidly deacetylated to 6-monoacetylmorphine (6-MAM) and subsequently to morphine by plasma and liver esterases, respectively. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7 >UGT1A1) and, to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7 >UGT1A1). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125297,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. LSD (lysergic acid diethylmide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.,""
125298,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125299,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Methamphetamine is mainly metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125300,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Phencyclidine is extensively metabolized to inactive metabolites by a variety of metabolic routes (mainly CYP3A4). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125301,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amyl nitrate is metabolized rapidly by hydrolytic denitration. Fostemsavir does not interact with this metabolic pathway. ,""
125302,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.Hydroxyurea undergoes metabolism via non-CYP mediated metabolism and is unlikely to affect concentrations of temsavir.,""
125303,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Non-pegylated interferon alpha appears to be metabolized principally in the kidney. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.,""
125304,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. ",""
125305,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. No effect of peginterferon alfa-2a on temsavir. The metabolism of peginterferon alfa-2a is not fully characterized, however studies in rats indicate that the kidney is a major organ for excretion. ",""
125306,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. o effect of peginterferon alfa-2b on temsavir is expected. ,""
125309,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolized analogously to natural purines. Fostemsavir does not interfere with this metabolic pathway. ",""
125312,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclosporin is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125313,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125314,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sirolimus is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125315,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tacrolimus is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. ,""
125317,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as half of bezafibrate dose is eliminated unchanged in the urine. Significant interactions are not expected with fostemsavir. ,""
125318,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolyzed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OAT1.",""
125320,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.,""
125321,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolyzed to an active metabolite, fenofibric acid. Significant interactions are not expected with fostemsavir. ",""
125329,Coadministration has not been studied. Simvastatin is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP3A4 but does inhibit OATPs and BCRP and has the potential to increase simvastatin exposure. Use the lowest possible starting dose and monitor for statin associated adverse events.,""
125324,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. ,""
125325,Coadministration has not been studied. Lovastatin is metabolised by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and BCRP and has the potential to increase lovastatin exposure. Use the lowest possible starting dose and monitor for statin associated adverse events.,""
125327,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir inhibits OATPs and BCRP but given that pravastatin is not a substrate of BCRP, temsavir is unlikely to cause a clinically significant increase in pravastatin exposure. ",""
125330,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acamprosate is eliminated unchanged in the urine both via glomerular filtration and active secretion (renal transporter unknown, possibly OATs or OCTs). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OATs or OCTs.",""
125331,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acetazolamide is predominantly excreted unchanged via active renal tubular secretion. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit renal transporters to a clinically significant extent.,""
125293,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cocaine is metabolized by several pathways (CYP and non CYP mediated), with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with cocaine. However, given the known QT prolongation risk associated with cocaine, ECG monitoring is recommended when coadministering both drugs.",""
125316,Coadministration has not been studied. Atorvastatin is metabolized by CYP3A4 and is a substrate of OATPs. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4 enzymes. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and BCRP and has the potential to increase atorvastatin exposure. Use the lowest possible starting dose and monitor for statin associated adverse events.,""
125323,Coadministration has not been studied. Fluvastatin is mainly metabolized by CYP2C9. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes but does inhibit OATPs and BCRP and has the potential to increase fluvastatin exposure. Use the lowest possible starting dose and monitor for statin associated adverse events.,""
125332,"Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely. Acitretin undergoes isomerisation and glucuronidation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125333,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Adrenaline is rapidly inactivated, mostly in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). ",""
125334,"Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product. ",""
125335,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP3A4 enzyme.,""
125336,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely as allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Fostemsavir does not interfere with this metabolic pathway. ,""
125337,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely when atropine is used either systemically or as eye drops. Although metabolism of atropine is not fully elucidated, up to 50% is excreted unchanged via the kidneys. There is therefore little potential for clinically significant interactions with fostemsavir via modulation of, or competition for metabolic pathways. ",""
125338,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Baclofen is primarily eliminated by glomerular filtration. ,""
125340,"Coadministration has not been studied but based on limited information concerning the metabolism and clearance of biperiden, there is little potential for clinically significant interaction. Limited human data suggest biperiden undergoes hydroxylation in the liver. Temsavir (active metabolite of fostemsavir) does not inhibit or induce drug metabolizing enzymes.",""
125342,Coadministration has not been studied but a clinically significant clinically significant interaction is unlikely. Caffeine is mainly metabolized by CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125344,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19 and is unlikely to significantly inhibit CYP3A4, UGT1A1 or intestinal transporters in the range of doses in clinical use. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
125363,"Coadministration has not been studied. Modafinil is largely metabolized by hydrolysis (esterase mediated) and to a lesser extent by CYP3A4 mediated oxidative metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. However, modafinil is a moderate inducer of CYP3A4 but is unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce the exposure of the active metabolite temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with modafinil.",""
125373,Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is eliminated renally. ,""
125374,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Probenecid is metabolized by CYP enzymes to a limited extent. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125375,"Coadministration has not been studied but based on limited data available an interaction appears unlikely. Propylthiouracil is extensively metabolised, predominantly via glucuronidation, but the exact glucuronidation pathways are unknown. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes.",""
125376,"Coadministration has not been studied but based on limited data available an interaction appears unlikely. The metabolism of protamine has not been fully elucidated, however protamine complexed with heparin is thought to be partially metabolised by fibrinolysin. ",""
125377,"Coadministration has not been studied but based on limited data available an interaction appears unlikely. Pyridostigmine is predominantly excreted unchanged via the kidneys, with up to 74% of renal clearance attributed to active tubular secretion (most likely by a cation transporter). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit renal transporters to a clinically significant extent.",""
125378,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for fostemsavir, but for any medication taken with sevelamer.]",""
125379,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as strontium is predominantly eliminated unchanged by the kidneys. However, food and milk can affect strontium absorption and administration should be separated by at least 2 hours. [Note: this interaction is not specific for fostemsavir, but for any medication taken with strontium ranelate.]Â ",""
125380,Coadministration has not been studied. Sulfasalazine is a substrate of BCRP. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir inhibits BCRP and has the potential to increase sulfasalazine exposure. Caution is advised. ,""
125381,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125382,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thalidomide is cleared by non-enzymatic hydrolysis. ,""
125383,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration. ,""
125385,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Varenicline is eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion by OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2.,""
125387,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darifenacin is metabolized by CYP3A4 and CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125388,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fesoterodine is rapidly hydrolysed to its active metabolite which is subsequently metabolized by CYP2D6 and CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125389,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes.",""
125390,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxybutynin is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125391,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Solifenacin is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125392,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Tolterodine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with tolterodine.,""
125393,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trospium is minimally metabolized and is mainly eliminated unchanged renally, in part by OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2.",""
125394,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ergometrine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125395,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mifepristone is predominantly metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125396,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Misoprostol is predominantly metabolised via fatty acid oxidising systems. ,""
125397,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elimination of oxytocin occurs via the liver, kidney, functional mammary gland and oxytocinase. The plasma half-life is approximately five minutes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Oxytocin has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with oxytocin.",""
125398,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely as apomorphine is metabolized by several pathways including glucuronidation, sulfation and to a lesser extent N-demethylation. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce drug metabolizing enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Apomorphine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with apomorphine.",""
125399,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as benserazide is hydrolysed to trihydroxybenzylhydrazine. ,""
125401,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In the presence of a peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) levodopa is metabolised mainly to 3-O-methyldopa by catechol-O-methyltransferase. Fostemsavir does not interact with this metabolic pathway. ,""
125402,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pramipexole is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporter OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit OCT2.,""
125403,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rasagiline is metabolised predominantly via CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes,""
125404,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolised predominantly via CYP1A2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes,""
125405,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone -17-monopropionate. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125407,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125408,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is a pro-drug activated by esterases in the lungs to des-ciclesonide which then undergoes CYP3A4-mediated metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125409,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clobetasol is a substrate of CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125411,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized in the liver to inactive metabolites, possibly via CYP3A. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.",""
125412,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125406,"Coadministration has not been studied. Betamethasone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. However, betamethasone is a moderate inducer of CYP3A4 but is unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce the exposure of the active metabolite temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with betamethasone.",""
125414,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125415,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125416,Coadministration has not been studied. No clinically relevant drug interactions are expected with the topical use of hydrocortisone. ,""
125417,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. ,""
125418,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125419,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125422,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisolone undergoes hepatic metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce drug metabolizing enzymes.,""
125423,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125424,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce drug metabolizing enzymes.,""
125425,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Testosterone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
125426,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes.,""
124722,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flecainide is metabolized mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also eliminated unchanged renally. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes and is unlikely to inhibit the renal elimination of flecainide. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with flecainide. However, given the known QT prolongation risk associated with flecainide, ECG monitoring is recommended when coadministering both drugs.",""
124763,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Moxifloxacin is predominantly glucuronidated by UGT1A1. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce UGT enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with moxifloxacin. However, given the known QT prolongation risk associated with moxifloxacin, ECG monitoring is recommended when coadministering both drugs.",""
124697,"Coadministration of fostemsavir (600 mg twice daily) in 16 individuals on stable methadone treatment (40-120 mg once daily, individualized doses) increased total methadone Cmax, AUC and Cmin by 15%, 14% and 10%; R-methadone increased by 15%, 13% and 9%; S-methadone increased by 15%, 15% and 10%. These changes are not considered to be clinically significant and were not associated with opioid withdrawal effects or with toxicity. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with methadone. However, given the known QT prolongation risk associated with methadone, ECG monitoring is recommended when coadministering both drugs.",""
125456,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with ritonavir increased temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes are not considered to be clinically significant and do not warrant a dose adjustment of fostemsavir.",""
124373,"Coadministration has not been studied. Sevelamer is a resin not absorbed from the GI tract that may affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for cabotegravir administered orally, but for any medication taken with sevelamer].",""
125604,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brimonidine is metabolized mainly by aldehyde oxidase.,""
124771,Coadministration with rifampicin is contraindicated as it may result in a potential loss of therapeutic effect. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (1200 mg single dose) in 15 individuals on rifampicin treatment (600 mg once daily) substantially decreased temsavir Cmax and AUC by 76% and 82%.,""
125532,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Alogliptin was shown to have no inhibitory or inducing effect on CYPs at concentrations achieved with the recommended dose of 25 mg alogliptin.&nbsp;Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporters OAT1, OAT3 or OCT2 and to cause no interactions with P-glycoprotein substrates.",""
124770,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (600 mg twice daily) and rifabutin (300 mg once daily) decreased temsavir Cmax, AUC and Cmin by 27%, 30% and 41% (n=22). Coadministration of rifabutin (150 mg once daily), ritonavir (100 mg once daily) and fostemsavir (600 mg twice daily) increased temsavir Cmax, AUC and Cmin by 50%, 66% and 158% (n=23). These changes are not considered to be clinically significant and do not warrant a dose adjustment of fostemsavir.",""
124685,"Coadministration of fostemsavir (600 mg twice daily) in 16 individuals on stable buprenorphine/naloxone treatment (doses between 8/2 and 24/6 mg once daily) increased Cmax, AUC and C24 of buprenorphine by 24%, 30% and 39% and those of norbuprenorphine by 24%, 39% and 36%. These changes are not considered to be clinically relevant and were not associated with opioid withdrawal effects or with toxicity.",""
125491,"Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Dolutegravir inhibits OCT2 and has the potential to cause seizures due to increased fampridine plasma concentration via OCT2 inhibition. Rilpivirine does not interfere with fampridine elimination pathway. Coadministration is contraindicated in the European product label for dolutegravir/rilpivirine, but the US product label advises that the potential benefits of taking dalfampridine should be considered against the risk of seizures.",""
124957,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (1200 mg single dose) in 17 individuals on raltegravir treatment (400 mg twice daily) increased temsavir Cmax, AUC and Cmin by 23%, 7% and 17%. These changes are not considered to be clinically significant and do not warrant a dose adjustment.",""
124963,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.&nbsp;Coadministration of fostemsavir and etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52% and increased etravirine Cmax, AUC and Cmin by 11%, 11% and 14% (n=14). These changes are not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
123004,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123500,"Coadministration has not been studied, but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Paliperidone is primarily eliminated renally (possibly OCT), with minimal metabolism occurring via CYP2D6 and 3A4. Cabotegravir and rilpivirine do not cause clinically relevant inhibition of renal transporters and have no inhibitory or inducing effects on CYP enzymes at clinically relevant concentrations.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with paliperidone. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124976,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (600 mg twice daily) and atazanavir/ritonavir (300/100 mg once daily) increased temsavir Cmax, AUC and Cmin by 68%, 54% and 57%, but did not alter significantly atazanavir (Cmax, AUC and Cmin increased by 3%, 9% and 19%) and ritonavir (Cmax, AUC and Cmin increased by 2%, 7% and 22%). The increase in fostemsavir exposure is not considered to be clinically significant and does not warrant a dose adjustment of fostemsavir.",""
124978,"Coadministration of fostemsavir and atazanavir/cobicistat has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir and atazanavir/ritonavir increased temsavir Cmax, AUC and Cmin by 68%, 54% and 57%, but did not alter significantly atazanavir (Cmax, AUC and Cmin increased by 3%, 9% and 19%) and ritonavir (Cmax, AUC and Cmin increased by 2%, 7% and 22%). The increase in fostemsavir exposure was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. A similar effect is expected with atazanavir/cobicistat.",""
123691,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is primarily metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
124980,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (600 mg twice daily) with darunavir/cobicistat (800/150 mg once daily) increased temsavir Cmax, AUC and Cmin by 79%, 97% and 124% (n=15). These changes are not considered to be clinically significant and do not warrant a dose adjustment of fostemsavir.",""
123118,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolized by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
124985,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.&nbsp;Coadministration of fostemsavir with ritonavir increased temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes are not considered to be clinically significant and do not warrant a dose adjustment of fostemsavir.",""
125144,"Coadministration of fostemsavir and norethisterone (1.5 mg once daily) combined with ethinylestradiol (0.030 mg once daily) had no significant effect on norethindrone Cmax and Cmin, but increased ethinylestradiol Cmax and AUC by 39% and 40% (mechanism unknown, possibly due to BCRP inhibition). Ethinylestradiol daily dose should not exceed 30 Âµg. Caution is advised particularly in patients with additional risk factors for thromboembolic events.",""
125539,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporter OCT2.",""
80266,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6.&nbsp;Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with trimipramine. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123697,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Trimipramine is metabolized mainly by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with trimipramine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123711,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with venlafaxine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
77735,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with primaquine. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125162,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir 2 hours after famotidine (40 mg single dose) under fasted conditions did not significantly alter temsavir pharmacokinetics (Cmax increased by 1%, AUC increased by 4%, Cmin decreased by 10%). Thus, temsavir solubility is not impacted by changes in pH and can be coadministered with PPIs or H2-antagonists without dose adjustment or separation.",""
125328,Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir inhibits OATPs and BCRP and has the potential to increase rosuvastatin exposure. Coadministration of rosuvastatin (10 mg single dose) and fostemsavir (600 mg twice daily) increased rosuvastatin Cmax and AUC by 78% and 69% (n=18). Use the lowest possible starting dose and monitor for statin associated adverse events.&nbsp;,""
123568,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Quinine is extensively metabolized by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with quinine. However,&nbsp;given the QT prolongation risk associated with quinine, caution is recommended.",""
125542,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Alogliptin was shown to have no inhibitory or inducing effect on CYPs at concentrations achieved with the recommended dose of 25 mg alogliptin. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporter OCT2.",""
124981,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.&nbsp;Coadministration of fostemsavir with darunavir/cobicistat increased temsavir Cmax, AUC and Cmin by 79%, 97% and 124%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir), but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine.",""
124948,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint.&nbsp;Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, and does not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine is metabolized by CYP3A4 and does not inhibit or induce CYP enzymes at clinically relevant concentrations. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir and rilpivirine have been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration. However, the product labels indicate that these antiretroviral drugs should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
123545,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Primaquine is metabolised mainly through a non-CYP mediated mechanism and only a small fraction of the drug is believed to be metabolised through CYP450. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with primaquine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125427,"Bictarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Bictegravir is metabolized by CYP3A4 and UGT1A1 whereas emtricitabine and tenofovir alafenamide are eliminated renally. Bictegravir has no inhibitory or inducing effects on drug metabolizing enzymes. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir) but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine.",""
125429,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, and does not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine is metabolized by CYP3A4 and does not inhibit or induce CYP enzymes at clinically relevant concentrations. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir and rilpivirine have been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration. However, the product labels indicate that these antiretroviral drugs should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125543,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporters OAT1 or OAT3.",""
125545,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporters OCT2.",""
123019,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Aripiprazole is metabolized by CYP3A4 and CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with aripiprazole. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
67164,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine. However, saquinavir is contraindicated in patients on concomitant therapy with other drugs that prolong the QT interval such as ciprofloxacin.",""
123105,"Ciprofloxacin is primarily eliminated unchanged through the kidneys (by glomerular filtration and tubular secretion via OAT3). Cabotegravir has been shown to inhibit OAT3 in vitro. The interaction between cabotegravir and ciprofloxacin was evaluated using a PBPK model. Coadministration was shown to cause a minimal effect on ciprofloxacin exposure thus dose adjustment is not needed. Rilpivirine does not inhibit OAT3. Ciprofloxacin is a moderate inhibitor of CYP3A4 and therefore could potentially increase rilpivirine exposure however to a limited extent, which does not require dose adjustment.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with ciprofloxacin. However, given the QT prolongation risk associated with ciprofloxacin, caution is recommended.",""
123023,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (CYP1A2 (major) and CYP3A4, CYP2D6 (minor)). Cabotegravir and rilpivirine do not inhibit or induce UGT or CYP enzymes at clinically relevant concentrations.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with asenapine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125547,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporters OAT1, OAT3 or OCT2 and to cause no interactions with P-glycoprotein substrates.",""
124956,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (600 mg twice daily) and maraviroc (300 mg twice daily) increased temsavir Cmax and AUC by 13% and 10% and decreased Cmin by 10%; maraviroc Cmax, AUC and Cmin increased by 1%, 25% and 37% (n=14). These changes are not considered to be clinically relevant.",""
125443,"Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir and etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52% and increased etravirine Cmax, AUC and Cmin by 11%, 11% and 14% (n=14). These changes are not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
125444,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Nevirapine is a weak inducer. Based on a drug-drug interaction study with etravirine, a moderate inducer, coadministration is not expected to result in a clinically significant interaction. Coadministration of fostemsavir with etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
103329,"Coadministration has not been studied. Venlafaxine is mainly metabolized by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Atazanavir/ritonavir could potentially increase venlafaxine concentrations although to a moderate extent. No a priori dosage adjustment is recommended.&nbsp;However, use with caution due to the risk of QT interval prolongation reported for both drugs.",""
125550,"Coadministration has not been studied but based on metabolism and clearance, as well as limited drug-drug interaction data, a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids.&nbsp;",""
125490,"Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Dolutegravir inhibits OCT2 and has the potential to cause seizures due to increased fampridine plasma concentration via OCT2 inhibition. Coadministration is contraindicated in the European product label for dolutegravir, but the US product label advises that the potential benefits of taking dalfampridine should be considered against the risk of seizures.",""
125640,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125641,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Colestyramine may delay or reduce the absorption of drugs. There is no risk of malabsorption when cabotegravir and rilpivirine are administered intramuscularly.,""
125642,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for atazanavir, but for any medication taken with colestyramine.]",""
125643,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for atazanavir/cobicistat, but for any medication taken with colestyramine.]",""
125644,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for atazanavir/ritonavir, but for any medication taken with colestyramine.]",""
125646,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for darunavir/ritonavir, but for any medication taken with colestyramine.]",""
125647,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for fosamprenavir, but for any medication taken with colestyramine.]",""
125648,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for indinavir, but for any medication taken with colestyramine.]",""
125649,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for lopinavir, but for any medication taken with colestyramine.]",""
125650,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for ritonavir, but for any medication taken with colestyramine.]",""
125651,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for saquinavir, but for any medication taken with colestyramine.]",""
125652,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for tipranavir, but for any medication taken with colestyramine.]",""
125653,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for efavirenz, but for any medication taken with colestyramine.]",""
125654,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for etravirine, but for any medication taken with colestyramine.]",""
125645,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for darunavir/cobicistat, but for any medication taken with colestyramine.]",""
125551,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125552,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism.&nbsp;,""
125554,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4.,""
125555,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atomoxetine is metabolized by CYP2D6 and atazanavir alone has no inhibitory effects on CYP2D6. However, use with caution as both drugs have possible risks of QT interval prolongation.&nbsp;",""
125451,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with darunavir/cobicistat increased temsavir Cmax, AUC and Cmin by 79%, 97% and 124%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir), but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine.",""
125455,"Coadministration with lopinavir/ritonavir has not been studied but is not expected to result in a pharmacokinetic interaction based on drug-drug interaction studies with other protease inhibitors. For example, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. The pharmacokinetics of darunavir or ritonavir were not significantly altered by fostemsavir (darunavir Cmax, AUC and Cmin decreased by 2%, 6% and 5%; ritonavir AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with lopinavir/ritonavir. However, the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125655,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for nevirapine, but for any medication taken with colestyramine.]",""
125457,"Coadministration with saquinavir has not been studied but is not expected to result in a pharmacokinetic interaction based on drug-drug interaction studies with other protease inhibitors. For example, coadministration of fostemsavir with darunavir/ritonavir (600/100 mg twice daily) increased temsavir Cmax, AUC and Cmin by 52%, 63% and 88%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. The pharmacokinetics of darunavir or ritonavir were not significantly altered by fostemsavir (darunavir Cmax, AUC and Cmin decreased by 2%, 6% and 5%; ritonavir AUC and Cmin increased by 15%, 19% whereas Cmax was unchanged). Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent fostemsavir concentrations are unlikely to occur during coadministration with lopinavir/ritonavir. However, the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125458,"Coadministration has not been studied but is not expected to result in a clinically significant interaction based on a drug-drug interaction study with etravirine, another inducer. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir with etravirine decreased temsavir Cmax, AUC and Cmin by 48%, 50% and 52%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
125468,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Atazanavir does not interfere with fampridine elimination pathway.,""
125469,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Atazanavir/cobicistat does not interfere with fampridine elimination pathway.,""
125470,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Atazanavir/ritonavir does not interfere with fampridine elimination pathway.,""
125471,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Darunavir/cobicistat does not interfere with fampridine elimination pathway.,""
125472,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Darunavir/ritonavir does not interfere with fampridine elimination pathway.,""
125473,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Fosamprenavir does not interfere with fampridine elimination pathway.,""
125474,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Indinavir does not interfere with fampridine elimination pathway.,""
125475,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Lopinavir does not interfere with fampridine elimination pathway.,""
125476,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Ritonavir does not interfere with fampridine elimination pathway.,""
125477,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Saquinavir does not interfere with fampridine elimination pathway.,""
125478,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Tipranavir does not interfere with fampridine elimination pathway.,""
125479,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Efavirenz does not interfere with fampridine elimination pathway.,""
125480,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Etravirine does not interfere with fampridine elimination pathway.,""
125481,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Nevirapine does not interfere with fampridine elimination pathway.,""
125482,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Doravirine does not interfere with fampridine elimination pathway.,""
125483,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Rilpivirine does not interfere with fampridine elimination pathway.,""
125484,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Maraviroc does not interfere with fampridine elimination pathway.,""
125485,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Raltegravir does not interfere with fampridine elimination pathway.,""
125486,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide do not interfere with fampridine elimination pathway.",""
125487,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Elvitegravir, cobicistat, emtricitabine and tenofovir-DF do not interfere with fampridine elimination pathway.",""
125488,Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Bictegravir inhibits OCT2 (although to a lesser extent than dolutegravir) and has the potential to cause seizures due to increased fampridine plasma concentration via OCT2 inhibition. Caution is recommended when coadministering these drugs. Emtricitabine and tenofovir alafenamide do not interfere with fampridine elimination pathway.,""
125489,"Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Doravirine and tenofovir-DF do not interfere with fampridine elimination pathway. However, due to fampridineâ€™s narrow therapeutic index, the European product label for fampridine advises caution with substrates of OCT2 such as lamivudine.&nbsp;",""
123050,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Betrixaban is largely eliminated unchanged through biliary secretion via P-gp. Cabotegravir and rilpivirine do not inhibit or induce P-gp.&nbsp;Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with betrixaban. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125656,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for doravirine, but for any medication taken with colestyramine.]",""
125657,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for rilpivirine, but for any medication taken with colestyramine.]",""
125658,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for maraviroc, but for any medication taken with colestyramine.]",""
125659,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, but for any medication taken with colestyramine.]",""
125660,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for elvitegravir, cobicistat, emtricitabine and tenofovir-DF, but for any medication taken with colestyramine.]",""
125492,"Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Dolutegravir inhibits OCT2 and has the potential to cause seizures due to increased fampridine plasma concentration via OCT2 inhibition. Coadministration is contraindicated in the European product label for dolutegravir/lamivudine, but the US product label advises that the potential benefits of taking dalfampridine should be considered against the risk of seizures.",""
125556,"Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6. Atomoxetine exposure could potentially increase, although to a limited extent, as cobicistat is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster. No a priori dosage adjustment is recommended. However, use with caution as both drugs have possible risks of QT interval prolongation.",""
125493,"Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Dolutegravir inhibits OCT2 and has the potential to cause seizures due to increased fampridine plasma concentration via OCT2 inhibition. Coadministration is contraindicated in the European product label for dolutegravir/abacavir/lamivudine, but the US product label advises that the potential benefits of taking dalfampridine should be considered against the risk of seizures.",""
125494,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Abacavir does not interfere with fampridine elimination pathway.,""
125495,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Didanosine does not interfere with fampridine elimination pathway.,""
125496,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Stavudine does not interfere with fampridine elimination pathway.,""
125497,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Tenofovir-DF does not interfere with fampridine elimination pathway.,""
125498,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Zidovudine does not interfere with fampridine elimination pathway.,""
125499,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Emtricitabine does not interfere with fampridine elimination pathway.,""
125500,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Emtricitabine and tenofovir alafenamide do not interfere with fampridine elimination pathway.,""
125501,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Emtricitabine and tenofovir-DF do not interfere with fampridine elimination pathway.,""
125502,"Coadministration has not been studied. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Due to fampridineâ€™s narrow therapeutic index, the European product label for fampridine advises caution with substrates of OCT2 such as lamivudine.&nbsp;",""
125503,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.&nbsp;,""
125504,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2 whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125505,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations and does not cause clinically relevant inhibition of renal transporters.,""
125506,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations and do not cause clinically relevant inhibition of renal transporters.,""
125507,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYPs or OCTs.,""
125508,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Darunavir, cobicistat, emtricitabine and tenofovir alafenamide do not interfere with fampridine elimination pathway.",""
125509,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fampridine is metabolized by CYP2E1 but is predominantly eliminated unchanged by the kidney with active secretion by OCT2. Rilpivirine, emtricitabine and tenofovir alafenamide do not interfere with fampridine elimination pathway.",""
67161,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine. However, caution is advised when prescribing lopinavir and medicinal products known to induce QT interval prolongation such as ciprofloxacin.",""
125661,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for darunavir, cobicistat, emtricitabine and tenofovir alafenamide, but for any medication taken with colestyramine.]",""
125662,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for doravirine, lamivudine and tenofovir-DF, but for any medication taken with colestyramine.]",""
125663,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for rilpivirine, emtricitabine and tenofovir alafenamide, but for any medication taken with colestyramine.]",""
125664,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for bictegravir, emtricitabine and tenofovir alafenamide, but for any medication taken with colestyramine.]",""
125665,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for raltegravir, but for any medication taken with colestyramine.]",""
125666,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for abacavir, but for any medication taken with colestyramine.]",""
125667,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for zidovudine, but for any medication taken with colestyramine.]",""
125668,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for dolutegravir, but for any medication taken with colestyramine.]",""
125669,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for dolutegravir, abacavir and lamivudine, but for any medication taken with colestyramine.]",""
125670,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for dolutegravir and lamivudine, but for any medication taken with colestyramine.]",""
125671,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for dolutegravir and rilpivirine, but for any medication taken with colestyramine.]",""
125672,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for didanosine, but for any medication taken with colestyramine.]",""
125673,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for stavudine, but for any medication taken with colestyramine.]",""
125674,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for emtricitabine, but for any medication taken with colestyramine.]",""
125680,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for tenofovir-DF, but for any medication taken with colestyramine.]",""
123591,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations.,""
123565,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quetiapine is metabolized mainly by CYP3A4. Cabotegravir was shown to have no effect on midazolam (a sensitive CYP3A4 substrate) in healthy subjects. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
125675,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for lamivudine, but for any medication taken with colestyramine.]",""
125676,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for emtricitabine and tenofovir alafenamide, but for any medication taken with colestyramine.]",""
125677,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for emtricitabine and tenofovir-DF, but for any medication taken with colestyramine.]",""
125678,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for oral cabotegravir, but for any medication taken with colestyramine.]",""
125679,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for fostemsavir, but for any medication taken with colestyramine.]",""
125681,"Coadministration has not been studied. Coadministration of atazanavir with proton pump inhibitors is not recommended. Lansoprazole decreased atazanavir (alone) AUC by 94%; omeprazole decreased atazanavir (+ ritonavir) AUC by 75%. A similar decrease is expected with dexlansoprazole. Coadministration is not recommended in treatment experienced patients. If coadministration is judged unavoidable in treatment-naive patients, close clinical monitoring is recommended and doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded and must be taken approximately 12 hours prior to the atazanavir.",""
125682,"Coadministration with atazanavir/cobicistat has not been studied. Coadministration of atazanavir with proton pump inhibitors is not recommended. Lansoprazole decreased atazanavir (alone) AUC by 94%; omeprazole decreased atazanavir (+ ritonavir) AUC by 75%. A similar decrease is expected with dexlansoprazole. Coadministration is not recommended in treatment experienced patients. If coadministration is judged unavoidable in treatment-naive patients, close clinical monitoring is recommended and doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded and must be taken approximately 12 hours prior to the atazanavir/cobicistat.",""
125683,"Coadministration with atazanavir/ritonavir has not been studied. Coadministration of atazanavir with proton pump inhibitors is not recommended. Lansoprazole decreased atazanavir (alone) AUC by 94%; omeprazole decreased atazanavir (+ ritonavir) AUC by 75%. A similar decrease is expected with dexlansoprazole. If coadministration is judged unavoidable, close clinical monitoring is recommended and doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded and must be taken approximately 12 hours prior to the atazanavir/ritonavir. The European SmPC recommends increasing the dose of atazanavir to 400 mg with 100 mg of ritonavir.",""
125684,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor) and is unlikely to alter absorption of darunavir or cobicistat.,""
125685,"Coadministration has not been studied but based on results with omeprazole (no effect on darunavir AUC, Cmax or Cmin), darunavir/ritonavir can be coadministered with proton pump inhibitors without dose adjustments.&nbsp;",""
123319,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is partly metabolized by alcohol dehydrogenase and partly by CYP3A4. Cabotegravir was shown to have no impact on midazolam (a sensitive CYP3A4 substrate) in healthy volunteers. Rilpivirine does not inhibit or induce CYP3A4 at clinically relevant concentrations.,""
125752,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.",""
125751,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. No effect on hydroxychloroquine is expected. Concentrations of bictegravir may increase due to inhibition of P-glycoprotein by hydroxychloroquine but this is unlikely to be clinically significant as clinical data have shown a good safety profile with up to a 2.4-fold increase in bictegravir AUC. However, concentrations of tenofovir may also increase and the recommended dose of 10 mg tenofovir alafenamide with P-gp inhibitors is not possible with Biktarvy which is only available as a fixed dose combination containing 25 mg tenofovir alafenamide, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile. No effect on emtricitabine is expected.",""
125753,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with hydroxychloroquine. However, given the QT prolongation risk associated with hydroxychloroquine, caution is recommended. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.",""
125754,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations.&nbsp;",""
125755,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Due to the multiple elimination pathways, a clinically significant interaction with lamivudine is unlikely.",""
125756,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxychloroquine undergoes CYP-mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Dolutegravir is not expected to inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with hydroxychloroquine. However, given the QT prolongation risk associated with hydroxychloroquine, caution is recommended. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.",""
125757,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with abacavir. Due to the multiple elimination pathways, a clinically significant interaction with lamivudine is unlikely.",""
125758,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Elvitegravir/cobicistat could potentially increase hydroxychloroquine exposure by inhibition of CYPs 3A4 and 2D6, but to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. Emtricitabine and tenofovir alafenamide are not expected to cause a clinically relevant drug-drug interaction.",""
125760,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Due to the multiple elimination pathways, a clinically significant interaction is unlikely.&nbsp;",""
125761,"Coadministration has not been studied but based on metabolism and clearance, as well as limited drug-drug interaction data, a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.",""
125762,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with hydroxychloroquine. However, given the known QT prolongation risk associated with hydroxychloroquine, ECG monitoring is recommended when coadministering both drugs.",""
125763,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney, whereas ibalizumab (a monoclonal antibody binding to the CD4 receptor) is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125759,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Elvitegravir/cobicistat could potentially increase hydroxychloroquine exposure by inhibition of CYPs 3A4 and 2D6, but to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. Emtricitabine and tenofovir-DF are not expected to cause a clinically relevant drug-drug interaction.",""
77579,"Based on metabolism and clearance a clinically signficant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19.&nbsp;A retrospective analysis of a TDM registry showed no significant effect of valproate on rilpivrine trough concentrations (n=7).",""
125557,"Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6. Atomoxetine exposure could potentially increase, although to a limited extent, as ritonavir is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster. No a priori dosage adjustment is recommended. However, use with caution as both drugs have possible risks of QT interval prolongation.",""
125559,"Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6. Atomoxetine exposure could potentially increase, although to a limited extent, as cobicistat is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster. No a priori dosage adjustment is recommended.",""
125560,"Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6. Atomoxetine exposure could potentially increase, although to a limited extent, as ritonavir is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster. No a priori dosage adjustment is recommended.",""
125564,Coadministration has not been studied. Concomitant use of saquinavir/ritonavir with other medicinal products that prolong the QT and/or PR interval is contraindicated. Atomoxetine is metabolized by CYP2D6. Saquinavir/ritonavir could potentially increase atomoxetine exposure although to a limited extent as ritonavir is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster.&nbsp;,""
125565,Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6 and concentrations may increase due to inhibition of CYP2D6 by tipranavir. Slower titration and a final lower dosage of atomoxetine may be necessary in presence of tipranavir/ritonavir.,""
125566,"Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6. Atomoxetine exposure could potentially increase, although to a limited extent, as cobicistat is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster. No a priori dosage adjustment is recommended. Atomoxetine does not interact with emtricitabine or tenofovir alafenamide.",""
125567,"Coadministration has not been studied. Atomoxetine is metabolized by CYP2D6. Atomoxetine exposure could potentially increase, although to a limited extent, as cobicistat is a weak inhibitor of CYP2D6 when used as a pharmacokinetic booster. No a priori dosage adjustment is recommended. Atomoxetine does not interact with emtricitabine or tenofovir-DF.",""
125569,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6.,""
76574,"Based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19. A retrospective analysis of a TDM registry showed no significant effect of valproate on maraviroc trough concentrations (n=17).",""
125572,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6 and doravirine does not inhibit or induce CYP enzymes.,""
125573,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6 and maraviroc does not inhibit or induce CYP enzymes.,""
125574,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6 and raltegravir does not inhibit or induce CYP enzymes.,""
125575,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Doravirine does not inhibit or induce CYP enzymes. Atomoxetine does not interact with lamivudine or tenofovir-DF.,""
125576,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atomoxetine is metabolized by CYP2D6 and rilpivirine does not inhibit or induce CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with atomoxetine. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125577,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Rilpivirine does not inhibit or induce CYP enzymes. Atomoxetine does not interact with emtricitabine or tenofovir alafenamide. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with atomoxetine. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.&nbsp;",""
125578,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6 and dolutegravir does not inhibit or induce CYP enzymes.,""
125579,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Dolutegravir does not inhibit or induce CYP enzymes. Atomoxetine does not interact with lamivudine or abacavir.&nbsp;,""
125580,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Dolutegravir does not inhibit or induce CYP enzymes. Atomoxetine does not interact with lamivudine.&nbsp;,""
125582,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Bictegravir does not inhibit or induce CYP enzymes. Atomoxetine does not interact with emtricitabine or tenofovir alafenamide.,""
125592,"Coadministration has not been studied but based on metabolism and clearance, as well as limited drug-drug interaction data, a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on CYP enzymes.",""
125593,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6 whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125594,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.&nbsp;,""
125595,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with atomoxetine. However, the product label for Cabenuva indicates that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
125596,Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses and the product label for fostemsavir indicates that fostemsavir should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Atomoxetine has a possible risk of QTc prolongation. An interaction to increase QTc prolongation is unlikely to occur with fostemsavir.,""
125598,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brimonidine is metabolized mainly&nbsp;by aldehyde oxidase.,""
125581,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atomoxetine is metabolized by CYP2D6. Dolutegravir and rilpivirine do not inhibit or induce CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with atomoxetine. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
115906,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19. Valproate has no inducing effects on metabolism. Valproate has been shown to significantly reduce total dolutegravir concentrations due to protein binding displacement. However, this interaction is not clinically relevant since the concentrations of free dolutegravir (pharmacologically active) are not decreased. No interaction is expected with lamivudine.",""
116641,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly glucuronidated by UGTs 1A6, 1A9 and 2B7 and metabolized by CYP2C9 and CYP2C19. Valproate has no inducing effects on metabolism. Valproate has been shown to significantly reduce total dolutegravir concentrations due to protein binding displacement. However, this interaction is not clinically relevant since the concentrations of free dolutegravir (pharmacologically active) are not decreased. No significant interaction is expected with abacavir or lamivudine.",""
125686,Coadministration has not been studied. Proton pump inhibitors can be administered at the same time as a dose of fosamprenavir with no change in plasma amprenavir concentrations.&nbsp;,""
125687,"Coadministration with dexlansoprazole has not been studied. Coadministration of indinavir and omeprazole decreased indinavir AUC (47%) and Cmin (55%). The addition of ritonavir (200 mg single dose) reversed the effects of omeprazole. Similarly, dexlansoprazole is predicted to decrease the exposure of indinavir alone whereas no significant interaction is predicted for indinavir/ritonavir.",""
125688,"Lopinavir can be coadministered with acid reducing agents with no dose adjustment. No reduction in lopinavir or ritonavir trough concentrations were observed over 48 weeks in HIV+ subjects receiving lopinavir/ritonavir with an acid reducing agent (antacids, proton pump inhibitors or H2 receptor antagonists).&nbsp;",""
125689,"<p>Based on interaction studies with lopinavir/ritonavir and atazanavir/ritonavir, concurrent administration of a proton pump inhibitor (omeprazole) or a H2-receptor antagonist(ranitidine) does not significantly modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change of exposure of about 6-18%.
</p>",""
125690,"Coadministration with dexlansoprazole has not been studied. Omeprazole significantly increased saquinavir concentrations and the combination is not recommended in the European SPC. The US Prescribing Information advises caution and recommends monitoring for potential saquinavir toxicities, particularly gastrointestinal symptoms, increased triglycerides, deep vein thrombosis and QT prolongation.",""
125691,"Coadministration has not been studied. The effect on dexlansoprazole concentrations is difficult to predict due to CYP3A4 inhibition and CYP2C19 induction by tipranavir/ritonavir. Coadministration is not recommended, but if judged unavoidable, this should be done under close clinical monitoring.",""
125692,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (&lt;10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir alafenamide do not interact with dexlansoprazole.",""
125693,"Coadministration has not been studied but is not expected to alter elvitegravir concentrations. No dose adjustment is needed when Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is combined with proton pump inhibitors. When omeprazole was administered 2 h prior to elvitegravir/cobicistat, elvitegravir AUC and Cmax increased by 10% and 16% but those of cobicistat decreased by 8% and 10%. Separating omeprazole and elvitegravir/cobicistat by 12 h had no effect (&lt;10% change) on the AUC or Cmax of elvitegravir or cobicistat. Emtricitabine and tenofovir-DF do not interact with dexlansoprazole.",""
125694,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor) and is unlikely to alter absorption of darunavir, cobicistat, emtricitabine or tenofovir alafenamide.&nbsp;",""
125695,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration with medicinal products that alter gastric pH would not be expected to affect efavirenz absorption.,""
125696,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration with medicinal products that alter gastric pH would not be expected to affect etravirine absorption.,""
125697,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration with medicinal products that alter gastric pH would not be expected to affect nevirapine absorption.,""
125698,"Coadministration has not been studied but based on the interaction study with pantoprazole, a clinically significant interaction is unlikely. Coadministration of doravirine and pantoprazole (40 mg) did not significantly alter doravirine pharmacokinetics consistent with doravirineâ€™s pH independent solubility.",""
125699,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor).,""
125734,"Coadministration has not been studied. Hydroxychloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Tipranavir/ritonavir could potentially increase hydroxychloroquine exposure by inhibition of CYPs 2C8, 3A4 and 2D6 although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity.",""
125740,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with hydroxychloroquine. However, given the QT prolongation risk associated with hydroxychloroquine, caution is recommended. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.&nbsp;",""
125733,Coadministration has not been studied. Saquinavir is contraindicated in patients on concomitant therapy with other drugs that prolong the QT interval such as hydroxychloroquine.,""
125700,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of omeprazole and raltegravir (400 mg twice daily) increased raltegravir AUC, Cmax and C12h by 37%, 51% and 24%. Population PK analysis showed that the effect of gastric pH altering agents on the pharmacokinetics of once daily raltegravir was minimal (~9% decrease in relative bioavailability), and was not statistically or clinically significant. Concomitant use of raltegravir with proton pump inhibitors and H2 blockers did not result in a unique safety signal in Phase 3 studies. No dose adjustment is required with twice daily or once daily raltegravir.&nbsp;",""
125701,"Coadministration with Delstrigo (doravirine, lamivudine, tenofovir-DF) has not been studied but based on the interaction study with doravirine and pantoprazole, a clinically significant interaction is unlikely. Coadministration of doravirine and pantoprazole (40 mg) did not significantly alter doravirine pharmacokinetics consistent with doravirineâ€™s pH independent solubility. Similarly, dexlansoprazole is unlikely to impact lamivudine and tenofovir-DF pharmacokinetics.&nbsp;",""
125702,Coadministration has not been studied and is contraindicated as significant decreases in rilpivirine plasma concentrations may occur.&nbsp;,""
125704,"Coadministration has not been studied. However, data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.&nbsp;",""
125705,"Coadministration has not been studied. However, data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with abacavir or lamivudine.&nbsp;",""
125706,"Coadministration has not been studied. However, data from an interaction study with omeprazole suggest that solubility of dolutegravir is not influenced by changes in gastric pH. Dolutegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with lamivudine.",""
125707,"Coadministration has not been studied. Coadministration is contraindicated due as significant decreases in rilpivirine plasma concentrations may occur due to gastric pH increase, which may result in loss of virologic response.",""
125708,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies have shown no evidence that bictegravir solubility is impacted by changes in pH and therefore can be coadministered with PPIs or H2-antagonists without dose adjustment or separation. No interaction is expected with emtricitabine and tenofovir alafenamide.,""
125718,"Coadministration has not been studied but based on metabolism and clearance, as well as limited drug-drug interaction data, a clinically significant interaction is unlikely. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor). Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on CYP enzymes.&nbsp;",""
125719,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Dexlansoprazole undergoes hepatic metabolism whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.&nbsp;",""
125720,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor). Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations. Solubility of cabotegravir is unlikely to be influenced by changes in gastric pH. Cabotegravir may be coadministered with PPIs or H2-antagonists without dose adjustment or separation.,""
125721,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir and rilpivirine. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Furthermore, rilpivirine absorption is not impacted by dexlansoprazole when administered intramuscularly.",""
125722,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Dexlansoprazole is mainly metabolized by CYP2C19 (major) and CYP3A4 (minor) and is unlikely to alter absorption of fostemsavir. Coadministration of fostemsavir 2 hours after famotidine (40 mg single dose) under fasted conditions did not significantly alter temsavir pharmacokinetics (Cmax increased by 1%, AUC increased by 4%, Cmin decreased by 10%). Thus, temsavir solubility is not impacted by changes in pH and can be coadministered with PPIs or H2-antagonists without dose adjustment or separation.",""
125531,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin is primarily excreted unchanged in the urine and undergoes negligible CYP-mediated metabolism. Alogliptin was shown to have no inhibitory or inducing effect on CYPs at concentrations achieved with the recommended dose of 25 mg alogliptin. Furthermore, alogliptin was shown to be neither a substrate nor an inhibitor of the renal transporters OAT1, OAT3 or OCT2 and to cause no interactions with P-glycoprotein substrates.
",""
123096,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Chloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). Cabotegravir and rilpivirine do not inhibit or induce CYP enzymes at clinically relevant concentrations. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses, but equivalent rilpivirine concentrations are unlikely to occur with chloroquine. However, given the QT prolongation risk associated with chloroquine, caution is recommended.",""
125724,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Atazanavir/cobicistat could potentially increase hydroxychloroquine concentrations (although to a moderate extent due to the multiple elimination pathways) due to inhibition of CYP3A4 and CYP2D6. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. Caution is advised when prescribing atazanavir and medicinal products known to induce QT interval prolongation such as hydroxychloroquine. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.",""
125723,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. No effect on atazanavir is expected but hydroxychloroquine concentrations may increase due to inhibition of CYP3A4 by atazanavir, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. Caution is advised when prescribing atazanavir and medicinal products known to induce QT interval prolongation such as hydroxychloroquine. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.",""
125725,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Hydroxychloroquine concentrations may increase due to inhibition of CYPs 2C8, 3A4 and 2D6 (although to a moderate extent due to the multiple elimination pathways). No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. Caution is advised when prescribing atazanavir and medicinal products known to induce QT interval prolongation such as hydroxychloroquine. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.",""
125726,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Darunavir/cobicistat could potentially increase hydroxychloroquine exposure due to inhibition of CYPs 3A4 and 2D6, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. No effect on darunavir or cobicistat is expected.",""
125727,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Darunavir/cobicistat could potentially increase hydroxychloroquine exposure by inhibition of CYPs 3A4 and 2D6, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. No effect on darunavir, cobicistat, emtricitabine or tenofovir alafenamide is expected.",""
125728,"Coadministration has not been studied. Hydroxychloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Darunavir/ritonavir could potentially increase hydroxychloroquine exposure due to inhibition of CYPs 2C8, 3A4 and 2D6, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity.&nbsp;",""
125729,"Coadministration has not been studied. Hydroxychloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Fosamprenavir/ritonavir could potentially increase hydroxychloroquine exposure due inhibition of CYPs 2C8, 3A4 and 2D6, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity.&nbsp;",""
125730,"Coadministration has not been studied. Hydroxychloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Indinavir and indinavir/ritonavir could potentially increase hydroxychloroquine exposure by inhibition of CYPs 3A4 and 2D6 (indinavir) and CYPs 2C8, 3A4 and 2D6 (indinavir/ritonavir), although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity.&nbsp;",""
125731,"Coadministration has not been studied. Hydroxychloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Lopinavir/ritonavir could potentially increase hydroxychloroquine exposure by inhibition of CYPs 2C8, 3A4 and 2D6 although to a moderate extent due to the multiple elimination pathways. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity. Caution is advised when prescribing Kaletra and medicinal products known to induce QT interval prolongation such as hydroxychloroquine.",""
125732,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Ritonavir could potentially increase hydroxychloroquine exposure by inhibition of CYPs 2C8, 3A4 and 2D6. No dosage adjustment is recommended for hydroxychloroquine but monitor toxicity.",""
125735,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Doravirine does not inhibit or induce CYP enzymes.&nbsp;",""
125736,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Doravirine does not inhibit or induce CYP enzymes. Due to the multiple elimination pathways, a clinically significant interaction with lamivudine or tenofovir-DF is unlikely.",""
125737,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Efavirenz could potentially increase hydroxychloroquine exposure (inhibition CYP2C8) or decrease hydroxychloroquine exposure (induction CYP3A4). These opposing effects are likely to mitigate the magnitude of the interaction. No dosage adjustment of hydroxychloroquine is recommended but monitor toxicity and efficacy.&nbsp;",""
125738,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Etravirine could potentially decrease hydroxychloroquine exposure due to induction CYP3A4, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment of hydroxychloroquine is recommended but monitor the efficacy.&nbsp;",""
125739,"Coadministration has not been studied. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Nevirapine could potentially decrease hydroxychloroquine exposure due to induction CYP3A4, although to a moderate extent due to the multiple elimination pathways. No dosage adjustment of hydroxychloroquine is recommended but monitor the efficacy.&nbsp;",""
125741,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Rilpivirine, emtricitabine and tenofovir alafenamide do not interact with hydroxychloroquine elimination pathway. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with hydroxychloroquine. However, given the QT prolongation risk associated with hydroxychloroquine, caution is recommended. Due to its very long half-life, the risk of QT prolongation may persist even after discontinuation of hydroxychloroquine.",""
125743,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Due to the multiple elimination pathways, a clinically significant interaction is unlikely.",""
125744,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Emtricitabine is eliminated renally. Due to the multiple elimination pathways, a clinically significant interaction is unlikely.",""
125745,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Emtricitabine and tenofovir alafenamide are excreted renally and are not expected to cause a clinically relevant drug-drug interaction. Dose Descovy according to the concomitant antiretroviral.",""
125746,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Emtricitabine and tenofovir-DF are excreted renally and are not expected to cause a clinically relevant drug-drug interaction.",""
125747,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Lamivudine is eliminated renally. Due to the multiple elimination pathways, a clinically significant interaction is unlikely.",""
125748,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Stavudine is eliminated renally. Due to the multiple elimination pathways, a clinically significant interaction is unlikely.",""
125749,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Hydroxychloroquine undergoes CYP mediated metabolism by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney. Tenofovir is eliminated renally. Due to the multiple elimination pathways, a clinically significant interaction is unlikely.",""
99099,"Symtuza is (darunavir, cobicistat, emtricitabine, tenofovir alafenamide)&nbsp;indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, tipranavir is expected to decrease the absorption (and thereby plasma concentrations) of tenofovir alafenamide due to induction of P-gp which may result in loss of therapeutic effect and development of resistance.",""
101418,"Symtuza&nbsp;(darunavir, cobicistat, emtricitabine, tenofovir alafenamide) and Delstrigo (doravirine, lamivudine, tenofovir-DF) are both&nbsp;indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, Symtuza contains emtricitabine and tenofovir alafenamide and must not be administered with products containing lamivudine and tenofovir-DF.",""
99076,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, efavirenz is expected to decrease darunavir/cobicistat exposure which may result in loss of therapeutic effect and development of resistance to darunavir.",""
98648,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, increased didanosine concentrations and toxicity has been observed when didanosine and tenofovir-DF are coadministered. A similar effect with tenofovir alafenamide cannot be excluded.",""
99084,"Symtuza is (darunavir, cobicistat, emtricitabine, tenofovir alafenamide)&nbsp;indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, Symtuza contains emtricitabine and tenofovir alafenamide must not be administered with other products containing emtricitabine and tenofovir alafenamide.",""
99089,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.&nbsp;
",""
99069,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) and&nbsp;Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, both products contain emtricitabine and tenofovir alafenamide and must not be administered with other products containing emtricitabine and tenofovir alafenamide.",""
124529,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with cabotegravir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Darunavir/cobicistat do not inhibit UGT enzymes and no interactions are expected with emtricitabine and tenofovir alafenamide.",""
123910,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with cabotegravir would be possible from a pharmacokinetic standpoint. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9. Darunavir/cobicistat do not inhibit UGT enzymes and no interactions is expected with emtricitabine and tenofovir alafenamide.",""
117271,"Triumeq (dolutegravir, abacavir, lamivudine) and Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, as Triumeq contains lamivudine it should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine.",""
117234,"Dovato (dolutegravir, lamivudine) and Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, Dovato contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine.",""
93907,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, increased didanosine concentrations and toxicity were observed when combined with tenofovir-DF. A similar effect with tenofovir alafenamide cannot be excluded.",""
99074,"Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with maraviroc (dosed at 150 mg twice daily) would be possible from a pharmacokinetic standpoint. Maraviroc is metabolized by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by darunavir/cobicistat. A pharmacokinetic interaction between maraviroc and emtricitabine or tenofovir alafenamide is not expected.",""
103440,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/ritonavir would be possible from a pharmacokinetic standpoint. Atazanavir/ritonavir may increase rilpivirine concentrations but not to a clinically relevant extent. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent rilpivirine concentrations are unlikely to occur during coadministration with atazanavir/ritonavir. However, the product labels for Odefsey indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Tenofovir alafenamide is dosed 25 mg in Odefsey whereas the recommended dose of tenofovir alafenamide is 10 mg with P-gp inhibitors such as atazanavir/ritonavir, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile.",""
88961,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with other antiretroviral agents is not recommended in the Odefsey product labels. If intensification of HIV treatment is needed, alternatives to fosamprenavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of fosamprenavir have not been established.",""
89337,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with indinavir or indinavir/ritonavir would be possible from a pharmacokinetic standpoint. Coadministration with indinavir (alone or with ritonavir) may increase rilpivirine concentrations, however, no dose adjustment is required. Tenofovir alafenamide is dosed 25 mg in Odefsey whereas the recommended dose of tenofovir alafenamide is 10 mg with P-gp inhibitors such as indinavir or indinavir/ritonavir, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile.",""
88965,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, the coadministration of ritonavir would be possible from a pharmacokinetic standpoint. Coadministration with ritonavir may increase rilpivirine concentrations, however, no dose adjustment is required. Rilpivirine is not expected to affect the plasma concentrations of ritonavir. No interaction is expected with emtricitabine. Tenofovir alafenamide (the prodrug of tenofovir) is a substrate of P-gp and inhibitors of P-gp such as ritonavir are expected to increase the absorption of tenofovir alafenamide, thereby increasing the systemic concentration. Tenofovir alafenamide is dosed 25 mg in Odefsey whereas the recommended dose of tenofovir alafenamide is 10 mg with P-gp inhibitors such as ritonavir, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile.",""
89338,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lopinavir/ritonavir would be possible from a pharmacokinetic standpoint. No dose adjustment is required when rilpivirine is co-administered with lopinavir/ritonavir. Coadministration of rilpivirine (150 mg once daily) and lopinavir/ritonavir (400/100 mg twice daily) increased rilpivirine Cmax, AUC and Cmin by 29%, 52% and 74%, respectively. Lopinavir Cmax, AUC and Cmin decreased by 4%, 1% and 11%, respectively. Rilpivirine has been associated with prolongation of the QTc interval at supra-therapeutic doses but equivalent rilpivirine concentrations are unlikely to occur during coadministration with lopinavir/ritonavir. However, the product labels for rilpivirine indicate that rilpivirine should be used with caution in combination with drugs with a known risk of Torsade de Pointes. Based on metabolism and clearance a pharmacokinetic interaction with emtricitabine is unlikely. Coadministration of lopinavir/ritonavir (800/200 mg once daily) with emtricitabine/tenofovir alafenamide (200/10 mg, once daily) increased tenofovir AUC and Cmax by 322% and 275% (n-10). No significant effects were observed on lopinavir pharmacokinetics relative to historical controls. Coadministration of lopinavir/ritonavir (800/200 mg once daily) and tenofovir alafenamide (10 mg once daily) increased tenofovir alafenamide AUC and Cmax by 47% and 119% but had no effect on lopinavir AUC or Cmax. Tenofovir alafenamide is dosed 25 mg in Odefsey whereas the recommended dose of tenofovir alafenamide is 10 mg with P-gp inhibitors such as lopinavir/ritonavir, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile.",""
89346,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. If intensification of HIV treatment is needed, alternatives to saquinavir should be considered.",""
88967,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. Furthermore, tipranavir could potentially decrease rilpivirine and tenofovir alafenamide exposure and thereby result in loss of efficacy.",""
124514,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where intensification of HIV treatment is needed, coadministration with cabotegravir would be possible from a pharmacokinetic standpoint. Coadministration of oral cabotegravir (30 mg) and oral rilpivirine (25 mg) did not significantly alter cabotegravir and rilpivirine pharmacokinetics. No interaction is expected with emtricitabine and tenofovir alafenamide.",""
100951,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, increased didanosine concentrations and toxicity has been observed when didanosine and tenofovir-DF are coadministered. In addition, the bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in drug formulations such as didanosine chewable/dispersible tablet.",""
99448,"Juluca (dolutegravir/rilpivirine) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, both products contain rilpivirine and should not be administered with additional rilpivirine.",""
116783,"Triumeq (dolutegravir, abacavir, lamivudine) and Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be co-administered with other antiretroviral medicinal products. Furthermore, products containing emtricitabine should not be administered with products containing lamivudine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.",""
99880,"Juluca (dolutegravir/rilpivirine) and&nbsp;Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, both products contain rilpivirine and should not be administered with additional rilpivirine.",""
125445,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as complete regimens for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Rilpivirine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir) but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine. Fostemsavir and rilpivirine have been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration. However, the product label indicates that these antiretroviral drugs should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
124966,"Odefsey (rilpivirine, emtricitabine, tenofovir alafenamide) is indicated for use as complete regimens for the treatment of HIV-1 infection.&nbsp;However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint.&nbsp;Rilpivirine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir) but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine. Fostemsavir and rilpivirine have been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration. However, the product label indicates that these antiretroviral drugs should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
100950,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with abacavir would be possible from a pharmacokinetic standpoint. Coadministration of abacavir with doravirine or lamivudine has not been studied, but a clinically significant interaction is unlikely. Coadministration of abacavir (300 mg single dose) and tenofovir-DF (300 mg once daily) had no effect on tenofovir AUC or Cmax, and abacavir AUC; abacavir Cmax increased by 12%.",""
93470,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with enfuvirtide would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
100466,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, increased didanosine concentrations and toxicity has been observed when didanosine and tenofovir-DF are coadministered. In addition, the bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in drug formulations such as didanosine chewable/dispersible tablet.&nbsp;",""
100956,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, Delstrigo contains lamivudine and should not be administered with emtricitabine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.",""
100962,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, Delstrigo contains lamivudine and tenofovir-DF and should not be administered products containing emtricitabine or tenofovir alafenamide.",""
100969,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products&nbsp;or with additional lamivudine.",""
100484,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint. Coadministration of zidovudine with doravirine or tenofovir-DF has not been studied, but a clinically significant interaction is unlikely. Coadministration of zidovudine (200 mg single dose) and lamivudine (300 mg twice daily) to 12 asymptomatic HIV-infected adult patients increased zidovudine Cmax and AUC by 28% and 13%, but had no effect on the pharmacokinetics of lamivudine.",""
116778,"Delstrigo (doravirine, lamivudine, tenofovir-DF) and Triumeq (dolutegravir, abacavir, lamivudine) are both indicated for use as complete regimens for the treatment of HIV-1 infection should not be administered with other antiretroviral products. In addition, both Delstrigo and Triumeq contain lamivudine and should not be taken with any other medicinal products also containing lamivudine.",""
117240,"Delstrigo (doravirine, lamivudine, tenofovir-DF) and Dovato (dolutegravir, lamivudine) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, both Delstrigo and Dovato contain lamivudine and should not be taken with any other medicinal products also containing lamivudine.",""
101031,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) and Delstrigo (doravirine, lamivudine, tenofovir-DF) are both indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Furthermore, Delstrigo contains lamivudine and tenofovir-DF and should not be administered products containing emtricitabine or tenofovir alafenamide.",""
125441,"Delstrigo (doravirine, lamivudine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected. Doravirine is metabolized by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Coadministration of fostemsavir with tenofovir disoproxil fumarate was shown to have no significant effect on temsavir pharmacokinetics. In contrast, fostemsavir increased tenofovir disoproxil fumarate Cmax, AUC and Cmin by 18%, 19% and 28% but these changes are not considered to be clinically relevant. No interaction is expected with lamivudine.",""
93928,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to fosamprenavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of fosamprenavir have not been established.",""
93930,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with indinavir or indinavir/ritonavir would be possible from a pharmacokinetic standpoint. The recommended dose of 10 mg tenofovir alafenamide with P-gp inhibitors is not possible with Biktarvy which is only available as a fixed dose combination containing 25 mg tenofovir alafenamide, but it should be noted that tenofovir alafenamide has been associated with a large clinical safety profile.",""
93937,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;&nbsp;Furthermore, tipranavir is expected to decrease the absorption (and thereby plasma concentrations) of tenofovir alafenamide due to induction of P-gp which may result in loss of therapeutic effect and development of resistance.",""
101315,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, the coadministration with doravirine would be possible from a pharmacokinetic standpoint. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4. Bictegravir is equally metabolized by CYP3A4 and UGT1A1. None of these antiretroviral drugs has any inhibitory or inducing effects on P450 or UGT enzymes therefore no significant interactions are expected between doravirine, bictegravir, emtricitabine, and tenofovir alafenamide.&nbsp;",""
93905,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with abacavir would be possible from a pharmacokinetic standpoint.",""
93916,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;If intensification of HIV treatment is needed, alternatives to stavudine should be considered.",""
93894,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and raltegravir is unlikely to be of clinical benefit.",""
116768,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, Triumeq (dolutegravir, abacavir, lamivudine) should not be taken with any other medicinal products containing emtricitabine&nbsp;due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and dolutegravir) is unlikely to be of clinical benefit.",""
117268,"Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. In addition, Triumeq (dolutegravir, abacavir, lamivudine) should not be taken with any other medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and dolutegravir) is unlikely to be of clinical benefit.",""
123209,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with emtricitabine and tenofovir-DF would be possible from a pharmacokinetic standpoint. Coadministration with cabotegravir LA or rilpivirine LA has not been studied. Coadministration of oral rilpivirine (150 mg once daily) and tenofovir-DF (300 mg once daily) decreased rilpivirine Cmax and Cmin by 4% and 1%, and increased AUC by 1%. Tenofovir Cmax, AUC and Cmin increased by 19%, 23% and 24%. No dose adjustment is necessary.",""
124545,"Cabenuva (cabotegravir LA, rilpivirine LA) and Triumeq (dolutegravir, lamivudine, abacavir) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., cabotegravir and dolutegravir) is unlikely to be of clinical benefit.",""
116033,"Dovato (dolutegravir/lamivudine) and Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, products containing emtricitabine should not be administered with products containing lamivudine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and dolutegravir) is unlikely to be of clinical benefit.",""
123212,"Cabenuva (cabotegravir LA, rilpivirine LA) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with enfuvirtide would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
93887,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) and Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, both products contain emtricitabine and tenofovir alafenamide and must not be administered with other products containing emtricitabine and tenofovir alafenamide.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and elvitegravir) is unlikely to be of clinical benefit.",""
93890,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) and Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) are indicated for use as complete regimens for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. In addition, products containing tenofovir-DF should not be coadministered with products containing tenofovir alafenamide.&nbsp;Furthermore, coadministering two integrase inhibitors (i.e., bictegravir and elvitegravir) is unlikely to be of clinical benefit.",""
117294,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ritonavir would be possible from a pharmacokinetic standpoint.&nbsp;Based on studies with boosted PIs, ritonavir is not expected to significantly affect dolutegravir pharmacokinetics. Using cross-study comparisons to historical pharmacokinetic data, dolutegravir did not appear to affect the pharmacokinetics of ritonavir. No interaction is expected with abacavir or lamivudine.",""
117265,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of atazanavir alone and dolutegravir increased dolutegravir AUC, Cmax and Ctrough by 91%, 50% and 180%, respectively. No significant effect on lamivudine and zidovudine concentrations was observed when atazanavir (400 mg once daily) was coadministered with lamivudine/zidovudine (150/300 mg twice daily). No interaction is expected with abacavir.",""
117287,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. Triumeq contains lamivudine and should not be taken with additional lamivudine.",""
117295,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. If intensification of HIV treatment is needed, alternatives to saquinavir should be considered.",""
116804,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with tipranavir is expected to decrease dolutegravir exposure. If intensification of HIV treatment is needed, alternatives to tipranavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of dolutegravir have not been established.&nbsp;The European product label for Triumeq does not recommend coadministration with tipranavir. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken. Coadministration of tipranavir/ritonavir and dolutegravir decreased dolutegravir AUC, Cmax and Ctrough by 59%, 47% and 76%, respectively; there was no effect on tipranavir or ritonavir. Coadministration of tipranavir/ritonavir decreased abacavir exposure by ~40%. The clinical relevance of the reduction in abacavir levels has not been established. Coadministration of tipranavir/ritonavir and lamivudine had no significant effect on lamivudine AUC or Cmax.",""
99882,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to saquinavir should be considered.",""
117267,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/ritonavir would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of atazanavir/ritonavir and dolutegravir increased dolutegravir AUC, Cmax and Ctrough by 62%, 34% and 121%, respectively. There was no effect on atazanavir or ritonavir. Coadministration of abacavir (600 mg once daily) and atazanavir/ritonavir (300/100 mg once daily) had no effect on atazanavir or ritonavir pharmacokinetics, but decreased abacavir AUC (17%) and Cmax (20%). These changes are unlikely to be clinically significant. No interaction is expected with lamivudine.",""
117270,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with darunavir/ritonavir would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of darunavir/ritonavir and dolutegravir decreased dolutegravir AUC, Cmax and Ctrough by 22%, 11% and 38%, respectively; there was no effect on darunavir or ritonavir. Coadministration of abacavir (600 mg once daily) and darunavir/ritonavir (900/100 mg once daily) decreased abacavir AUC, Cmax and Cmin by 27%, 22% and 38%, respectively (n=19). No interaction is expected with lamivudine.",""
117269,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with darunavir/cobicistat would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of dolutegravir (50 mg once daily) and darunavir/cobicistat (800/150 mg once daily) decreased dolutegravir Cmax, AUC, and C24 by 11%, 16% and 19%, respectively (n=9). Darunavir Cmax, AUC, and C24 decreased 21%, 13% and 18%, respectively, and cobicistat Cmax, AUC and C24h decreased by 14%, 12% and 2%, respectively. No interaction is expected with abacavir or lamivudine.",""
117284,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with fosamprenavir is expected to decrease dolutegravir exposure. If intensification of HIV treatment is needed, alternatives to fosamprenavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of dolutegravir have not been established.&nbsp;The European product label for Triumeq states no dose adjustment is necessary. However, the US product label for Triumeq recommends that an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, should be taken. Coadministration of fosamprenavir/ritonavir and dolutegravir decreased dolutegravir AUC, Cmax and Ctrough by 35%, 24% and 49%, respectively; there was no effect on fosamprenavir or ritonavir. No interaction is expected with abacavir or lamivudine.",""
116800,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with indinavir or indinavir/ritonavir would be possible from a pharmacokinetic standpoint.&nbsp;No interaction is expected with dolutegravir. Coadministration of indinavir alone with lamivudine or abacavir showed no clinically significant interactions.",""
116781,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and coadministration with nevirapine is not recommended. Nevirapine, an inducer of CYP3A4, could potentially decrease dolutegravir concentrations. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with nevirapine would be possible from a pharmacokinetic standpoint if an additional dolutegravir 50 mg tablet, separated by 12 hours from Triumeq, is taken. Note, the bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in liquid formulations such as nevirapine oral suspension.",""
116782,"Triumeq (dolutegravir, abacavir, lamivudine) is indicted for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with rilpivirine would be possible from a pharmacokinetic standpoint.&nbsp;No clinically significant pharmacokinetic interaction was observed between rilpivirine and dolutegravir. Coadministration of rilpivirine (25 mg once daily) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Ctrough by 13%, 12% and 22%, respectively. Rilpivirine Cmax, AUC and Ctrough increased by 10%, 6% and 21%, respectively. No interaction is expected with abacavir or lamivudine.",""
116785,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. If intensification of HIV treatment is needed, alternatives to didanosine should be considered. The bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in drug formulations such as didanosine chewable/dispersible tablet.",""
116792,"Triumeq (dolutegravir, abacavir, lamivudine) can be used as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.&nbsp;No interaction is expected with dolutegravir. Coadministration of single doses of abacavir (600 mg), lamivudine (150 mg), and zidovudine (300 mg) showed no clinically relevant changes in the pharmacokinetics of abacavir. Lamivudine AUC decreased by 15% and zidovudine AUC increased by 10% with concurrent abacavir. No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed with coadministration of zidovudine (200 mg, single dose) and lamivudine (300 mg single dose).",""
99867,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with emtricitabine would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
117299,"Triumeq (dolutegravir, abacavir, lamivudine) can be used as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.&nbsp;Coadministration of single doses of abacavir (600 mg), lamivudine (150 mg), and zidovudine (300 mg) showed no clinically relevant changes in the pharmacokinetics of abacavir. Lamivudine AUC decreased by 15% and zidovudine AUC increased by 10% with concurrent abacavir. No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed with coadministration of zidovudine (200 mg, single dose) and lamivudine (300 mg single dose).",""
117291,"Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. If intensification of HIV treatment is needed, alternatives to raltegravir should be considered as coadministering two integrase inhibitors (i.e., raltegravir and dolutegravir) is unlikely to be of clinical benefit.",""
116773,"Triumeq (dolutegravir/abacavir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ibalizumab would be possible from a pharmacokinetic standpoint.&nbsp;No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Dolutegravir and abacavir undergo mostly hepatic metabolism, and lamivudine is eliminated renally. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Dose modifications of ibalizumab are not required when administered with any other antiretroviral.",""
117230,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/cobicistat would be possible from a pharmacokinetic standpoint.&nbsp;Atazanavir/cobicistat is expected to increase dolutegravir plasma concentrations, but dolutegravir is not expected to affect the pharmacokinetics of atazanavir/cobicistat. No interaction is expected with lamivudine. However, cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. Atazanavir/cobicistat should not be coadministered with lamivudine in patients with creatinine clearance less than 70 ml/min.",""
116059,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with atazanavir/ritonavir would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with atazanavir/ritonavir. Coadministration of atazanavir/ritonavir and dolutegravir increased dolutegravir AUC, Cmax and Ctrough by 62%, 34% and 121%, respectively. There was no effect on atazanavir or ritonavir. No interaction is expected with lamivudine.",""
117233,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with darunavir/cobicistat would be possible from a pharmacokinetic standpoint. Coadministration of dolutegravir (50 mg once daily) and darunavir/cobicistat (800/150 mg once daily) decreased dolutegravir Cmax, AUC, and C24 by 11%, 16% and 19%, respectively (n=9). Darunavir Cmax, AUC, and C24 decreased 21%, 13% and 18%, respectively, and cobicistat Cmax, AUC and C24h decreased by 14%, 12% and 2%, respectively. No interaction is expected with lamivudine.",""
116061,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration of darunavir/ritonavir would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with darunavir/ritonavir. Coadministration of darunavir/ritonavir and dolutegravir decreased dolutegravir AUC, Cmax and Ctrough by 22%, 11% and 38%, respectively; there was no effect on darunavir or ritonavir. No interaction is expected with lamivudine.",""
117248,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. If intensification of HIV treatment is needed, alternatives to fosamprenavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics of dolutegravir have not been established. Coadministration with other antiretroviral drugs is not recommended in the US Prescribing Information for Dovato, however, the European product label for Dovato advises that no dose adjustment is necessary with fosamprenavir. Fosamprenavir/ritonavir decreases dolutegravir concentrations, but based on limited data, did not result in decreased efficacy in Phase III studies. Coadministration of dolutegravir and fosamprenavir/ritonavir decreased dolutegravir AUC, Cmax and Cmin by 35%, 24% and 49%, respectively. There was no change in fosamprenavir or ritonavir pharmacokinetics.",""
99463,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with indinavir or indinavir/ritonavir would be possible from a pharmacokinetic standpoint. Based on studies with other boosted PIs, indinavir/ritonavir is not expected to significantly affect dolutegravir pharmacokinetics. Coadministration with indinavir (alone or with ritonavir) may increase rilpivirine concentrations, however, no dose adjustment is required. Rilpivirine is not expected to affect concentrations of indinavir.",""
117252,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with lopinavir/ritonavir would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with lopinavir/ritonavir. Coadministration of lopinavir and dolutegravir decreased dolutegravir AUC and C24 by 4% and 6% and had no effect on Cmax; there was no effect on lopinavir or ritonavir. No change in the pharmacokinetics of lopinavir was observed with stavudine and lamivudine in clinical studies.",""
117241,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with efavirenz would be possible from a pharmacokinetic standpoint. The European product label for Dovato recommends an additional 50 mg tablet of dolutegravir should be administered, approximately 12 hours after Dovato, during coadministration with efavirenz. Coadministration of dolutegravir and efavirenz decreased dolutegravir AUC, Cmax and Cmin by 57%, 39% and 75%, respectively. There was no change in efavirenz when compared to historical controls. Coadministration of lamivudine (150 mg twice daily) with efavirenz (600 mg once daily) increased lamivudine Cmin by 265%, but had no effect on lamivudine Cmax or AUC.&nbsp;",""
117254,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with nevirapine would be possible from a pharmacokinetic standpoint. The European product label for Dovato recommends an additional 50 mg tablet of dolutegravir should be administered, approximately 12 hours after Dovato, during coadministration as nevirapine, an inducer of CYP3A4, could potentially decrease dolutegravir concentrations. Note, the bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in liquid formulations such as nevirapine oral suspension.",""
117256,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with rilpivirine would be possible from a pharmacokinetic standpoint. Coadministration of rilpivirine (25 mg once daily) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Ctrough by 13%, 12% and 22%, respectively. Rilpivirine Cmax, AUC and Ctrough increased by 10%, 6% and 21%, respectively. No interaction is expected with lamivudine.",""
117236,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. If intensification of HIV treatment is needed, alternatives to didanosine should be considered. The bioavailability of lamivudine has been shown to be significantly reduced in a dose dependent manner by sorbitol which is present in drug formulations such as didanosine chewable/dispersible tablet.",""
116041,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with enfuvirtide would be possible from a pharmacokinetic standpoint as no clinically relevant drug-drug interaction is expected.",""
117249,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ibalizumab would be possible from a pharmacokinetic standpoint. No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Dolutegravir undergoes mostly hepatic metabolism, and lamivudine is eliminated renally. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
117253,"Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with maraviroc (dosed at 300 mg twice daily) would be possible from a pharmacokinetic standpoint. Maraviroc is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of maraviroc (300 mg twice daily) and lamivudine/zidovudine (150/300 mg twice daily) increased lamivudine AUC (14%) and Cmax (16%), but is not considered to be clinically significant. Maraviroc concentrations were not measured, but no effect is expected.",""
99871,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. If intensification of HIV treatment is needed, alternatives to fosamprenavir should be considered as appropriate doses of this combination with respect to safety, efficacy and pharmacokinetics have not been established.",""
99879,"Juluca&nbsp;(dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. Juluca should not be taken with any other medicinal product containing rilpivirine, except in case of co-administration with rifabutin.",""
125432,"Juluca (dolutegravir/rilpivirine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGT enzymes. Fostemsavir and rilpivirine have been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration. However, the product labels indicate that these antiretroviral drugs should be used with caution in combination with drugs with a known risk of Torsade de Pointes.",""
85462,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infections. However, in specific clinical situations where an intensification of HIV treatment is needed, the coadministration of rilpivirine would be possible from a pharmacokinetic standpoint. Coadministration is expected to increase rilpivirine concentrations however no dose adjustment is required.",""
85887,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products.&nbsp;Furthermore, Genvoya contains emtricitabine and should not be administered with lamivudine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.&nbsp;",""
85474,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint.",""
86495,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) and Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) are both indicated for use as complete regimens for the treatment of HIV-1 infection and must not be administered with other antiretroviral products. In addition, both products contain elvitegravir, cobicistat and emtricitabine and must not be administered with other products containing elvitegravir, cobicistat and emtricitabine. Furthermore, Genvoya contains tenofovir alafenamide and should not be administered with tenofovir-DF.&nbsp;",""
125434,"Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir may increase tenofovir alafenamide exposure (due to intestinal inhibition of BCRP by temsavir) but to a modest extent with no clinically relevant impact. No interaction is expected with emtricitabine.",""
86513,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, increased didanosine concentrations and toxicity were observed when combined with tenofovir-DF.",""
86524,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, Stribild contains tenofovir-DF and should not be administered with additional tenofovir-DF.&nbsp;",""
73021,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Dolutegravir does not inhibit or induce CYP1A2 or P-glycoprotein.,""
73011,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Etravirine has no inhibitory effect on CYP1A2, however, it inhibits weakly P-glycoprotein and could potentially increase zolmitriptan absorption although to a limited extent.",""
125410,"Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. However, dexamethasone is a moderate inducer of CYP3A4 but is unlikely to alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce the exposure of the active metabolite temsavir by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation also applies when fostemsavir is coadministered with dexamethasone.",""
86540,"<p>Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Stribild should not be used in conjunction with protease inhibitors inhibitors due to potential drug-drug interactions including altered and/or suboptimal pharmacokinetics of cobicistat, elvitegravir, and/or the coadministered antiretroviral products. Stribild should not be administered concurrently with products containing ritonavir or regimens containing ritonavir due to similar effects of cobicistat and ritonavir on CYP3A.
</p>",""
73020,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Maraviroc does not inhibit or induce CYP1A2 or P-glycoprotein.,""
125815,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Doravirine does not inhibit or induce CYP1A2 or P-glycoprotein.,""
125819,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Dolutegravir does not inhibit or induce CYP1A2 or P-glycoprotein. Zolmitriptan does not interact with lamivudine.,""
125820,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Dolutegravir and rilpivirine do not inhibit or induce CYP1A2 or P-glycoprotein.,""
125821,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Bictegravir does not inhibit or induce CYP1A2 or P-glycoprotein. Zolmitriptan does not interact with emtricitabine or tenofovir alafenamide.,""
73013,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Abacavir does not affect the zolmitriptan metabolic pathway.,""
123260,"Coadministration has not been studied. Fluconazole is a moderate inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. No dose adjustment is required for rilpivirine when co-administered with azole antifungal agents, but clinical monitoring for breakthrough fungal infections is recommended when azole antifungals are co-administered with rilpivirine.",""
125807,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Atazanavir has no inhibitory effect on CYP1A2, however, it does inhibit P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
125808,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Atazanavir/cobicistat has no inhibitory effect on CYP1A2, however, it does inhibit P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
125809,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Darunavir/cobicistat has no inhibitory effect on CYP1A2, however, it does inhibit P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
125810,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with atazanavir/ritonavir. However, atazanavir/ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
125811,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with darunavir/ritonavir. However, darunavir/ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
73003,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with lopinavir/ritonavir. However, lopinavir/ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
73005,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Ritonavir induces CYP1A2, however, coadministration with rifampicin (another CYP1A2 inducer) caused a small (&lt;18%) decrease in zolmitriptan exposure. Similarly, no significant decrease in zolmitriptan exposure is expected with ritonavir. However, ritonavir inhibits P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day.",""
73007,Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Tipranavir/ritonavir is a weak inducer of CYP1A2 but a potent inducer of intestinal P-glycoprotein and could reduce zolmitriptan absorption. Close monitoring is recommended and dose modify if required.,""
125812,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Elvitegravir/cobicistat has no inhibitory effect on CYP1A2, however, cobicistat does inhibit P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day. Zolmitriptan does not interact with emtricitabine and tenofovir alafenamide.",""
125813,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Elvitegravir/cobicistat has no inhibitory effect on CYP1A2, however, cobicistat does inhibit P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day. Zolmitriptan does not interact with emtricitabine and tenofovir-DF.",""
125814,"Coadministration has not been studied. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Darunavir/cobicistat has no inhibitory effect on CYP1A2, however, it does inhibit P-glycoprotein and could potentially increase zolmitriptan absorption. Consider limiting the maximal dose of zolmitriptan to 5 mg per day. Zolmitriptan does not interact with emtricitabine and tenofovir alafenamide.",""
73010,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Efavirenz does not induce CYP1A2 or P-glycoprotein.,""
73012,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Nevirapine does not induce CYP1A2 or P-glycoprotein.,""
125817,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Rilpivirine does not inhibit or induce CYP1A2 or P-glycoprotein. Zolmitriptan does not interact with emtricitabine or tenofovir alafenamide.,""
125829,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan is metabolized by CYP1A2 and the N-demethylated metabolite (active) undergoes further metabolism by MAO-A. In vitro data indicate that zolmitriptan is a substrate of P-glycoprotein. Raltegravir does not inhibit or induce CYP1A2 or P-glycoprotein.,""
125836,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as fosamprenavir inhibits CYP3A4 (minor pathway). However, fosamprenavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease fosamprenavir exposure leading to loss of therapeutic effect and possible development of resistance.",""
125837,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as indinavir inhibits CYP3A4 (minor pathway). However, indinavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease indinavir exposure leading to loss of therapeutic effect and possible development of resistance.",""
125838,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as ritonavir inhibits CYP3A4 (minor pathway). However, ritonavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease ritonavir exposure leading to loss of therapeutic effect and possible development of resistance.",""
125839,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as lopinavir inhibits CYP3A4 (minor pathway). However, lopinavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease lopinavir exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, lopinavir has a possible QT risk and androgen deprivation therapy may prolong the QT interval.",""
125840,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as saquinavir inhibits CYP3A4 (minor pathway). However, saquinavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease saquinavir exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, saquinavir has a possible QT risk and androgen deprivation therapy may prolong the QT interval.",""
125841,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may significantly increase as tipranavir is a strong inhibitor of CYP2C8. However, tipranavir/ritonavir is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease tipranavir/ritonavir exposure leading to loss of therapeutic effect and possible development of resistance.&nbsp;",""
125842,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as cobicistat inhibits CYP3A4 (minor pathway). However, elvitegravir/cobicistat is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease elvitegravir/cobicistat exposure leading to loss of therapeutic effect and possible development of resistance. Enzalutamide does not interact with emtricitabine and tenofovir-DF.&nbsp;",""
125843,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as cobicistat inhibits CYP3A4 (minor pathway). However, elvitegravir/cobicistat is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease elvitegravir/cobicistat exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, enzalutamide may induce P-gp and thereby decrease the absorption of tenofovir alafenamide. No interaction is expected with emtricitabine.",""
125844,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may increase to a limited extent as darunavir/cobicistat inhibits CYP3A4 (minor pathway). However, darunavir/cobicistat is metabolized by CYP3A4 and enzalutamide is a strong inducer of CYP3A4 and may significantly decrease darunavir/cobicistat exposure leading to loss of therapeutic effect and possible development of resistance. Furthermore, enzalutamide may induce P-gp and thereby decrease the absorption of tenofovir alafenamide. No interaction is expected with emtricitabine.",""
125845,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may significantly increase as efavirenz is a strong inhibitor of CYP2C8 (efavirenz has been shown to significantly increase the exposure of the CYP2C8 substrate amodiaquine). Enzalutamide is a strong inducer of CYP3A4 and could reduce efavirenz exposure although to a limited extent based on the interaction study with rifampicin. Concurrent use is not recommended. If coadministration is necessary, closely monitor and consider a reduction of enzalutamide dosage in case of adverse events.&nbsp;",""
125846,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Enzalutamide concentrations may decrease as nevirapine was shown to reduce the exposure of amodiaquine, a CYP2C8 substrate. In addition, enzalutamide is a strong inducer of CYP3A4 and could significantly reduce nevirapine exposure leading to loss of therapeutic effect and possible development of resistance.",""
125847,Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Enzalutamide could significantly reduce etravirine exposure leading to loss of therapeutic effect and possible development of resistance.&nbsp;,""
125848,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Maraviroc is metabolized by CYP3A4 but has no inducing effects on CYPs. Coadministration of a non-licensed dose of maraviroc (100 mg twice daily) and rifampicin (another strong CYP3A4 inducer) decreased maraviroc exposure by 60-70%. A similar decrease is expected with enzalutamide. Consider increasing maraviroc to 600 mg twice daily in presence of enzalutamide. Enzalutamide has a long half-life (5.8 days), therefore the maraviroc dose should be kept at 600 mg twice daily for a minimum of 2 weeks (but preferably4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.",""
125849,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Doravirine is metabolized by CYP3A4 but has no inducing effects on CYPs. Coadministration is expected to significantly reduce doravirine concentrations which may result in loss of therapeutic effect and development of resistance. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks, but preferably 4 weeks, cessation period is recommended prior to initiation of doravirine due to the persisting inducing effect upon discontinuation of a strong inducer.&nbsp;",""
125850,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Doravirine is metabolized by CYP3A4 but has no inducing effects on CYPs. Coadministration is expected to significantly reduce doravirine concentrations which may result in loss of therapeutic effect and development of resistance. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks, but preferably 4 weeks, cessation period is recommended prior to initiation of doravirine due to the persisting inducing effect upon discontinuation of a strong inducer. Enzalutamide does not interact with lamivudine and tenofovir-DF",""
125851,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Rilpivirine is metabolized by CYP3A4 but has no inducing effects on CYPs. Coadministration is expected to significantly reduce rilpivirine concentrations which may result in loss of therapeutic effect and development of resistance. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks, but preferably 4 weeks, cessation period is recommended prior to initiation of rilpivirine due to the persisting inducing effect upon discontinuation of a strong inducer. Furthermore, rilpivirine has been associated with prolongation of the QT interval at supra-therapeutic doses and androgen deprivation therapy may prolong the QT interval.&nbsp;",""
125852,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Rilpivirine is metabolized by CYP3A4 but has no inducing effects on CYPs. Coadministration is expected to significantly reduce rilpivirine concentrations which may result in loss of therapeutic effect and development of resistance. In addition, enzalutamide may induce P-gp and thereby decrease the absorption of tenofovir alafenamide. No interaction is expected with emtricitabine. Enzalutamide has a long half-life (5.8 days) therefore a minimum of 2 weeks, but preferably 4 weeks, cessation period is recommended prior to initiation of rilpivirine due to the persisting inducing effect upon discontinuation of a strong inducer. Furthermore, rilpivirine has been associated with prolongation of the QT interval at supra-therapeutic doses and androgen deprivation therapy may prolong the QT interval.&nbsp;",""
125853,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and can induce UGT1A1. Raltegravir is metabolized by UGT1A1 but has no inducing effects on CYPs. Coadministration may decrease raltegravir concentrations. Consider increasing raltegravir dose to 800 mg twice daily when coadministering with enzalutamide. Coadministration of once daily raltegravir is not recommended. Enzalutamide has a long half-life (5.8 days), therefore the raltegravir dose should be kept at 800 mg twice daily for a minimum of 2 weeks (but preferably4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.",""
125854,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Enzalutamide can induce UGT1A1. Dolutegravir is metabolized by UGT1A1 and to a lesser extent by CYP3A4. Dolutegravir has no inducing effects on CYPs. Coadministration is expected to decrease dolutegravir concentrations, thus dolutegravir should be administered at 50 mg twice daily in the absence of integrase class resistance. In the presence of integrase class resistance this combination should be avoided. Enzalutamide has a long half-life (5.8 days), therefore the dolutegravir dose should be kept at 50 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer.",""
125855,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Enzalutamide can induce UGT1A1. Dolutegravir is metabolized by UGT1A1 and to a lesser extent by CYP3A4. Dolutegravir has no inducing effects on CYPs. Coadministration is expected to decrease dolutegravir concentrations, thus dolutegravir should be administered at 50 mg twice daily in the absence of integrase class resistance. In the presence of integrase class resistance this combination should be avoided. Enzalutamide has a long half-life (5.8 days), therefore dolutegravir dose should be kept at 50 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer. Enzalutamide induces UGTs and may decrease abacavir concentrations but to a limited extent and no dose adjustment is required. Enzalutamide does not interact with lamivudine.",""
125856,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Enzalutamide can induce UGT1A1. Dolutegravir is metabolized by UGT1A1 and to a lesser extent by CYP3A4. Dolutegravir has no inducing effects on CYPs. Coadministration is expected to decrease dolutegravir concentrations, thus dolutegravir should be administered at 50 mg twice daily in the absence of integrase class resistance. In the presence of integrase class resistance this combination should be avoided. Enzalutamide has a long half-life (5.8 days), therefore the dolutegravir dose should be kept at 50 mg twice daily for a minimum of 2 weeks (but preferably 4 weeks) following cessation of enzalutamide due to the persisting inducing effect upon discontinuation of a strong inducer. Enzalutamide does not interact with lamivudine.",""
125857,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Dolutegravir is metabolized by UGT1A1 and CYP3A4; rilpivirine is metabolized by CYP3A4. Dolutegravir and rilpivirine have no inducing effects on CYPs. Coadministration is expected to significantly reduce rilpivirine and dolutegravir concentrations which may result in loss of therapeutic effect and development of resistance. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks (but preferably 4 weeks) cessation period is recommended prior to initiation of dolutegravir/rilpivirine due to the persisting inducing effect upon discontinuation of a strong inducer. Furthermore, rilpivirine has been associated with prolongation of the QT interval at supra-therapeutic doses and androgen deprivation therapy may prolong the QT interval.&nbsp;",""
125858,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Enzalutamide induces also UGT1A1. Bictegravir is metabolized by UGT1A1 and CYP3A4 and has no inducing effects on CYPs. Coadministration is expected to significantly reduce bictegravir concentrations which may result in loss of therapeutic effect and development of resistance. Furthermore, enzalutamide may induce P-gp and thereby decrease the absorption of tenofovir alafenamide. No interaction is expected with emtricitabine. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks (but preferably 4 weeks) cessation period is recommended prior to initiation of bictegravir due to the persisting inducing effect upon discontinuation of a strong inducer.",""
125859,Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and induces UGTs. Coadministration may decrease abacavir concentrations due to induction of UGTs although to a limited extent. No a priori dose adjustment is required.,""
125860,"Coadministration has not been studied. Enzalutamide is primarily metabolized by CYP2C8 and may induce P-gp resulting in decreased absorption of tenofovir alafenamide. However, intracellular tenofovir-DP concentrations are still expected to be higher than those achieved by standard dose tenofovir-DF alone. If coadministration is required, use tenofovir alafenamide 25 mg once daily. Enzalutamide does not interact with emtricitabine.",""
125861,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enzalutamide is primarily metabolized by CYP2C8.&nbsp;,""
125868,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enzalutamide is primarily metabolized by CYP2C8. Albuvirtide is a peptide which is eliminated by catabolism to its constituent amino acids. In vitro human microsomal studies and limited in vivo drug-drug interaction data indicate that albuvirtide has no inhibiting or inducing properties on P450 enzymes.,""
125869,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enzalutamide is primarily metabolized by CYP2C8 whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",""
125870,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and induce UGTs. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9 and has no inducing effects on CYPs. Based on a drug interaction study with rifampicin (another inducer of UGTs), coadministration is expected to significantly reduce cabotegravir concentrations which may result in loss of therapeutic effect and development of resistance. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks (but preferably 4 weeks) cessation period is recommended prior to initiation of cabotegravir due to the persisting inducing effect upon discontinuation of a strong inducer.&nbsp;",""
125871,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Enzalutamide does also induce UGTs. Cabotegravir is mainly metabolized by UGT1A1 and to a lesser extent UGT1A9 and rilpivirine is metabolized by CYP3A4. Cabotegravir and rilpivirine have no inhibitory or inducing effects on CYPs. Coadministration is expected to significantly reduce cabotegravir and rilpivirine concentrations which may result in loss of therapeutic effect and development of resistance. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks (but preferably 4 weeks) cessation period is recommended prior to initiation of cabotegravir/rilpivirine due to the persisting inducing effect upon discontinuation of a strong inducer. Furthermore, rilpivirine has been associated with prolongation of the QT interval at supra-therapeutic doses and androgen deprivation therapy may prolong the QT interval.&nbsp;",""
125872,"Coadministration has not been studied but is not recommended. Enzalutamide is primarily metabolized by CYP2C8 and is a strong inducer of CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. Coadministration with enzalutamide may substantially reduce temsavir exposure which may result in a potential loss of therapeutic effect. Enzalutamide has a long half-life (5.8 days), therefore a minimum of 2 weeks (but preferably 4 weeks) cessation period is recommended prior to initiation of fostemsavir due to the persisting inducing effect upon discontinuation of a strong inducer. Furthermore, fostemsavir has been associated with prolongation of the QT interval at supra-therapeutic doses and androgen deprivation therapy may prolong the QT interval.",""
86501,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF)&nbsp;is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Stribild should not be used in conjunction with non-nucleoside reverse transcriptase inhibitors due to potential drug-drug interactions including altered and/or suboptimal pharmacokinetics of cobicistat, elvitegravir, and/or the coadministered antiretroviral products.",""
125874,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with atazanavir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore atazanavir/cobicistat may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving atazanavir/cobicistat concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125875,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with atazanavir/ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore atazanavir/ritonavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving atazanavir/ritonavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125876,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with darunavir/ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore darunavir/ritonavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving darunavir/ritonavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125877,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with darunavir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore darunavir/cobicistat may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving darunavir/cobicistat concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125878,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with fosamprenavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore fosamprenavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving fosamprenavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125879,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with indinavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore indinavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving indinavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125880,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with lopinavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore lopinavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving lopinavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125881,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with saquinavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore saquinavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving saquinavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125873,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with atazanavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore atazanavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving atazanavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125883,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with elvitegravir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore elvitegravir/cobicistat may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, increased MMAE AUC by 34%. Brentuximab vedotin does not interact with emtricitabine and tenofovir alafenamide. Patients receiving elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to dosing recommendations for neutropenia in the product label for brentuximab vedotin.&nbsp;",""
125885,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with darunavir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore darunavir/cobicistat may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, increased MMAE AUC by 34%. Brentuximab vedotin does not interact with emtricitabine and tenofovir alafenamide. Patients receiving darunavir, cobicistat, emtricitabine and tenofovir alafenamide concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125886,"Coadministration has not been studied. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with efavirenz. However, MMAE is a substrate of CYP3A4 and P-gp, therefore efavirenz may decrease concentrations of MMAE. Coadministration of brentuximab vedotin and the strong inducer rifampicin decreased MMAE AUC by 46%. A less pronounced interaction is expected with efavirenz. No a priori dose adjustment of brentuximab vedotin is necessary as the contribution of free MMAE to efficacy is minimal.",""
125887,"Coadministration has not been studied. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with nevirapine. However, MMAE is a substrate of CYP3A4 and P-gp, therefore nevirapine may decrease concentrations of MMAE. Coadministration of brentuximab vedotin and the strong inducer rifampicin decreased MMAE AUC by 46%. A less pronounced interaction is expected with nevirapine. No a priori dose adjustment of brentuximab vedotin is necessary as the contribution of free MMAE to efficacy is minimal.",""
125888,"Coadministration has not been studied. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with etravirine. However, MMAE is a substrate of CYP3A4 and P-gp, therefore etravirine may decrease concentrations of MMAE. Coadministration of brentuximab vedotin and the strong inducer rifampicin decreased MMAE AUC by 46%. A less pronounced interaction is expected with etravirine. No a priori dose adjustment of brentuximab vedotin is necessary as the contribution of free MMAE to efficacy is minimal.",""
125889,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with maraviroc. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both maraviroc and MMAE have no inhibitory or inducing effects on CYPs.&nbsp;",""
125890,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with doravirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both doravirine and MMAE have no inhibitory or inducing effects on CYPs.&nbsp;",""
125891,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with doravirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both doravirine and MMAE have no inhibitory or inducing effects on CYPs. Brentuximab vedotin does not interact with lamivudine and tenofovir-DF.",""
125892,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with rilpivirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both rilpivirine and MMAE have no inhibitory or inducing effects on CYPs.",""
125893,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with rilpivirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both rilpivirine and MMAE have no inhibitory or inducing effects on CYPs. Brentuximab vedotin does not interact with emtricitabine and tenofovir alafenamide.",""
125894,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with raltegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as raltegravir has no inhibitory or inducing effects on CYP and brentuximab vedotin has no inhibitory or inducing effects on UGT1A1.",""
125895,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with dolutegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir has no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1.",""
125882,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with tipranavir/ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore tipranavir/ritonavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. The increase in MMAE exposure might be less with tipranavir/ritonavir given its mixed inhibitory effect on CYP3A4 and inducing effect on P-gp. Patients receiving tipranavir/ritonavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125896,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody does not interact with dolutegravir as it undergoes elimination via intracellular catabolism. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir has no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1. Brentuximab vedotin does not interact with abacavir or lamivudine.",""
125897,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with dolutegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir has no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1. Brentuximab vedotin does not interact with lamivudine.",""
125898,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with dolutegravir or rilpivirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir and rilpivirine have no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1.",""
125900,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with abacavir. MMAE is a substrate of CYP3A4 and P-gp but abacavir does not interfere with these pathways.&nbsp;",""
125901,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with didanosine. MMAE is a substrate of CYP3A4 and P-gp but didanosine does not interfere with these pathways.&nbsp;",""
125902,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with emtricitabine. MMAE is a substrate of CYP3A4 and P-gp but emtricitabine does not interfere with these pathways.&nbsp;",""
125903,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with emtricitabine/tenofovir alafenamide. MMAE is a substrate of CYP3A4 and P-gp but emtricitabine/tenofovir alafenamide does not interfere with these pathways. ",""
125904,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with emtricitabine/tenofovir-DF. MMAE is a substrate of CYP3A4 and P-gp but emtricitabine/tenofovir-DF does not interfere with these pathways.",""
125905,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with lamivudine. MMAE is a substrate of CYP3A4 and P-gp but lamivudine does not interfere with these pathways.&nbsp;",""
125906,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with stavudine. MMAE is a substrate of CYP3A4 and P-gp but stavudine does not interfere with these pathways.&nbsp;",""
125907,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with tenofovir-DF. MMAE is a substrate of CYP3A4 and P-gp but tenofovir-DF does not interfere with these pathways.&nbsp;",""
125908,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with zidovudine. MMAE is a substrate of CYP3A4 and P-gp but zidovudine does not interfere with these pathways.&nbsp;",""
125909,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. Both brentuximab vedotin and albuvirtide are eliminated via intracellular catabolism. MMAE is a substrate of CYP3A4 and P-gp but albuvirtide does not interfere with these pathways.",""
125910,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. Both brentuximab vedotin and ibalizumab are eliminated via intracellular catabolism. MMAE is a substrate of CYP3A4 and P-gp but ibalizumab does not interfere with these pathways.",""
125911,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with cabotegravir. MMAE is a substrate of CYP3A4 and P-gp, but no interaction is expected as cabotegravir has no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on UGTs.",""
125912,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with cabotegravir or rilpivirine. MMAE is a substrate of CYP3A4 and P-gp, but no interaction is expected as cabotegravir or rilpivirine have no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on UGTs or CYP3A4.",""
125913,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with fostemsavir. MMAE is a substrate of CYP3A4 and P-gp, but no interaction is expected as temsavir, the active metabolite of fostemsavir, has no inhibitory or inducing effects on CYP3A4.&nbsp;",""
125915,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with atazanavir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore atazanavir/cobicistat may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving atazanavir/cobicistat concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125914,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with atazanavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore atazanavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving atazanavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125916,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with atazanavir/ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore atazanavir/ritonavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving atazanavir/ritonavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125917,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with darunavir/ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore darunavir/ritonavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving darunavir/ritonavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125918,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with darunavir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore darunavir/cobicistat may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving darunavir/cobicistat concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
86517,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, it must not be administered with additional emtricitabine.",""
125919,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with fosamprenavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore fosamprenavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving fosamprenavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125920,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with indinavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore indinavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving indinavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125921,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with lopinavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore lopinavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving lopinavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125922,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore ritonavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving ritonavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125923,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with saquinavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore saquinavir may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Patients receiving saquinavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125924,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with tipranavir/ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore tipranavir/ritonavir may increase concentrations of MMAE and the incidence of toxicities. The increase in MMAE exposure might be less with tipranavir/ritonavir given its mixed inhibitory effect on CYP3A4 and inducing effect on P-gp. Patients who are receiving tipranavir/ritonavir concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.",""
125930,"Coadministration has not been studied. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with nevirapine. However, MMAE is a substrate of CYP3A4 and P-gp, therefore nevirapine may decrease concentrations of MMAE. Coadministration of polatuzumab vedotin and the strong inducer rifampicin is predicted to decrease MMAE AUC by 63%. A less pronounced interaction is expected with nevirapine. No a priori dose adjustment of polatuzumab vedotin is necessary as the contribution of free MMAE to efficacy is minimal.",""
125927,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with darunavir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore darunavir/cobicistat may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Polatuzumab vedotin does not interact with emtricitabine and tenofovir alafenamide. Patients receiving darunavir, cobicistat, emtricitabine and tenofovir alafenamide concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.&nbsp;",""
125928,"Coadministration has not been studied. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with efavirenz. However, MMAE is a substrate of CYP3A4 and P-gp, therefore efavirenz may decrease concentrations of MMAE. Coadministration of polatuzumab vedotin and the strong inducer rifampicin is predicted to decrease MMAE AUC by 63%. A less pronounced interaction is expected with efavirenz. No a priori dose adjustment of polatuzumab vedotin is necessary as the contribution of free MMAE to efficacy is minimal.",""
125884,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with elvitegravir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore elvitegravir/cobicistat may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, increased MMAE AUC by 34%. Brentuximab vedotin does not interact with emtricitabine and tenofovir-DF. Patients receiving elvitegravir, cobicistat, emtricitabine and tenofovir-DF concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125931,"Coadministration has not been studied. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with etravirine. However, MMAE is a substrate of CYP3A4 and P-gp, therefore etravirine may decrease concentrations of MMAE. Coadministration of polatuzumab vedotin and the strong inducer rifampicin is predicted to decrease MMAE AUC by 63%. A less pronounced interaction is expected with etravirine. No a priori dose adjustment of polatuzumab vedotin is necessary as the contribution of free MMAE to efficacy is minimal.",""
125925,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with elvitegravir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore elvitegravir/cobicistat may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Polatuzumab vedotin does not interact with emtricitabine and tenofovir alafenamide. Patients receiving elvitegravir, cobicistat, emtricitabine and tenofovir alfenamide concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.&nbsp;",""
125926,"Coadministration has not been studied but should be used with caution. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with elvitegravir/cobicistat. However, MMAE is a substrate of CYP3A4 and P-gp, therefore elvitegravir/cobicistat may increase concentrations of MMAE and the incidence of toxicities. Coadministration of polatuzumab vedotin and ketoconazole, a strong inhibitor of CYP3A4 and P-gp, is predicted to increase MMAE AUC by 45%. Polatuzumab vedotin does not interact with emtricitabine and tenofovir-DF. Patients receiving elvitegravir, cobicistat, emtricitabine and tenofovir-DF concomitantly with polatuzumab vedotin should be closely monitored for signs of toxicities.&nbsp;",""
125929,"Coadministration has not been studied but should be used with caution. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with ritonavir. However, MMAE is a substrate of CYP3A4 and P-gp, therefore ritonavir may increase concentrations of MMAE and the incidence of neutropenia. Coadministration of brentuximab vedotin and ketoconazole (a strong inhibitor of CYP3A4 and P-gp) increased MMAE AUC by 34%. Patients receiving ritonavir concomitantly with brentuximab vedotin should be closely monitored for adverse reactions of brentuximab vedotin. If neutropenia develops, refer to the dosing recommendations for neutropenia in the product label for brentuximab vedotin.",""
125932,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with maraviroc. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both maraviroc and MMAE have no inhibitory or inducing effects on CYPs.&nbsp;",""
125933,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with doravirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both doravirine and MMAE have no inhibitory or inducing effects on CYPs.&nbsp;",""
125934,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with doravirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both doravirine and MMAE have no inhibitory or inducing effects on CYPs. Polatuzumab vedotin does not interact with lamivudine and tenofovir-DF.",""
125935,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with rilpivirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both rilpivirine and MMAE have no inhibitory or inducing effects on CYPs.",""
125936,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with rilpivirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as both rilpivirine and MMAE have no inhibitory or inducing effects on CYPs. Polatuzumab vedotin does not interact with emtricitabine and tenofovir alafenamide.",""
125937,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with raltegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as raltegravir has no inhibitory or inducing effects on CYP and polatuzumab vedotin has no inhibitory or inducing effects on UGT1A1.",""
125938,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with dolutegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir has no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1.",""
125939,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody does not interact with dolutegravir as it undergoes elimination via intracellular catabolism. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir has no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1. Polatuzumab vedotin does not interact with abacavir or lamivudine.",""
125940,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with dolutegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir has no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1. Polatuzumab vedotin does not interact with lamivudine.",""
86518,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, Stribild contains emtricitabine and should not be administered with lamivudine due to the risk for intracellular interactions between cytidine analogues such as emtricitabine and lamivudine.&nbsp;",""
125941,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with dolutegravir or rilpivirine. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as dolutegravir and rilpivirine have no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1.",""
125943,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with abacavir. MMAE is a substrate of CYP3A4 and P-gp but abacavir does not interfere with these pathways.&nbsp;",""
125944,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with didanodine. MMAE is a substrate of CYP3A4 and P-gp but didanosine does not interfere with these pathways.&nbsp;",""
125945,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with stavudine. MMAE is a substrate of CYP3A4 and P-gp but stavudine does not interfere with these pathways.&nbsp;",""
125946,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with lamivudine. MMAE is a substrate of CYP3A4 and P-gp but lamivudine does not interfere with these pathways.&nbsp;",""
125947,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with tenofovir-DF. MMAE is a substrate of CYP3A4 and P-gp but tenofovir-DF does not interfere with these pathways.&nbsp;",""
125948,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with zidovudine. MMAE is a substrate of CYP3A4 and P-gp but zidovudine does not interfere with these pathways.&nbsp;",""
125949,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with emtricitabine. MMAE is a substrate of CYP3A4 and P-gp but emtricitabine does not interfere with these pathways.&nbsp;",""
125950,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with emtricitabine/tenofovir alafenamide. MMAE is a substrate of CYP3A4 and P-gp but emtricitabine/tenofovir alafenamide does not interfere with these pathways. ",""
125951,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with emtricitabine/tenofovir-DF. MMAE is a substrate of CYP3A4 and P-gp but emtricitabine/tenofovir-DF does not interfere with these pathways.",""
125952,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. Both polatuzumab vedotin and albuvirtide are eliminated via intracellular catabolism. MMAE is a substrate of CYP3A4 and P-gp but albuvirtide does not interfere with these pathways.",""
125953,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. Both polatuzumab vedotin and ibalizumab are eliminated via intracellular catabolism. MMAE is a substrate of CYP3A4 and P-gp but ibalizumab does not interfere with these pathways.",""
125954,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with cabotegravir. MMAE is a substrate of CYP3A4 and P-gp, but no interaction is expected as cabotegravir has no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on UGTs.",""
125955,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with cabotegravir or rilpivirine. MMAE is a substrate of CYP3A4 and P-gp, but no interaction is expected as cabotegravir or rilpivirine have no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on UGTs or CYP3A4.",""
125956,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with fostemsavir. MMAE is a substrate of CYP3A4 and P-gp, but no interaction is expected as temsavir, the active metabolite of fostemsavir, has no inhibitory or inducing effects on CYP3A4.&nbsp;",""
125899,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. T The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with bictegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as bictegravir has no inhibitory or inducing effects on CYPs and brentuximab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1.&nbsp;Brentuximab vedotin does not interact with emtricitabine and tenofovir alafenamide.",""
125942,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Polatuzumab vedotin is an antibody-drug conjugate comprising a monoclonal antibody and monomethyl auristatin E (MMAE), a potent chemotherapeutic agent. T The monoclonal antibody undergoes elimination via intracellular catabolism and does not interact with bictegravir. MMAE is a substrate of CYP3A4 and P-gp but no interaction is expected as bictegravir has no inhibitory or inducing effects on CYPs and polatuzumab vedotin has no inhibitory or inducing effects on CYP3A4 or UGT1A1.&nbsp;Polatuzumab vedotin does not interact with emtricitabine and tenofovir alafenamide.",""
124954,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with fostemsavir would be possible from a pharmacokinetic standpoint. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Coadministration of fostemsavir with tenofovir disoproxil fumarate was shown to have no significant effect on temsavir pharmacokinetics. In contrast, fostemsavir increased tenofovir disoproxil fumarate Cmax, AUC and Cmin by 18%, 19% and 28%, but these changes are not considered to be clinically relevant. No interaction is expected with emtricitabine.",""
95400,"Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir-DF) is indicated for use as a complete regimen for the treatment of HIV-1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with ibalizumab would be possible from a pharmacokinetic standpoint.&nbsp;No drug interaction studies have been conducted with ibalizumab: based on ibalizumabâ€™s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Inhibition of metabolism by elvitegravir/cobicistat is unlikely to affect ibalizumab, a monoclonal antibody binding to the CD4 receptor, which is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies. Dose modifications of ibalizumab are not required when administered with any other antiretroviral.",""
124941,"Coadministration has not been studied. Thioridazine is metabolized by CYP2D6 and to a lesser extent by CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP or UGTs enzymes. Thioridazine is a moderate inducer of CYP3A4 but is unlikely alter temsavir exposure significantly. Coadministration of fostemsavir with rifabutin (a moderate inducer) was shown to reduce temsavir exposure by 30%. This decrease was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. This recommendation does also apply when fostemsavir is coadministered with Thioridazine. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with thioridazine. However, given the known QT prolongation risk associated with pimozide, ECG monitoring is recommended when coadministering both drugs.",""
123351,"Coadministration has not been studied. Ketoconazole is a strong inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. No dose adjustment is required for rilpivirine when co-administered with azole antifungal agents, but clinical monitoring for breakthrough fungal infections is recommended when azole antifungals are co-administered with rilpivirine. Coadministration of oral rilpivirine (150 mg once daily) and ketoconazole (400 mg once daily) increased rilpivirine Cmax, AUC and Cmin by 30%, 49% and 76%, respectively. Ketoconazole Cmax, AUC and Cmin decreased by 15%, 24% and 66%, respectively.",""
123535,"Coadministration has not been studied. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4). Posaconazole is a strong inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. No dose adjustment is required for rilpivirine when co-administered with azole antifungal agents, but clinical monitoring for breakthrough fungal infections is recommended when azole antifungals are co-administered with rilpivirine.",""
123719,"Coadministration has not been studied. Voriconazole is a strong inhibitor of CYP3A4. No effect is expected on cabotegravir as it is mainly metabolized by UGT1A1 and to a lesser extent by UGT1A9, however, rilpivirine exposure may increase. No dose adjustment is required for rilpivirine when co-administered with azole antifungal agents, but clinical monitoring for breakthrough fungal infections is recommended when azole antifungals are co-administered with rilpivirine.",""
125766,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although atazanavir/cobicistat inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on atazanavir/cobicistat is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125767,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although atazanavir/ritonavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on atazanavir/ritonavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125768,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although darunavir/cobicistat inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on darunavir/cobicistat is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125765,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although atazanavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on ataznavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125769,"Coadministration has not been studied but a clinically significant interaction is unlikely when cabergoline is administered as a single dose to suppress lactation. Cabergoline is extensively metabolized by the liver, predominantly via hydrolysis (non-CYP mediated metabolism), and is a substrate of P-gp. Cabergoline exposure was shown to increased 2.6- to 4-fold in the presence of the strong P-gp inhibitors itraconazole or clarithromycin. Although darunavir/ritonavir inhibits P-gp, no dose adjustment of cabergoline is required when cabergoline is administered as a single dose to suppress lactation. No effect on darunavir/ritonavir is expected as cabergoline does not inhibit or induce drug metabolizing enzymes.",""
125186,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Catâ€™s claw is a strong inhibitor of CYP3A4 in vitro and increased concentrations of atazanavir, saquinavir and ritonavir were reported in a patient receiving Catâ€™s claw. However, catâ€™s claw is unlikely to significantly increase temsavir. Coadministration of fostemsavir with ritonavir (a strong CYP3A4 inhibitor) was shown to increase temsavir Cmax, AUC and Cmin by 53%, 45% and 44%. These changes were not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124741,"Coadministration has not been studied. Clarithromycin is a strong inhibitor of CYP3A4 and P-gp and coadministration is predicted to increase temsavir (the active metabolite of fostemsavir) but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir. Fostemsavir has been associated with prolongation of the QTc interval at supra-therapeutic doses but these are unlikely to occur during coadministration with clarithromycin. However, given the known QT prolongation risk associated with clarithromycin, ECG monitoring is recommended when coadministering both drugs.",""
124878,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Ketoconazole is a strong inhibitor of CYP3A4 and P-gp and coadministration is expected to increase temsavir, but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
124838,Coadministration has not been studied. Nefazodone is metabolized mainly by CYP3A4 and is a strong inhibitor of CYP3A4. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration is expected to increase temsavir but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.,""
124881,"Coadministration has not been studied. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Posaconazole is a strong inhibitor of CYP3A4 and a moderate inhibitor of P-gp and coadministration may increase temsavir exposure, but to a modest extent. Coadministration of fostemsavir with cobicistat (a strong CYP3A4 and P-gp inhibitor) increased temsavir exposure by 93%. This increase was not considered to be clinically significant and did not warrant a dose adjustment of fostemsavir.",""
115453,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Dolutegravir does not interact with flunisolide metabolism.,""
115457,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide undergoes CYP3A4-mediated metabolism. Rilpivirine does not interact with flunisolide metabolism.,""
116477,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrocortisone is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. No interaction is expected with lamivudine.,""
